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Abstract 
 
Human endogenous retroviruses are the remnants of ancient retroviral infections 
present within our genome.  These molecular fossils show similarities with present day 
exogenous retroviruses but act as typical Mendelian elements that are passed vertically 
between generations.  Despite being repeatedly linked to a number of autoimmune 
diseases and disorders, no conclusive proof has been identified.  Rheumatoid arthritis 
(RA) is one such disease which has been associated with an increase in HERV 
expression, compared to controls. 
In order to elucidate a clear role for HERVs in RA pathogenesis, autoantigens 
implicated in disease pathogenesis were scanned for sequence homology to retroviral 
genes.  Such epitopes would induce antibodies cross reactive with host proteins, 
resulting in disease.  Short peptides mimicking these regions were synthesised and the 
prevalence of anti-HERV antibodies was determined in RA patients and disease 
controls.  Additionally, a novel real-time Polymerase Chain Reaction (PCR) assay was 
developed to accurately quantify levels of HERV-K (HML-2) gag expression, relative 
to normalised levels of housekeeping gene expression.  Both serological and molecular 
assays showed significant increases in HERV-K (HML-2) activity in RA patients 
compared to disease controls with CD4+ lymphocytes harbouring the highest activity.   
The real-time assay was also used to determine whether factors within the synovium 
could modulate HERVs, resulting in their upregulation.  Exogenous viral protein 
expression and pro-inflammatory cytokines were shown to exert a significant 
modulatory effect over HERV-K (HML-2) transcription.  From this data, it is clear that 
RA patients have increased levels of HERV-K (HML-2) gag activity compared to 
controls.  Despite this it is likely that factors within the synovium such as exogenous 
viral expression and pro-inflammatory cytokines also influence HERV-K (HML-2) 
transcription possibly contributing to a role of bystander activation, i.e. being 
influenced by external factors, rather than actively contributing to disease processes.  
The exact role of HERVs in RA pathology remains elusive; however this research 
proposes several mechanisms by which HERV-K (HML-2) may contribute to disease. 
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Chapter 1: Retroviruses and Rheumatoid Arthritis 
  
 
 
1.1. Retroviruses & HERVs 
 
1.1.1. Retroviruses  
 
The retroviruses comprise a diverse range of viruses of vertebrates, united by a 
mechanism of replication comprising two unique features (Gifford et al., 2005).  
Firstly, their life cycle involves the integration of a DNA copy of the viral RNA 
genome (provirus) into the chromosomal DNA of their host (Figure 1.2).  The second 
unusual feature of retroviral replication is that they have the ability to reverse the usual 
direction of information flow in biological systems, i.e. from DNA to RNA to protein.  
Consequently, the family is so named for its possession of the unique enzyme 
responsible for this reversal - ‘reverse transcriptase’ (Latin, retro = backwards).   
 
1.1.2. Retroviral structure 
 
The Retroviridae family is split into seven genera (Table 1.3) of which just two 
contain members that cause disease in humans - the BLV-HTLV retroviruses (e.g. 
Human T-cell lymphotropic virus) and the Lentiviruses (e.g. Human immunodeficiency 
virus - HIV) (Colmegna and Garry, 2006).  Typically, retroviruses are 80-100 nm in 
diameter with a genome of 7-13 kilobases (kb).  They are enveloped viruses, with a 
diploid positive strand RNA genome and a life cycle characteristically mediated by a 
DNA intermediate.  This intervening step is attributed to the presence of an RNA-
dependent DNA polymerase called ‘Reverse transcriptase’ (RT) which uses a single 
stranded RNA template to produce a double stranded DNA copy (Temin, 1962).  All 
retroviruses can be categorised based upon their genome structure, which is either 
simple or complex (Figure 1.1).  Simple retroviruses carry just four core genes, with 
complex viruses containing the core genes, in addition to a number of accessory genes, 
responsible for aiding and facilitating replication (Coffin J. M. et al., 1999).  The roles 
and functions of the core retroviral proteins observed in simple and complex 
retroviruses are discussed below. 
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1.1.2.1. Core retroviral proteins: Gag (Group-associated antigen) 
 
 The group antigen is so called as antibodies produced against the Gag proteins 
cross-react with related retroviruses, of same species, but not others.  Gag also acts as 
the precursor to the internal structural proteins of all retroviruses, and is initially 
synthesised as an immature polyprotein prior to being cleaved by the viral protease to 
produce three distinct proteins.   
 
 
 
 
 
 
Figure 1.1  The genome structure of both simple & complex retroviruses [amended from (Coffin et al., 1999)]. 
Retrovirus genomes whether simple or complex share 3 major open reading frames.  These genes code for the 
Gag, Pol and Env proteins.  Complex retroviruses utilise mechanisms such as frame shifting and splicing to 
produce multiple accessory proteins from different reading frames in order to minimise their genome size, 
thus minimising the number of mutations potentially made by the error-prone reverse transcriptase enzyme.  
Accessory proteins are generally utilised to facilitate and regulate viral replication. 
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All Gag proteins share similar basic organisation from their amino to their 
carboxyl terminus: (NH2) – MA – X – CA – NC – Y – (COOH) with the minimal Gag 
unit being MA – CA – NC (Matrix – Capsid – Nucleocapsid).  The Gag polyprotein in 
infectious virus self-assembles at the cell membrane to form immature virions.  During 
maturation it is proteolytically cleaved by the protease into the Matrix, Capsid, 
Nucleocapsid and several low mass cleavage products (including p1, p2 and p6).  In 
HIV-1 the matrix shell comprises of approximately 2000 copies of Ma protein which 
lies under the inner surface of the lipid membrane.  The CA is the largest of the three 
domains (between 200-270aa in size) and the most antigenic, containing the highly 
conserved ‘major homology region’.  The virus’s conical core, located at the centre of 
the particle is composed of ~2000 CA proteins (capsomeres).  The core contains the 
viral genetic material which is in the form of 2 single strands of genomic RNA (diploid) 
that are stabilised through binding with the nucleocapsid proteins as a ribonucleoprotein 
complex in HIV.  The nucleocapsid is a small basic protein (size 60-90aa) which 
displays a high affinity for RNA and may play a role in helping to form and stabilise 
the RNA dimer formation of the diploid retroviral genome (Fu et al., 1994).  It has also 
been suggested to stimulate RT through facilitation of the binding of the primer tRNA 
to the primer binding site and promoting strand transfer, in addition to playing a central 
role in assembly and budding through the presence of ‘assembly domains’ (Wills and 
Craven, 1991).  Morphologically the inner core has an electron dense, icosahedral vase 
or cone shaped appearance in HIV. 
 
1.1.2.2. Core retroviral proteins: Pol (Polymerase)  
 
The pol gene is the most conserved of all retroviral genes and one that is 
essential for replication (Xiong and Eickbush, 1990).  It has two coding domains, 
leading it to act as a precursor for both the Reverse Transcriptase (RT) and Integrase 
(IN) proteins.  During the early 1970’s the controversial discovery of the RT enzyme 
revolutionised the field of Retrovirology (Baltimore, 1970).  Being an RNA dependent 
DNA polymerase with RNaseH properties, it allows the degradation of DNA-RNA 
hybrid templates and is essential in ensuring the synthesis of DNA complementary to 
genomic viral RNA template (Temin and Mizutani, 1970). The reverse transcription 
step occurs within the capsid at a stage shortly after viral entry into the cell, prior to 
entry into the nucleus.  In HIV, RT is initially packaged into particles as a Gag-Pol 
precursor, with proteolytic cleavage initially producing a homodimer of two p66 
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molecules.  Subsequent proteolytic excision of one RNaseH domain results in the 
mature p66-p51 heterodimer (Turner and Summers, 1999).   The IN is the second 
replication enzyme and is primarily concerned with the insertion of the provirus into the 
host cell’s chromosomal DNA.  The Protease (Pro) is an additional enzyme encoded 
between the gag and pol genes which acts late in assembly of the viral life cycle 
proteolytically cleaving the precursor polyprotein.  PR is generally translated as a Gag-
Pol fusion product produced by a ribosomal frameshift (Jacks et al, 1988).  The enzyme 
is released from the polyprotein by an autocatalytic mechanism (Farmerie et al, 1987). 
 
1.1.2.3. Core retroviral proteins: Env (Envelope)  
 
The env gene encodes a polyprotein that is cleaved to form two components of 
the viral envelope - the Surface protein (SU) and the Transmembrane protein (TM).    
Whilst the SU is primarily responsible for receptor binding and anchoring particles to 
the surface of cells, the TM is thought to be linked with cellular fusion and entry.  
Consequently, both play central roles in determining cell and receptor tropism, e.g. 
CD4 and HIV.  The TM consists of an N-terminal ectodomain, a transmembrane 
domain, and a C-terminal intra viral segment that interacts with the matrix below the 
lipid membrane and may play a role in fusion during both budding and cell entry, 
through this close association with the MA (Brody and Kern, 2004).  The presence of 
the env gene distinguishes retroviruses from retrotransposons and other classes of 
retroelements (Mills et al, 2007).  Figure 1.2 shows the distribution of these proteins in 
a typical exogenous retrovirus particle. 
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1.1.2.4. Other proteins 
 
The majority of endogenous retroviruses possess a simple genome 
configuration, although some members of the HERV-K family possess genes that show 
homology to exogenous accessory proteins (Armbruester et al., 2002, Mayer et al., 
2004).  Using HIV as an example other accessory proteins are predominantly concerned 
with regulation of replication. 
Tat is a regulatory protein which plays a role in stimulating both structural and 
replication proteins (including itself).  In order to exert its effect, Tat depends upon a 
short sequence of nucleotides called ‘TAR’ (Tat responsive sequence) which can be 
located at the start of the viral genome and is included in all mRNA transcripts of the 
HIV viral genome.  Whereas Tat is able to increase the production of all viral proteins, 
a second regulatory protein called Rev enables the integrated virus to selectively 
increase either regulatory or structural components of the virus.  Rev also acts along 
two other pathways.  Firstly, it is able to selectively prevent transcripts (including its 
own) from being translated into proteins.    Secondly it is able to interact with proteins 
Figure 1.2 Typical structural organisation of an exogenous retrovirus particle using HIV as an example. 
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in order to override the repressive pathways effects.  Rev participates in sequence 
specific transport of unspliced and incompletely spliced vRNAs from the nucleus to the 
cytoplasm.  It interacts specifically to the ‘Rev response element’ (RRE), which is 
located in unspliced viral transcripts of env (Malim et al., 1990).  Once replication 
occurs, interactions between Tat and Rev hold viral growth in check. 
The two pathways interact with one another with Tat increasing both itself and 
Rev, whilst Rev acts upon itself and Tat by binding to RRE, thereby favouring the 
replication of structural proteins.   
When expressed, HIV Nef is a 27 kDa regulatory factor that is expressed at high 
concentrations shortly after infection (Goldsmith et al., 1995) and is thought to have at 
least two main roles within the replication cycle, including the enhancement of viral 
replication and down regulation of CD4 expression upon the infected cells surface 
(Salghetti et al., 1995).  This decrease in CD4 is thought to occur through interaction of 
Nef and the cytoplasmic tail of the CD4 receptor.  This reduction in CD4 may 
indirectly enhance viral replication by reducing the chances of premature Env binding 
to CD4 and thus being prevented from entering the immature viral particle.  A 
downregulation of CD4 has also been suggested to prevent reinfection of nascent 
progeny virions after budding (Mangasarian & Trono, 1997). 
The virion infectivity factor (Vif) appears to enhance the infectivity of viral 
particles once they have budded from the host cell membrane to infect nearby cells.  
HIV Vif is a 23kDa viral accessory protein required for the production of infectious 
virus in a cell specific manner.  vif defective viruses were observed to be unable to grow 
in certain ‘non-permissive’ cell lines, including T cells and Macrophages, compared to 
wild type virus (Borman et al., 1995) whilst permissive cells (SupT1 and Jurkat) 
allowed growth of the defective viruses.  Heterokaryon analysis of cells fused from both 
permissive and non-permissive cell lines suggested that non-permissive cells did not 
allow replication in the absence of Vif due to the presence of a cellular transcription 
factor (Madani and Kabat, 1998; Simon et al., 1998).  This transcription factor, named 
APOBEC3G was identified as a member of the APOBEC family of cytidine 
deaminases, a group of proteins which actively deaminated cytosine residues.  
APOBEC3G specifically induces C to U mutations in the minus strand viral DNA, 
resulting in G to A changes in the coding strand thus causing mutated and nonviable 
virions (Lou et al., 2007).  It is thought that Vif targets APOBEC3G for 
polyubiquitination and degradation (Yu et al., 2003). 
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1.1.2.5. Long terminal repeats (LTRs) 
 
The viral protein coding genes are bracketed by two identical stretches of 
sequence termed the long terminal repeats (LTR), which can each be further separated 
into three separate domains – U3, R and U5 (Figure 1.3).  The LTRs are exact copies of 
one another at opposing ends of the retroviral genome and play significant roles in the 
initiation and transcription stages of the retroviral lifecycle (Urnovitz and Murphy, 
1996).   The Primer Binding Site (PBS), which is located at the end of the U5 region 
spans ~18 nucleotides and is complementary to the 3’ end of a specific cellular tRNA.  
This complementarity causes the tRNA to bind to this region, where it is used to prime 
DNA synthesis by the viral RT.  Each different group of viruses shares a specific tRNA 
primer for this function.  As different types of retroviruses use different tRNAs as 
primers, a taxonomy system for classifying ERVs based upon their use of tRNA 
primers is used (Urnovitz and Murphy, 1996).  The U3 region is similar to the U5, in 
that it is a unique non-coding region of length 200-1200 nt which forms the 5’ end of 
the provirus.  This sequence also plays an important role in initiation and facilitation of 
replication via a number of binding sites for cellular transcription factors along its 
length,  which are able to interact with a large number of host cell factors, cytokines 
and cellular transcription signals (Bandziulis et al., 1989, Maniatis et al., 1987, 
Urnovitz and Murphy, 1996) (Figure 1.5).   Consequently, the U3 region has a 
significant influence over the cell tropism and tissue specificity of the virus and it has 
become apparent that dynamics between cellular factors and viral sequences are almost 
as important in regulation of expression as the cellular receptors used for entry 
(Maniatis et al., 1987).  The U5 region is a unique non-coding region of 75-250 nt in 
length and forms the 3’ end of the provirus.   
The 5’ LTR contains enhancer and promoter sequences in its U3 region to 
provide signals recognised by the cellular machinery for transcription initiation, 
whereas the 3’ LTR with its U5 region provides polyadenylation signals.  This DNA 
copy of the retrovirus then integrates itself into the host cells DNA.  At this point in the 
viral life cycle, the provirus may be processed by cellular replication machinery in 
order to express viral proteins and virions. 
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1.1.3. Retroviral classification 
 
The International committee on the taxonomy of viruses (ICTV) has classified 
the retroviridae family into seven genera, based upon both phylogenetic analysis and 
sequence analysis of the RT gene (Zsiros et al., 1999).  The majority of these groups 
are found in piscine (epsilonretrovirinae), avian (alpharetrovirinae) and other non-
primate vertebrates.  Amongst those groups previously reported in humans, are the 
Spumavirinae, Lentivirinae and BLV-HTLV retrovirinae (formerly the Oncovirinae) 
(Table 1.1).   
Spumaviruses are a genus of exogenous viruses that are widespread in mammals 
and that cause a characteristic foamy cytopathic effect when grown in primate cells.  
Any association with disease in humans however, is as yet unclear (Flugel et al., 1987).  
The Lentiviruses are generally involved in slow infections (those with long incubation 
phases), with clinical disease typically characterised by immunosuppression, e.g. HIV 
and Acquired immunodeficiency syndrome (AIDs) (Gifford and Tristem, 2003).  The 
BLV-HTLV retroviruses are distinguished by their characteristic genomes and 
oncogenicity. 
Until recently, Lentiviruses and BLTV-HTLV retroviruses were the only genera 
to exclusively contain exogenous retroviruses.  Recently however, the discovery of the 
first endogenous lentivirus - Rabbit endogenous lentivirus type-K (RELIK) was 
reported in the European rabbit.  RELIK showed evidence of tat and rev genes by 
sequence homology and corresponding RNA secondary structural motifs, proving that 
lentiviral germ-line infections can occur (Katzourakis et al., 2007). 
Figure 1.3  The typical structure of a retroviral LTR showing locations of transcriptional control binding sites for cellular 
transcription factors [diagram adapted from (Urnovitz and Murphy, 1996)] 
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1.1.4. Endogenous retroviruses: Definition & Classification 
 
Courtesy of the recent sequencing of the human genome (Lander et al., 2001), 
we now know that just 3% is made up of protein coding sequences.  The remaining 
97% is made up of so-called ‘junk’ DNA, which may include transcriptionally active 
sequences (ENCODE, 2007) and ~9% of which is comprised of HERV-like sequences 
of the LTR element class (Lander et al., 2001).  Endogenous retroviruses in humans 
were not discovered until the early 1980s (Bonner et al., 1982, Martin et al., 1981).  
Unfortunately, the systems of classification for both exogenous and endogenous 
retroviruses have since evolved separately and are poorly integrated, therefore some 
ERVs are clearly endogenised variants of exogenous viruses e.g. mouse mammary 
tumour virus (MMTV) and Jaagsiekte sheep retrovirus (JSRV) and Koala retrovirus 
(KoRV), all of which rather confusingly have both exogenous and endogenous forms 
(Salmons and Gunzburg, 1987, Palmarini et al., 2004, Tarlinton et al., 2006) 
 
 
Genera Example Virus 
morphology 
Genome Endogenous 
form 
Alpha retrovirus  Avian sarcoma & 
leukosis viral 
group 
Rous Sarcoma 
virus 
Central, spherical 
core 
“C particles” 
Simple - 
Betaretrovirus Mammalian B-
type viral group 
Mouse 
mammary 
tumor virus 
Eccentric, 
spherical core 
“B particles” 
Simple Class II 
Gammaretrovirus Murine leukemia-
related viral group 
Moloney 
murine 
leukemia 
virus 
Central, spherical 
core 
“C particles” 
Simple - 
Deltaretrovirus Human T-cell 
leukaemia- bovine 
leukaemia viral 
group 
Human T-cell 
leukemia 
virus 
Central, spherical 
core 
Complex Class I 
Epsilon 
retrovirus 
D-type viral group Walleye 
dermal 
sarcoma virus 
Cylindrical core 
“D particles” 
Simple - 
Lentivirus Lentiviruses Human 
immunodefici
ency virus 
Cone-shaped core Complex - 
Spumavirus Spumaviruses Human foamy 
virus 
Central, spherical 
core 
Complex Class III 
 
 
 
Table 1.1 Schematics of retroviral classification of the exogenous retroviridae according to the ICTV (Coffin et al., 1992) 
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The majority of retroviruses are only able to infect somatic cells, consequently 
limiting infections to horizontal transmission.  Rarely, instances occur however when 
these viruses successfully infect germ line cells, thereby colonising the host germ cells 
(Gifford and Tristem, 2003) allowing vertical transmission of proviral DNA to host 
progeny.  Once the initial germ line colonisation has occurred by the founder virus, a 
rapid period of amplification follows before activity decreases as mutations accumulate 
within the open reading frames.  This decline is attributable to host selectional 
mechanisms and the lack of a purifying selection within the retroviral coding regions.  
The final point at which accumulations lead to inability to express proteins is termed 
‘extinction’ resulting in intergenic DNA.  Although extinction is an inevitable 
occurrence for most lineages, some retain varied levels of expression for millions of 
years, e.g. HERV-K (Reus et al., 2001).   
This retention of coding ability may be due to mechanisms such as 
complementation in trans (Certo et al., 1999, Browning et al., 2001, Beasley and Hu, 
2002) or if the initial colonisation and subsequent amplifications conferred advantages 
upon the host (Mi et al., 2000, Andersson et al., 2002, Stoye, 2002).  Those retroviruses 
that enter the germ line in this way are termed endogenous in order to distinguish them 
from their exogenous counterparts (Baltimore, 1975).  Once in the germ line, unless 
insertions are disadvantageous to the host, ERVs are transmitted vertically to host 
progeny, increasing their frequency within the host population through mechanisms 
such as mutational drift and hitch-hiking (Smith and Haigh, 1974).  Simultaneously 
ERVs may retain their capacity to replicate, resulting in further germ line insertions via 
retrotransposition (Cantrell et al., 2005) and reinfection (Belshaw et al., 2004), 
resulting in a mixed population of fixed and non-fixed elements (Gifford and Tristem, 
2003).    Figure 1.4 shows some of the proposed main evolutionary events which led to 
the insertion of the main ERV families into the primate lineage.  In some species, ERVs 
that have both fixed and un-fixed forms include Jaagsiekte retrovirus causing lung 
cancer in sheep (Palmarini et al., 2004), Feline leukaemia virus causing leukaemia and 
lymphomas in cats (Roy-Burman, 1995) and Koala endogenous retrovirus.  This is of 
particular interest as it represents a newly emerging retrovirus that is not only 
threatening the species, but also in the process of undergoing endogenisation 
(Tarlington et al., 2006). 
Endogenous retroviruses have since been found in all vertebrates investigated, 
ranging from mice to humans (Herniou et al., 1998).  In humans they comprise 
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approximately 200,000 entities, including 230 full length proviruses, around 8,100 
elements containing pol-related sequences and 3,661 of these with full or partial open 
reading frames (Lander et al., 2001, Seifarth et al., 2005).  Endogenous classification 
follows that of exogenous retroviruses, with around 31 distinct families or lineages 
(Gifford, 2006, Gifford and Tristem, 2003) classified into three classes (Table 1.2), 
based on the sequence homology of their pol regions with the pol genes of exogenous 
gamma-retroviruses, beta-retroviruses and spumaviruses.  Whilst many ERVs are 
defective, a limited number retain the potential to produce viral products and indeed 
form viral particles  (Ogasawara et al., 2003), although some have been reported to be 
active, at least to a transcriptional level, within several tissues (Stauffer et al., 2004).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Timeline showing events resulting in the insertion of different HERV families into the primate lineage.  
Diagram compiled from data presented in following references:  HERV-P (Yi et al., 2007); HERV-F (Kjellman et al., 
1999); HERV-I (Lee and Kim 2006); HERV-E grp I & grp II (Yi and Kim 2007a); HERV-S (Yi et al., 2004); HERV-
R/ERV3 (Herve et al., 2004); HERV-W (Kim et al., 1999); HERV-H Ia & II (Anderssen et al., 1997) & (Mager and 
Freeman 1995); ERV9 (Di Cristofano et al., 1995); HERV-T (Yi and Kim 2007b); HERV-K (Flockerzi et al., 2005, Lavie 
et al., 2004, Leib-Mosch et al., 1993) 
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1.1.4.1. Class-I HERVs 
 
Class I HERVs share sequence similarities with the gamma retroviruses such as 
Murine leukaemia virus (MLV).  This group of endogenous viruses make up the largest 
class with approximately twenty members (Tristem, 2000), with the majority exhibiting 
genomes of simple organisation (with the exception of HERV-H and HERV-FRD 
which lack env and possess an additional gag respectively).  Viruses of this class also 
exhibit varying copy numbers ranging from one (ERV3) to several hundred, although 
this is dependent upon the family and selection criteria used (Gifford and Tristem, 
2003).  Almost all class-I elements are highly defective although several families do 
show evidence of intact, or nearly intact open reading frames, including HERV-W 
(Blond et al., 1999, Blond et al., 2000), HERV-H (Lindeskog et al., 1998, Lindeskog et 
al., 1999) and HERV-F (Kjellman et al., 1999).  Three families within this class show 
homology with MLV and Baboon endogenous virus (BaEV) in the highly conserved 
pol, gag and env regions.   
 
1.1.4.2. Class-II HERVs 
 
Often referred to as the ‘HERV-K superfamily’ Class-II elements, show the 
greatest sequence homology to Beta-retroviruses such as MMTV, although not all 
members possess a tRNAlys PBS (Lysine primer binding site – Section 1.1.2.5) 
(Tristem, 2000).    All class II retroviruses (exogenous and endogenous) produce a Gag-
Pol polyprotein via one or two ribosomal frameshifting sites rather than the via a stop 
codon as commonly observed in other retroviruses (Petropoulus, 1997).  Additionally 
many of these viruses share a short glycine-rich region related to the G-patch domain 
found in many RNA-binding proteins (Aravind and Koonin, 1999).  They were initially 
identified through hybridisation studies using the pol gene of MMTV and Syrian 
hamster A-type particles (Deen and Sweet, 1986, Ono et al., 1986).  The complete 
sequence of one of these clones has since become the prototypic sequence for the 
HERV-K family although it lacks a 290 bp fragment from the env gene due to 
occurrence of a stop codon due to a C to T substitution (Ono et al., 1986).  Subsequent 
studies using cross-hybridisation identified a further 9 subgroups within the HERV-K 
family termed HERV-K (NMWV1-9) (Franklin et al., 1988).  This was followed up by 
a further study using degenerate primers to HERV-K10 pol, which identified 6 
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subgroups termed HERV-K (HML1-6).  HERV-K (HML2) contains the prototypic 
sequence for the group - HERV-K10 (Medstrand and Blomberg, 1993).  The subfamily 
has attracted recent attention for its increased numbers of insertional polymorphisms 
most likely resulting from recent transpositional activity (Belshaw et al., 2005).  
Proviruses from the HTDV/HERV-K (clone K10) (Boller et al., 1997) and from the 
HERV-K(C4) (Tassabehji et al., 1994) family have been fully sequenced.   
 
 
 
Class Examples Organisation Disease 
association 
I (Gamma/ C-type) HERV-H LTR-gag-Δpol-LTR 
LTR-gag-pol-env-LTR 
Cancer 
 HERV-F - - 
 HERV-W LTR-gag-pol-env-LTR MS, 
Schizophrenia, 
Psoriasis, Cancer 
 HERV-R (ERV9) LTR-part gag-part pol-env-
LTR 
RA 
 HERV-P (HuERS-P, HuRRS-P) LTR-gag-pol-env-LTR - 
 HERV-E (4-1, ERVA, NP-2) LTR-gag-pol-env-LTR Cancer, SLE, 
MCTD 
 RRHERV-I (HERV 15, ERV3) LTR-Δpol-env-LTR CHB, RA 
 HERV-T (S71, CRTK1, CRTK6) Gag-Δpol-LTR - 
 HERV-I (RTVL-1) LTR-gag-pol-env-LTR - 
 HERV-IP-T47D (ERV-FTD) - - 
II (Beta, A, B, & D) HERV-K (HML 1.1) LTR-gag-pol-env-LTR Seminoma, CML 
 HERV-K10 (HML2) LTR-gag-pol-env-rec-np9-LTR Testicular cancer/ 
RA 
 HERV-K18 LTR-gag-pol-env-SAG-LTR JRA, Diabetes 
type 1 
 HERV-K-T47D (HML4) LTR-gag-pol-env-LTR - 
 HERV-K-NMWV2 (HML-5) - - 
 HERV-K (HML-6) LTR-gag-pol-env-LTR - 
 HERV-K-NMWV7) (HML-7) - - 
 HERV-K-NMWV3 (HML-8) - - 
 HERV-K-NMWV9 (HML-9) - - 
 HERV-K C4 (HML-10) LTR-gag-pol-env-LTR - 
 HERV-K113 LTR-gag-pol-env-LTR SS, MS 
 HERV-K115 LTR-gag-pol-env-LTR - 
III (Spuma) HERV-L LTR-?gag-pol-?env-LTR 
LTR-gag-pol-DUT-LTR 
RA 
 HERV-S (HERV18) - - 
 HERV-U - - 
 HERV-U3 - - 
 
   
 
 
 
 
 
 
Table 1.2 Classification of human endogenous retroviruses, coupled with coding ability of those discovered and disease associations 
from within the literature. Δ signifies entire gene sequenced but contains obvious deletions.  ? Indicates partial sequence.  SAG: 
Superantigen; RA: Rheumatoid Arthritis; SS: Sjogrens syndrome; MS: Multiple sclerosis; CML: Chronic myeloid leukemia; 
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1.1.4.3. Class-III HERVs 
 
Class-III HERVs were originally described  on the basis of sequence similarity 
to the Spumaretroviruses (Cordonnier et al., 1995).  Only four families were assigned 
to this class (Tristem, 2000, Benit et al., 2001) with the HERV-L family being the 
largest, with a copy number of 200-500, followed closely by HERV-H (Gifford and 
Tristem, 2003). 
 
 
1.1.5. HERV expression within humans 
 
All human cell and tissue types show a baseline of HERV transcriptional 
activity (Krieg et al., 1992, Medstrand et al., 1992, Brodsky et al., 1993).  However 
evidence has been building that specific families of HERVs are differentially regulated 
by different tissue and cell types (Sjottem et al., 1996, Anderssen et al., 1997, Baust et 
al., 2001, Schon et al., 2001).  Class I endogenous retroviruses appear more 
transcriptionally active in the skin, uterus and cervix than Class II HERVs, that exhibit 
higher levels of transcription in Peripheral Blood Mononuclear cells (PBMC’s), brain 
and mammary glands (Seifarth et al., 2005).  This differential expression may be due to 
the presence of different cellular transcription factors.  This is supported by evidence 
showing binding sites for such cellular factors along the length of the U3 LTR region.  
These sites have been suggested to play central roles in the initiation, efficiency and 
regulation of retroviral replication (La Mantia et al., 1992, Knossl et al., 1999, de 
Parseval et al., 1999a, Lee et al., 2003b).  HERV transcriptional activity appears 
elevated in those tissues or cell types with higher rates of proliferation or metabolic 
activity, than observed in highly specialised non-proliferative cells, e.g. muscle cells 
(Seifarth et al., 2005).  This variation emphasises the importance of cellular 
transcription factors and their requirement in retroviral replication. 
Class I and II HERVs are the most active with a large amount of reported 
evidence that activity correlates with age.  Class II HERVs in a number of studies have 
shown lower levels of activity.  This has been suggested to be the result of their 
elimination from gene-rich regions via purifying selection through evolution (Landry et 
al., 2002).  The fact that the HERV-K family are reported to be the most recent 
integrations into the human genome is reflected in their activity relative to other 
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HERVs.  Distribution across the genome of HERVs was considered non-random with 
chromosomes 4, 19, X and Y having the highest number of HERVs with maximal 
concentrations identified on the Y chromosome  (Villesen et al., 2004).  HERVs were 
also reported to preferentially migrate across the genome to regions of chromosomes 
with increased levels of heterochromatin, thereby increasing their chances of being 
retained within the host genome  (Kjellman et al., 1995).   
 
1.1.6. HERVs and Host genomic evolution 
 
Despite the fact that ~45% of the human genome is made up of millions of 
retroelements (Lander et al., 2001), evidence is only now beginning to hint at the 
specific roles for these sequences within the genetic evolution and function of their 
host.   
 
 
 
 
The term retroelements is inclusive of transposons, retrotransposons and the 
LTR retroelements (Figure 1.5) which are all characterised by their ability to generate 
multiple DNA copies that can be integrated into new chromosomal positions.  New 
evidence now suggests however, that integration no longer appears the random process 
it was once assumed to be with groups of retroelements exhibiting distinct patterns of 
distribution across the genome.  Exogenous retroviruses have been shown to have a 
varying preference for integration sites with MLV exhibiting preferences for promoter 
regions and CpG islands (commonly associated with promoters in humans) (Mitchell et 
al., 2004) whilst Avian leukosis virus (ALV), avoids such sites (Weidhaas et al., 2000).  
Figure 1.5 Structural classification of 
the retroelements.  Triangles represent 
the short direct repeats flanking the 
retroelements.  Internal promoters, LTR 
elements, open reading frames (ORF), 
genes and poly (A) tails are indicated.  
Diagram taken from Andersson  et al. 
1998. 
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Similarly, complex integration patterns have also been reported for endogenous LTR 
retroelements.  Previous investigations have reported an increased propensity, with age, 
for HERVs to  accumulate/migrate to non-gene coding AT-rich regions, such as on the 
Y chromosome (Kjellman et al., 1995).  This allosomal clustering has been attributed to 
its recombinatorial isolation from the remainder of the autosomal genome and its 
increased level of heterochromatin (Junakovic et al., 1998).  Younger HERV families 
on the other hand  preferentially integrate into regions of increased GC content and 
open chromatin although even different families have a tendency to differ significantly 
from one another both in prevalence in genic regions and in their orientational bias (van 
de Lagemaat et al., 2006).  Additionally, HERVs have been noted to cluster in higher 
numbers around fragile sites, chromosomal breakpoints and recombination hotspots 
(Taruscio and Manuelidis, 1991, Meese et al., 1996, Andersson et al., 1998), a pattern 
that has also been observed in the genomes of mice (De Castro and Balagura, 1976).  
Class II ERVs differ from other  groups as they preferentially integrate into regions of 
increased gene density, specifically about 5 – 20 kb upstream of gene coding sequences 
(Medstrand et al., 2002).  Integrations into transcriptionally active areas of the genome 
such as these can increase the likelihood of host gene disruption and at these points, 
host selection is at its maximum, supporting the idea that insertional inactivation of 
genes has been strongly selected against in the lineage leading to modern humans.  This 
is reflected in the fact that 80% of HERVs in intergenic regions are in anti-sense 
orientation to the gene sequence (Bushman, 2003).   One example where this is 
observed within the human genome is the human C4 gene involved in the complement 
cascades (Carasso et al., 1976).  Reports of HERVs in areas of gene transcription have 
thus lent credence to a new role for HERVs within the human genome i.e. one of a 
regulatory nature contributing to tissue specific expression.  Documented examples 
supporting this hypothesis include Salivary amylase and HERV-E (Ting et al., 1992), 
HERV-K and ISNL4 placental expression (Mu et al., 2003), a HERV LTR driving 
Beta1,3-galactosyltransferase beta3Gal-T5 expression (Mare and Trinchera, 2007) and 
an ERV9 LTR driving Alcohol dehydrogenase 1C (ADH1C) expression (Chen et al., 
2002).  Additionally, it is noteworthy that the majority of documented HERV insertions 
into gene coding regions, resulting in HERV driven tissue specific expression have 
been in those genes concerned with energy metabolism.  Such evidence support a 
regulatory role for ERVs within the host genome (Dunn et al., 2003) with differential 
HERV expression occurring between host tissues (Seifarth et al., 2005).   
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After the initial integration of the provirus into the infected cell’s genome, there 
follows a period of intense reintegration and reinfection in which each of the 
integrations has the potential to reduce host and proviral fitness; therefore subjecting 
the provirus to a highly purifying selectional pressure.  Solitary retroviral LTRs also 
become abundant through this process leading to an increase in their numbers within 
the host genome by retrotransposition, and this can result in their influencing of host 
genes expression.  Retroviral HERVs and LTRs may modulate cellular gene expression 
by a number of possible mechanisms;  
 
1. Alternative splicing from the 5’ LTRs using cellular splice acceptors. 
2. Initiation of cellular transcripts from 3’ LTRs. 
3. Insertion of retroelements directly into gene promoter sequence. 
 
A chimeric cDNA clone of a fusion transcript containing the 5’ LTR sequences 
and leader region of a HERV-H element fused to the human calbindin gene (coding for 
a cytosolic calcium-binding protein) was identified in a cell line derived from a prostate 
metastasis.    The HERV-H element splices to the second exon of the calbindin gene, 
introducing a different leader peptide sequence in its place, and thus altering the 
calcium binding motif structure of the protein (Liu and Abraham, 1991).  
A HERV-K (HML-10) element was found to be involved in tissue specific 
expression of the insulin-like growth factor gene INSL4 in human placenta (Bieche et 
al., 2003).  In this case, the cellular gene was transcribed from the 3’ LTR of a 
truncated provirus lacking the 3’ end of the 5’ LTR including the PBS.  This resulted in 
a 10-fold upregulation of INSL4 expression in differentiated syncytiotrophoblasts, 
compared to the corresponding cytotrophoblasts, suggesting a potential role in human 
placenta morphogenesis.   
Retroelements can play a role in influencing gene regulation by inserting 
themselves directly into human gene promoters (Jordan et al., 2003).  Additionally, 
HERVs and endogenous LTR elements have also shown the ability to be influenced by 
endocrine agents such as progesterone and steroidal modulation.  Upregulation of 
HERVs in response to the presence of steroids  may be particularly important in the 
reproduction process, particularly with the role of progesterone in the temporal 
regulation of the HERV-W Env protein, syncytin in the endometrium of rhesus 
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monkeys (Okulicz and Ace, 2003) and the development  and function of the placenta 
(Taruscio and Mantovani, 1998).  Additionally, the importance of retroviral activity 
within the reproductive process was eloquently illustrated by a recent investigation 
involving the administration of retroviral ‘env’ blockers to pregnant ruminants.  In this 
study, morphino-antisense oligonucleotides designed to inhibit the expression of 
enJSRV env mRNAs, were administered in utero to sheep on day 8 of pregnancy.  
Injection of these oligonucleotides were shown to correlate with reductions in enJSRV 
env production in the conceptus trophectoderm, which resulted in pregnancy loss by 
day 20, thereby illustrating the important role in placental morphogenesis ERVs may 
play.  Authors also concluded that this role may also be observed in other mammalian 
species (Spencer et al., 2007). 
A significant number of genes have been reported to have been influenced by 
retroviral endogenisation.  Such examples include HERV-W and syncytin (Mi et al., 
2000), apoptotic and to ubiquitination related proteins (Villesen et al., 2004, Campillos 
et al., 2006) and specific components of both the human immune response (van Gent et 
al., 1996, Agrawal et al., 1998).  Retroviral influence has also led to the evolution of 
defenses against potential retroviral invaders.  The development of the innate anti-
retroviral immune response proteins of the RNA editing protein families APOBEC and 
Trim-5α are two recent and topical examples.  Both are transcription factors that 
become incorporated into the nascent virions as they bud from infective cells and 
subsequently sabotage the retroviral genomes upon infection of the new host cells by 
causing promiscuous guanine-to-adenine hypermutations (Towers, 2007; Chiu and 
Greene, 2008).  Such mechanisms have recently been reported to suppress activity of 
endogenous LINE-1 retro-transposition (Kinomoto et al., 2007).  A second pathway 
involves Trim-5α, which acts to block retroviral replication prior to integration through 
specific interactions with structural components of the retroviral virion (Stremlau et al., 
2004, Stremlau et al., 2006). These innate mechanisms are in addition to measures such 
as methylation (Yoder et al., 1997) and genetic mechanisms for downregulating 
transcription [including small interfering (si) RNA and micro (mi) RNA] (Jensen et al., 
1999).  HERV LTRs have also been identified near to genes involved in the JAK-STAT 
and cytokine response pathways and hence may play potential roles in their regulation 
and function (Vinogradova et al., 1997).  Finally, HERV sequences in the MHC class II 
gene cluster were increased ten-fold in number in comparison to the remainder of the 
human genome (Kulski et al., 1999).   Examples include ERV9 LTRs within the (HLA)-
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DR region that may function as γ-IRE transcriptional enhancers for the DR genes in 
which they are located, (Svensson and Andersson, 1997) and the MHC class-II 
superantigen expressing HERV-IDDMK1,222 isolated from Type-1 diabetes patients 
(Conrad et al., 1997).    
HERVs at any stage may retain fitness despite their fixed mutations, through a 
variety of mechanisms including co-packaging or recombination between other 
homologous HERVs  or LINE elements (Pavlicek et al., 2002, Gifford et al., 2005) or 
through recreation of functional hybrid genomes by gene conversion (Liao et al., 1997).   
Of those HERVs in the genome, only 13% are intragenic, thus HERVs are 
generally under-represented within coding regions (Villesen et al., 2004) although 
recent findings may suggest alternative roles in influencing host gene expression for 
those HERVs in the ‘junk DNA’ (ENCODE, 2007).  The majority of those genes with 
intragenic HERV sequences (constituting 813 genes) have been identified as being 
orientated in an antisense direction, again suggesting possibilities of an ancient form of 
antiviral defence using mechanisms such as dsRNA formation or RNA interference 
(Mack et al., 2004).   
HERV gene expression can also confer a selective advantage onto its host, 
resulting in a purifying selection keeping the intact provirus and its reading frames.  
Examples of HERV coding regions that have been maintained by natural selection in 
the human genome are the HERV-W env gene (Syncytin – 1), which has led to the 
formation of the syncytiotrophoblast layer of the placenta (Blond et al., 2000, Mi et al., 
2000, Muir et al., 2004).  Dysregulation or disruption of the syncytin protein causes 
defects in the cell fusion process which can lead to development of hypertensive 
disorders (e.g. preeclampsia and HELLP syndrome (Villarreal, 1997).  The HERV env 
encoded protein may also play a role in the immunosuppression of the maternal 
immune system attacking the fetus (Haraguchi et al., 1995, Villarreal, 1997) and in the 
origins of the salivary amylase gene (Meisler and Ting, 1993).  There are many 
examples of HERV proteins possessing immunosuppressive or immunomodulatory 
domains including peptide domains in HERV-H env (Mangeney et al., 2001) and the 
HERV-E CKS–17 peptide (Cianciolo et al., 1985).  Such immunomodulatory domains, 
both immunosuppressive and immunostimulatory, i.e. superantigens, have already been 
suggested to play central roles in the development of aspects of the immune system, 
such as peripheral tolerance in the thymus and the evolution of the diverse specificity of 
the immune response (Lewis and Wu, 1997, Agrawal et al., 1998, Meylan et al., 2005). 
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Expression of HERV sequences as mRNA transcripts or translated protein may 
also confer a selective advantage upon the host through protection against exogenous 
retroviruses (Larsson and Andersson, 1998), possibly acting to protect the fetus from 
infection in the maternal blood.  Cellular resistance against infection of spleen necrosis 
virus has been demonstrated by transfection of cultured cells with an expression 
plasmid containing an HERV-W env insert (Ponferrada et al., 2003). 
 
1.1.7. HERVs and human disease 
 
 
Despite a number of studies associating HERVs with a large number of clinical 
conditions (Table 1.3i and 3ii) none, so far, have reported any conclusive findings, 
specifically implicating HERVs as the causal agents.  Many of these associations exist 
in the form of circulating anti-retroviral antibodies and increased levels of HERV gene 
expression in disease samples versus controls. 
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Disease HERV Reference 
Cancer 
Ovarian cancer HERV-W 
HERV-E 
L1-retrotransposon 
(Wang-Johanning et al., 2007) 
(Hu et al., 2006) 
(Menendez et al., 2004) 
Germ cell tumour - Seminoma HERV-K (Rakoff-Nahoum et al., 2006) 
Germ cell tumour - 
gonadoblastoma 
HERV-K (Herbst et al., 1999) 
Gastrointestinal cancer HERV-H (Wentzensen et al., 2007) 
Prostate carcinoma HERV-E (Wang-Johanning et al., 2003) 
(Molinaro et al., 2006) 
Breast cancer HERV-K (Ejthadi et al., 2005) 
Bladder/ Urothelial / renal cell 
carcinoma 
LINE-1/ HERV-K (Florl et al., 1999) 
(Jurgens et al., 1996) 
Childhood lymphocytic 
leukemia 
misc (Iwabuchi et al., 2004) 
CLL/ CML/ ALL (leukemias) HERV-K (Depil et al., 2002) 
Stem cell myelopathy disorder HERV-K (Guasch et al., 2003) 
Melanoma HERV-K108 
HERV-K 
HERV-K (MEL) 
(Hirschl et al., 2007) 
(Buscher et al., 2006) 
(Buscher et al., 2005) 
(Schiavetti et al., 2002) 
Atherosclerosis Misc HERVs/ 
retroelements 
(Hiltunen and Yla-Herttuala, 2003) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.3i Association of HERVs with human cancers and leukemias reported within the literature. 
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Autoimmune disease 
Rheumatoid arthritis HERV-K 
HERV-L 
ERV9 
ERV3/ λ4-1 
(Ejtehadi et al., 2006, Nelson et al., 1999) 
(Seidl et al., 1999, Nakagawa et al., 1997) 
(Stransky et al., 1993, Takeuchi et al., 1995) 
(Ehlhardt et al., 2006) 
Psoriasis HERV-E/ K/ W/ ERV9 
HERV-E 
(Moles et al., 2005) 
(Bessis et al., 2004) 
Opitz Syndrome HERV-K/ HERV-E (Moles et al., 2005) 
Congenital heart block ERV-3 (de Parseval et al., 1999b) 
(Li et al., 1996) 
Autoimmune liver disease 
(Primary biliary cirrhosis) 
HIAP (Mason et al., 1998) 
(Meilof and Smeenk, 1998) 
Addisons disease LTR13 (Pani et al., 2002) 
(Gambelunghe et al., 2005) 
Alopecia areata HIAP (La Placa et al., 2004) 
Essential thrombocytopenia HERV-K10 (Morgan and Brodsky, 2004) 
Type 1 Diabetes  LTR13 
HERV-K18 
(Bieda et al., 2002) 
(Stoker et al., 1999) 
(Marguerat et al., 2004) 
Juvenile rheumatoid arthritis HERV-K (Ogasawara et al., 1999) 
Systemic Lupus Erythematosus HERV-E(4-1) (Piotrowski et al., 2005) 
(Sekigawa et al., 2006) 
(Sicat et al., 2005) 
Sjogrens Syndrome HIAP 
HERV-K113 
(Garry et al., 1990) 
(Sander et al., 2005) 
(Moyes et al., 2005) 
Mixed connective tissue disease HERV-E (4-1) (Hishikawa et al., 1997) 
Multiple sclerosis MSRV 
HERV-W 
(Mameli et al., 2007) 
(Perron et al., 2005) 
(Antony et al., 2006) 
Neurological 
Bipolar disorder/ Depression HERV-K (HML-2) 
HERV-W 
(Frank et al., 2005) 
(Weis et al., 2007) 
Schizophrenia HERV-K (HML-2) 
ERV-9 
(Yolken RH, 2000) 
(Huang, 2006) 
(Weis et al., 2007) 
Motor neuron disease HERV-W (Oluwole et al., 2007) 
Miscellaneous 
Interstitial lung disease HERV-E (4-1) (Tamura et al., 1997) 
Acquired immunodeficiency syndrome Misc HERVs 
HERV-K 
(McIntosh and Haynes, 1996) 
(Contreras-Galindo et al., 2007) 
(Contreras-Galindo et al., 2006) 
Aging Misc HERVs & retroelements (Fuke et al., 2004) 
 
 
 
 
 
Table 1.3ii Association of HERVs with human autoimmune and neurological diseases as reported previously within the literature. 
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1.1.8 Mechanisms by which HERVs may cause disease 
 
HERVs may induce disease through several mechanisms including expression 
of superantigens and induction of cross-reacting antibodies via molecular mimicry to 
host proteins (Perl, 2001).  These mechanisms are outlined below (Figure 1.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 Potential mechanisms by which viruses may cause autoimmune disease.  HERVs may induce disease 
through several mechanisms within their host.  These are summarised in the above diagram and include: A) 
Presentation of HERV protein by APC to activate immune cells, resulting in an immune response.  HERV proteins, to 
which the immune system may not have encountered previously may be treated as non-self, and therefore have no 
level of tolerance to, thereby resulting in an immune response being mounted, which may lead to disease.  B) 
Antibodies to HERV proteins: HERV proteins may be expressed upon the surface of cells, or released from dying 
cells, thereby coming under immune surveillance.  This may result in the initiation of an immune response in which 
antibdies specific for the HERV protein are produced.  These may also detect HERV proteins in other cells/tissues , 
and target such tissues if treated as non-self or foreign.  Anti-HERV specific antibodies may also come into contact 
with HERV proteins and bind to them forming immune complexes which then deposit within tissues, leading to 
activation of complement and ensuing immune reactions.  Anti-HERV antibodies may also bw crossreactive with self 
proteins that share sequence or conformational homology with HERVs.   C) Retroviruses and several bacterial 
species are able to bypass antigenic specificity and activate large numbers of immune cells through interaction with 
the hypervariable region of the TCR.  This can lead to large numbers of activated lymphocytes circulating the host, 
increasing the changes of ‘hit and run’ immune responses, in addition to anergy.  D)  Danger theory suggests that 
rather than responding to exogenous signals that represent non-self, the immune system is controlled from within, 
responding to endogenous signals that originate from stressed or damaged cells.  HERV components or proteins may 
be released from stressed cells and come into contact with a naïve immune response that treats components released 
from tissues as non-self, resulting in ensuing immune responses. APC: Antigen presenting cell; MHC: Major 
histocompatibility.  Such a release of cellular debris may also result in the initiation of eiptope spreading. 
A B 
C D 
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1.1.8.1. Expression of Neo-antigens 
 
Viral infection usually results in the production and presentation of peptides derived 
from viral protein, being presented to the immune system.  If viral epitopes had been 
previously sequestered within the tissues, in immuno-privileged locations, then 
tolerance would not have had a chance to develop.  This would result in an immune 
system being naïve to such epitopes and thus treating them as foreign.  An immune 
response targeting any such epitopes within tissues would likely damage tissues, 
leading to disease.   
 
1.1.8.2. Expression of super-antigens 
 
Superantigens are proteins so far identified in retroviruses and some bacteria, 
that are able to bypass the normal MHC restrictive processes of T-cell stimulation 
resulting in the activation of 103 - 105 more T-cells than conventional antigens 
(Sundberg et al., 2002) and commonly resulting in the breakdown of peripheral 
tolerance and induction of clonal anergy and apoptosis (Nelson et al., 2004).  The 
mechanism is based upon their capacity to bind to MHC class II proteins and Vβ chains 
of the T-cell receptor, regardless of antigen specificity (Huber et al., 1996).  Such a 
phenomenon has frequently been observed in retroviruses (Fleischer, 1991) either in 
exogenous or endogenous forms, with some even suggested to be adopted into our 
genome through evolutionary mechanisms to aid early stages of host peripheral 
tolerance control (Meylan et al., 2005).  Endogenous forms of superantigens have also 
been reported to be influenced by several members of the Herpesviridae, including 
Epstein Barr virus (EBV), which has been reported to play roles in both viral 
persistence (Sutkowski et al., 2001) and Type-1 diabetes (Conrad et al., 1994).  
Notably, the presence of EBV LMP-2A has been reported to transactivate the HERV-
K18 SAg (Sutkowski et al., 2004). 
Evidence of increased Superantigen (sAg) activity has been reported in the 
synovial fluid of rheumatoid arthritis patients (Paliard et al., 1991, Uematsu et al., 
1991) and a HERV-K18 superantigen has been proposed as a contributory factor in the 
development of Juvenile Rheumatoid Arthritis (JRA) (Sicat et al., 2005).  A HERV-
K18 sAg associated with Type-1 diabetes (Conrad et al., 1997) and also reported as a 
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possible cause of Multiple Sclerosis, after HERV-W was found to bias the T-cell 
immune response in patients (Perron et al., 2001).   
Viruses may also cause aberrant expression of host proteins, thus skewing the 
resulting immune response.  An example of this is HTLV-1’s ability to up regulate 
MHC expression on the surface of infected cells (Iwakura et al., 1991).  This provides 
the ‘extra boost’ required for an immune event to become an autoimmune reaction in 
RIP-LCMV mice – an animal model for Type 1 Diabetes (Evans et al., 1996). 
 
1.1.8.3. Transcriptional activation 
 
 
HERVs may act as insertional mutagens or cis-regulatory elements causing 
activation, inhibition, or alternative splicing of cellular genes involved in immune 
function.  A-type retroviruses, for example, can operate as transpositional elements and 
sequences within their LTRs can activate cellular genes, including those of cytokines or 
oncogenes.  HERVs also may encode elements similar to Tat in HIV-1 and Tax in 
HTLV-1, both of which encode proteins capable of transactivating cellular genes.  
Alternatively a HERV-encoded protein may act in trans to regulate gene expression.  
 
1.1.8.4. Molecular mimicry 
 
Molecular mimicry occurs when an exogenous protein shares an amino acid 
sequence with that of a host component (Oldstone, 2005).  One example is the 
association between Group A streptococcal M protein and cardiac myosin in the 
development of rheumatic fever, although direct evidence for this in RA is lacking 
(Hyrich and Inman, 2001).  Viral infection results in the activation of virus specific 
immune cells, which may cross-react with host self-antigens which share sequence or 
conformational identity with the viral proteins.  Despite its simplicity, such a 
hypothesis is deceptively difficult to prove.   
 
1.1.8.5. Direct modulation of the host immune response 
 
Viruses may also affect the immune response of the host directly, by nature of 
their cellular or tissue tropism.  Viruses infecting immune cell populations can cause 
significant immune dysregulation, e.g. HTLV-1 (Murphy et al., 2004); 
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immunosuppression, e.g. HIV (Zandman-Goddard and Shoenfeld, 2002) and defects in 
cell mediated immunity, e.g. Epstein-Barr virus (EBV) (Parolini et al., 2000).  These 
pathogens can also use these cells for transport to locations within the host and trigger 
local responses, such as in the Synovium, as observed in CAEV (Peterhans et al., 
1999).  Arthritis may be one outcome of such an impaired or abnormal immune 
response. 
The mere presence of some viruses can also trigger immune responses of the 
innate immune system.  Double stranded RNA (potentially from a replicating RNA 
virus) can initiate immune responses resulting in development of arthritis (Zare et al., 
2004) and the release of pro-inflammatory cytokines, leading to local and systemic 
inflammation.   
 
1.1.9. HERVs and their association with Rheumatoid arthritis 
 
As with other viruses, earlier reports implicating HERVs in Rheumatoid 
Arthritis focus upon serological investigation.  The majority of these identified anti-
HIV and HTLV-1 reactive antibodies in patients (Pelton et al., 1988, Ziegler et al., 
1989, Talal et al., 1990, Douvas et al., 1996), despite a lack of evidence of infection by 
either virus (Nelson et al., 1994, Nelson et al., 1995, Seemayer et al., 2002).  
Additionally, virus particles with retrovirus Type-C like morphology have been 
observed within the synovial fluid of RA patients (Stransky et al., 1993, Roberts et al., 
1995). 
More recently, investigations have focussed on the detection of increased levels 
of viral genetic material at disease sites with the development of more sensitive 
techniques, such as PCR.  Nakagawa and colleagues used RT-PCR on synovial fluid 
from RA patients and healthy donors to detect increases in HERV-L, HERV-K and 
ERV-9 (Nakagawa et al., 1997).  Nelson compared synovial fluid samples from RA 
patients against samples from healthy donors showing increases in HERV K10 
compared to levels seen in controls (Nelson et al., 1999), with these results being 
confirmed by a subsequent follow up study (Davari Ejtehadi et al., 2005).   
Other groups of HERVs such as ERV3, Lambda 4-1, HRV-5 and L1-
transposons have also been implicated in RA (Takeuchi et al., 1995, Griffiths et al., 
1999, Brand et al., 1999, Neidhart et al., 2000).  A number of studies however have 
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published contradictory evidence, thereby questioning a role for HERVs in Rheumatoid 
arthritis (Norval et al., 1979, Stoye, 1999, Gaudin et al., 2000). 
Elevated levels of HERV-K expression in patients with rheumatic diseases 
(including SLE, RA and SS), as opposed to healthy controls, showed increased levels 
of antibodies to HERV-K18 superantigen. These were predominantly in SLE patients 
(Herve et al., 2002).  The HERV-K18 superantigen was originally shown to be 
activated by EBV infection (Sutkowski et al., 2001).  However a similar role to that 
demonstrated by Herve and colleagues has been reported in Juvenile Rheumatoid 
Arthritis (JRA).  Sicat et al (2005) reported significantly increased levels of K18 
superantigen in JRA patients compared to controls using a semi-quantitative RT-PCR.  
This increase was determined to be irrespective of other factors such as EBV infection, 
IFN-alpha (IFN-α) levels and expansion of T cells within the peripheral blood.   
Additionally, a novel endogenous retrovirus of the HERV-E family – HERV E 
CD5 has been identified in a small subset of B cells (B1a and B1b cells) that are 
involved in the production of rheumatoid factors (a disease marker for RA) 
(Renaudineau et al., 2005).  Expression of the HERV-E CD5 provirus induces a second 
alternative cellular promoter which may result in initiation of replication shifting from 
exon 1 to exon 3.  This leads to production of a truncated protein which loses its ability 
to translocate to the plasma membrane, ultimately leading to reductions in transduction 
of the BCR and an increase in the production of autoantibodies.   HERV K (HML-2) 
Rec protein has also been identified within synovial tissues and cells in both RA 
patients and controls, although the authors concluded this was most likely not causal of 
the disease process (Ehlhardt et al., 2006).  Much interest has also surrounded the 
finding that a HERV-K10 LTR (LTR3) was identified in the HLA class II region 
(Kambhu et al., 1990).  This was investigated almost a decade later and identified as a 
potential disease marker for RA, being significantly more frequent in RA patients than 
in healthy controls (Seidl et al., 1999).  Other studies have highlighted the potential for 
LTRs in the HLA-DRB1 region to play a role in disease pathology (Pascual et al., 
2001, Pascual et al., 2003). 
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1.1.10. Other factors influencing HERVs and the development of 
RA 
1.1.10.1. Other viral pathogens 
 
Although this study is focussed specifically upon the potential role of HERVs in 
RA, one theory that is becoming more popular is that HERVs are actually influenced 
either directly or indirectly by the presence of exogenous viruses within the synovium.  
The best candidates for such a role include the Retroviruses, the Herpes viruses and 
Parvovirus B19 (Masuko-Hongo et al., 2003).  Major human retroviral pathogens HIV 
and HTLV-I cause well characterised diseases in humans such as AIDs and T cell 
leukaemia respectively.  HIV and HTLV-I however, also give rise to neurological 
complications which mimic some of the inflammatory autoimmune symptoms (e.g. 
HAAP and an inflammatory condition of the salivary glands resembling Sjogren’s 
syndrome).  These perhaps represent the most convincing arguments for the 
involvement of ERVs in autoimmune disease.  A more detailed breakdown of viruses 
implicated in RA is shown in Table 1.2  Members from all three aforementioned viral 
families have been shown to interact directly with HERVs (Sutkowski et al., 2004; 
McIntosh and Haynes 1996; Lee et al., 2003c). 
 
1.1.10.2. Immune components: Inflammatory cytokines  
 
Another aspect of autoimmune disease pathogenesis which may play a role in 
influencing HERVs are the inflammatory cytokines – specifically IL-1, IL-6 and TNF-
α., all of which are major players in RA, in addition to being known to modulate viral 
expression (Walev et al., 1995).  Increased levels of inflammatory cytokines and the 
oxidative conditions that they induce can also lead to somatic mutations and DNA 
damage.  This has been shown in RA, particularly through the presence of somatic 
mutations in the p53 tumour suppressor gene within the synovium.  This protein in 
particular plays an important role in surveillance of mutations within genes (Firestein et 
al., 1997, Reme et al., 1998, Inazuka et al., 2000).  Additionally the presence of 
microsatellite instability may contribute to the expression of DNA mismatch repair 
enzymes – an indicator of DNA damage (Lee et al., 2003a).  Thus, it is therefore 
possible that host cells infected and activated by exogenous or endogenous viruses 
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could migrate into the synovium releasing pro-inflammatory cytokines such as IL-6 
(Mitchell, 2002) and TNF-α (Naito et al., 2003) or that activated synoviocytes produce 
cytokines (Firestein, 2003) that activate or mutate DNA leading to the activation of 
HERVs. 
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1.2. Rheumatoid arthritis 
 
1.2.1. General Introduction 
 
The word ‘arthritis’ is derived from the Greek word for ‘joint’ (arthron) and 
describes over 200 forms of arthritis affecting both young and old alike.  These 
arthritides can be varied in presentation, being of either an inflammatory or non-
inflammatory nature.  The most common type of inflammatory arthritis is Rheumatoid 
Arthritis (RA) with a global prevalence of between 1-3% (Firestein, 2003). Other 
inflammatory arthritides include Ankylosing Spondylitis (AS), Gout, Psoriatic Arthritis 
(PA) and Systemic Lupus Erythematosus (SLE) (Klippel and Dieppe, 1997).  
Although atypical symptoms of these diseases predominantly focus upon the 
effects of the inflammation within the joint, their overall presentation is varied and can 
be either local or systemic in nature (Figure 1.7). 
 
 
 
 
 
 
Figure 1.7 The main classification path for diagnosis of Rheumatic disease.  RA: Rheumatoid Arthritis; AS: Ankylosing 
spondylitis; OA: Osteoarthritis; Mono: Monoarticular; Poly: Polyarticular.   Taken from ‘Clinical assessment of the 
muscularskeletal system: A handbook for medical students, Arthritis Research Campaign.  2005. 
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1.2.2. Inflammation 
 
The process of inflammation represents an important physiologic response to a 
wide array of stimuli such as infections and tissue damage, which occurs prior to the 
establishment of an immune response.    Despite acting independently of the ensuing 
immune response, the two are inextricably linked as the inflammatory process 
subsequently results in the infiltration of immune cells into the site of inflammation.  
Inflammatory responses can be localised or systemic with an acute or chronic response.  
The duration and intensity of a local response must be carefully regulated in order to 
prevent tissue damage and complement necessary tissue-repair mechanisms.  In many 
autoimmune diseases, this is accompanied with a systemic acute phase response which 
typically exhibit increases in levels of acute phase proteins within the plasma, such as 
C-reactive protein.  Either way, the inflammatory process triggers a series of non-
specific events that confer protection, restricting tissue damage to the site of 
infection/injury (Delves and Roitt, 2000).   
A localised inflammation exhibits symptoms characteristic of inflammation 
including swelling, redness, heat, pain and loss of function.  Within minutes of injury, 
vascular dilation results in an increase in the volume of blood at the site, typically 
resulting in the symptoms of increased redness and heat.  This increase in vasodilation 
is accompanied by increases in vascular permeability, i.e. leakage of fluid from vessels 
which can build up in the surrounding tissues (edema).  As this leakage occurs, kinins, 
clotting factors and fibrinolytic systems become activated through the action of 
bradykinins and fibropeptides (Male et al., 2006). 
Within hours of onset, neutrophils begin to adhere to endothelial walls of blood 
vessels within the vicinity of the injury site, before migrating through vessel walls into 
the surrounding tissue.  These cells play crucial early roles in the establishment of 
inflammation, with numbers peaking within the first 6 hours to almost ten-fold normal 
levels (Pillinger and Abramson, 1995).  Circulating leukocytes are coaxed from the 
periphery in response to the increased expression of adhesion molecules such as E and 
S-selectin, mediated via pro-inflammatory cytokines Interleukin-1 and Tumour 
Necrosis factor – alpha (IL-1 and TNF-α) (Sweeney and Firestein, 2004).  Circulating 
neutrophils become tethered to the vascular endothelium via integrin, before migrating 
through the endothelial layers to the damaged tissue, following chemokine attractant 
gradients established at the site of injury.  Upon arrival at the site of inflammation, 
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neutrophils upregulate increased levels of receptors for chemokines upon their surface, 
thereby establishing chemotaxis (Szekanecz and Koch, 2001).  These can include 
several chemokines; complement split products, fibrinopeptides, prostaglandins and 
leukotrienes.  Activated neutrophils express increased levels of Fc receptors for 
antibody/complement, thereby enhancing phagocytosis of complement/antibody coated 
micro-organisms.  Neutrophils are also able to release reactive oxygen intermediates or 
reactive nitrogen intermediates in eliminating pathogens, although this also contributes 
to tissue injury (Corrigall and Panayi, 2002).  Macrophages enter the inflamed tissues 
between 12-24 hours later, after following chemotactic gradients to the site.  Upon 
arrival they become activated, thereby enhancing phagocytosis and the increased 
production and release of pro-inflammatory mediators and cytokines.  Following 
activation, tissue macrophages secrete IL-1, TNF-α and IL-6, all of which propagate the 
inflammatory process.  Subsequently, more circulating monocytes, neutrophils and 
lymphocytes recognise adhesion molecules and migrate through vascular endothelium 
into the tissue space (Szekanecz and Koch, 2000).  A chronic inflammatory response 
may develop from an initial acute response, where antigen persists, usually resulting in 
a significant degree of tissue damage.  This is characterised by the accumulation and 
activation of macrophages, which in some cases may lead to granuloma formation.  
A systemic response is also able to occur simultaneously with the localised 
response.  This leads to generalised symptoms such as induction of fever, increased 
hormone synthesis, e.g. hydrocortisone, increase in the production of white blood cells 
or the production of acute phase proteins.  During such a period systemic levels of 
inflammatory markers such as C-reactive protein, acting to enhance complement 
mediated phagocytosis, may increase almost 1000-fold (Male et al., 2006). 
    
1.2.3. Rheumatoid Arthritis (RA) 
 
RA is a chronic inflammatory disease of unknown aetiology and complex 
multifactoral pathogenesis, affecting joints and other tissues.  Global prevalence ranges 
between 1-3%, although some populations may have levels as high as 5% (Ferucci et 
al., 2005).  As the most common inflammatory and destructive arthropathy, it has a 
major socio-economic impact in the UK, estimated to cost around £1.3 billion per year 
(Palmer and Cooper, 2006). RA is commonly associated with a group of anti-IgG 
autoantibodies called Rheumatoid Factors (RF) (Westwood et al., 2006).  RA also has a 
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strong genetic association with certain Class II antigens, such as Human Leukocyte 
Antigen (HLA)-DR4, encoded within the Major Histocompatibility Complex (MHC) 
concerned with antigen presentation to T cells (Reviron et al., 2001).  Although RA can 
develop at any age, advancing age is a strong risk factor in developing the disease with 
peaks occurring in the sixth to eighth decades of life (Doran et al., 2002).  Like many 
other autoimmune diseases, gender also appears to play a role with a female to male 
patient ratio of 3 to 1 (Cutolo et al., 2002).  
 
1.2.4. Pathogenesis of Rheumatoid Arthritis 
 
Typical presentations of RA begin as a progressive, symmetrical polyarthritis in 
the peripheral joints.  This then spreads to the larger more central joints as the disease 
progresses, resulting in bone damage and other systemic complications, e.g. nodules.  
RA is characterised by a cell-mediated immune response in the synovial joints (Figure 
1.8). Most researchers agree however, that RA is most likely initiated by an 
antigenic/autoantigenic peptide complexed to either the rheumatoid-associated MHC 
Class II molecules [(HLA)-DR4 or DR1] on the surface of Antigen-Presenting Cells 
(APC), or to antibody leading to the formation of an immune complex (Zvaifler, 1973). 
Immune complexes are presented to APCs with the appropriate receptors, subsequently 
resulting in their activation.  This leads to surface expression of activation markers, 
including the Interleukin-2 receptor (IL-2r), MHC Class II molecules and CD69.  
Expression of such markers leads to the increased production of lymphokines, 
including Interferon Gamma (IFN-γ) and IL-2 (Chung et al., 2006).  Activated CD4 + T 
lymphocytes, through direct cell surface contact and by the release of IFN-γ, stimulate 
monocytes to differentiate into macrophages which play a pivotal role in disease 
pathology, due to numbers present within the pannus and at the Cartilage Pannus 
Junction (CPJ) (Chung et al., 2006).  Macrophages also release IL-1 and TNF-α which 
act to stimulate mesenchymal and endothelial cells, resulting in the release of the 
Matrix Metalloproteinases (MMPs) such as collagenase and stromelysin, which 
degrade connective tissue causing joint damage (Hanaoka et al, 2003).  IL-1 and TNF-
α also act to upregulate the expression of adhesion molecules, further facilitating the 
recruitment of inflammatory cells into the synovial joints and thus driving the 
inflammatory process.  IL-1 and TNF induce the Fibroblast-like Synoviocytes (FLS) to 
express IL-6, chemokines and MMPs, thereby further contributing to articular damage.  
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Additionally IL-1 mediates cartilage degradation directly by inducing MMP expression 
in chondrocytes.  CD4+ T cells, B cells and macrophages infiltrate the synovium, 
leading in particular patient subsets to the formation of lymphoctyic aggregates and 
germinal centres (Goronzy and Weyand, 2005).  The overall increase in synovial 
immune activity results in the activation of fibroblast-like synoviocytes in the thin 
acellular membrane lining the joint, causing them to proliferate producing a 
hyperplastic villus called a ‘Pannus’, which extends across the surface of the 
cartilage/bone assuming an almost tumour-like phenotype (Firestein, 1999).  These 
cells also contribute to monocyte migration by increasing chemokine and IFN-γ 
expression (van Boekel et al, 2002).  Where autoimmune and inflammatory 
mechanisms account for many of the features of RA, the Pannus is primarily 
responsible for the radiologically detected damage of the joint.  This joint destruction 
may also be induced through the deposition of immune complexes upon the surface of 
the cartilage.   
These act as points of binding for neutrophils and complement, which release 
proteolytic and granular contents directly onto the bone.  Free immune complexes 
further activate complement cascades, resulting in further articular degradation 
(Firestein, 2003) and increases in levels of proinflammatory cytokines resulting in the 
upregulation of Receptor Activator for Nuclear factor κB Ligand (RANKL) upon the 
surface of fibroblast-like synoviocytes.  RANKL induces the accelerated maturation of 
osteoclasts (bone-resorption cells) (Schett et al., 2005). A large proportion of the 
cartilage damage is caused by the action of proteases released by the activated 
fibroblast-like synoviocytes in the pannus (Sweeney and Firestein, 2004).  As the 
cartilage disappears, fibrous adhesions are formed and the bone ends are bound together 
by fibrous tissue (bony ankylosis).   
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Figure 1.8  The main immunological processes and cellular interactions active in Rheumatoid Arthritis disease pathogenesis.  
(figure taken from http://www.ambion.com/ -Permission to use diagram given by www.ambion.com).  The pathology of RA is 
characterised by the infiltration of several inflammatory cells in both the Pannus and joint fluid.  Articular manifestations are 
mediated by antigen presented in the context of MHC-II to T lymphocytes.  Upon activation these cells express both chemokines 
and proinflammatory cytokines which act to both further propagate and regulate inflammatory responses.  Activated MHC-II 
molecules secrete regulatory cytokines and growth factors.  TNF-α plays a central role in these processes through indirect 
mechanisms leading to bone and damage, both via induction of IL-1β and through accelerated differentiation of Osteoclasts.  
TNF-α also acts to increase expression of  endothelial cellular adhesion molecules resulting in the recruitment of more immune 
cells into the joint.   
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1.2.5. Clinical manifestations of RA 
 
Like the majority of Rheumatic diseases, the clinical presentation of RA is 
heterogenous and characterised by a wide variation in presentation, prognosis and 
disease severity.  Such heterogeneity makes diagnosis and treatment difficult, with 
clinical manifestations and course being typically characterized by periods of 
exacerbation and remission (Grassi et al., 1998). 
The most common manifestations appear as a symmetrical polyarticular 
arthritis, whose onset occurs early in the disease course.  This primarily affects the 
smaller diarthroidial joints, (most frequently the metacarpophalangeal and proximal 
interphalangeal joints, usually in a symmetrical pattern.    Clinical manifestations of RA 
tend to depend upon the joint involved and the disease stage.  Overall the disease is 
presented as an acute/subacute inflammatory arthritis with patterns of presentation 
being palindromic (episodic), monoarticular (slow and acute), extra-articular 
(tensynovitis and bursitis), in addition to the accompaniment of more generalised 
symptoms, e.g. malaise, fatigue, weight loss and fever.  In order to make a diagnosis of 
RA, a patient must satisfy four or more of the revised criteria for at least 6 weeks, listed 
by the American Rheumatism Association  (ARA) (Table 1.4) (Arnett et al., 1988).  
Such criteria have become useful in the classification of patient subgroups and in the 
assessment of disease frequency and diagnosis.  The disease is not just confined to an 
inflammatory reaction within the joints and manifestations can include extra-articular 
involvement such as rheumatoid nodules.  Vasculitis complications may be evident in 
the small vessels leading to gangrene and arteritis and cardiac involvement can include 
the development of nodules, resulting in valve damage.  Pulmonary involvement may 
include interstitial fibrosis, pulmonary nodules, and pleural effusions.  Overall, the 
course of the disease is primarily progressive with intermittent remission and 
worsening, but continuing disease activity, supported through the slow progression of 
joint symptoms which are atypical of RA.  Regular radiologic studies are of crucial 
value in both prognosis and treatment of patients (Salaffi et al., 1994). 
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                           ARA revised criteria for rheumatoid arthritis 
classification 
Morning stiffness. 
Arthritis of three or more joint areas. 
Arthritis of hand joints. 
Symmetric arthritis. 
Rheumatoid nodules. 
Serum rheumatoid factor. 
Radiographic changes. 
 
 
 
 
1.2.6. The Immunology of different cell types involved in RA 
 
The normal synovium is a relatively acellular structure containing a thin layer of 
synoviocytes.  The sublining is made up of an extracellular matrix consisting of blood 
cells, synoviocytes and mononuclear cells.  In the inflamed synovium of RA patients 
this differs, with patients showing an extensive infiltration of T cells and B cells into 
the joint.   Each of these populations plays a distinct role in the disease pathology of 
RA (Zvaifler, 1973). 
 
1.2.6.1. Roles of B cells in Rheumatoid Arthritis 
 
B cells constitute an essential maintenance of the cellular and humoral 
protective memory and may play a pathogenic role in RA via a number of mechanisms, 
including the production of autoantibodies (AuAbs), activation of APC function, 
modulation of T cells, synthesis of cytokines and ectopic neolymphadenogenesis 
(Lipsky, 2001).   
The evidence supporting a role for B cells in RA initially came after the finding 
of a large number of auAbs to self proteins in RA patients.  Autoantibodies also play a 
role in the generation of immune complexes, which result in the activation of the 
complement cascade pathways (Firestein, 2003).  Potential autoantigens involved in 
RA include Collagen II (Wooley et al., 1984), Sa (Menard et al., 2000), BiP (Berner et 
al., 2000) and p205 synovial protein (Hain et al., 1996).  The majority of those 
identified however, exhibited a typical lack of specificity (Routsias et al., 2004).  Two 
Table 1.4. The revised criteria for the diagnosis of Rheumatoid Arthritis (Arnett et al., 1988). 
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autoantibodies with a notable specificity for RA however, include Rheumatoid Factor 
(RF) and Anti-citrullinated cyclic peptide (anti-CCP).  RF are antibodies directed to 
determinants on the Fc portion of IgG molecules (Westwood et al., 2006), whereas 
anti-CCP recognise the presence of deiminated arginine upon the surface of proteins 
such as Fibrinogen, Filaggrin and Vimentin (Zhou and Menard, 2002).  Interest has 
been generated in these two in particular due to their high sensitivity and specificity, in 
addition to the fact that their presence is detectable years prior to the onset of disease, 
suggesting that the breakdown of immunological tolerance actually begins at an early 
stage, with viable symptoms occurring at an advanced stage of disease (Rantapaa-
Dahlqvist et al., 2003).  The role of B cells in RA pathology is not limited to 
autoantibody production.  They may also play a crucial role in a particular subset of 
patients (11%) whose synovitis is characterised by the generation of Germinal Centres 
(GC) (Kim and Berek, 2000).  With the main cellular component of GCs being 
activated, they provide an environment in which B cells are able to differentiate locally 
into plasma cells.  Furthermore, analysis of the B cell repertoire in GCs suggests a local 
antigen-driven immune response, with most B cells isolated from GCs in the synovium 
exhibiting unmutated VH (Hypervariable) genes.  This supports the hypothesis that they 
recently entered the synovium and were activated at the site of disease (Kim and Berek, 
2000).  Such mutations are limited and subsequent gene rearrangements and mutations 
implicate synovial autoimmunity directed against autoantigens (Clausen et al., 1998).  
It is likely that TNF-α plays a major role in the formation of lymphoid tissue 
(Pasparakis et al, 1996).  Analysis in immune deficient mice has shown that B cells 
express lymphotoxin-α with the expression of this molecule essential for the 
development of Follicular Dendritic cell (FDC) networks (Fu et al., 1998).  One 
suggestion has been that autoantibodies such as RF are produced as a result of B cell 
activation within such follicular structures in the synovial tissue.  Interestingly studies 
using hybridoma lines with RF specificity from an RA patient showed that several lines 
expressed an identical VH gene rearrangement, suggesting an increased affinity for full 
immunoglobulin, leading to the conclusion that RF specific B cells undergo the affinity 
maturation within the synovium (Randen et al., 1992).   The further importance of B 
cells in these structures was shown by the treatment of these regions with anti-CD20 
resulting in the destruction of such structures accompanied by the complete loss of FDC 
networks and disruption of T cell activation (Takemura et al., 2001).  This supports the 
hypothesis that B cells play a pivotal role in synovial inflammation when GCs are 
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involved in pathogenesis.  Work has also focussed more upon B cells expressing B 
lymphocyte stimulator (BlyS) or B cell activating factor (BAFF).  This molecule 
enables the survival of plasma cells that undergo cycles of high antibody-mediated 
inflammation (Dorner, 2006).  BlyS levels in RA are significantly increased to controls 
with RA patients exhibiting enhanced B cell activity (Salzer et al., 2005).  BlyS levels 
in the synovial fluid are increased over that in plasma, suggesting B cell differentiation 
may occur at the site of disease (Dorner, 2006).  The contribution of T cells appears not 
to be necessary for the development of B cell function.  Cross-linking of immune 
complexes with B cell receptor (BCR) or binding of Toll-Like receptors (TLR), may 
result in the activation and conversion of B cells to plasma cells.  Such changes are 
likely to result in the synthesis of proinflammatory cytokines and chemokines, 
including IL-1, IL-6 and TNF-α (Lau et al., 2005).  IL-10 produced by B cells plays an 
important role in inducing dendritic cell activation which results in the enhanced 
antigen presentation and the further differentiation of B cells to plasma cells.  The 
increase in plasma cells then results in the synthesis of autoantibodies such as RF and 
anti-CCP, leading to the local production of immune complexes (Firestein et al., 2003).     
The recent discovery of a spontaneous arthritis mouse model, in which mice 
produce antibodies to the ubiquitous antigen, ‘Glucose-6-Phosphoisomerase (GPI)’, has 
led to a resurgence of interest in autoantibodies and immune complexes (Kouskoff et 
al., 1996) and although the mere presence of autoantibodies within serum may not be 
specific for RA, they could well represent a type of antibody signature for subsets of 
patients.  Innate immunity also plays a role in antibody-mediated arthritis with mast 
cells and TLRs being required for the disease onset in some models (Terato et al., 1995, 
Lee et al., 2002, Ronaghy et al., 2002). 
 
1.2.6.2. Roles of T cells in Rheumatoid arthritis 
 
T-cells are a key component of the human adaptive response and there is now 
growing evidence supporting a potential role for them in RA pathogenesis.  T-cells are 
the dominant species of lymphocyte within the synovium – most likely due to clonal 
expansion (Weyand, 2000).  CD4+ T-cell infiltrates within the synovium typically form 
follicular aggregates with B cells and with CD8+ T cells occupying interfollicular 
tissue.  In fact the synovium appears to provide an environment promoting the survival 
of T cells as despite a high level of expression of apoptotic markers on cells, T cell 
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death rates remain low (Salmon et al., 1997).  T cells themselves within the joint are 
involved in a wide array of activities, including the production of pro-inflammatory 
cytokines, cell to cell interactions, antigen specific responses, osteoclast activation and 
bone resorption suggesting they may play a central role in any disease process 
(Firestein and Zvaifler, 2002).  In addition to this, a distinct correlation of TH1/TH2 (T-
Helper cell subsets) ratios with disease activity has also been reported (van der Graaff 
et al., 1999).  Further evidence supporting the role of a TH1 response in RA 
pathogenesis has been hinted at due to clinical remission of symptoms during 
pregnancy (Olsen and Kovacs, 2002) and decreased prevalence of allergens in RA 
sufferers most likely due to predominant roles of IL-2 and IFN-γ in skewing responses 
to that of a TH 1 nature (Verhoef et al., 1998).  Furthermore studies have shown 
increased numbers of CD4+ T cells producing IFN- γ in the synovial fluid of RA 
patients, compared to controls (Davis et al., 2001) with a distinct association of T cell 
activation marker CD69, with severe disease (Iannone et al., 1996).  Circulating levels 
of CD69+ cells are low, leading to suggestions that T cells expressing CD69 within the 
synovium are likely to be activated at the site of disease.  CD69+ cells may also 
contribute to disease via the induction of CD40 ligands, which have been shown to be 
responsible for the promotion of B cell proliferation, Ig production, monocyte 
activation and dendritic cell differentiation (MacDonald et al., 1997).   
Much speculation has centred upon a role for T cells within RA.  Such claims 
are further supported by the observation that elimination of T cells from rheumatoid 
arthritis patients results in the amelioration of symptoms, although this effect is only 
temporary suggesting it is not a causative role (Vaughan et al., 1984).  Additionally, T 
cells have been shown to passively transfer disease from humans to immunocompetent 
SCID mice models.  Mice with synovial grafts were able to transfer disease symptoms, 
which were subsequently reduced upon treatment with anti-CD2 antibodies (Klimiuk et 
al., 1999).  With the relative risk of developing RA in monozygotic twins (12-62 times) 
and with dizygotic twins (2-17 times) higher than in unrelated individuals (Weyand, 
2000), such evidence suggests a genetic basis for the disease.  To date the best 
identified risk factor for RA has come in the correlation of HLA-DR with incidence of 
inflammatory arthritis (Winchester and Gregersen, 1988).  Conversely a triggering 
antigen may not be a necessary requirement for autoimmunity due to the excessive 
numbers of autoreactive T cells in the synovium (Goronzy et al., 1998, Auger et al., 
1998).  
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The Regulatory T cell (TRegs) response may also be functionally compromised in 
RA patients.   Tregs (CD25+/ CD4+) play the role of policing immunological T cell 
responses, thereby maintaining self tolerance and suppressing proliferation of effector T 
cells.  These cells in RA patients showed an anergic phenotype of effector T cells in 
addition to an inability to suppress proinflammatory cytokines (Ehrenstein et al., 2004).  
They also contribute to disease pathogenesis through the conversion of the synovium 
into lymphoid tissue with T-cell dependent germinal centres, formed from CD4+ T 
cells and CD20+ B cells (Goronzy and Weyand, 2005).  Costimulatory molecules play 
important roles in the T cell activation and the ensuing response, adding a further 
regulatory mechanism to the process of T cell activation.  One of the more prominent T 
cell costimulatory receptors is CD28, which is expressed upon most T cells.  It is a 
receptor responsible for interacting with the B7 family of proteins of which B7-1 
(CD80) and B7-2 (CD86) are the best characterised.  Both are expressed upon the 
surface of APCs and studies in knockout mice have shown their roles to be essential for 
a full, functional T cell response in mice (Shahinian et al., 1993).  In vitro and in vivo 
studies in RA patients have also hinted at a significant role in disease activity with 
upregulated expression of both CD80/86 proteins in the synovium, hinting at a self 
sustained mechanism for T cell activation, even in the absence of a triggering antigen 
(Genovese et al., 2005). 
With increased knowledge of potential T-cell pathways and their subsequent 
role in disease, novel therapeutic strategies have already been designed, targeting T cell 
autoreactivity.  One example is the use of CTLA-4 to interfere in binding between 
CD28 and CD80/86 (Kremer et al., 2003).  Additionally, subsets of T cells 
(CD4+CD28-) have been identified in patients with RA, which bypass the requirement 
for a costimulatory receptor.  Their presence has been reported to correlate with 
progressive erosive disease in patients with early RA.  These cells share some features 
with those of Natural killer (NK) cells with the surface expression of regulatory killer 
activating and inhibitory receptors, in addition to exhibiting cytolytic activity 
accompanied by the synthesis of high levels of pro-inflammatory cytokines (Goronzy et 
al., 2004).   
 
1.2.6.3. The role of fibroblast-like synoviocytes in RA 
 
The rheumatoid synovium harbours cell populations of synoviocytes which can 
be separated into two distinct subfamilies - those of monocyte lineage (macrophage like 
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synoviocytes) and those of fibroblast lineage (Fibroblast-like synoviocytes) (Duke et 
al., 1982).  Originally these cells were thought to play roles of little or no importance in 
disease pathogenesis.  It is now becoming apparent however, that both populations 
(particularly those cells of fibroblast-like origin) are actively engaged in the initiation 
and perpetuation of rheumatoid arthritis) and it is this feature that distinguishes RA 
from other inflammatory arthritides (Huber et al., 2006). 
Fibroblast-like synoviocytes appear to be differentiated into several different 
subpopulations of cells within the synovium, dependent upon their location 
(Fassbender, 1983).  These populations also differ in their secretion patterns of matrix 
proteins, cytokines, adhesion molecules, i.e. VCAM-1 and costimulatory molecules, 
e.g. CD40 (Buckley, 2003).  Synoviocytes within the acellular synovial membrane 
lining in RA patients (RASFs) have been found to differ substantially from those found 
at deeper levels within synovial tissue, as they take on an activated phenotype 
associated with an invasive and aggressive nature (Pap et al., 2000b).  These activated 
cells are able to cause disease, either by direct processes, i.e. the attachment to cartilage 
via an upregulation of adhesion molecules and the subsequent production of matrix 
digestive enzymes (Muller-Ladner et al., 1996), or by indirect mechanisms such as the 
induction and differentiation of macrophages into osteoclasts via the upregulation of 
RANKL, in response to proinflammatory cytokines (Nakano et al., 2004, Gravallese, 
2002, Takayanagi et al., 2000). 
There are a number of potential mechanisms by which these cells can be 
activated.  These include innate immune mechanisms, signalling from neighbouring 
fibroblasts and also by components of the immune response.  TLRs are key structures 
in the innate immune response for the recognition of conserved microbial patterns 
(Uematsu and Akira, 2006).  Their activation can result in the upregulation of 
proinflammatory cytokines and chemokines (Pierer et al., 2004).  Subsequent reactions 
lead to the establishment of a chronic inflammatory reaction within the synovium.  
Production of proinflammatory cytokines contributes to the activation of RASFs, in 
addition to growth factors and cross-talk between neighbouring fibroblasts.  TNF-α is 
one of the major players in triggering inflammation and joint destruction with its 
importance demonstrated in the TNF transgenic mouse model (hTNFtg) (Keffer et al., 
1991) in which systemic overexpression leads to the initiation of chronic synovitis, 
cartilage destruction and bone erosion (Zwerina et al., 2004).  Other cytokines that may 
contribute to fibroblast activation include IL-1, IL-15, IL-22 and IL-21R (Jungel et al., 
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2004, Ikeuchi et al., 2005).  However cytokines do not play an exclusive role in 
activating RASFs as has been shown in SCID mouse co-implantation models (Geiler et 
al., 1994, Muller-Ladner et al., 1996), which showed that disease processes could still 
occur in the absence of both inflammatory cells and proinflammatory mediators 
(Muller-Ladner et al.,, 2003).  Amongst the direct consequences of fibroblast activation 
is the upregulation of adhesion molecules upon their surface.  This increase in 
expression enables the direct attachment of RASFs to articular cartilage.  In RA, the β1 
subfamily of integrins plays an important role.  These integrins mediate the attachment 
of RASFs to fibronectin-rich sites on cartilage and collagen (Ishikawa et al., 1996).  
Upon binding, integrins activate the early cell cycle within the RASF, activating 
expression of MMPs, i.e. zinc containing endopeptidases involved in tissue 
remodelling.  Together with oncogenes c-fos and c-myc, these all play roles in 
activating RASF, leading to tissue destruction (Fujiwara et al., 1995, Dike and Farmer, 
1988). 
The process of tissue degradation comprises four major stages: 
 
• Growth and activation. 
• Spreading. 
• Invasion of inflamed synovial tissue. 
• Destruction of cartilage. 
With the overall degradation process being mediated by MMPs, cathepsins and an 
activated plasmin system (Trabandt et al., 1991, Huber et al., 2006), the exact 
mechanisms by which RASFs are activated in RA are still unknown, although it is clear 
that the altered aggressive phenotype of RASFs mirror specific alterations within the 
intracellular signalling pathways and transcriptional profiles, e.g. apoptotic profiles, 
upregulation of oncogenes and the downregulation of tumour suppressor genes, may all 
contribute to the subsequent activation of RASFs.  Transcriptional profiles particularly 
can be significantly modified by stimulation with either TH1 (IFN-γ) or TH 2 (IL-4) 
(Parsonage et al., 2003).  Evidence suggests that the subsequent hyperplasia within the 
synovial tissue occurs due to impairment in apopotic mechanisms of RASFs and 
macrophages.  The resulting deficiency in apoptosis results in the prolonged survival of 
72 
 
RASFs.  This is supported by upregulated levels of bcl-2, sentrin-1 and FLICE-
inhibitory proteins (FLIP) identified at the sites at the cartilage/pannus junction (Catrina 
et al., 2002, Goberdhan and Wilson, 2003).  This activation or changes in cellular 
expression may also be due to changes in tumour suppressor gene expression.  
Phosphatase and tensin homolog (PTEN) is involved in cell cycle arrest and apoptosis, 
with its expression in RA patients shown to be significantly reduced to that observed in 
healthy synovial fibroblasts, whilst little or no expression has also been recorded at the 
cartilage pannus junction (Pap et al., 2000a).  
Although overexpression of wild type (wt) p53 is characteristic of RA, its 
expression has also been shown to be significantly reduced in RA patient SF cells 
invading articular cartilage (Seemayer et al., 2003).  p53 is a transcription factor that 
plays a central role cell growth, cell cycle control, DNA repair and apoptosis and as 
such it has been reported to be mutated in about 55% of human cancers (Hollstein et al., 
1991).  Overexpression of p53 occurs when DNA damage occurs within the cell, 
however if DNA strand breaks are severe and persistent this may result in mutations of 
p53 that may result in the dysregulation of apoptosis and tumor suppression 
mechanisms.  This can prove significant in RA as inactivation or mutation of wt-p53 has 
already been shown to result in enhanced FLS proliferation, incease anchorage 
independent growth and lead to invasiveness into the cartilage (Pap et al., 2001; 
Aupperle et al., 1998).  Additionally, mutant versions of p53 have been shown to lose 
their gene repressor activity i.e. that of MMP1,3 and 13 (Sun et al., 2004)    L1 
retrotransposons in synoviocytes have also been shown to induce Mitogen-activated 
protein kinase (MAPK) p38 with p38 able to induce and upregulate MMP-1, MMP-3, 
IL-6 and IL-8 (Suzuki et al., 2000). 
Another theory recently proposed, suggests the inflammatory response is a result of 
the inability of the RASFs to switch off the resulting inflammation, thus resulting in the 
inappropriate retention of leucocytes within the synovium, with increased expression of 
surface chemokines, i.e. CXCL12, reported on RASFs (Buckley et al., 2000).  Such 
increases may result in CD4+ T cells accumulating within the synovium at a point 
when the inflammatory response should be winding down (Buckley et al., 2004).  This 
ectopic expression of chemokines has also been observed in other autoimmune 
manifestations (Amft et al., 2001), in addition to being upregulated in stromal cells in 
response to microbial infection (Mazzucchelli et al., 1999). 
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1.2.7. Treatment strategies in Rheumatoid arthritis 
 
It has now been identified that joint damage occurs early in the course of 
disease pathogenesis in RA patients; therefore within two years of disease ~60% 
patients show some radiographical evidence of some degree (van der Heijde, 1995).  
Whilst the effectiveness of early use of disease modifying anti-rheumatic drugs 
(DMARDS) has been well documented, these approaches until recently have been 
limited to mono- or combination therapy with either immunosuppressives or DMARDs 
such as Prednisolone (Saag et al., 1996), intramuscular injections of gold salts 
(Myochrysine® and Solganal - which have been reported previously to work through 
inhibition of T cell proliferation (7932408) (Rau et al., 1997) and Sulphasalazine and 
Methotrexate (Ortendahl et al., 2002).  With the overall efficacy and response to new 
drugs defined by an outcome measure of the American College of Rheumatology 
(Felson et al., 1995) in recent years, several new drugs have been developed in order to 
target specific points within the disease process.  Through observations made in mouse 
models and its established upregulation of RANKL (Keffer et al., 1991), TNF-α plays 
an important role in the pathogenic mechanisms of RA (Choy and Panayi, 2001).  
Three agents have recently been developed in order to target and inhibit the effects of 
this particular cytokine.  Infliximab is a chimeric anti-TNF-α antibody consisting of the 
antigen binding region of mouse antibody and the constant region of human antibody.  
It has shown the ability to bind to both soluble and membrane bound TNF-α, thereby 
eliminating binding to receptors and those cells expressing it upon their surface 
(Goldblatt and Isenberg, 2005).  Etanercept is a soluble TNF-α receptor fusion protein 
composed of two dimers each with ligand binding portions of type-2 receptors (p75) 
linked to the Fc portion of human IgG1.  Proteins are able to bind to both TNF-α and 
TNF-β, thus preventing each from interacting with their respective receptors.  
Adalimumab is a recombinant human IgG1 monoclonal antibody with the ability to 
bind TNF-α, thereby precluding binding to its receptor.  The monoclonal antibody is 
also able to lyse cells that express the cytokine upon their surface.  As a human 
recombinant antibody it has the advantage of avoiding the generation of anti-chimeric 
antibodies.  Several side effects and problems have been associated with the use of anti- 
TNF-α therapies ranging from minor side effects (Day, 2002), to the exacerbation of 
infections such as histoplasmosis and tuberculosis (Nakelchik and Mangino, 2002, 
Kroesen et al., 2003) and demyelinating neurological diseases (Mohan et al., 2001).   
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IL-1 is a pro-inflammatory cytokine produced by stimulated monocytes, 
macrophage and synoviocytes (Dinarello, 1996).  IL-1 receptor antagonists compete 
with IL-1 for binding to the receptor and thus subsequently downregulating IL-1 
activity.  IL-1 has been shown to stimulate the release of MMPs and increase the bone 
resorption of osteoclasts, thereby having a direct influence over bone erosion.  This was 
shown in mice, deficient in IL-1 receptor antagonists which developed inflammatory 
arthritis similar to RA (Horai et al., 2000).  It was also shown in RA patients who 
exhibited levels of IL-1ra lower than expected, relative to levels of circulating IL-1 
(Arend et al., 1998). 
Contrary to long standing belief that RA was a predominantly T cell mediated 
disease, the role and importance of B cells in disease pathogenesis was reaffirmed by 
the development and trials of B cell depletion therapies, most notably that of Rituximab 
(Leandro et al., 2002).  B cells contribute to RA pathogenesis through a number of 
mechanisms (Section 1.2.6.1).  Autoantibodies have the ability to drive their own 
production, this thereby provided the initial rationale for the proposal that the 
elimination of B cells may result in prolonged disease remission (Edwards et al., 1999).  
B cell development is generally defined by a series of changes in surface markers.  
CD20 is expressed at intermediate stages before being lost prior to the final 
maturation/terminal differentiation into plasma cells.  Rituximab is the form of a 
chimeric antibody raised to human CD20 and is thought to act via complement 
mediated antibody dependent cell-mediated cytotoxicity, induction of apoptosis and 
inhibition of cell growth (Reff et al., 1994).  Treatment results in the rapid depletion of 
CD20+ B cells in the peripheral blood.  These are subsequently replenished by stem 
cells within 3-12 months after treatment (Maloney et al., 1997).  IL-6 is produced by 
lymphocytes, monocytes, fibroblast synoviocytes and endothelial cells and is a major 
cytokine in the process of inflammation and haematopoiesis (Nishimoto and Kishimoto, 
2006).  Whilst evidence clearly shows a role in inflammatory processes, over 
expression leads to the generation of autoreactive T cells and osteoclasts, stimulation of 
autoantibody production and the release of inflammatory mediators (Nishimoto and 
Kishimoto, 2004).  Atlizumab is a humanised anti-IL-6 receptor monoclonal antibody.  
Despite limited success at targeting T-cell pathways, i.e. anti CD4+ antibodies (Smolen 
and Steiner, 2003), anti-CD5 ricin toxin immunoconjugate (Olsen et al., 1996) and anti-
CD7 therapy (Keystone, 2002) , some therapies targeting such pathways have shown 
promise.  A successful example of interfering with T-cell regulatory pathways includes 
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‘CTLA4lg’.  CTLA4lg works via interference with the CD80/86 pathway (Section 
1.2.6.2) which acts as a negative feedback loop for suppression of T cell activity and as 
a safeguard against autoimmunity.  CTLA4lg is a fusion protein that binds to CD80/86, 
thereby preventing their binding to other CD28 receptors, thus activating further T 
cells.  This approach has shown promising results in trials (Firestein, 2003).    
Eculizumab is a humanised monoclonal antibody, which prevents the cleavage of 
complement component C5 into its pro-inflammatory components (Kaplan, 2002, 
Smolen and Steiner, 2003).  Antibodies to adhesion molecules such as Intracellular 
Adhesion Molecule-1 (ICAM-1) which act to block the entry of lymphocytes into the 
joint have also shown promising results (Mikecz et al., 1995). 
 
1.2.8. Risk factors for RA 
 
Despite intensive research into the triggering cause of RA, the underlying causal 
agents have remained elusive with a combination of environmental and genetic factors 
likely being responsible.  Risk factors highlighted within the literature include age, 
gender, hormonal and reproductive factors and lifestyle (Goronzy, 2005).  Increasing 
age has been reported to correlate with incidence of disease with increasing age peaking 
between 75-85 years (Doran et al, 2002).  Peaks are also observed in women at 
menopausal age (Voigt et al, 1994) and this combined with observations of remissions 
during pregnancy suggest a role for hormonal and autocrine modulation (Masi et al, 
1995).  Evidence has been reported suggesting associations with the Oral contraceptive 
pill (OCP).  The OCP has been suggested to have a protective effect against RA, 
however this has yet to be substantiated (Spector and Hochberg, 1990).  Thyroid and 
neuroendocrine hormones can also influence RA, partly through actions in 
macrophages (Wilder and Elenkov, 1999).  Other associations have included a positive 
link between smoking and incidence of RA in women (Hernandez Avila et al., 1990, 
Stolt et al., 2003) which has recently also been linked to the strong genetic background 
of a (HLA)-DRB1 genotype (Padyukov et al., 2004).  These have additionally been 
linked, as with OCP to lower androgen levels – a risk factor for the onset of RA (James, 
1993).  Other plausible links include environmental factors including red meat (Pattison 
et al., 2004b), which acts as a susceptibility marker.  Oil-rich diets, such as those in the 
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Mediterranean, (Cyranowski et al., 2004) and vitamin C (Pattison et al., 2004a) have 
been reported to have a protective effect.  
 
Virus Genus / 
family 
Genome Protein Disease Comment 
Retroviruses 
(endogenous) 
Dep. on family ssRNA Varied: 
Simple 
Varied: 
None conclusive 
For most part lie 
dormant within human 
genome 
HTLV HTLV-BLV 
(formerly 
Oncovirinae) 
Diploid RNA 
 
6 ATL/ L/ TSP Distinguished by 
typical genome and 
ability to cause 
tumours 
Rubella Rubivirus / 
Togaviridae 
 
RNA - GM/ PA-(adults) - 
Parvovirus 
B19 
Erythrovirus / 
Parvoviridae 
ssDNA 
 
3 EI/ AC/ FI 
 
Can form persistent 
infection in 
immunocompromised 
patients. 
EBV γ-Herpesvirinae/ 
Herpesviridae 
 
Linear 
dsDNA 
80-100 IM/ L Ubiquitous virus 
CMV β- Herpesvirinae 
/ Herpesviridae 
dsDNA 
Linear 
80-100 IM-like disease 
 
Important in transplant 
recipients 
Risk of maternal 
infection 
HHV-6 β- Herpesvirinae 
/ Herpesviridae 
dsDNA 
Linear 
80-100 ES/R– children 
IM-like disease - 
(adults) 
- 
HSV 1/2 α-herpesvirinae/ 
Herpesviridae 
 
Linear 
dsDNA 
80-100 HW Ubiquitous virus 
Hepatitis B Orthohepadnavir
us / 
Hepadnaviridae 
Circ. dsDNA 
 
6 HC/ LC/ CH Spread by blood or 
sexual activity 
Hepatitis C Hepatitis C-like 
virus / 
Flaviviridae 
dsDNA 11 HC/ LC Blood borne 
Adenovirus Mastadenovirus 
/ Adenoviridae 
 
Linear 
dsDNA 
- RI/ PF/ EK/ GI Airborne, 
ubiquitous 
 
 
 
 
 
 
 
 
Much of the disease pathology and the immunological mechanisms at work in 
disease processes suggest an initial trigger is responsible for the disease.  The identity 
of this agent has however remained elusive, despite a large number of studies focusing 
upon the question.  Those investigated have included bacterial and fungal agents such 
as Proteus and Klebsiella (Tani et al., 1997), Candida albicans (Hida et al., 2007) and 
Mycoplasma species (Postepski et al., 2003).  Much attention has also focused upon 
viral pathogens, and potential roles that they may play in either triggering or 
propagating disease processes (Masuko-Hongo et al., 2003) (Table 1.5) 
Table 1.5 The main viruses that have been implicated in the pathogenesis of rheumatic disease-like symptoms within 
the literature (Section 1.18.1). 
(Key: ATL: Adult T-cell leukaemia; L: Lymphoma; TSP: Tropical Spastic Paraparesis; EI: Erythema Infectiosum; 
AC: Aplastic Crisis; FI: Fetal infection; IM: Infectious Mononucleosis; ES: Exanthema Subitum; R: Roseola (Slapped 
cheek syndrome); HW: Herpetic warts; GM: German Measles; HC : Hepatocellular Carcinoma ; LC : Liver 
Cirrhosis ; CH : Chronic Hepatitis ; PA : Polyarthritis; RI: Respiratory infection; PF: Pharyngoconjunctivial Fever; 
EK: Epidemic Keratoconjunctivitis) 
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1.3. Aims and Objectives 
 
The overall aims of this research project were to test the association between the 
expression of HERV-K and onset of Rheumatoid Arthritis.  This involved the direct 
elucidation of those mechanisms by which HERVs may play a role in, or trigger disease 
immunopathology.  This was undertaken in an approach that ran parallel to the central 
dogma of biology itself, with investigations taking place on a DNA, RNA and protein 
level.  This approach enabled the determination of the nature of HERV upregulation, 
i.e. whether it resulted in protein production, suggesting a complete open reading frame 
read-through, thus narrowing down potential mechanisms by which HERV-K may 
trigger or propagate the disease.  Such approaches included: 
 
1. DNA: A bioinformatic approach to the identification of putative HERV-K 
encoded epitopes that may play a role in molecular mimicry through shared sequence 
homology with disease autoantigens (Chapter 3). 
2. RNA: The development of a real-time PCR assay and its use in the analysis of 
HERV gag gene expression in RA patients and controls and the use of the 
aforementioned tools and reagents in the exploration of different mechanisms by which 
HERVs may trigger or participate in disease pathogenesis (Chapter 5). 
3. Protein: An immunological assay of epitope expression in patient samples 
comparing RA versus disease controls (Chapter 4). 
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Chapter 2: Materials & Methods 
 
All reagents were purchased from Sigma, UK unless otherwise stated. 
 
 
2.1. Ethics applications 
 
Ethical approval involving work with NHS patient samples, during the project 
was sought from the relevant Local Regional Ethics Committees (LRECs) (Table 2.1).  
Ethical approval for selected project protocols was also granted from internal 
University ethics committees. 
 
Committee Reason for 
Application 
Site/Sample type Date 
Approved 
Wolverhampton LREC EPE New Cross/  SF, PB 09/04 
University of Wolverhampton  Internal ethics – ST RES20a/b 02/04 
Wolverhampton LREC EPE New Cross/ ST 04/05 
Wolverhampton LREC SA New Cross/ IBD PS 11/06 
 
 
 
 
2.2. Collection and processing of patient samples 
 
2.2.1. Collection of patient samples 
 
The ethics committees of the New Cross Hospital, Wolverhampton granted 
ethical approval for the collection of patients’ samples (project number 985). Specific 
inclusion criteria stipulated that all patients with RA must be in attendance at the 
Rheumatology clinic, New Cross Hospital, Wolverhampton, and have fulfilled the 
diagnostic criteria set by the American College of Rheumatology (ACR).  No exclusion 
criteria were set for this investigation.  Blood was also taken from other non-RA 
patients in attendance at the clinic (IBD, SLE and OA) and all samples were taken by 
staff working at the clinic.  10ml of venous blood were collected in sterile preservative-
free heparin from each patient after informed consent had been given.  Blood samples 
were also obtained from healthy volunteers of known age and sex.  In order to 
Table 2.1 Ethics applications submitted for work carried out during this research project.  (Key: SF – Synovial Fluid; PB – 
Peripheral Blood; ST – Synovial Tissue; SA – Substantial Amendment; SSE – Site Specific Extension; EPE - Existing Project 
Extension; IBD PS– Irritable Bowel Disease patient serum.). 
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maximise accuracy of the investigation all blood samples were processed within 3 
hours.  All steps were performed under aseptic conditions. 
 
2.2.2.  Isolation of PBMN cells from whole venous blood 
 
Mononuclear cells were separated from 10ml whole blood using a Ficoll 
gradient method.    Anti-coagulated venous blood was layered onto 7ml Histopaque®-
1077 in a 20ml sterile universal.   This was then centrifuged at 400 x g for 30 min at 
room temperature.  During centrifugation, erythrocytes and granulocytes were 
aggregated by polysucrose and rapidly sedimented at the base of the tube whilst 
lymphocytes and mononuclear cells remained at the plasma-Histopaque®-1077 
interface (Figure 2.1).  The upper layer (plasma) ending approximately ‘0.5cm’ (see 
Fig.2.1), above the central opaque interface (containing mononuclear cells) was 
aspirated and transferred to a sterile universal using a Pasteur pipette. Plasma was 
stored at -70ºC until required in serological investigations.  The opaque interface was 
also transferred to a sterile centrifuge tube.  These cells were resuspended in 1 ml of 
TRI reagent for RNA extraction (Chomczynski and Sacchi, 1987).  
 
 
 
 
 
 
 
 
Figure 2.1  Principle of gradient separation procedure used to separate different cell populations from patient blood. 
A) Histo-Paque was placed at the bottom of a tube, B) Venous blood was layered on top of the Histopaque. C) After 
centrifugation the following layers were visible in the tube, from top to bottom: Plasma and other constituents; Mono-
nuclear cells (PBMC/MNC); Histo-paque, erythrocytes & granulocytes (sometimes pelleted at the tubes base). 
 
A B C 
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2.2.3. Isolation of cells from synovial fluid 
 
Between 10-20 ml of synovial fluid were aspirated from the knee joints of RA 
and OA patients and kept on ice in sterile universals.  Synovial fluid was diluted in 
10ml 1x PBS before being centrifuged at 350 × g for 10 min.  The supernatant was 
discarded and the cell pellet washed 2-3 times with PBS.  In order to prevent red blood 
cell (RBC) contamination, cell pellets were incubated in lysis buffer (0.144 M NH4Cl, 
1mM NaHCO3) for 15-20 min at room temperature before centrifuging at 350 x g for a 
further 10 min.  Cells were resuspended in 1ml TRI reagent for RNA extraction 
(Chomsacchi method) (2.8.2).  
 
2.3. Separation of specific cell populations using paramagnetic beads 
 
For a small number of new samples, different species of lymphocytes were 
separated from one another to ascertain levels of HERV-K (HML-2) in different cell 
populations.  This was done using a series of washes with paramagnetic beads coated 
with antibody specific for CD19 (B-cells), CD4 and CD8 (T-cells).  The Ficoll interface 
containing mononuclear cells was separated into three equal aliquots.  Each aliquot was 
then mixed with dynabeads specific for the cell population being extracted i.e. B-cell 
(CD-19).  Dynabeads (25ul/ml-1 sample) were added to the interphase and incubated at 
4ºC under agitation before incubating at room temperature for 2 min with the MPC 
Dynal magnet (Dynal technologies, UK).  After separation the supernatant was 
discarded and cells/dynabeads washed 5 times with PBS/ 0.1% BSA.  Beads and cells 
were separated from one another using commercially available Detachabead® kits 
(Dynal technologies, UK).  Cells and Detachabead® reagents were mixed and 
incubated together at room temperature for 45 min before placing upon the MPC Dynal 
magnet, for a further 5 min were decanted into a sterile centrifuge tube and washed 
three times in RPMI/1% FCS before centrifuging for 8 min at 500 x g.  Cell pellets 
were finally resuspended in appropriate volumes of RPMI/1% FCS.  These cells were 
then lysed in RLT buffer for RNA extraction using the QIAAmp kits (Qiagen, UK). 
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2.4. Bioinformatic analysis 
 
Reference sequences of potential autoantigens were identified in rheumatic 
diseases and their protein sequence was extracted from the NCBI/ Genbank online 
database (www.ncbi.nlm.nih/).  Sequences were edited accordingly using a standard 
text editor. 
 
2.4.1. Primary and Secondary structure analysis 
 
Protein residues were analysed via in silico analysis of physicochemical 
parameters, using normalised scales derived from previous experimental data, in order 
to elucidate the antigenic structure of each autoantigen.  Predictions were made using 
computerised algorithms for Hydrophilicity (Hopp and Woods, 1981), Residue polarity 
(Grantham, 1974), Solvent accessibility (Janin, 1979) and flexibility index (Bhaskaran 
and Ponnuswamy, 1988).  These analyses were performed with the bio-computing 
software programmes from http://www.expasy.ch/cgi-bin/protscale.pl.  Window 
lengths on these programs were set to ‘9 residues’ to mirror the length of the peptide 
being produced.  Thresholds were designated as the top 25% of values for each protein.  
All residues with values within this top 25% were considered to be over the threshold 
level, and therefore antigenic.  All studies were run in parallel with, and results 
compared to, a previously published B-cell epitope prediction algorithm called 
BCEPRED (http://www.imtech.res.in/raghava/bcepred/) that has been claimed to reach 
80% prediction accuracy (Saha and Raghava, 2004).   
Protein secondary structure analysis including the elucidation and mapping of  
Beta-turns was examined using the neural network tool ‘Betatpred2’ server at 
http://www.imtech.res.in/raghava/betatpred2/ (Kaur and Raghava 2003) and the 
PSIPRED tool (McGuffin et al.,, 2000) available online from 
http://globin.bio.warwick.ac.uk/psipred/.  The PSIPRED program had repeatedly scored 
highly in prediction accuracy using the CASP4 and EVA projects 
(http://cubic.bioc.columbia.edu/eva.html).  Protein sequence alignments were 
performed using an online alignment tool LALIGN 
(http://www.ch.embnet.org/software/LALIGN_form.html). 
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2.5. Peptide and bleed synthesis 
 
A single peptide ‘PLSK’ (VGPLESKPRGPSPLSA) was synthesised manually 
using Fmoc solid phase synthesis.  Synthesis was carried out on a 0.2 mM scale.  Kaiser 
tests were employed to verify coupling and deprotection (Chan et al., 2000).  Peptide 
identity was verified by molecular weight using Matrix assisted laser desorption 
ionisation time of flight mass spectrometry (MALDI-TOF) (Kratos Analytic Kompact 
probe, UK).  The peptide was freeze dried and resuspended in sterile phosphate 
buffered at 10mM concentration and stored at -20ºC. Peptides ‘GfPN1kpr’ 
(GPSESKPRGTSPLPAG) and ‘GfPN2eip’ (PCPKEIPKESKNTEVL) and specific 
antiserum were synthesised commercially (Severn Biotech, UK). 
Antibodies specific for these two peptides (identified in Chapter 3 - GfPN1kpr 
and GfPN2eip) were raised commercially (home office license no.: 40\2154).  These 
peptides were conjugated to the carrier - Purified protein derivative (PPD) prior to 
inoculation into two rabbits in order to obtain polyclonal antibodies to the peptide.  
Bleeds were harvested at specific time intervals including pre-immunisation, 7, 14, 21 
and 28 days post-immunisation.  Polyclonal serum was subsequently used for 
optimisation and comparison purposes.  The final optimized assay and reagents were 
then used to detect anti-HERV antibodies in RA patient serum and disease controls. 
 
2.7. Serological assays 
 
2.6.1. Indirect ELISA 
 
Wells on a 96 well plate were coated with 400ng/50µl of peptide and incubated 
overnight at 37ºC.  Plates were washed three times with PBS using a Well washer 4 
MK2 (Thermo lab systems, Waltham, MA) and blocked with 2% Bovine serum 
albumin (BSA) in PBS for one hour at 37ºC.  After three washes with PBS/ Tween20 
(Tw20) (0.1%) primary antibody was diluted in PBS/ Tw20 (0.05%)/ BSA (2%) and 
50µl was added to the wells and incubated at 37ºC for one hour.  After washing three 
times with PBS/ TW20 (0.1%), conjugate (Dako, UK) was diluted appropriately 
according to manufacturers instructions in PBS/ TW20 (0.1%) / BSA (2%) and 
incubated for one hour at 37ºC in the dark.  Plates were washed with PBS/ TW20 
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(0.1%) before 3, 3’, 5, 5’-Tetramethyl Benzidine (TMB) liquid substrate system was 
added to each well.  Reactions were stopped after 5 minutes using 2N Hydrochloric 
acid.  Absorbance was measured at 450nm using a Multiscan MS spectrophotometer 
(Thermo lab systems, Waltham, MA). 
 
2.6.2. Inhibition ELISA 
 
An inhibition assay was performed as described previously (Westwood & Hay, 
2000).  Standard curves were produced for each antibody of interest using the indirect 
ELISA protocol above.  Analysis of curves was used to predict the dilution giving an 
absorbance of 0.5.  This antibody dilution was then made up in diluent with PBS/ Tw20 
(0.05%)/ BSA (2%) and incubated with 0.5 log10 dilutions of the appropriate or control 
peptide for 1 hour at room temperature.  Incubated preparations were transferred to a 
plate pre-coated with the 400ng/50 µl of corresponding peptide, with each sample 
repeated in triplicate.  After washing three times with PBS/ TW20 (0.1%) the 
appropriate conjugate (Dako) was diluted in PBS/ TW20 (0.1%)/ BSA (2%) according 
to manufacturers instructions and incubated for one hour at 37ºC in the dark.  Plates 
were washed with PBS/ TW20 (0.1%) before 3, 3’, 5, 5’-Tetramethyl Benzidine (TMB) 
liquid substrate system was added to each well.  Reactions were stopped after 5 min 
using 2N Hydrochloric acid.  Absorbance was read at 450nm using a Multiscan MS 
spectrophotometer (Thermo lab systems, Waltham, MA). 
 
2.6.3. Semi quantitative RF assays 
 
The RA latex test kit (Plasmatec, UK) was used in order to test serum samples 
for the presence of rheumatoid factor (RF).  After allowing the kit reagents and patient 
serum samples to equilibrate to room temperature upon the test slide using disposable 
sterile pipettes.  The latex reagent was placed next to the serum and both were mixed 
using the spatula provided.  RF was quantitatively determined in patient samples by 
comparing agglutination at different serum dilutions (Table 2.2).  Four sterile eppendorf 
tubes were labelled and 100 μl of saline provided, was placed in each tube.  In the first 
tube, 100 μl of patient serum was also added and the two were briefly mixed.  Serial 
dilutions of serum were then established in the remaining tubes using 100 μl of diluted 
patient sample.  These were then tested as described above with latex reagent upon the 
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test slide.  Positive and negative controls supplied by the kit were used with each 
sample. 
 
 
Dilutions 1/2 1/4 1/8 1/16 
Sample serum 100 μl - - - 
Saline 100 μl 100 μl 100 μl 100 μl 
 → 100 μl   
  → 100 μl  
   → 100 μl 
Sample volume 100 μl 100 μl 100 μl 100 μl 
8xNo. Of 
dilution 
8 x 2 8 x 4 8 x 8 8 x 16 
RF titre 
(I.U/ml) 
16 32 64 128 
 
 
 
2.6.4. Immunofluoresence 
 
Cells were cultured at appropriate seeding concentrations (e.g. 5 x 106) in BD 
Falcon Polystyrene vessel 8 chamber culture slides (Becton Dickinson) with 500μl 
fresh supplemented medium (see Appendix III) at 37ºC with 5% CO2  until the 
monolayer grew to between‘70-90%’ confluency.  Spent medium was then discarded 
and cover slips washed with PBS without Ca2+/Mg2+ before incubating in 2ml of 
Methanol at room temperature.  Methanol was removed using disposable Pasteur 
pipettes and monolayers were incubated a further 2 min in 2ml Acetone to fix cells.  
Acetone was removed and fixed cells were washed twice in 2ml 1 x PBS without 
Ca2+/Mg2+.  Cover slips were blocked by incubating in 2ml 2% BSA for 1 hour in order 
to prevent non-specific binding.  Primary antibody was diluted to appropriate 
concentration using 1 x PBS/ BSA (2%) before adding 250 μl to each culture chambers 
and incubating at room temperature for 1 hour under agitation.  Cells were washed 
three times with PBS without Ca2+/Mg2+ for 5 min under agitation.  Slides were then 
Table 2.2Table showing the dilution strategy required for quantitation of rheumatoid factor in patient serum 
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treated with a secondary conjugate (with a goat anti-rabbit – FITC) (Dako, UK).  After 
staining, chamber sides were removed using the tool provided before a single drop of 
anti-photobleach agent containing DAPI counter-stain (Vectashield™) was added to the 
slide.  Sterile glass coverslips were placed over the fixed and stained cell monolayers 
and sealed with nail varnish before drying for 2 - 5 min in the absence of light.  Slides 
were then checked for immunofluoresence using the confocal microscope (Carl Zeiss, 
US) using the FITC and DAPI filters. 
 
2.7. Cell culture 
 
A diverse number of cell types were grown for work within the project ranging 
from cancer cell lines to lymphocytes and primary cells derived from disease tissue.  
Cells were grown in conditions dictated by their characteristics i.e. adherent, semi-
adherent or suspension.  Medium was made up freshly and supplemented accordingly 
dependent upon the requirements of each cell line (for specific passaging conditions 
and reagents refer to Appendix III). 
 
2.7.1. Adherent cells 
Cultures were monitored using an inverted microscope (Olympus UK, UK) to 
assess both confluency and the presence of bacterial or fungal contaminants.  Spent 
medium was removed using disposable sterile glass pipettes and the monolayer washed 
with a volume equivalent to half the culture medium of PBS without Ca2+/ Mg2+.  Cells 
were washed before adding Trypsin/ EDTA to the washed monolayer using 1ml per 
25cm2 of surface area.  The flask was tilted to allow the whole monolayer to come in 
contact with trypsin before incubating at 37ºC for 2-10 min or until cells detached.  
Cells were resuspended in 8ml fresh serum containing medium to inactivate the trypsin 
(at this stage a small volume was removed for a cell count when required).  For those 
cultures able to grow in the presence of diluted trypsin (e.g. HEK-293, MCF7), an 
appropriate number of cells were transferred to a new flask of pre-warmed medium.  In 
cultures sensitive to trypsin (e.g. Tera-1), cells were transferred to a sterile universal 
and spun at low speeds (110 x g) for 5 min.  Medium was discarded and the cell pellet 
resuspended in an appropriate volume of fresh medium.  This was then transferred 
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appropriately to new flasks of pre-warmed medium and incubated at 37ºC with 5% CO2 
until culture reached 70-90% confluency. 
2.7.2. Semi-adherent cells 
Semi-adherent cell lines such as B95-8 cell lines show characteristics of a mixed 
culture with a proportion of cells adherent whilst others remain in suspension.  The 
degree of confluency was determined using an inverted phase contrast microscope 
(Olympus UK, UK).  Spent medium was decanted into a sterile centrifuge tube and 
retained for further use.  The monolayer was then washed with PBS without Ca2+/Mg2+ 
using 1-2 ml per 25cm2 of flask surface area.  Trypsin was then added at 1 ml per 
25cm2 surface area into the flask, taking care to immerse the whole monolayer before 
decanting excess trypsin.  The flask was then placed in an incubator for 2-10 min or 
until cells detached.  Trypsinised cells were transferred to the universal containing 
spent medium and suspended cells, before being diluted appropriately to seed new 
flasks (at this point cell counts were performed when required).  Appropriate dilutions 
of cells were added to new flasks which were incubated at 37ºC with 5% CO2 until the 
monolayer reached 70-90% confluency.  This was repeated generally every 72-96 
hours, although this was dependent upon the cell line involved. 
2.7.3. Suspension cultures 
Generally, cell lines derived from blood cells such as lymphocytes grow in 
suspension.  Cultures were viewed using an inverted phase contrast microscope with 
healthy cells appearing bright, round and refractile under a phase contrast inverted light 
microscope.  Cell counts were performed upon small aliquots of the culture before the 
flask contents was diluted appropriately in fresh supplemented medium and transferred 
to new sterile flasks containing fresh supplemented medium.  
2.7.4. Resuscitation of frozen cell lines 
 
Cells were stored between usage at -180ºC in a solution of 60% (v/v) RPMI-
1640, 10% (v/v) dimethyl sulphoxide (DMSO) and 30% (v/v) fetal bovine serum 
(PAA, UK).  Aliquots of 5x106 cells were defrosted by placing in vials of water at room 
temperature, and then added to 8ml of supplemented media (warmed to 37ºC) in order 
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to dilute out DMSO.  Cells were then incubated overnight before media was changed in 
order to eliminate any further toxicity due to residual DMSO.  Media in each flask was 
replaced every 48 hours and cells were grown until 70%-90% confluent, approximately 
every 96-120 hours. 
 
2.7.5. Cell viability assays 
 
The effect of treatments upon cellular viability in in vitro cellular models was 
monitored using the CellTiter 96 AQueous cell proliferation assay (Promega, UK) 
(Berglund et al., 2005).  Once all reagents had thawed to ambient temperature, 20ul of 
Celltiter 96 AQueous one solution reagent (Promega, UK) was added to wells on a 96 
well plate containing samples in 100ul culture medium.  Plates were incubated at 37ºC 
with 5% CO2 for 1-4 hours before fluoresence was read on a 96 well plate reader 
(Thermo lab systems, Waltham, MA) and absorbances were plotted onto a standard 
curve in order to calculate cell viabilities. 
 
2.8. Molecular assays 
 
2.8.1. Methodology for RNA extraction 
 
All patient samples collected during the project or in previous studies had RNA 
templates extracted using the Chomczynski and Sacchi methodology (Section 2.8.2).  
Those samples collected during the latter stages of the project (i.e. primarily cell 
separations, treatments and in vitro models) were extracted using commercially 
available RNeasy kits (Qiagen, UK). 
 
2.8.2. Chomczynski and Sacchi RNA extraction 
 
After treatment, cells were collected and washed in PBS and were subsequently 
immersed in Tri®-reagent for 5 min under agitation.  Chloroform was added at a 5:1 
ratio before incubating at ambient temperature, resulting in phase separation.  Layers 
were further defined by centrifugation at 10,000 rpm for 20 min at 4˚C.  After layering, 
three phases were evident (Figure 2.1).     
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• Colourless upper aqueous phase (containing RNA). 
• Opaque interphase (containing DNA). 
• Red organic phase (containing protein). 
 
The RNA phase was incubated in the presence of isopropanol (1:1 Tri®-reagent) 
before being incubated overnight at 4˚C.  Samples were then centrifuged at 12,000 xg 
for 20 minutes at 4˚C and the supernatant subsequently removed.   The resulting pellet 
was then washed in 75% ethanol before being re-centrifuged for 5 minutes at 4˚C.  The 
supernatant was discarded and the pellet was allowed to air-dry before being re-
suspended for quantification in 85ul of nuclease free dH20, 5ul RNase inhibitor (5U) 
(Promega, UK) to inhibit the action of any RNases and 10µl RNase-free DNase (1U) 
(Promega, UK) to remove any contamination by genomic DNA.  The sample was then 
incubated at 37˚C for 30 min to aid dissolution and action of DNase.  Samples were 
then either snap-frozen on dry ice and stored at -80˚C or quantified. 
 
2.8.3. Assessing RNA integrity and DNA contamination of RNA samples 
 
Before using the total RNA in subsequent reverse transcription, it was checked 
for structural damage and contamination with genomic DNA (Fig. 2.3). The RNA was 
analysed by agarose gel electrophoresis using 1% agarose-Loening gel, containing 
Ethidium bromide (0.5 mg/l EtBr).  The electrophoresis was performed in 1 X Loening 
buffer (718 mM Tris base, 680 mM Sodium dihydrogen orthophosphate, 20 mM 
EDTA; pH 7.7) at 70V for one hour.  Gels were visualised with ‘Grabber’ software 
(Perceptics, Knoxville, TN) using a BioVision UV gel imager (Perceptics, Knoxville, 
TN). 
 
2.8.4. Quantification of total RNA 
 
The concentration of total RNA was determined using a spectrophotometer 
(Geneflow, UK).  Once set to measure RNA the instrument was zeroed using 70 μl of 
nuclease-free water.  RNA (7μl) was appropriately diluted 1:10 with nuclease-free 
water (63 μl) and gently mixed before transferring to a quartz microcuvette. The 
cuvette was inserted into the Genova (Geneflow, UK) and the RNA concentration 
(μg/ml) and A260/A280 ratio (purity) were measured. 
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2.8.5. Two – step quantitative Real-time RT-PCR 
 
cDNA template was synthesised using 1 μg of total RNA and was converted 
into cDNA using oligodT primers and the avian myeloblastosis virus (AMV) RT 
enzyme (Promega, UK).  RT cycles consisted of an initial step of 5 mins at 72°C 
incubating template with random primers (Promega).  This was followed by addition of 
mastermix containing Magnesium ions (1mM), Reverse transcription buffer, dNTPs 
and sterile nuclease-free dH20.  This was then incubated at 42°C for 1 hour and 20 min 
before heating to 95°C for 5 min.  cDNA was diluted 1:5 prior to running in the real-
time assay.  Reagents for the gene of interest (GOI) and housekeeping genes (HKG) 
were mixed with cDNA in separate 0.5ml eppendorf tubes (Table 2.3).  These included 
9 μl of sterile nuclease-free dH20, 0.5 μl HERV-K10 gag1 set1 primers (nM), 2.5 μl of 
template (diluted 1:5 in dH20) and 12.5 μl Absolute SYBR green master mix (Abgene, 
UK).  Once mixed, reagents were transferred to a 96-well plastic plate (Abgene, UK) 
and capped using plastic strips (Abgene, UK) before being sealed using plate sealers 
(Abgene, UK) preventing possibility of evaporation.  Final optimised cycling 
parameters are listed below (Table 2.4). 
 
Component Volume ( μl) Final concentration 
SYBR Green Master Mix (Abgene) 12.5 1x 
Forward Primer (70nM) 0.5 nM 
Reverse Primer (70nM) 0.5 nM 
Template 2.5 <500ng/reaction 
Nuclease Free Water 9  
Total volume 25  
 
 
Cycle Step Repeats Temp Time 
(mins:secs) 
1 1 1x 95 15:00 
2 1 95 00:30 
 2 56 00:30 
 3 
 
40x 
72 00:30 
Data collection and real-time analysis enabled. 
3 1 1x 56 01:00 
4 1 80x 56 00:10 
Increase set point temperature after cycle 2 by 0.5ºC 
Melt curve data collection and analysis enabled. 
 
Table 2.3 Constituent reagents making up the mastermix for HERV-K10 gag1 real-time PCR. 
Table 2.4 Cycling parameters for HERV-K(HML-2) gag1 qRT-PCR
91 
 
2.8.6. Primer design:  A comparison of 3 different programmes for primer 
design 
 
All primers were designed using the reference sequence for HERV-K10 (Ono et 
al., 1986)(accession no: M14123) in the NCBI Nucleotide sequence database 
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Nucleotide&itool=toolbar).  The 
performance of three different primer design programs was assessed based upon the 
success rates of predicted primers.  The performance of Primer3 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3.cgi) (Korwin-Kossakowska et al., 
2006), PrimerSelect (LaserGene version 5.0; DNAstar Inc, Madison, WI) (Breslauer et 
al., 1986, Freier et al., 1986, Baldino et al., 1989, Rychlik et al., 1990) and Beacon 
designer version 5.0 (Premier Biosoft Int., Palo Alto, CA) (Ram and Shanker 2005) 
were compared and contrasted.  Specificity of all primer sets were confirmed using 
melt-curve analysis. 
 
2.8.7. Determination of primer efficiency & specificity 
 
Primer reaction efficiency was determined by standard curve analysis.  cDNA was 
diluted appropriately over a ten-fold dilution series ranging from 1ng down to 1pg.  All 
dilutions were made using nuclease free water (Promega).  Four different 
concentrations were run in triplicate in order to construct a standard curve.  ‘iCycler’ 
software ‘iQ’ was used to calculate primer efficiency using the standard curve (Figure 
5.6). 
Primer specificity was confirmed by purifying three PCR products using RNA 
from several different cell lines (well 1- Tera-1, well 5- HEK-293 and well 6- synovial 
fibroblasts) using Minielute gel purification kits (Qiagen, UK).  DNA sequencing was 
performed by the Sequencing service (School of Life Sciences, University of Dundee, 
Scotland, www.dnaseq.co.uk) using Applied Biosystems Big-Dye version 3.1. 
Chemistry on an Applied Biosystems model 3730 automated capillary DNA sequencer.  
Sequencing was carried out using gene specific primers unless otherwise stated.   
DNA sequences of PCR products were then run through the BLAST sequence 
database to identify most similar matches. 
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2.8.8. Assay sensitivity & Cloning 
 
PCR product was run in a 2% agarose gel, and the 120bp amplicon cut out 
under exposure to long wave UV light.  This was then purified using MiniElute gel 
extraction kit (Qiagen, UK, UK) and cloned into the pGEM-T cloning vector (Promega, 
UK) and transformed into JM-109 competent cells (Promega, UK).  Transformed 
bacteria were incubated overnight before blue-white screening identified colonies 
positive for the K10PCR-pGEM-T plasmid.  Positive colonies were then incubated 
overnight, at 37˚C in LB broth.  Plasmids were extracted and purified using a QIAPREP 
mini kit (Qiagen, UK) and the purified plasmid preps were run in an agarose gel prior 
to digestion with restriction enzymes to confirm the identity of the insert.  Once the 
presence of insert within the plasmid had been confirmed 100ng of plasmid/insert was 
aliquoted, and serial diluted ten-fold to give nine dilutions ranging from 100ng to 1fg 
K10PCR-pGEM.  A QPCR reaction incorporating all optimised conditions was run 
with the nine plasmid dilutions and negative controls (NTC, Plasmid no insert, 
Irrelevant plasmid – TOPO (Invitrogen) in triplicate. 
 
 
2.8.9. Data analysis, Quantification and Normalisation. 
 
Fluorescence data was copied and pasted from the ‘iQ’ software (BioRad) 
directly into Excel.  The freeware programme LinRegPCR (Ramakers et al., 2003) was 
then utilised for analysis and comparison of PCR reaction efficiencies during all 
investigations.  Validated results showed PCR efficiencies between ‘1.7 and 2.1’, with 
correlations ‘>0.999’.  Results outside of these margins were discarded and repeated.  
Final 2-ΔΔCT values were calculated by determining average CT values over repeated 
runs and applying these normalised values to the relative quantitation formula.  
Statistics and graphical analysis were performed using Prism 4 (Graphpad software, 
CA). 
 
2.8.10. Confirmation of PCR product from patient samples 
 
In order to confirm the identity of PCR products and specificity of the real-time 
PCR for HERV-K10 gag1 the PCR reaction mix was run in a 2% agarose gel after 
amplification.  The PCR product band was cut from the gel under long wave UV light 
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using a scalpel and the purified using the Minielute PCR purification kit (Qiagen, UK).  
DNA sequencing was performed by the Sequencing service (School of Life Sciences, 
University of Dundee, Scotland, www.dnaseq.co.uk) using Applied Biosystems Big-
Dye version 3.1 chemistry, on an, ‘Applied Biosystems model 3730’, automated 
capillary DNA sequencer.  Sequencing was carried out using gene specific primers 
unless otherwise stated. 
 
2.9. HERV Microarray analysis 
 
2.9.1. Sample RNA: Total RNA was extracted and purified from cultured and treated 
cells using the RNeasy RNA extraction kits (Qiagen, UK) according to manufacturer’s 
instructions.  Eluted RNA was checked for integrity by running in a 1% gel and 
quantified using a spectrophotometer. 
 
2.9.2. Reverse transcription and PCR labelling:  DNA-free mRNA (50 – 100ng) 
was reverse transcribed as described previously (section 2.8.5).    CY3-labeled DNA 
probes were synthesised by PCR using primer mixes MOP-1 and MOP-2 as described 
by (Seifarth et al., 2003).  Amplified DNA fragments were purified using MinElute 
biospin columns (Qiagen, UK), ethanol precipitated and air dried before being 
redissolved in 25 μl of buffer containing 3 x SSC (1 x SSC containing 0.15 M NaCl and 
0.0015 M sodium citrate), 0.5 % sodium dodecyl sulfate, 50 % formamide and 50 mM 
sodium phosphate buffer (pH 7.4). 
 
2.9.3. Mixed oligonucleotide primers (MOP) for multiplex PCR:  For amplification 
of RT-related sequences, two primer cocktails, MOP-1 and MOP-2 were used.  Primer 
sequences correspond to highly conserved regions present within the reverse 
transcriptase gene of all known human retroviruses and related animal viruses.  All 
anti-sense primers were modified with Cy3 fluorochrome.  Therefore all specific 
amplification products generated in the polymerase chain reaction were labelled with 
Cy3 at the 5’ end.  Set MOP-1 is a complex mixture of 16 primers, which preferentially 
amplify human and betaretroviral reverse transcriptase genes, whereas the MOP-2 
primer mixture (12 primers) allows the amplification of human and mammalian 
gammaretroviral RT sequences and RT sequences of various human exogenous 
retroviruses, such as HIV, HTLV and Spuma viruses.  For each MOP primer set, a 
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separate PCR reaction was performed.  As an internal standard for the assessment of 
RNA quality, a mixed primer set for primer amplification of five housekeeping genes 
(HKG mixture: ubiquitin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), α-
tubulin, β-Actin, hypoxanthine-phosphoribosyltransferase (HPRT) was designed.  HKG 
primers were added to each MOP-1 and MOP-2 PCR reaction. 
 
2.9.4. Hybridisation procedure:  Hybridisation was carried out under the 
standardised conditions.  All handling steps involving fluorochromes were carried out 
in dimmed light conditions.  Prehybridisation of glass slides was performed in Falcon 
50 ml tubes (Greiner Bio-One Ltd., Stroudwater, UK) in 6 x SSC, 0.5% sodium 
dodecyl sulfate (SDS), 1% bovine serum albumin (BSA) at 45ºC for at least 2 hours.  
Slides were then washed five times (1 min each) in water under agitation.  
Subsequently, slides were dried by a short centrifugation step (500 x g) for 1 min at 
RT).  For hybridisation, a ‘22 x 22’ mm glass lifter slip (Erie Scientific Co.) was taped 
to the microarray.  Subsequently, 25 μl of the denatured (5 mins at 95 ºC) Cy3-labeled 
probe were applied to the small space between the coverslip and slide and sealed with 
Fixogum rubber cement (Marabu Gmbh, Tamm, Germany).  Sealed slides were 
incubated in a humid chamber for 16 hours at 42 ºC.  Hybridised slides were then 
washed three times without agitation (10 min each) at 22 ºC in 1 x SSC, 0.5 x SSC and 
0.1 x SSC, respectively.  After a brief centrifugation step (500 x g for 1 min at RT) the 
hybridised microarrays were stored in the dark at room temperature until scanning. 
 
2.9.5. Multiplex PCR 
 
Cy3-labelled samples were synthesised by PCR in a total volume of 50 μl using 
components and reaction conditions listed below (Table 2.5 and Table 2.6).  Aliquots of 
amplification products were analysed on 2.5% TBE agarose gels stained with ethidium 
bromide.  Amplification products of both MOP-1/HKG and MOP-2/HKG were 
combined and stored at -20 until hybridisation.  Immediately before hybridisation step, 
Cy3-labelled DNA was ethanol precipitated, air dried and redissolved in 25μl of 
hybridisation buffer containing 3x SSC, 0.5% SDS, 50% formamide, 50mM sodium 
phosphate buffer and adjusted to pH 7.4. 
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Component MOP-
1/HKG (µl) 
(x1 
reaction) 
MOP-
2/HKG (µl) 
(x1 
reaction) 
Final 
concentration 
Nuclease free water 35 35 - 
10x PCR buffer 5 5 1x 
dNTP’s 0.5 0.5 25mM 
MOP-1 (β – 
retroviruses) 
2 - 50μM 
MOP-2 (γ – 
retroviruses) 
- 2 50μM 
HKG 1 1 50μM 
MgCl2 3 3 3mM 
cDNA template 3 3 - 
Enzyme 0.4 0.4 25mM 
Total volume  50  
 
 
 
 
 
2.9.6.  Chip scanning and visualisation 
 
Microarrays were scanned using a GenePix 4100 (Molecular Devices, 
Sunnydale, CA) using recommended settings for Cy3 fluorochrome.  High resolution 
images were saved as bitmap (*.BMP) file format (24-bit) and further analysed using 
GenePix Pro (version 6.0.1.22) and Photoshop CS (Adobe, San Jose, CA). 
 
 
Cycle Step Repeats Temp Time 
(mins:secs) 
1 1 94 00:30 
 2 45 03:00 
 3 
 
3x 
72 01:00 
2 1 94 00:30 
 2 50 02:00 
 3 
 
30x 
72 01:00 
3 4 1 72 10:00 
4 5  4 ω 
 
 
 
 
 
 
 
 
 
Table 2.6 Cycling parameters for the PCR amplification programme for synthesis of Cy3 labelled PCR 
products for HERV-specific microarray. 
Table 2.5 Components of the HERV microarray amplification reaction mix 
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2.10.  Transfection 
 
2 x 104 cells (HEK-293 and human fibroblast-like synoviocytes) were seeded in 
500μl of supplemented growth medium (see Appendix III for reagents and growth 
conditions) until 50-80 % confluent.  For each sample 0.2-0.4µg DNA was mixed in 
25µl Opti-MEM without serum (Invitrogen, UK).  Between 0.5-5µl of lipofectamine 
(Invitrogen, UK) was diluted in 25µl Opti-MEM medium (without serum) before 
combining both aliquots.  These were mixed gently before incubating for 15-45 min at 
room temperature.  0.2ml of transfection complexes were then added to cells mixing 
gently in addition to 0.2ml growth medium.  These cells were then incubated for 12 
hours at 37°C in a CO2 incubator.  After incubation, 0.4ml growth medium containing 
2X normal serum concentration was added to the cells.  Transgene activity was tested 
for 24-72 hours post transfection as appropriate for cell type and vector. 
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3.0 Abbreviations 
 
 
Amino acids (aa) 
Antigen: antibody (Ag: Ab) 
Artificial neural network (ANN) 
Autoantigens (AuAgs) 
Caprine arthritis encephalitis virus (CAEV) 
Congenital heart block (CHB) 
Complementarity determining regions (CDRs) 
Cyclic citrullinated peptide (CCP) 
Epitope spreading (ES) 
Experimental allergic encephalomyelitis (EAE) 
Glutamic acid decarboxylase (GAD65) 
Gold standard (GS) 
Human immunodeficiency virus (HIV) 
Human T cell lymphotropic virus-I (HTLV-I) 
Immunoglobulin (Ig) 
Major histocompatibility complex (MHC) 
Monoclonal rheumatoid factor antibody (mRFAB) 
National centre for biotechnology information (NCBI) 
Non-obese diabetic mice (NOD) 
Position - specific iterative basic local alignment search tool (PSI-BLAST) 
Position - specific iterative prediction (PSI-PRED) 
Rheumatoid arthritis (RA) 
Rheumatoid factor (RF)   
Sjogrens syndrome (SS) 
Sliding Window (SW) 
Sub-sclerosing (SScl) 
Systemic lupus erythematosus (SLE) 
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Chapter 3 – Bioinformatic analysis:  An investigation of the 
potential for RA disease pathology via molecular mimicry 
with HERVs 
3.1 Autoimmune diseases 
 
Autoimmune diseases can be classified broadly based upon the distribution of 
their pathologies.  Organ-specific autoimmunity is characterised by autoimmune 
reactivity that is directed against antigens found in a specific organ or tissue, e.g. 
autoimmune thyroiditis.  Organ-nonspecific autoimmunity, by contrast, is characterised 
by a disease pathology that is not organ specific, but rather directed against ubiquitous 
cellular antigens, e.g. such as that observed in Systemic lupus erythematosus (SLE) 
(Routsias et al., 2004). 
Rheumatoid Arthritis (RA) is one of the major systemic autoimmune diseases 
whose patients exhibit elements of both organ specific and systemic autoimmunity in 
its symptoms (Firestein, 2003).  Despite a number of bacterial and viral pathogens 
having been implicated (Masuko-Hongo et al., 2003) an infectious trigger has thus far 
remained elusive.  RA patients typically present a diverse array of autoantibodies, 
targeting a large number of autoantigens, found both systemically and locally within the 
joint (Corrigall and Panayi, 2002).  The presence of many autoantibodies overlapping 
in a number of closely related syndromes, makes specific diagnosis difficult and it is 
this mix of auto-antibodies, specific for both systemic and cellular components, that 
makes the focussed nature of the immunopathology within the joint so intriguing 
(Griesmacher and Peichl, 2001).   
The mapping of the targets of auto-antibodies is useful in the diagnosis of 
patients as diagnostic criteria or disease markers (Table 3.1) (Arnett et al., 1996, 
Tzioufas et al., 2000) and in the classification of clinical subsets (Kuwana et al., 1993).  
Elucidation of such targets also contribute to the understanding of how tolerance is lost 
the nature of subsequent mechanisms leading to this loss, i.e. molecular mimicry and 
epitope spreading (Albert and Inman, 1999, Powell and Black, 2001).  Such knowledge 
can also aid the development of novel assays, incorporating synthetic peptides as 
antigens (Fournel and Muller, 2003) or vaccines (Chacon et al., 2003).   
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Disease Autoantibody/ 
Autoantigen 
Diagnostic/Prognostic 
 implication 
Reference 
RA RF & CCP Poor prognosis & severe radiological 
damage 
(Corrigall and Panayi, 2002) 
(Kroot et al., 2000) 
 
Ribosomal P protein Neurological complications (Arnett et al., 1996), (Tzioufas 
et al., 2000) 
 
Anti-Ro/SSA Indicative of subcutaneous lupus, or 
neonatal lupus in pregnant women 
(Conrad and Schlosler, 2002) 
 
SLE 
Anti-histone antibodies 
& 
Anti-dsDNA 
Presence suggests drug-induced SLE 
Associated with nephritis & 
increased disease activity 
(Shen et al., 1998) 
(Lefkowith et al., 1996) 
(Raman, 2002) 
(Rahman and Hiepe, 2002) 
 
 
SS SS-A/Ro 
SS-B/La 
Link to CHB and neonatal lupus in 
pregnant mothers 
(Scofield, 2004) 
(Tzioufas et al., 2002) 
 
SScl DNA-Topoisomerase I Disease marker & associated with 
PIF. 
(Rizou et al., 2000) 
 
 
 
 
 
3.1.1 Epitopes & Epitope mapping 
 
Antibodies are proteins produced by B-cells in response to immunogenic 
substances such as viruses, vaccines and other allergens.  B-cell or antibody-related 
epitopes are the molecular structures within the antigen that make specific contacts with 
residues of soluble and membrane bound antibody.  There are several different types of 
epitopes; however, for the purposes of this investigation two broad distinctions will be 
made. 
 
• Linear (Continuous) epitopes. 
• Conformational (Discontinuous) epitopes. 
 
Continuous epitopes typically consist of several consecutive amino acid 
residues, i.e. predicted directly from the protein’s primary structure, whereas 
discontinuous epitopes refer to those of a more conformational or spatial nature that 
form when distant regions of a protein come together as protein folds and mature 
(Routsias et al., 2004).   
Table 3.1 Examples of autoantigens that feature important roles in the diagnosis of their respective disease.  Their 
presence is important in the distinguishing of several disease subsets from their parent diseases, e.g.  SLE and RA.  SScl: 
Subacute  Sclerosis.  RF: Rheumatoid Factor.  CHB: Congenital heart block.  CCP: Cyclic citrullinated peptide. 
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Discontinuous epitope predictions rely upon analysis of secondary and tertiary 
structure of proteins.  No single method is currently capable of identifying all epitopes 
on a protein; however, large numbers of techniques are available for the mapping and 
study of such regions.  These range from the use of phage peptide libraries (Smith et 
al., 2004) to recombinant autoantigen expression in in vivo systems such as baculovirus 
and bacterial hosts,  although each method has its own advantages and disadvantages 
(Schmitt and Papisch, 2002).  The Pepscan methodology presents an alternative to 
recombinant technology, involving the synthesis of thousands of synthetic peptides 
adhered to polyethylene rods (Fournel and Muller, 2003) and despite it lacking the 
reproducibility problems associated with recombinant autoantigens, it can only be used 
to detect continuous epitopes and may be beyond the financial capabilities of some 
laboratories.  It is here that the use of ‘in silico’ epitope prediction methods in the 
design of synthetic peptides, presents a cost effective alternative.  Techniques in in 
silico epitope mapping primarily use immunoinformatics tools – derived from the 
branch of bioinformatics, charged with the analysis of biological data, with reference to 
immunological processes (Flower, 2003).  Immunoinformatics describes both T cell 
and B-cell orientated applications, ranging from the structural modelling of Major 
histocompatibility complex (MHC) (Schueler-Furman et al., 1998) to B-cell epitope 
mapping and modelling of immunoglobulin (Martin et al., 1989).  The field, however, 
has been somewhat uneven in its coverage with the majority of the research focussed 
upon T-cell epitopes, whilst B-cell epitope analysis has been comparatively neglected 
(Flower, 2003).  This T-cell bias has been largely due to the fact that B-cell epitope 
prediction is significantly complicated by the conformational aspects of antibody 
binding.  As a result even the best predictions have fared only marginally better than 
random (Blythe and Flower, 2005).   
The key to the identification and use of synthetic peptides in investigating 
protein antigenicity is therefore to predict those sequences that play key roles in the 
interactions with antibodies.  Such mapping studies are important, as they provide 
information defining subsets of patients within disease groups (Shen et al., 1998, 
Routsias et al., 2004).  Additionally, knowledge of sites where antibodies bind on 
proteins may suggest the mechanisms responsible for the generation of the antibodies 
themselves.   
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3.1.2 Mechanisms of Antibody: Antigen binding 
 
The exact mechanisms at work governing Antigen: Antibody binding and 
recognition remain unknown despite intense scrutiny; however such answers are 
fundamental to our understanding of the workings of the mammalian immune system.  
At present most of the evidence for Antigen: Antibody (Ag: Ab) binding has been 
derived from the analysis of data sets obtained from experimental investigations.  X-ray 
crystallography studies elucidating the structures of Ag: Ab complexes have provided 
valuable information of their molecular architecture and shed considerable light upon 
potential influencing factors, including the identities of contacting residues, the number 
of H-bonds formed and conformational changes occurring within both proteins.  
Additionally, residues at the Ab:Ag interface have been observed to be predominantly 
aromatic, i.e. Tyrosine and Tryptophan, with a notable absence of charged residues 
such as Aspartic acid, Glutamate and Lysine (Lo Conte et al., 1999).  Increased levels 
of Arginine have also been reported, an observation attributed to its ability to form 
multiple bonds (Bogan and Thorn, 1998). 
Antibody molecules themselves are homodimers composed of two identical 
polypeptide chains of approximately 450 amino acids (heavy chains – H) which are 
covalently linked to identical polypeptide chains of 250 amino acids (Light chains  – 
L).  Based upon amino acid sequences, H and L chains may be divided into N-terminal 
variable (V) and C-terminal portions.  Each of the VH and VL domains have been 
broken up into three segments or loops that connect the β-strands and are highly 
variable in length and nature between different antibodies.  These loops are called 
‘Complementarity determining regions’ (CDRs). 
Although the exact mechanisms at work in the process of molecular recognition 
are still unclear, it has become apparent that the antigen binds directly to CDRs; thereby 
these regions exert a major influence over binding site conformation.  Of the 6 CDRs, 
the binding of as few as two can result in recognition (Decanniere et al., 1999).  A 
number of properties governing normal protein: protein interactions also have influence 
over this interface with both antibodies and antigens demonstrating a high degree of 
shape and chemical complementarity.  These include hydrophobicity, charged residues 
and side-chains, and cleft binding conformation (Lo Conte et al., 1999).  The degree of 
geometric match between the 2 juxtaposed surfaces has also been reported to play an 
important role, although the matching observed between proteins indicates poorer shape 
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correlation in comparison to other protein: protein interactions (Zuurbier and Huijing, 
1993).  This has been suggested to be due to the lack of evolutionary optimisation 
compared to other protein: protein interactions.  This may help explain the evolution of 
additional mechanisms such as affinity maturation (Jones and Thornton, 1996). 
Generally the combining sites of antibodies recognising larger proteins tend to 
be relatively planar in comparison to other protein: protein binding surfaces (Jones and 
Thornton, 1996).  Antibodies recognising smaller antigens such as peptides and DNA, 
tending to exhibit a groove antigen contacting surface, whilst  haptens bind via distinct 
cavities (Rees et al., 1994).  A common feature for the majority of anti-peptide 
antibodies studied has been that they allow peptides to adopt beta-turn motifs once in 
the binding site.  This has been observed for type-I (Rini et al., 1992), Type-II 
(Stanfield et al., 1990) and multiple tight beta-turns (Garcia et al., 1992).  The 
importance of water within the binding process is also apparent within the literature, 
emphasised through the fact that it is present in all but one of the published X-ray 
crystallography studies of Ag:Ab complexes (Muller et al., 1998).  Its presence has 
been suggested to improve fit and neutralise impaired H-bond groups and also 
compensate for the lack of evolutionary optimisation between the Ag: Ab interface.   
One final factor which aids the structural recognition of antigens is the changes 
that occur in the conformational structure of both antigen and antibody upon binding.  
The term ‘induced fit’ was first coined to describe the induction of an active state in an 
enzyme by a substrate molecule (Koshland, 1958).  In terms of an Ag: Ab relationship, 
this theory implies that the binding reaction between the two induces conformational 
changes leading to a better complementarity or ‘fit’ between the two proteins.  Changes 
in both proteins upon formation of the protein complex have been documented 
previously.  These vary from the small movements within the CDR loops (<3Å), slight 
shifts in orientation of the VL and VH domains (equivalent to up to 3Å), to somewhat 
larger changes including CDR loop displacement (of up to 7Å), which have been 
described upon binding to DNA and peptides (Tormo et al., 1994).  These movements 
have been suggested to help play a role in affinity maturation processes (Sundberg and 
Mariuzza, 2002).  An alternative theory to the induced fit is that of ‘conformational 
selection’ although the exact mechanisms at work are still unclear (Berger et al., 1999). 
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3.1.3 B-cell epitope mapping 
 
From previously published work four main assumptions were followed in this 
analysis.   
• B-cell epitopes can contain sequential or non-sequential amino acids 
(Routsias et al., 2004) 
 
• B-cell epitopes on native proteins generally are composed of 
hydrophilic amino acids on the protein surface that are topographically 
accessible to membrane bound or free antibody (Scofield and Harley, 1991). 
 
• B-cell epitopes tend to be located in flexible regions of an immunogen 
and display site mobility (Ponnuswamy et al., 1980). 
 
• Complex proteins contain multiple overlapping B-cell epitopes, some 
of which are immunodominant (James and Harley, 1998). 
 
Epitope mapping predictions were constructed using bioinformatic tools that 
process information on certain physico-chemical properties of amino acid residues, i.e. 
hydrophilicity, polarity, etc.  All of the tools employed algorithms that operated using 
the ‘sliding window’ principle.  Predictions using combined algorithms available on the 
ExPASy server were made using the four physicochemical properties described 
previously (Section 2.4).  These were also later combined with beta-turn analysis in an 
attempt to improve prediction accuracy.  The performance of ExPASy was compared 
and contrasted with a newer prediction server – BCEPRED.  This program had the 
advantage of choice of up to seven different algorithms including hydrophilicity, 
flexibility/mobility, accessibility, polarity, exposed surface and beta-turns, all using the 
sliding windows algorithms.  In addition to incorporating secondary structure analysis, 
the tabular output of this method eliminated the requirement for output to be formatted 
manually, thereby saving time and resources. 
A significant number of studies have highlighted that hydrophilicity, 
accessibility and flexibility are the best criteria for identifying these regions of 
antigenicity (Parker et al., 1986, Strynadka et al., 1988, Pellequer and Westhof, 1993, 
Hopp, 1994, Alix, 1999).  Other properties cited as also being useful have included 
beta-turns (Pellequer and Westhof, 1993), antigenicity (Welling et al., 1985) and 
hydrophobicity (Beardsley et al., 2003). 
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3.1.3.1.1 Hydrophilicity 
 
Hydrophilicity was the first criterion identified to correlate with antigenicity and 
its popularity has since been reflected in its common usage throughout the literature in 
the prediction of epitopes (Galbraith et al., 2000, Chacon et al., 2003, Beardsley et al., 
2003).  Hopp & Woods, (1981) derived a set of parameters to be used to predict 
hydrophilicity, based upon previously published solvent accessibility studies (Levitt, 
1976).  These were designed to identify exposed regions of mixed charge, i.e. polar, 
with few or no large hydrophobic residues.  Typically, regions that are highly exposed 
with lesser charge were more likely to bind antibodies, compared to those regions 
which were highly exposed, but devoid of charge (Hopp, 1993).   
A second data set of hydrophilicity values was published by Parker et al, (1986) 
who claimed increased prediction accuracy.  These values were based on experimental 
retention times of the 20 amino acid residues in an HPLC reverse phase column.  The 
accuracy of predictions was also reported to increase further when used in conjunction 
with accessibility and flexibility (Parker et al., 1986).  
 
3.1.3.2  Flexibility 
 
 
Flexibility or mobility has been cited in the literature to correlate better with 
antigenicity than other properties (Westhof et al., 1984, Karplus and Schulz, 1985).  
The main source of flexibility within a protein occurs about the Φ and Ψ bonds.  Large 
residue side chains have a significant effect upon the flexibility of their respective 
residues and thus, the flexibility of an amino acid can have profound effects upon the 
protein.  This was confirmed in further work by Vihinen et al, (1994) who suggested 
that flexibility played a crucial role in the binding, and allostery of proteins.    
The ExPASy tool used the parameter index derived by Bhaskaran et al (1988), 
who had reformulated a previously published differential equation model used to 
predict residue flexibility.  The old model could not account for fluctuations from the 
predicted values for each amino acid, due to the presence and behaviour of residues 
within secondary structures.  The new flexibility index was developed by categorising 
residues based on their mode of activity within 20 structure and was normalised to a 
value between ‘0-1’ (one being maximum flexibility, and 0 being indicative of no 
flexibility).  The index was validated against 19 proteins of known structure.   
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3.1.3.3.1 Accessibility 
 
Antigenic epitopes require good accessibility on protein surfaces in order to 
guarantee their recognition and interaction with antibodies and other immune cells.  
Therefore, the accessibility or positioning of a residue at the surface was the third 
criterion used for the selection of immunodominant regions.  The bioinformatic tool on 
ExPASy operates on values derived from the x-ray and solvent accessibility analysis of 
the structures of 22 proteins.  Parameters were then calculated using derived formulae.  
The resulting values represented the partition coefficient of each amino acid residue 
between the surface and the inside volume of the protein (Janin, 1979).  
These formulae have since been used successfully in studies investigating 
antigenicity (Emini et al., 1985) and in numerous database/computer tools (Parker et 
al., 1986, Saha and Raghava, 2004).   
 
3.1.3.3.2 Polarity 
 
Studies of the accessibility of amino acid residues to solvents in several proteins 
have already confirmed the suggestion that those residues of increased polarity are most 
frequently found on the surface of proteins (Lee and Richards, 1971, Shrake and 
Rupley, 1973).  Therefore, it seems logical that the more polar residues are likely to be 
located on the surfaces of proteins.  This coupled with the fact that the majority of 
immunodominant sites are found on the surface of the proteins (Hopp, 1993), suggested 
that polarity would be a good indicator of surface epitopes.  Long runs of charged and 
polar residues have been reported in autoantigens involved in rheumatic disease 
(Brendel et al., 1991), including CREST in CENP-B and DSc in Topoisomerase-I 
(D'Arpa et al., 1988).  A recently published study (Saha and Raghava, 2004) also 
concluded that the combination of more criteria involved in the selection of epitopes, 
results in increased accuracy of predictions.  For these reasons, polarity was identified 
as a fourth additional criterion, with which to use to predict surface epitopes. 
Table 3.2 shows the classification of different amino acid residues based upon their 
polar nature. 
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3.1.4 The ‘Sliding window’ technique 
 
All the algorithms used in this investigation to predict the physico-chemical 
properties of specific residues in the primary structure of a protein, were based upon the 
‘Sliding window’ (SW) principle.    The main concept behind this technique has been 
used previously for purposes ranging from electronics to marketing and weather 
forecasting with the only requirement being an experimentally derived data set for each 
property analysed.  After a window size has been determined (default size of 9) the 
window progresses along the length of the query sequence.  The amino acid at the 
centre of each window has its value calculated by assigning it the average of all 
parameter values of residues within the window (Figure 3.1).  Despite an accuracy level 
of ~60%, and a low level of sensitivity and specificity the sliding windows main 
strength is its robustness (Claverie and Notredame, 2006).  It is for this reason that the 
majority of the computer-based methods, available on the internet, for elucidating 
primary structure use this principle behind their calculations. 
 
 
 
 
 
 
 
 
 
 
 
Group  Amino Acid 
Non‐polar/ Hydrophobic  Val, Leu, Ile, Ala, Phe, Trp, Met, Tyr, Cys 
Polar/ Hydrophilic  Ser, Thr, Lys, Arg, His, Asp, Glu, Asn, Gln 
Charged  Gly, Pro 
Table 3.2 Examples of amino acid categorisation of different amino acid residues based upon their polar properties [taken 
from (Krane and Raymer., 2002)]. 
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3.1.5  Importance of threshold values 
 
It has been suggested that each globular protein contains a finite number of 
epitopes, each confined to a discete, yet accessible area and pre-determined by overall 
protein conformation.  This has been shown to be incorrect, with the majority of the 
surface on some globular proteins being potentially antigenic in nature (Newman, 
1982).  It has thus become important in epitope mapping studies to be able to 
distinguish between major and minor ‘false’ epitopes.  Threshold values therefore are 
not just critical to the speed of the analysis but play a central role in the accuracy and 
specificity of the predictions.  The higher the threshold values, the fewer epitopes 
predicted and the more stringent the selection conditions, however this may result in the 
missing of some less antigenic epitopes.  The lower the threshold values, the less 
stringent the selection conditions, however this results in a large increase in ‘false 
positive’ epitopes, i.e. those of limited antigenicity that play little role in the resulting 
immune response.  Threshold values were therefore determined in order to distinguish 
Ala  ‐0.5 
Arg  3 
Asn  0.2 
Asp  3 
Cys  ‐1 
Gln  0.2 
Glu  3 
Gly  0 
His  ‐0.5 
Ile  ‐1.8 
Leu  ‐1.8 
Lys  3 
Met  ‐1.3 
Phe  ‐2.5 
Pro  0 
Ser  0.3 
Thr  ‐0.4 
Trp  ‐3.4 
Tyr  ‐2.3 
Val  ‐1.5 
BOX 1: Ref: Proc. Natl. Acad. Sci. 
U.S.A. 78:3824‐3828(1981).  
 
Figure.3.1 The mechanism of the ‘sliding windows’ mechanism in action.  Box 1 (right/yellow) contains data set for amino 
acid hydrophilicity values determined by experimental investigation.  A default window of 9 amino acids is selected for 
analysis.  Values for hydrophilicity (Box 1) are applied to the relevant amino acid residues within the window.  An average 
of all 9 hydrophilicity values are calculated and assigned to the residues at the centre of the window, i.e. Valine at position 
127.  The window then advances one position with the average of all in the window is again assigned to the amino acid at 
its centre, this time glutamic acid at position 128 (Claverie and Notredame, 2006). 
Window size – 9 amino acids 
 
 
 
 
 
 
  Hydrophilicity =   
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between the small subset of those epitopes that were likely to be with the 
immunodominant immune response.  
 
3.1.6 Epitope Spreading 
 
Threshold values play an important role in the process of epitope prediction 
through the identification and distinction of primary epitopes from secondary epitopes 
which may play lesser (if any) roles in disease pathogenesis.  The term ‘epitope 
spreading’ (ES) was first coined in the early 1990’s to describe the ability of the B and 
T-cell immune response to diversify  at the level of specificity from a single determinant 
to many sites on the autoantigen (Lehmann et al., 1992).  Such diversity would be 
advantageous for any immune system, which has evolved to efficiently attack as many 
targets as possible.  The mechanism describes the development of immune responses 
against endogenous epitopes, secondary to the release of self antigen during either 
chronic autoimmune or infectious responses.  These responses can be located either 
upon the same (intramolecular) or upon different proteins (Intermolecular) with 
secondary epitopes often being cryptic or hidden epitopes located upon the same protein 
or as dominant epitopes on neighbouring molecules (Powell and Black, 2001).  Such a 
lack of tolerance to self-antigens in immuno-priveledged sites has been reported through 
occurrence of autoantibodies to sperm antigens and ocular lens crystalline after tissue 
trauma.  This phenomenon may play a key role in the normal response against infectious 
agents and have been described previously during viral infection (Milich et al., 1987).  
During HBV infection it has been reported that the priming of murine helper T cells can 
drive the production of antibodies targeting both HBcAg (core) and HBsAg (surface) 
providing primed mice are boosted with intact virus.  When mice were primed with 
separate antigen preparations, ES did not occur suggesting that both proteins must be 
associated for the phenomenon to occur.  Additionally, it may account for the natural 
recovery from acute autoimmune phenomena, resulting in an amelioration of symptoms 
as observed in Lewis rats and adjuvant arthritis (Moudgil, 1998). 
Studies in two animal models of multiple sclerosis, experimental autoimmune 
encephalomyelitis (EAE) and Theiler’s murine encephalalitogenic induced 
demyelinating disease (TMEV-IDD) have shown conclusively that epitope spreading 
plays a pathological role in ongoing disease and that by blocking this process by 
induction of tolerance to myelin epitopes or blocking T cell costimulation, this blocks 
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ongoing clinical disease.  ES with the murine model of relapsing experimental 
autoimmune encephalomyelitis (R-EAE) being one well characterised example.    Other 
models include that observed in non obese diabetic mice (NOD) – a mouse model for 
Type-1 diabetes, which develop immune responses to GAD65 (a 65kDa isoform of 
glutamic acid decarboxylase), also develop responses also targeting pancreatic islet cells 
(Tisch et al., 1993).  Induction of tolerance to GAD65, leads to the amelioration of the 
autoreactive response to pancreatic β cell antigens (Tian et al., 1996).  Evidence for the 
incidence of ES is also evident in human diseases, notably involving clusters of target 
molecules such as those forming macromolecular complexes.  Ro60 is one such 
molecule which was shown through the immunisation of rabbits to induce antibodies 
specific for multiple epitopes on both Ro60 and La (a macromolecular complex which 
frequently binds to Ro60).  Additionally, antibodies that were cross reactive with 
epitopes on other common spliceosomal proteins were also observed (Smets and Sokal, 
2002) suggesting that a loss of tolerance to a single epitope could induce an autoimmune 
response involving epitopes on other proteins potentially leading to immune responses 
typically observed in patients with rheumatic diseases.  Other studies have also reported 
mechanisms which may result in the occurrence of such phenomena which include a 
conserved ‘driver’ epitope or motif which may act as an initiator.   Although ES has 
been observed to involve both B and T cell components, the simultaneous involvement 
of both has not yet been reported (James and Harley, 1998).   
Many investigators of ES have focussed upon lupus, a disease involving a large 
number of auto-antibodies, to self components including those of the spliceosome and 
nucleosome (McClain et al., 2002).  One spliceosome component in particular – the 
Sm-B/B’ protein, possesses two sequences which have generated much interest – 
PPPGMRPP & PPPGIRGP.  These motifs were highlighted by studies using the MRL 
lpr/lpr murine model (Williams et al., 1990) and by patient sera containing anti-Sm 
autoantibodies (James and Harley, 1992).  Studies of several serial lupus patient sera 
over several years showed that these proline-rich motifs were the first epitopes to which 
patients mounted a response.  Over time these responses diversified significantly, with 
one female patients sera eventually showing reactivity with 17 different groups of 
peptides from Sm-B/B’ (James et al., 1995).  The same phenomenon has been observed 
in rabbits immunised with the PPPGMRPP peptides.  These rabbits’ sera were cross-
reactive with the PPPGIRGP peptides, in addition to up to 74 others (many of these 
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being to the same regions of Sm-B/B’ as that seen in humans).  Similar results were 
also observed in several mouse models (James and Harley, 1998).   
 
3.1.7 Secondary structure: The significance of Beta-turns 
 
Knowledge of secondary structure can be central to understanding a complex 
protein structure, in addition to further validating initial primary structure predictions 
(Creighton, 1992).  The secondary structure of a protein describes the assignment of 
helices and sheets to the primary structure (produced by the hydrogen-bonding patterns 
of the main chain).  This generally includes: 
• The alpha helices. 
• Beta-turns and beta strands. 
• Coiled coil regions. 
As proteins fold upon themselves, assuming their native structures, this results 
in the formation of small groups of amino acids producing patterns with one another on 
a local scale.  It is the location and direction of these regular structures that make up a 
protein’s secondary structure.  This process is governed by a number of factors 
including the different side chains on each amino acid and their effects, in terms of 
steric collision, polarity, and the formation of H-bonds between different residues.    
Secondary structure elements such as alpha helices and beta-sheets provide the 
rigid and stable framework of the protein; however Beta-turns have been deemed 
important in the prediction of 
antigenicity.  Beta-turns were 
originally identified in model building 
studies (Venkatachalam, 1968) and 
tend to consist of 4 consecutive 
residues (i, i+1, i+2 and i+3) that are 
not present within the alpha-helix.  
They share a difference, between i and 
i+3, of <7Å (Rose et al., 1985) with 
turns resulting in a change in the 
direction of the polypeptide chain of up  
 
 
  
Figure 3.2.  The general structure of an Artificial neural network.  The network is made up of distinct layers composed of a 
series of nodes within each layer.  The structure is designed to be analogous to that of the neurons within the human brain.  
Information is passed between processing nodes.  As PSIPRED is a forward feed network the movement of the information is 
always forward through the network.  Diagram taken from (Claverie and Notredame, 2006). 
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to 180° (Chou and Fasman, 1974).  This reversal may also be accompanied by the 
formation of an H-bond between the carboxyl and amino groups, between the i and i+3 
residues (Nemethy and Scheraga, 1980).   
These turns play important roles in the globular structure of a protein in terms of 
structural and functional roles, tending to be involved in the formation of highly 
compact structures in proteins as well as acting as binding sites for their ligands (Dong 
et al., 2003).  As a result, they tend to occur at exposed surfaces, thereby representing 
antigenic sites or those involved in mediating transient bonding with other proteins 
(Branden and Tooze., 1999).  These are one of the fundamental properties of an ideal 
epitope (Alix, 1999) and exist as U-like structures, formed when a beta strand reverses 
direction in an anti-parallel beta-sheet.  Additionally, Beta-turns were selected as they 
have been previously reported to occur on or adjacent to antigenic regions (Chacon et 
al., 2003).   
 An Artificial neural network (ANN) was recruited in order to reliably predict 
the location of Beta-turns in protein autoantigens, important in RA.  Artificial neural 
networks are information processing paradigms, whose structure has been inspired by 
the structure of the mammalian brain.   Essentially ANNs are a collection of 
interconnected mathematical models designed to emulate a biological synapse network.  
This results in a large number of interconnected processing elements analogous to 
neurons, tied together with weighted connections analogous to synapses.   ANNs also 
show the ability to learn and are trained to identify patterns in their output that follow 
from those within their ‘training’ data set.   
ANNs operate using two feed-forward neural networks, each with a single 
hidden layer.  These two networks operate independently, but in succession for each 
turn to be predicted (Figure 3.2).  The input into this first network is the position 
specific matrices generated by the Position-Specific iterative Basic local alignment 
search tool (PSI-BLAST) analysis (Altschul et al., 1997).  This information is then used 
to predict location of Beta-turns in the amino acid sequence.  The data produced by the 
first network is validated using the second network.  It does this by comparing the 
output from the first network with the secondary structure predictions produced by 
Position Specific Iterative Prediction (PSI-PRED) (Jones, 1999).  This further validates 
the output, increasing its potential accuracy.  PSI-PRED is a publicly available protein 
secondary structure prediction programme, located at 
(http://bioinf.cs.ucl.ac.uk/psipred/).  PSIPRED is used to detect distant homologues of a 
113 
 
query sequence, and thus generate a position specific scoring matrix as part of the 
prediction process (Jones, 1999) and it is this matrix which acts as a direct input into 
the networks.  The BetaPred2 is an online resource available for the prediction of beta-
turns (http://www.imtech.res.in/raghava/betatpred2/).  BetaPred2 consists of 2 forward-
feed networks (describing the direction in which information travels through the 
network), with a standard back propagation learning algorithm which acts to minimise 
the difference between the actual output of the network and the desired output for 
patterns in the training set.  The training of the database was performed on a set of 426 
non-homologous protein chains by 7-fold cross-validation.  The first network is 
responsible for sequence to structure conversion and trained in the occurrence of 
various residues in a specific size of sliding window (9 residues), correlated with the 
output of the central residue.  The predicted turn/non-turn output of the first net is then 
incorporated along with predicted secondary structure information in the second filtered 
structure-to structure network.  This is trained to filter the unreasonably isolated 
residues predicted as turns.  Both networks have single output units, i.e. 1 for turns, 0 
for non-turns.  Input into the networks occurs in the form of multiple protein 
alignments.  Predictions from these alignments, rather than a single sequence improves 
prediction accuracy (Cuff and Barton, 1999).  These are submitted as results using the 
PSI-BLAST server. 
 
3.1.8  Alignment of epitopes  
 
Once the epitopes for both retroviruses and putative autoantigens had been 
identified, they were aligned to identify sequence homology and thus potential 
molecular mimicry.  The LALIGN programme (available publicly from 
http://www.ch.embnet.org/software/LALIGN_form.html) was used as it was able to 
show results from local alignments between two specific input sequences.  LALIGN 
passed query sequences through a substitution matrix such as BLOSUM 50 and aligned 
peptide sequences in a manner in which the conservation score was highest.  
 
 
 
114 
 
3.1.9 The potential for molecular mimicry between HERVs & 
Autoantigens in Rheumatoid Arthritis 
 
Little is known surrounding the origins of RA and its underlying causes 
although it has been suggested that both environmental and genetic elements may be 
significant contributors to triggering the resultant immunopathology.  Such a response 
could evolve to encompass other host proteins through mechanisms such as epitope 
spreading and molecular mimicry, resulting in disease pathology.  Through the 
identification of regions of homology between the primary structure of HERVs and 
autoantigens involved in disease pathogenesis, this may help identify early events in 
disease development prior to the subsequent autoimmune response and clinical disease. 
After optimising the novel bioinformatic technique of epitope prediction, it was applied 
to map epitopes on 13 different families of retroviruses (Table 3.3) and 26 autoantigens 
(Table 3.4), all previously associated with RA disease pathogenesis.  Two additional 
non-human ‘control’ sequences were included in the analysis in order to prevent bias 
within the results.   
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Virus  Protein  Accession 
number 
Reference 
HERV-K10 Gag1 & 2/ Pol/ Env M14123 (Ono et al., 1986) 
 
HERV-K (T47D) Gag1/ Gag2/ Pol/ Env AF020092 (Seifarth et al., 1998) 
 
HERV-E (4-1) Gag1/ Gag2/ Pol/ Env M10976 (Repaske et al., 1985) 
 
ERV3 Pol/ Env M12140 (Cohen et al., 1985) 
 
ERV9 - X57147 (La Mantia et al., 1991) 
 
HERV-L - X89211 (Tristem, 2000) 
 
HRES-1 P15/ P25 X16660 (Bengtsson et al., 1996) 
 
HIV Gag-Pol/ Pro/ Int/ RT/ Pol NP_057849 (Coffin J. M. et al., 1999) 
 
HTLV-I GP1/ Tax/ Rex/ Env NC_001436 (Coffin J. M. et al., 1999) 
 
HRV-5 Gag/ Pro/ Pol AAM81188 (Griffiths et al., 1999) 
 
CAEV Gag/ Pol/ Env/ S/ Q NP_040938/ 
NP_040939/ 
NP_040940/ 
(Saltarelli et al., 1990) 
 
Controls 
Arabidopsis thaliana 
 
Reverse Transcriptase AAL06422 (Wright and Voytas, 2002) 
 
Arabidopsis thaliana 
 
Gypsy/ Ty3 element AAG51464 GenScan+** 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.3 HERV families implicated/associated with RA pathogenesis within the literature.  These families were analysed 
using immuno-informatic techniques outlined in Section 3.3.  Reference sequences for all viruses were identified and 
extracted from the NCBI sequence database.  
 ** - GeneScan+ is a gene prediction programme running at http://CCR-081.mit.edu/GENSCAN.html.  Two potential non-
human negative controls were included from plants.   
HIV: Human Immunodeficiency virus.  HTLV-I: Human T cell lymphotrophic virus-I.  CAEV: Caprine arthritis encephalitis 
virus. 
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Autoantigen Accession number Reference 
Collagen II NP_001835 (Wang et al., 2002) 
Aggrecan P16112 (Zou et al., 2003) 
Cartilage GP-39 P36222 (Steenbakkers et al., 2003) 
Filaggrin XP_048104 (Simon et al., 1993) 
Sa AAH53370 (Goldbach-Mansky et al., 
2000) 
Collagen I NP_000079 (Wang et al., 2002) 
Glucose Phosphate Isomerase (GPI) P06744 (Herve et al., 2003) 
Biglycan NP_001702 (Polgar et al., 2003) 
Decorin P_598013 (Polgar et al., 2003) 
MMP1 NP_002412 (ter Steege et al., 2003) 
La P08865 (McNeilage et al., 1990) 
DEK NP_003463 (Adams et al., 2003) 
LRP-2 NP_004516 (Ooka et al., 2003) 
Heat Shock protein 90 (HSP90) NP_005339 (Minota et al., 1988) 
PADI 4 Q9UM07 (Suzuki et al., 2003) 
hRNPA2 NP_002128 (Fritsch et al., 2002) 
hRNP A1 NP_112533 (Fritsch et al., 2002) 
Calpastatin NP_775083/ (Mimori and Tanaka, 2002) 
Chondroitin Sulphate O14594 (Chang et al., 2005) 
BiP Q9HG01 (Bodman-Smith et al., 2003) 
YKL-39 Q15782 (Sekine et al., 2001) 
RA-A47 NP_001226 (Hattori et al., 2000) 
Jo-1 NP_002100 (Routsias et al., 2004) 
Ro52/SSA NP_003132 (Eggleton et al., 2000) 
Nucleolin NP_003132 (Hiscox, 2002) 
Calreticulin NP_004334 (Itoh and Reichlin, 1992) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.4  Host autoantigens implicated in rheumatic diseases that were included in this epitope mapping study.  
All sequences used for putative autoantigens were registered reference sequences on the NCBI public database.  
All autoantigens within the table were epitope mapped, before epitope and whole protein sequences were aligned 
with virus sequences listed in Table 3.3. 
GP-39: Glycoprotein 39kDa; MMP-1: Matrix metalloproteinase 1; LRP-2: Low Density lipoprotein-related 
protein 2; PADI-4: Protein-Arginine deiminase type-4; hRNPA2: Heterogenous nuclear ribonucleoprotein A2; 
hRNPA1: Heterogenous nuclear riboprotein A1; BiP: Immunoglobulin heavy chain-binding protein; YKL-39: 
Chitinase 3-like protein 2 precursor; RA-A47: Rheumatoid Arthritis related antigen 47kDa. 
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3.1.10 Aims and Objectives 
 
The aims of this chapter were: 
 
• To determine the success rates of the current process of epitope prediction, and to adapt 
this in order to maximise this predictive accuracy. 
 
• To use this novel optimised methodology to predict potential targets of autoantibodies 
which may be important in the early events of RA disease immunopathology. 
 
• To correlate these epitopes with those regions of shared sequence between both groups 
 
• To short-list those epitopes that would be the most suitable candidates for molecular 
mimicry between HERVs and autoantigens, for synthesis as short peptides for 
incorporation into an ELISA for screening patient blood.  
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3.2 Methods 
 
3.2.1 In silico analysis 
 
Reference sequences of potential autoantigens were identified in rheumatic 
diseases and their protein sequence was extracted from the NCBI/ Genbank online 
database (www.ncbi.nlm.nih/).  Sequences were edited accordingly using a standard 
text editor. 
 
3.2.2 Primary and Secondary structure analysis 
 
Protein residues were analysed via in silico analysis of physicochemical 
parameters, using normalised scales derived from previous experimental data, in order 
to elucidate the antigenic structure of each autoantigen.  Predictions were made using 
computerised algorithms for hydrophilicity (Hopp and Woods 1981), residue polarity 
(Grantham 1974), solvent accessibility (Janin 1979) and flexibility index (Bhaskaran 
and Ponnuswamy 1988).  These analyses were performed with the bio-computing 
software programmes (available from http://www.expasy.ch/cgi-bin/protscale.pl).  
Window lengths on these programs were set to ‘9 residues’ to mirror the length of the 
peptide being produced.  The top 25% of peaks for each protein were considered to be 
over the threshold level (Parker et al, 1986) and therefore the antigenicity of each 
protein was assessed on an individual basis.  Where four or more properties (out of 
five) were above the threshold, the residue was considered antigenic.  All studies were 
run in parallel with, and results compared to, a previously published B-cell epitope 
prediction algorithm called BCEPRED (http://www.imtech.res.in/raghava/bcepred/) 
that has been reported to have a prediction accuracy of 80% (Saha and Raghava, 2004).  
Recommended defaults were used with all predictions made using this database.   
Protein secondary structure analysis including the elucidation and mapping of 
alpha helices and Beta-turns was examined using the neural network tool Betatpred2 
server (http://www.imtech.res.in/raghava/betatpred2/) (Kaur and Raghava 2003) and 
the PSIPRED tool (McGuffin et al. 2000) (http://globin.bio.warwick.ac.uk/psipred/).  
The PSIPRED program had repeatedly scored highly in prediction accuracy using the 
CASP4 and EVA projects (http://cubic.bioc.columbia.edu/eva.html). All alignments 
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between the HERV and autoantigen epitopes were performed using the online tool 
LALIGN (http://www.ch.embnet.org/software/LALIGN_form.html).  Peptides were 
chosen to be synthesized on the basis of levels of antigenicity and sequence homology 
to autoantigens implicated in RA.  The best candidate peptides for involvement in 
molecular mimicry were selected. 
 
3.2.3 Molecular modelling 
 
All proposed peptides were visualized using the Deep View Swiss Pdb Viewer 
(vers.3.7 – SP5) (http://www.expasy.org/spdbv/).  This program was used at default 
settings, with all protein sequences inputted in FASTA format.   
Figure 3.3 summarises the process of selecting potential epitopes from a 
database of both nucleotide and protein sequences stored on the NCBI database. 
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Figure 3.3 The main steps involved in the process of epitope mapping of viral and host proteins, and determining any regions of 
homologous sequence shared between them.  Steps 1-3 (nucleotide sequence, translation of nucleotide sequence and determination of 
ORF are not essential steps if the protein sequence/Open Reading Frame have been experimentally determined. 
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3.3 Results 
 
3.3.1 Selection of static or dynamic threshold values for ExPASy analysis 
 
 The retrospective prediction of known epitopes of autoantigens involved in RA 
disease pathogenesis was included within the auspices of this study as a measure of 
independent validation of the approach described here.  7 autoantigens involved in 
rheumatic disease were selected at random.  A review of the literature was also carried 
out compiling all experimentally derived continuous epitopes published previously on 
these 7 autoantigens.  These 21 experimental derived epitopes formed a data set of Gold 
Standards (GS) that were subsequently used to optimise and assess the performance and 
accuracy of both ExPASy and BCEPRED methodologies. Table 3.5 shows details for 
each GS epitope identified within the literature that formed part of this dataset. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Epitope Autoantigen Accession Disease Details Reference 
1 - 
2 6/16 SLE 
3 11/16 SLE 
4 
Calreticulin AAB51176  
RA 
10/16 SLE 
Eggleton et 
al., 2000 
5 NP_001800 Reactivity with > 85% 
anti-ACA/ 17/19 patient 
sera 
Muro et al., 
1996 
6 
CENP 
 
 
RA 
Pepscan showed 18/9 
patient sera 
 
 
Mahler et 
al., 2000 
7 Reacted with anti-Ro 
monospecific sera 
8 Immunodominant 
profile/ detected 
preferentially by SS 
Routsias et 
al., 1996 
9 
60 Ro/SS-A NP_004591  
 
 
SLE 
Octa-peptides showed 
reactivity to anti-
Ro/SSA serum. 
Scofield and 
Hurley, 
1991 
10 
11 
12 
> 70% of 122 sera 
samples reactive 
13 >90% of 122 sera 
samples reactive 
Yiannaki et 
al., 1998 
14 Most reactive to anti-
SSB/La serum 
15 
La/SSB NP_003133  
 
 
SLE 
Reactivity varied – may 
contain several epitopes 
Kohsaka et 
al., 1990 
16 Ribosomal P 
protein 
NP_000995 SLE 10-20% SLE serum Elkon et al., 
1986 
17 PM/Scl-100 CAA46904 Sclerosis Peptide based 
mutational analysis 
Bluthner et 
al., 2000 
18 
19 
20 
21 
Topoisomerase-1 NP_003277 SScl Lie in proximity to beta-
turns/ reactive against 
81 patient sera 
Rizou et al., 
2000 
Table 3.5 Details and references of those experimentally derived epitopes selected as gold standards for the grading and validation of  
B cell epitope prediction methodologies outlined within this chapter.  RA: Rheumatoid Arthritis; SLE: Systemic lupus erythematosus; 
SScl: Sub-acute sclerosis. 
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Using this dataset, the epitope prediction methodology was optimised for 
maximum accuracy.  The first step in this optimisation that was considered was 
investigating the role of threshold values within the prediction framework and their 
impact upon resultant prediction output.  Using 4 physicochemical properties the 
prediction success rates using static threshold values (Table 3.6) and dynamic 
thresholds (highest 25% of residues) were compared.  As the results show (Table 3.7) 
the methodology using static threshold values performed poorly in contrast to that with 
the dynamic threshold.  Static values achieved just 14.3% success in predicting 
experimentally derived epitopes in comparison to the dynamic methodology, which 
correctly predicted 41%.  From this analysis it was concluded that dynamic threshold 
values would achieve greater accuracy in final epitope predictions. 
 
Physico-chemical property Original threshold value 
Hydrophilicity (Hopp & Woods) 1.5 
Polarity (Grantham) 10 
Accessibility (Janin) 7 
Flexibility (Ponnuswamy & Bhaskaran) 0.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.6 Static threshold values used in initial/early epitope mapping studies.  These thresholds were the ‘default’ 
values reported by those experimental studies that first determined the data sets. References for studies: 
Hydrophilicity (Hopp & Woods, 1982), Polarity (Grantham 1974), Accessibility (Janin 1979) and Flexibility 
(Ponnuswamy & Bhaskaran 1988).   
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Epitope Published epitope ExPASy 
 
Static 
ExPASy 
 
Dynamic 
1 34LSSGKFYGDEEKDKG48 × × 
2 142KDIRCKDDEFTHLYT156  × 
3 193DPDASKPEDWDERAK207 × × 
4 253EYKGEWKPRQIDNPDYKGTWIHPEIDNPEY282   
5 3PRRRSRKPEAPRRRS17  × 
6 22PTPGPSRRGPSLGASSH38   
7 169TKYKQRNGWSHKDLLRSHLKP190   
8 211ELYKEKALSVETEKLLKYLEAV232  × 
9 485EYRKKMDI492  × 
10 147HKAFKGSI154   
11 291NGNLQLRNKEVT302   
12 301VTWEVLEGEVEKEALKKI318   
13 349GSGKGKVQFQGKKTKF364   
14 88KIRRSPSKPLPEVT101  × 
15 283LGKDANNGNLQLRNRNKEVTWEV-
LEGEVEKEALKKIIEDQQESLNKWKSK-
GRRFKG338 
 × 
16 90 KKEEKKEESEEEDEDMGFGLFD111 × × 
17 231LDVPPALADFIHQQR245   
18 205WWEEERYPEGIKWKFLEHKG224   
19 349RIANFKIEPPGLFRGRGNHP368   
20 397PGHKWKEVRHDNKVTWLVSW416   
21 517ELDGQEYVVEFDFLGKDSIR536   
  
Total successfully predicted (out of 21) 
 
3 
 
9 
 % Prediction success (Sensitivity) (successful 
predictions / total no. published epitopes) 
14.3% 
(3/21) 
43% 
(9/21) 
 
 
 
 
 
 
 
 
Table 3.7 The impact of incorporating dynamic threshold values into the epitope prediction process.  The first column 
(static) shows the success of predicting GS epitopes when using static threshold values, i.e. default values listed in Table 3.6.  
The second column shows the success of predicting GS epitopes when using dynamic thresholds, i.e. the highest 25% of 
values.  Analysis was carried out using just four physico-chemical properties – Hydrophilicity (Hopp & Woods, 1982), 
Polarity (Grantham 1974), Accessibility (Janin 1979) and Flexibility (Ponnuswamy & Bhaskaran 1988).  X = Match 
between predicted and published/gold standard epitope.  Blank boxes indicate no match between the predicted peptides in 
this investigation and those previously published within the literature. 
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3.3.2 Optimisation of dynamic threshold values for ExPASy analysis 
 
The next step was to determine the best threshold values, which would result in 
the highest sensitivity and specificity.  High threshold values would be stringent, but 
may result in ‘missing’ an epitope.  Lower values would be more promiscuous, 
resulting in the prediction of more false positives, leading to the methodology 
becoming more time and labour intensive.  Using the reactivity of a number of 
rheumatoid factor monoclonal antibodies specific for the Immunoglobulin (Ig) (IgG1) 
Fc region (Section 3.2.3), a new dataset of experimentally defined epitopes was utilised 
(unpublished data).  In addition to the 4 physico-chemical properties of primary 
structure, the presence of beta-turns was also included within this analysis.  Figure 3.4 
shows a graphical breakdown of how residues were considered under or over thresholds 
with threshold values of 25%, 30% and 40% investigated.  Figure 3.4A shows the 
hydrophilicity profile of IgG1 Fc region.  Figures 3.4B-D show how the top 25-40% of 
residues in the plot was selected for further analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4  The principles of selecting the top percentage of residues when using dynamic threshold values.  Plot A shows a 
typical plot produced by the hydrophilicity algorithm available at http://www.expasy.au.  Once obtained a threshold is chosen 
by selecting the top 25% (Plot B), 30% (Plot C) or 40% (Plot D).  Once the threshold was been set, only those residues within 
the shaded areas were considered to be important for analysis, i.e is hydrophilic in nature. 
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Due to the relatively small size of the IgG1 Fc region, i.e. 223 amino acids, 
there are relatively few additional epitopes predicted by the 40% threshold, in 
comparison to the lower 25% (Table 3.8).  The higher threshold (40%) resulted in 6 
additionally predicted epitopes.  This effect was protein-specific as analyses of larger 
proteins such as Filaggrin (4061 aa) have shown.  Epitope mapping of Filaggrin 
resulted in 25 epitopes (using 25%), which increased to 80 epitopes (using a threshold 
of 40%) (Data not shown).   
 
Location of 
fragment 
Peptide sequence No. Prop. over threshold Method 
Anal. 
25% 
290-304 (295-301) VHNAKTKPREEQYNS 5 
337-351 (340-347) PIEKTISKAKGQPRE 5 
355-370 (359-366) YTLPPSRDELTKNQVS 4 
386-401 (389-397) EWESNGQPENNYKTTP 4 
269-283 (272-279) VVDVSHEDPEVKFNW 4 
 
ExPASy 
 Total (5/4) 5 (2/3)  
30% 
292-306 (295-303) NAKTKPREEQYNSTY 5 
339-353 (342-350) EKTISKAKGQPREPQ 5 
269-283 (272-280) VVDVSHEDPEVKFNW 5 
317-331 (320-328) QDWLNGKEYKCKVSN 5 
387-401 (390-398) WESNGQPENNYKTTP 5 
356-369 (359-366) TLPPSRDELTKNQV 4 
413-427 (416-424) YSKLTVDKSRWQQGN 4 
246-260 (249-257) VFLFPPKPKDTLMIS 4 
 
 
ExPASy 
 Total (5/4) 8 (5/3)  
40% 
292-306 (295-304) NAKTKPREEQYNSTY 5 
339-353 (342-350) EKTISKAKGQPREPQ 5 
268-282 (272-279) VVVDVSHEDPEVKFN 5 
413-427 (416-424) YSKLTVDKSRWQQGN 5 
317-331 (320-328) QDWLNGKEYKCKVSN 5 
386-400 (388-398) EWESNGQPENNYKTT 5 
355-369 (358-366) YTLPPSRDELTKNQV 4 
330-344 (333-341) SNKALPAPIEKTISK 4 
397-411 (402-406) YKTTPPVLDSDGPFF 4 
439-449 (444-449) HNHYTQKSLSLSPGK 4 
247-261 (248-257) FLFPPKPKDTLMISR 4 
 
 
 
ExPASy 
 Total (5/4) 11 (6/5)  
 
 
 
Table 3.8 Differences in epitopes predicted using different threshold cut-off values using IgG1 Fc region (AAD38158) as model.   
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In terms of prediction success, i.e. the correlation of predictions and 
experimental data generated from the Pepscan analysis, the in silico analysis showed a 
high degree of accuracy.  The majority of those extra antigenic regions were those in 
which five properties were in excess of thresholds. 
Table 3.9 shows the breakdown of the accuracy of the prediction method in 
comparison to each Monoclonal Rheumatoid factor antibody (mRFAB) in the Pepscan 
analysis.  Using 25% threshold, on average 70% of the predictions agreed with those 
identified in vitro.  These ranged from 80% observed in polyclonal RF and mRFAB, to 
60% of those epitopes targeted by monoclonal antibody and anti-Fc mAb.  Using 
thresholds of the top 30% of values, in all but one case the accuracy decreased.  
Monoclonal RF was the exception to this, showing a 2.5% increase in correct 
predictions correlating with antibody binding to particular peptides.  The final threshold 
of 40% (Figure 3.6D) showed a further reduction in prediction accuracy.  This showed 
the largest decrease in accuracy to an average 43.8% (a drop of 15.6%).  This is 
unsurprising as there was a larger gap between % thresholds than the previous two.   
The antibody that showed the least level of correlation was the anti-Fc mAb, which saw 
the percentage prediction accuracy almost halve above 25%.  The best correlations 
were observed with the polyclonal rheumatoid factor.  There was a clear peak in 
prediction accuracy when using just the top 25% of values (attaining 70% accuracy).  
When using the highest 40% of values to predict which regions were epitopes, overall 
accuracy (number agreeing with experimental results/total number predicted) was 
reduced to 43.8%.  Following this analysis it was decided to incorporate the 25% 
thresholds into the technique/analysis, in order to efficiently identify regions of 
antigenicity, in addition to limiting the number of false-positives generated. 
 
 Percentage Accuracy (total correctly predicted/total number predicted) 
Type of 
Rheumatoid factor 
25 30 40 
Polyclonal RF 80% 75% 58.5% 
Monoclonal RF 60% 62.5% 50% 
Anti-Fc mAb 60% 37.5% 25% 
mRFAB 80% 62.5% 42% 
Overall accuracy 70% 59.4% 43.8% 
 
 
Table 3.9 Percentage accuracy of epitope mapping predictions made using different threshold levels.  Peptide functionality 
was confirmed using polyclonal and monoclonal rheumatoid factor, in addition to monoclonal antibodies and antibodies 
targeting the IgG Fc region. (RF: Rheumatoid Factor; mAb: Monoclonal antibody) 
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3.3.3 The importance of secondary structure within epitope mapping 
 
The impact of incorporating secondary structural data upon prediction results is 
shown in Table 3.10.  Overall the inclusion of beta-turns resulted in a 28% increase in 
prediction accuracy when applied to the identification of the 21 GS epitopes in 
conjunction with dynamic thresholds using ExPASy.  Secondary structure resulted in 
six additional epitopes being identified (on six different autoantigens). 
 
Epitope Published epitope ExPASy ExPASy + 
BetaPred2 
1 34LSSGKFYGDEEKDKG48 × × 
2 142KDIRCKDDEFTHLYT156 × × 
3 193DPDASKPEDWDERAK207 × × 
4 253EYKGEWKPRQIDNPDYKGTWIHPEIDNPEY282  × 
5 3PRRRSRKPEAPRRRS17 × × 
6 22PTPGPSRRGPSLGASSH38  × 
7 169TKYKQRNGWSHKDLLRSHLKP190  × 
8 211ELYKEKALSVETEKLLKYLEAV232 × × 
9 485EYRKKMDI492 × × 
10 147HKAFKGSI154   
11 291NGNLQLRNKEVT302   
12 301VTWEVLEGEVEKEALKKI318   
13 349GSGKGKVQFQGKKTKF364  × 
14 88KIRRSPSKPLPEVT101 × × 
15 283LGKDANNGNLQLRNRNKEVTWEV-
LEGEVEKEALKKIIEDQQESLNKWKSK-
GRRFKG338 
× × 
16 90 KKEEKKEESEEEDEDMGFGLFD111 × × 
17 231LDVPPALADFIHQQR245  × 
18 205WWEEERYPEGIKWKFLEHKG224  × 
19 349RIANFKIEPPGLFRGRGNHP368   
20 397PGHKWKEVRHDNKVTWLVSW416   
21 517ELDGQEYVVEFDFLGKDSIR536   
 Total successfully predicted (out of 21) 9 15 
 % Prediction success (Sensitivity) (successful 
predictions / total no. published epitopes) 
43% 
(9/21) 
71% 
(15/21) 
 
 
 
 
 
 
Table 3.10 The importance of secondary structure, i.e. beta turns, in epitope prediction is summarised here.  This summary shows the 
increase in success of predicting experimentally determined epitopes when secondary structure is taken into consideration.  Data in the 
first column was predicted using ONLY the 4 physico-chemical properties of primary structure.  Predictions within the second column 
were generated using BOTH primary structure (4 physico-chemical properties) and the locations of secondary structure motifs, i.e. 
beta-turns specifically.  In order for an epitope to be predicted at least 4 properties must be over the threshold value for that protein.  
X = Match between predicted and published epitopes.  Blank boxes indicate no match between the predicted peptides in this 
investigation and those in the literature. 
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3.3.4 Comparison of BCEPRED vs. ExPASy 
 
The combined performances of the algorithms used in ExPASy and BetaPred2 
were compared to those utilised within a recently developed online prediction database 
– BCEPRED (Saha, 2003).  The gold standard dataset were used to grade each method 
upon its performance in the prediction of each of the 21 GS epitopes.  Recently 
optimised dynamic thresholds of 25% were used as cut-offs in ExPASy analysis.  
BCEPRED analysis used a default threshold value of 2.37.  Table 3.11 shows a 
comparison of algorithms employed by each prediction methodology. 
When the performance of both prediction programs was compared, BCEPRED 
exhibited a 14% increase in prediction accuracy over ExPASy, predicting 18/21 GC 
epitopes (Table 3.12).  Despite this, BCEPRED also predicted almost twice the number 
of epitopes of that of ExPASY.  The majority would have been considered weaker/ 
insignificant regions by ExPASy.  As a result, this showed a reduction in the 
algorithm’s sensitivity and specificity compared to ExPASy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ExPASy BCEPRED 
Primary structure analysis 
Hydrophilicity (Hopp and Woods, 1981) 
 
Hydrophilicity (Parker et al., 1986) 
 
Polarity (Grantham, 1974) 
 
Flexibility (Karplus, 1985) 
Flexibility (Janin, 1979) 
 
Accessibility (Emini, 1985) 
Accessibility (Bhaskaran and Ponnuswamy, 1988) 
 
Antigenic propensity (Kolaskar, 1990) 
 Exposed surface (Janin, 1978) 
 Polarity ( Ponnuswamy, 1980) 
Secondary structure analysis 
*B-Turns – using Betapred2 (ANN) (Kaur and 
Raghava, 2004) 
 
http://www.imtech.res.in/raghava/betatpred2/ 
Turns (Pellequer, 1993) 
Table 3.11 Approaches taken by each ExPASy and BCEPRED databases, when making predictions of B cell epitopes.   
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Epitope 
Published epitope ExPASy & 
BetaPred2 
BCEPRED 
1 34LSSGKFYGDEEKDKG48 × × 
2 142KDIRCKDDEFTHLYT156 × × 
3 193DPDASKPEDWDERAK207 × × 
4 253EYKGEWKPRQIDNPDYKGTWIHPEIDNPEY282 × × 
5 3PRRRSRKPEAPRRRS17 × × 
6 22PTPGPSRRGPSLGASSH38 ×  
7 169TKYKQRNGWSHKDLLRSHLKP190 × × 
8 211ELYKEKALSVETEKLLKYLEAV232 × × 
9 485EYRKKMDI492 × × 
10 147HKAFKGSI154   
11 291NGNLQLRNKEVT302  × 
12 301VTWEVLEGEVEKEALKKI318  × 
13 349GSGKGKVQFQGKKTKF364 × × 
14 88KIRRSPSKPLPEVT101 × × 
15 283LGKDANNGNLQLRNRNKEVTWEV-
LEGEVEKEALKKIIEDQQESLNKWKSK-
GRRFKG338 
× × 
16 90 KKEEKKEESEEEDEDMGFGLFD111 × × 
17 231LDVPPALADFIHQQR245 × × 
18 205WWEEERYPEGIKWKFLEHKG224 × × 
19 349RIANFKIEPPGLFRGRGNHP368  × 
20 397PGHKWKEVRHDNKVTWLVSW416  × 
21 517ELDGQEYVVEFDFLGKDSIR536   
  
Total successfully predicted (out of 21) 
 
15 
 
 
18 
 % Prediction success (successful predictions / total 
no. published epitopes) 
71% 
(15/21) 
85% 
(18/21) 
 Method Sensitivity (Best epitopes predicted (5) 
correlating with total correct predictions) 
47% 
(7/15) 
22%  
(4/18) 
 Overall Specificity (number of correct epitopes/ 
Total number of epitopes predicted) 
25.4% 
(15/59) 
17% 
 (18/105) 
 
 
 
 
 
Table 3.12 Summary of the levels of success of two methods of epitope prediction, in predicting 22 pre-published linear 
epitopes.  X = Match between predicted and published epitopes..  Blank boxes indicate no match between the predicted 
peptides in this investigation and those in the literature. 
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3.3.5 Identification of candidates for testing the potential role of HERVs in 
molecular mimicry 
 
When the maximum level of prediction accuracy was achieved, the technique 
was applied to predict potential epitopes present upon 26 autoantigens, and 13 
retroviruses associated with RA.  Upon prediction, resulting epitopes were then aligned 
with one another in order to detect regions of primary structure homology.  Table 3.13 
shows the best alignments between epitopes of both HERV and autoantigen derived 
epitopes.   
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  # 3 4 8 5 9 4 7 10 4 3 2 2 5 4 1 
Aggrecan 28                 
Bip 13                
Calpastatin 29                
Calreticulin 11                
Collagen I 22                
Collagen IIα 24                
DEK 10                
DNA Topo-1 36                 
G-6-PI 15                
GP-39 9                
HSP-90 15                
Ku-86 8                
La/SSB 13                
MMP-1 9                
PADI-IV 12                
RA-47 8                
Ribosomal 40S 4                
Ro 52 10                
A
ut
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s 
Ro 60 16                
    6 matches  5 matches  4 matches 
Table 3.13   Level of homologous sequences shared between epitopes of autoantigens and HERVs alike.  Yellow shading indicates 
matches of 6 residues or more.  Blue indicates matches of 5 residues and red shading shows homology of 4 amino acids. 
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Those shown are the best candidates for molecular mimicry as epitopes from 
both groups of proteins share sequence homology (more than 4 consecutive amino 
acids).  Unexpectedly, more matches of 5 consecutive residues were identified in 
comparison to 4 consecutive residues.  HERV K and HERV-E (4-1) both showed the 
most homology between their epitopes, whilst HERV-H showed the least. 
 
3.3.6 Incorporation of Negative controls into the investigation 
 
Often small data sets contain a strong bias for both positive and negative data, 
since data was selected using a stringent set of rules (Donnes and Elofsson, 2002).  One 
way to lower potential bias and its influence over a set of results was to include some 
random epitopes, to which it was assumed there would be little or no binding.  Thus, 
potential epitopes predicted on autoantigens and HERV proteins alike were also aligned 
with two presumed negative control peptides selected from epitopes predicted from the 
two control sequences – retroviral elements identified in plants (Table 3.14).     Of 
those epitopes that matched, the most consecutive homologous residues equalled 3 
(Table 3.15).   
 
Organism Gene Location Sequence 
5-20 RSSQEEDVKGKGVEKE 
56-70 TAKRVTEGEKVLDRS 
290-303 YRPVKEVEQKSDHL 
340-353 EVLSDDDHEQKPMP 
369-382 MGVKGTVDKRDLFI 
1031-1045 SWSQDILRRKSKIVV 
199-213 MAELKKLQETDGLVE 
278-291 TWSQKGTRSGGSYR 
414-427 AVADGRKLNVDGQI* 
516-531 CVREVVSDEEQEIGSI 
588-602 YVVHQKDEIDKIVQD 
677-691 QVRMDPDDIQKTAFK 
737-751 LIYSSSIEEHKEHLR 
775-789 ISAREIETDPAKIQA 
929-943 FIIKTDQRSLKYLLE 
1062-1076 SGMGGRSGRDASHQR 
 
 
 
 
 
 
 
 
Gypsy/Ty3 
element 
(AAG51464) 
 
 
 
 
 
 
 
 
- 
1401-1414 YILERKLVKRQGRA 
33-47 GGMTVVKNEKDELI 
207-222 SEKGIEVDKGKVEVMM 
Athila 4 
(AAL06422) 
Reverse 
transcriptase 
59-72 DYRKLNAASRKDHF 
 
 
 
Table 3.14   The potential epitopes mapped out on the surface of two plant retroviral elements.  Epitopes were mapped out 
using the ExPASy/BetaPred2 methodology with 25% threshold.   The two epitopes shaded in yellow indicate those used to 
align with autoantigen epitopes in order to eliminate bias in the investigation.  *: Negcont1 used in serological investigations. 
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This occurred with epitopes on 5 autoantigens including Collagen I and Collagen II, as 
well as DEK, DNA Topoisomerase and Ku-80.  Only those matches where there were 5 
or more consecutive residues were deemed significant, therefore it was assumed there 
was minimal bias within the investigation structure. 
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3.3.7 Short listing of candidates for synthesis as short peptides 
 
Those epitopes that exhibited the most homology to autoantigen epitopes were 
then short-listed for progressing to phase two of the investigation, i.e. synthesis of 
peptide and screening of patient blood.  Table 3.16 shows those epitopes most likely to 
be involved in playing a role in molecular mimicry and thus triggering RA disease 
pathogenesis.  Novel peptides of notable interest include ‘GfPN1kpr’ which showed 
homology to epitopes on Collagen II and ‘RA-HK-g-1’, which was a significantly 
antigenic epitope on HERV K.  Table 3.17 shows a selection of peptides, which showed 
no particular disease association but were considered to be novel and of interest.  
‘GfPN2eip’,  for example, was a predicted epitope which aligned with the HERV-K 
superantigen region to which antibodies have been reported in patients with rheumatic 
diseases (Herve et al. 2002).   
 
 
 
 
Table 3.15 Sequence homology between epitopes from host autoantigens and negative control epitope sequences.  
Alignments were carried out using the LALIGN programme.  Blue indicates 5 consecutive residues matching, Red 
shows 4 consecutive residues matching and yellow indicates 3 consecutive residues matching. 
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Disease Peptide name Comments Peptide sequence 
RA HERV K10 Gag1 
(GfPN1kpr) 
? 4th most antigenic peptide from K10 Gag1. 
? Flexible region - beta turn structure. 
? Best alignment = Collagen II 1076-1096. 
PSESKPRGTSPLPAG 
RA HERV K10 Pol/Env 
(RA-HK10PE-1) 
? 4th most antigenic peptide for Pol/Env. 
? High Polar and accessible region. 
? Best alignment = DNA Topoisomerase I 18-
36 (~6). 
DLTESLDKHKHKKLQ 
 
RA HERV K10 Pol/env 
 
? Epitope on Calpastatin binds twice to 
HERV K10 Pol/env. 
GSPTAAGKKTEKEESTEV
LKA 
RA ERV3 Env 
(RA-ERV3E-1) 
? 2nd most antigenic region of ERV3. 
? Located at N-terminal of Beta-turn region – 
increased flexibility. 
? High levels of Polarity and accessibility. 
LWRGKSNNSESPHPSP 
 
RA HERV K Gag 
(RA-HK-g-1) 
• 2nd most antigenic peptide on K Gag. 
• Located on Beta turn region. 
VGPLESKPRGPSPLS 
 
 
 
Disease Peptide name Comments Peptide 
sequence 
MISC HERV K10 Pol/Env 
(GFPN2eip) 
? Located in super antigen region of Env. 
? 2nd best epitope on K Env. 
? Good overall hydrophilicity, accessibility 
and polarity. 
PCPKEIPKESKNTEV 
 
MISC Collagen II 
(CII-1) 
? 2nd most antigenic epitope in Collagen II. 
? High hydrophilicity and Polarity values. 
? Highly flexible - long Beta-turn region. 
? Similarity to two regions of HRES-1 p25 
gene. 
GSPGPAGPTGKQGDR
GEAGA 
 
MISC HERV K10 Pol/Env 
(HK10PE-2) 
? 2nd most antigenic peptide for K10 
Pol/Env. 
? Increased Polarity and flexibility. 
? Best Alignment - AHNAK. 
QIENRKIKPQKIEIR 
 
MISC Ku 86/90 (165-187) 
(Ku-1) 
? Best alignment - HERV protein and 
Autoantigen epitopes. 
? Significantly high hydrophilicity and 
polarity levels. 
LPF SLGKEDGSGDR 
 
MISC Heat Shock protein 90 
(693-708) 
(HSP90-1) 
? High hydrophlicity, accessibility and 
polarity values. 
? Located on beta-turn region. 
? Best alignment: E (4-1) Gag. 
KLGLGIDEDDPTADD 
 
 
Table 3.16 Peptides selected as best candidates for testing molecular mimicry between HERVs and autoantigens associated with RA. 
Table 3.17 Peptides selected as best candidates for implicating HERVs in triggering Rheumatic disease by molecular 
mimicry.  These peptides were selected for their homology to epitope and antigenic regions on autoantigens involved in 
rheumatic disease. 
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3.4. Discussion  
 
3.4.1 Prediction of epitopes 
 
During the course of this investigation a method for the prediction of potential B 
cell epitopes was optimised.  This method was used to epitope map those autoantigens 
and HERVs previously associated with triggering rheumatoid arthritis.  For the purpose 
of this analysis, we compiled a panel of 21 gold standard (GS) epitopes, from 7 
autoantigens implicated in systemic rheumatic disease pathogenesis.  All GS epitopes 
were continuous in nature and had been published in the literature previously after 
being determined by experimental methodologies.  These 21 epitopes formed a dataset 
of positive controls which could be used in to determine prediction accuracy reliably.  
The existing methodology of B-cell epitope prediction used in-house incorporated the 4 
physico-chemical properties of hydrophilicity, polarity, flexibility and Accessibility and 
based analysis upon 4 experimentally derived scales (Hopp and Woods, 1981, 
Grantham, 1974, Janin, 1979, Bhaskaran & Ponnuswamy, 1988).  These were selected 
as they had been reported previously to be successful (Pellequer, 1991).  Previous 
studies had also shown that overall predictive accuracy was increased when predictions 
from more than one property were combined (Alix, 1999) although a number of 
previous studies have ignored this, making predictions based upon single algorithms 
(Galbraith et al., 2000).   
Using the predictive power of combined properties, initial studies were carried 
out using default cut-off values i.e. values generated by individual algorithms which 
suggest residues is not significantly important.  These original values were as dictated 
by authors of original experimental data scales (Table 3.6).  It became apparent that 
predictions made using these cut-off values, showed limited accuracy (Table 3.7).  As a 
result, dynamic threshold/cut-off values were trialled which resulted in an accuracy of 
43% (an increase of 28% with 9/21 GS epitopes being predicted).  These markers of 
significance assessed proteins upon an individual basis rather than as a marker for all 
proteins.  Additionally, 25% was shown as the most optimal cut-off value when applied 
to the IgG1 Fc region.  This was backed up by experimental data from four separate 
monoclonal antibodies (Table 3.8 – 9).  This data showed that although more epitopes 
were detected using 40% threshold values (Filaggrin alone generated in excess of 80 
individual epitopes), overall accuracy (total positive epitopes/total number of 
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predictions) was increased when using 25% cut-off values (43.8% and 70% 
respectively). 
Additionally, incorporation of protein secondary structure also led to 28% 
increase in predictive accuracy (Table 3.10).  Locations of Beta-turns were made using 
the BetaPRED2 forward feed neural network, with PSI-BLAST matrix results, 
combined with secondary structure data as input.  Results were further refined in the 
second layer in order to determine location of secondary structure motifs (Kaur and 
Raghava, 2003).  Such methodologies had been reported previously to attain accuracy 
levels of 80%, compared to the 60 – 65% achieved via sliding windows algorithm 
based methodologies (CASP4, 2000).  Overall combining primary and secondary 
factors in the prediction of epitopes in the GS dataset resulted in the correct prediction 
of 15/21 (71%) compared to 9/21 (43%) based upon just primary. 
Once fully optimised the performance of the novel prediction methodology was 
compared with that of a recently developed and publicly available online server – 
BCEPRED (Saha, 2003).  BCEPRED differed from the ExPASy methodology in that it 
had 6 criteria (Table 3.11), all of which were algorithms based upon the sliding window 
principle.  Overall when assessed using the GS dataset, BCEPRED predicted 85% 
(18/21) of epitopes compared to the 71% (15/21) managed by ExPASy.  Despite this, 
when assessed in terms of sensitivity and specificity ExPASy fared better than 
BCEPRED, overall predicting fewer, and more antigenic epitopes (Table 3.12).  These 
would be less likely to be eliminated from early stages of prediction due to their 
increased antigenicity.   Although results initially suggest the increased potential for the 
ExPASy method in contrast to that of BCEPRED, it should be taken into consideration 
that this analysis was based upon a small dataset of 21 epitopes.   Often small data sets 
encourage a strong bias for the results (Donnes and Elofsson, 2002)  Any future work 
should take this into consideration, increasing the size of this dataset before further 
analysis. 
One of the main problems with such an approach is that so far, the measure of 
error in predicting B cell epitopes is unknown, with very few studies addressing this 
problem (Blythe and Flower, 2005, Greenbaum et al., 2007).  Those investigations 
which have tackled this issue have had to overcome difficulties such as how to 
differentiate between true positive, true negatives, false positives and false negatives 
when much of the field is theoretical (Baldi et al., 2000).  This is further complicated 
by mechanisms such as epitope spreading (Section 3.1.6) that are characterised by 
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antibodies to secondary epitopes which appear at different stages during a response 
(James and Harley, 1998).  Despite many of the associations linking ES to disease, it is 
likely that it operates as a vital component of the protective immune response and it has 
been well recognised that over time there is a progressive and ordered accumulation of 
antibodies generated to infectious agents.  Many of these serological profiles such as 
that in HIV, form crucial parts of patient management.  In Hepatitis B virus (HBV) 
infection, T-cells primed with the nucleocapsid (core) protein of HBV (HbcAg) are able 
to drive antibody production against the HBV surface protein (Milich et al., 1987).  ES 
may also play a role in the resolution of/protection against autoimmunity.  Evidence of 
such a role has been observed in animal models including that of adjuvant arthritis in 
Lewis rats (Moudgil et al., 1997) and the natural recovery of patients suffering from 
acute autoimmune phenomenon such as Guillain-Barre syndrome (Powell and Black 
2001).  Despite this evidence however, there are cases where successful immune 
responses are mounted against infectious agents, in the absence of ES (Whitton et al., 
1989, Klavinskis et al., 1989, Levely et al., 1991, Cole et al., 1995, Mikszta et al., 
1997). 
 
3.4.2 Selection of epitopes for peptide synthesis 
 
Once optimised, the technique for predicting antigenic epitopes was applied to 
the identification of epitopes on 26 autoantigens and 13 endogenous retroviruses.  After 
identification, epitopes originating from autoantigens were aligned with those from 
retroviral proteins, using a local alignment program to identify regions of shared 
homology (Table 3.13 – 3.14).  Those regions of shared sequence were then highlighted 
and short listed as candidates for synthesis into short polypeptides and for subsequent 
incorporation into ELISA for screening of patient blood for antibodies to their relevant 
epitope.  Of those peptides short-listed (Section 3.3.7), two were selected for synthesis - 
GfPN1kpr (Figure 3.6A/B) and GfPN2eip.  GfPN1kpr showed the best alignment with 
Collagen II.  Collagen II is a major autoantigen in RA (Wang et al, 2002), with strong 
evidence observed in animal models in mice (Brand et al., 2004).  This epitope was in 
the top four most antigenic epitopes on HERV-K10 Gag, in addition to being located 
next to a Beta-turn, a potential marker of antigenic regions.  GfPN2eip was selected due 
to its location within the superantigen region of HERV-K.  Super antigens are 
molecular protein’s capable of activating large numbers of immune cells, leading to 
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clonal exhaustion, senescence and autoreactivity (Ivars, 2007).  Such a region had been 
previously implicated in development of rheumatic disease pathogenesis (Herve et al, 
2004).  Additionally, Eip was located within an antigenic region making it the second 
most antigenic region identified on HERV-K.   
 
 
 
 
 
 
 
 
A third peptide was also selected for manual synthesis using in-house facilities.  
PLSK (for sequence see Table 4.2) was derived from the same region as GfPN1kpr, 
however was derived from the HERV-K provirus, rather than HERV-K10.  This was 
reflected in the 9 amino acids difference between the two and was included in order to 
identify differences between members of the same sub-family – HERV-K (HML-2). 
At present, there appears to be a poor understanding of the rules governing what 
exactly constitutes a functional epitope (Greenbaum et al., 2007) with many studies 
appearing to have been content with using areas of high hydrophilicity alone as markers 
for epitopes (Galbraith et al., 2001).  Furthermore validations of published 
experimental derived epitopes have shown this approach to be inadequate (personal 
observation).  In particular this highlights a more general problem within the field, i.e. 
that of a lack of standardisation.  This is especially evident when confronted with the 
myriad of different techniques available, both commercially and for public use, with 
most based around identical principals.  Further validation and analysis of larger 
Figure 3.5 (A) A graphical representation of the peptide – GfPN1kpr.  The molecular backbone and side chains of the 
peptide: GfPN1kpr (VGPLESKPRGPSPLS) which was synthesised and used in an ELISA style assay for evaluation of 
HERV-K10 reactivity in RA patient sera in chapter 4.  (B) A diagram showing the electron and charge distribution across 
the surface of the peptide. 
The above images were produced using a publicly available software package available from the ExPASy server 
(http://us.expasy.org/spdbv/).  This application allows the visualisation of proteins in terms of structure and any interactions 
they may have wilth other proteins.  Deepview application has been developed with the Swiss-MODEL PDB database and 
modelling server. 
B A 
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datasets of proteins are required, as well as extensive comparison studies between the 
different approaches.   
 
3.4.3 Conclusions 
 
In this chapter, an in silico based methodology for the prediction of B cell 
epitopes was optimised and applied for the determination of antigenic regions likely to 
bind antibodies in RA patients.  Epitopes in HERVs and RA autoantigens were cross 
referenced between each other to detect the presence of any sequence homology, and 
such regions were then short-listed for synthesis as short peptides for incorporation into 
an ELISA (Chapter 4).  During this analysis, the methodology was validated using a 
small data set of experimentally derived linear epitopes, identified upon 7 randomly 
selected autoantigens involved in systemic rheumatic diseases. 
Currently, one of the largest obstacles for progress with the field of B cell 
epitope mapping is the lack of standardisation between individual investigations.  The 
introduction of performance scales such as AROC (Berman et al., 2002), may help to 
solve this problem and act as a bench mark for progress, however techniques such as 
this must be utilised by all groups researching this area, rather than many groups 
developing and using their own individual methodologies with no real means for 
comparison.  
From this work the following conclusions can be made: 
 
• The field of B cell epitope mapping requires standardisation, in terms of both tools used 
as well as controls. 
• The level of sequence homology between HERVs and human autoantigens in RA was 
less than expected. 
• Three peptides were identified for synthesis as short peptides and incorporation into a 
novel ELISA for surveying of patient samples.  These epitopes have been identified as 
epitopes on RA autoantigen proteins that share sequence homology with endogenous 
retroviral sequences.  
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Abbreviations 
 
 
 
Optical density (OD) 
American Rheumatism Association (ARA) 
Bovine serum albumin (BSA) 
Chronic fatigue syndrome (CFS) 
Enzyme-linked immunosorbent assay (ELISA) 
Epstein-Barr virus (EBV) 
Human endogenous retrovirus (HERV) 
Hydrochloric acid (HCl) 
Immunofluoresence (IF) 
Inhibition ELISA (iELISA) 
Inflammatory bowel disease (IBD) 
Matrix assisted laser desorption ionisation - time of flight (MALDI-TOF) 
Mixed cryoglobulinaemia (MC) 
Non-specific binding (NSB) 
Normal healthy donors (NHD) 
Osteoarthritis (OA) 
Phosphate buffered saline (PBS) 
Purified protein derivative (PPD) 
Rheumatoid arthritis (RA) 
Rheumatoid factors (RF) 
Sjogrens syndrome (SS) 
Standard error of mean (SEM) 
Synovial fluid (SF) 
Systemic lupus erythematosus (SLE) 
Trifluoroacetic acid (TFA) 
Trimethyl-benzene (TMB) 
Tween 20 (TW20) 
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Chapter 4 – Optimisation & development of ELISA for 
detection of anti-HERV-K antibodies within patient samples 
 
4.1 Introduction 
 
4.1.1 History of the ELISA 
 
Enzyme assays have been in use for several decades, with applications ranging 
from the detection of antigen in tissues (Nakane and Pierce, 1966) to antibody 
quantification, using polystyrene centrifuge tubes as the solid phase (Van Weemen and 
Schuurs, 1971, Engvall and Perlmann, 1972).  The 96-well microtitre plate format was 
first utilised by a group testing for antibodies to the malaria parasite Plasmodium 
falciparum in the mid-1970’s (Voller et al., 1974).  Today, the enzyme immunoassay is 
a fundamental technique, commonplace in many immunological laboratories 
worldwide.  One of the most common forms of immunological enzymatic tests used is 
the Enzyme-linked immunosorbent assay (ELISA) (Schmitt and Papisch, 2002), which 
has widespread use as an assay for specific antibodies and protein antigens in body 
fluids and tissue extracts (Cantarero et al., 1980).  As a detection method, ELISA has a 
number of advantages over the indirect Immunofluoresence (IF) methodologies, 
including increased specificity and sensitivity (Borg, 1997).  A number of previously 
published studies have already used ELISA in the detection and determination of anti-
retroviral antibodies, exploring their potential roles in rheumatic disease (Deas et al., 
1998, Bengtsson et al., 1996, Herve et al., 2002) whilst other studies have identified 
increased levels of HERV transcriptional activity in Rheumatoid Arthritis (RA) 
patients, compared to disease controls (Ejtehadi et al., 2006). 
Additionally the HERV-K (HML-2) ELISA was used to correlate levels of 
antibodies specific for HERV-K (HML-2) Gag and Env proteins, with the presence of 
Rheumatoid factors (RF).  RF were first discovered almost 75 years ago by Waaler 
(Natvig and Tonder, 1998) and Rose (Christian, 1998) and target the constant region of 
IgG (Fc region, typically in the γ2-γ3 cleft) (DeLano et al., 2000).  Initially their 
activity was thought to be specific for RA.  This is now known not to be so (Westwood 
et al., 2006) and despite their inclusion as one of the seven criteria set out by the 
American rheumatism association (ARA) for the diagnosis of RA (Arnett et al., 1988), 
RF have been identified in other autoimmune [e.g. Sjogrens syndrome (SS) (Shlomchik 
et al., 1987a, Shlomchik et al., 1987b), Systemic lupus erythematosus (SLE) (Tan, 
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1989), Mixed cryoglobulinaemia (MC) (Martin and Pasquali, 1992, Procaccia et al., 
1987)] and infectious diseases [Chlamydia (Peeling et al., 2000), Hepatitis B 
(Steigmann et al., 1974)] and Syphilis (Cerny et al., 1985)].  Additionally, their 
presence has also been detected to a lesser extent in both healthy and elderly 
individuals and may form part of the normal immune response.  Some pathogens have 
also been reported to be influenced by RF levels, such as Epstein Barr virus (EBV) 
(Yang et al., 2004) thus levels of RF were determined and correlated with levels of 
responses to HERV-K proteins. 
 
4.1.2 Aims and Objectives 
 
This chapter outlines the serological phase of this investigation addressing 
whether HERV-K (HML-2) plays a role in the pathogenesis of RA through protein 
production.  Herein, 4 main themes are addressed: 
 
1. To develop and optimize a specific and sensitive ELISA, incorporating epitopes 
predicted in chapter 3 using bioinformatic analysis. 
2. To use the novel ELISA to determine levels of antibodies to predicted epitopes in RA 
patients and disease controls.  This may give an indication as to whether these epitopes 
play a role in disease pathogenesis. 
3. To compare the levels of anti-HERV antibodies in both the synovial fluid and blood, 
correlating both with levels of RF.  This may give an indication as to whether RF can 
modulate HERV-K activity and also whether the non-specific binding of RF was 
playing a role in influencing ELISA OD values. 
4. To assess the performance of and to validate the output of the bioinformatics 
methodology, as described in chapter 3, through a number of means including 
biotinylation of peptides and the use of a negative control peptide. 
 
A novel ELISA was thus developed using the peptide and corresponding 
polyclonal rabbit bleed in order to optimise assay conditions before using it to test RA 
patient and control antisera.   
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4.2 Materials & Methods 
 
All reagents were derived from (Sigma-Aldrich, Gillingham, UK) unless specified 
otherwise 
 
4.2.1. Patient samples 
 
Blood samples were taken from 48 RA patients who attended the Rheumatology 
Clinics at New Cross Hospital, Wolverhampton.  All RA patients satisfied the criteria 
set out by the ARA (Arnett et al, 1988).  Serum samples were also taken from control 
groups including 27 Osteoarthritis (OA - non-inflammatory joint disease) and 17 
inflammatory bowel disease patients (IBD) (7 diagnosed with active Crohn’s disease, 7 
with inactive Crohn’s disease and 3 with Ulcerative colitis).  IBD patients acted as non-
joint inflammatory disease controls.  Furthermore, 23 rheumatic disease controls with 
Systemic lupus erythematosus (SLE) and 37 Normal healthy donors (NHD) were 
selected.  Specific inclusion criteria stipulated that all patients with RA must be in 
attendance at the Rheumatology clinic, New Cross Hospital, Wolverhampton, and 
fulfilled diagnostic criteria set by the American College of Rheumatology (ACR).  No 
exclusion criteria were set for this investigation.  All samples were taken by staff 
working at the clinic and constituted 10ml of venous blood were collected in sterile 
preservative-free heparin from each patient after informed consent had been given.  
Blood samples were also obtained from healthy volunteers of known age and sex.  In 
order to maximise accuracy of the investigation all blood samples were processed 
within 3 hours.  All steps were performed under aseptic conditions. 
 
4.2.2 Peptide synthesis 
 
A single peptide ‘PLSK’ was synthesised manually using Fmoc solid phase 
synthesis as described previously (Fields and Noble, 1990).  Synthesis was carried out 
on a 0.2 mM scale.  Amino acid side chains were protected as t-butyl esters (Aspartic 
acid and Glutamine), esters (Serine, Threonine and Tyrosine) and urethanes (Lysine 
and Histidine).  Guanidino and thiol groups of arginine and cysteine were protected by 
4-methoxy-2, 3, 6-trimethylbenzenesulphonyl and trityl groups respectively (Hancock 
and Battersby, 1976). Kaiser tests were employed to verify coupling and deprotection 
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(Chan and White, 2000).  Cleavage and side-chain deprotection was accomplished for 
appropriate lengths of time with Trifluoroacetic acid (TFA).  Biotin was attached to 
nascent peptides prior to the cleavage step, via the addition of a cysteine residue at the 
N-terminal.  This addition also facilitated the binding of the PPD immunogen via the 
cysteine’s side chain thiol group.  Peptide identity was verified by molecular weight 
using ‘Matrix Assisted Laser Desorption Ionisation - Time of Flight’ mass spectrometry 
(MALDI-TOF) (Shimadzu UK Ltd, Milton Keynes, UK).  Peptides were lyophilised 
and resuspended in sterile phosphate buffer to a concentration of 10mM and stored at -
20ºC.  Peptides ‘GfPN1kpr’ and ‘GfPN2eip’ were synthesised commercially (Severn 
Biotech, Kidderminster, UK).  ‘Negcont1’ peptide was synthesised commercially 
(Severn Biotech, Kidderminster, UK), however like PLSK it lacked specific antiserum. 
 
4.2.3 ELISA micro-titre plate optimisation 
 
Four 96-well microtitre plates [Nunclon Δ surface (Sigma, UK), Falcon 
Flexiplate (Falcon, CA), HB2 (DYNEX technologies, INC, USA) and HB4 
(Immunolon, UK)] were trialed using the GfPN1kpr peptide as described previously 
(Section 2.6.1).  Wells were coated with 400ng/50 µl of peptide and positive serum was 
diluted in a seven-step two fold dilution series starting at 1/50, and blocked with 2% 
Bovine serum albumin (BSA)/1 x Phosphate buffered solution (PBS) (0.05% TW20).  
Absorbance readings were taken at 450 nm after an incubation of 5 mins at room 
temperature, in the absence of light, using a Trimethyl-benzene (TMB) (Sigma, UK) 
and a Multiscan platereader (Labsystems, Thermo, CA).  All experiments were 
completed in triplicate and repeated independently three times in order to compensate 
for intra and inter assay variation.  
 
4.2.4 Determination of optimal antigen concentration 
 
 
The checkerboard titration technique was used to test both the peptides and their 
respective terminal bleeds against one another (Crowther, 2000).  A second plate was 
also run with titrated peptide against a second unrelated polyclonal antibody in order to 
confirm there was no cross-reactivity between the two peptides.  Concentrations of 
peptide started at 80µgml-1 and were further diluted two-fold across the plate (column 
1-11).  Serum was also diluted two-fold over 7 dilutions, ranging from 1/50 to 1/3200.  
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Diluted antibody only and peptide/ no antibody controls respectively were also included 
upon the plate.  This was repeated using GfPN2eip to coat the wells, in order to assess 
the potential for cross-reactivity between the polyclonal Kpr-specific bleed and other 
short peptides incorporating HERV epitopes. 
 
4.2.5 Blocking agent optimisation 
 
Several candidates for blocking agents were chosen from previously published 
studies and investigations were conducted to determine their blocking efficiency (Table 
4.1).  Blocking agents were assessed using the ‘final rabbit bleeds’ for specific peptides 
- Kpr and Eip (at 1/200 dilution) and an antigen coating of 10µgml-1.  The nature of 
these non-specific interactions was investigated by omitting both the antigen and 
primary antibody in two separate investigations.  The elimination of antigen from the 
assay allowed the determination of the Non-specific binding (NSB) capacity of the 
primary antibody within the assay (Figure 4.6).  Through omission of the primary 
antibody, this allowed the determination of the level of non-specific binding occurring 
as a result of the conjugate (Figure 4.7).  All blocking agents were made up in diluent 
(1 x PBS) to a concentration of 2%, unless otherwise stated.   The same diluent was 
also used as a negative control.  
 
 
Blocking agent Reference 
Bovine Serum Albumin (BSA) (Herrmann et al., 1979) 
Casein (Herve et al., 2002) 
Gelatin (fish skin) (Gary et al., 1985) 
Milk powder (Marvel) (Vogt et al., 1987) 
Ovalbumin (Crowther et al., 2001) 
 
 
 
 
 
4.2.6 Incubation of substrate and reaction stopping time 
 
ELISA was performed using HB2 plates and 2% BSA blocking buffer, both of 
which had been optimised in previous steps.  A 1/200 dilution of primary antibody 
Table 4.1 shows the different blocking agents tested for suitability within the ELISA assay.  
All blocking buffers were used at 2% concentrations unless otherwise stated. 
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(GfPN1kpr terminal bleed) was added at 50 µl per well.  Absorbance values were read 
at 450nm using the MS Multiscan plate reader at different time intervals.  Readings 
were taken for reactions immediately after adding TMB substrate, and for periods 
between 1-10 minutes, at 1 min intervals.  All incubations were carried out in the dark 
and at room temperature.  A stopping solution of 50µl of 2N Hydrochloric acid (HCl) 
was used to stop each enzymatic reaction with each reaction time tested three times in 
triplicate over three separate plates. 
 
4.2.7 Bleed evaluation 
 
Commercially synthesised peptides and their respective bleeds were tested in an 
ELISA in order to measure their reactivity at different concentrations and to confirm 
bleed functionality in addition to determining optimal dilutions for use within the assay.  
Bleeds for each peptide were taken pre-immunisation, and at 7 day intervals including 
7, 14, 21 and 28 days. 
 
4.2.8 Inhibitory studies using GfPN1kpr and GfPN2eip 
 
Inhibition ELISA (iELISA) was used as a method for validating peptide 
specificity by showing that the bleeds used to develop the assay were specific for the 
peptide and not due to reactions of a non-specific nature.  The iELISA protocol was 
separated into two phases.  An initial phase involved the incubation of the primary 
antibody with log dilutions of the peptide it had been raised against.  Incubated serum 
was then tested in the assay using the same peptide as antigen.  A correlation between 
an increase in Optical Density (OD) and increasing log dilutions of peptide incubated 
with the antibody suggested OD were indicative of a specific interaction between 
epitope and paratope.  The inhibition assay was also carried out using an irrelevant 
peptide (Negcont1) and irrelevant antiserum (GfPN2eip) further emphasising the 
specificity and lack of cross-reactivity between peptides and bleeds alike.  The 
Negcont1 peptide was included as a negative control in order to eliminate bias. 
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4.2.9 Investigation of anti-HERV-K Gag & Env antibodies within the synovial 
fluid 
 
 Levels of antibodies to epitopes Kpr and Eip were also measured in the 
Synovial Fluid (SF).  This was investigated by substituting synovial fluid, diluted to 
1/200 in 2% blocking buffer (0.05% Tween 20 (TW20), into the ELISA in place of 
primary serum.  This gave an indication of the antibody responses to HERVs at the site 
of disease, within the joint.  
 
4.2.10 Quantification of rheumatoid factor levels within the synovial fluid & blood 
 
Levels of RF in patient samples (both serum and synovial fluid) were measured 
using a commercially available quantitative agglutination assay (Plasmatec, Bridport, 
UK).  The assay was carried out according to manufacturers’ instructions, with positive 
and negative controls included on each run. 
 
4.2.11 Biotinylated ELISA 
 
Biotinylated ELISA was carried out using React-bind™ NeutrAvidin™ coated 
96-well plates (Pierce, Rockford, IL).  400 ng/50 µl of biotinylated peptides were added 
to each well and washed three times in 1 x PBS/ 0.1% TW20 before ELISA was carried 
out as described previously (Section 2.6.1). 
 
4.2.12  Immunofluoresence 
 
 
2 x 103 cells (T47D, Tera1 and human fibroblast-like synoviocytes) were used to 
seed each well on a BD Falcon culture slide (BD Biosciences, Oxford, UK).  Each 
seeding volume was diluted with 300µl of supplemented medium (for details see 
Appendix III) and incubated for 12-16 hours at 37°C at 5% CO2.  After incubation, 
spent media was discarded and cells were washed 3 times for 10 min with 1 X PBS.  
Cells were then fixed with 2% formaldehyde in PBS/pH 7.4 for 15 min at 20°C, before 
washing 3 times with 1 x PBS for 10 min. 0.2% Triton X-100 / PBS/ 1% BSA (pH 7.3) 
was added to permeablise cells, for 5 min on ice. Fixed cells were washed 3 times for 
10 min with PBS/ 1% BSA before the slide was incubated in a humidity chamber with 
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50μl of antibody at 1/200 dilutions in PBS/ 1% BSA/ 0.1% TW20 for 1 hour at room 
temperature, or overnight at 4°C.  After 3 x 10 min washes with PBS/ 1% BSA, slides 
were incubated for a further hour with the secondary antibody, conjugated to FITC 
(Dako, Glostrup, Denmark) at appropriate dilutions (manufacturers’ recommendations).  
After a further 3 x 10 min washes with PBS/ 1% BSA, slides were allowed to drain 
before a single drop of Vectorshield™ mountant (with DAPI) (Vector labs, 
Burlingame, CA) was added, and sandwiched using a sterile coverslip.  Slides were 
sealed using clear nail varnish before setting and viewing with DAPI fluorescing at 461 
nm as blue and FITC fluorescing at 521 nm as green, using the LSM 510 Meta confocal 
microscope and analysed with LSM 5 Meta software (Carl Zeiss IMT Corp, 
Thornwood, NY). 
 
4.2.13 Statistical analysis 
 
Statistical analysis of differences between > 2 groups was carried out using a 
one-way ANOVA test and Tukey-Kramer test in order to compare all groups and 
individual pairs of groups, not assuming Gaussian distributions amongst samples 
(Graphpad version 5.1, San Diego, CA).  SPSS (SPSS, Chicago, IL) was also used to 
assess variance between sample results.  Analysis of two paired samples was carried 
out using 2-way paired t-tests, and Mann Whitney tests.  P values of <0.05 were taken 
as significant.    
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4.3 Results 
 
4.3.1 Peptide/Antigen selection and development 
 
Three synthetic peptides of 15-17aa were designed incorporating epitopes using 
in silico analysis of putative HERV protein sequences involved in potential molecular 
mimicry with disease autoantigens.  One peptide incorporating an epitope derived from 
a Gypsy/ Ty3 element found in Arabidopsis thaliana was also included as a negative 
control to prevent bias within the analysis (Table 4.2).  Peptides ‘GfPN1kpr’, 
‘GfPN2eip’ and ‘Negcont1’ were commercially synthesised.  Specific antiserum was 
produced for both Kpr and Eip, but not Negcont1.  These peptides contained charged 
amino acids predicted to be of a hydrophilic nature and thus exposed at the surface of 
the molecule.  High titres of polyclonal antiserum were then harvested after 
immunisation of rabbits with PPD-coupled Kpr and Eip peptides.  A fourth peptide 
‘PLSK’ was synthesised using in-house facilities at the University of Wolverhampton 
(Section 4.2.2) and its identity confirmed using MALDI-TOF analysis (Figure 4.1).  No 
accompanying bleed was raised to PLSK and its purity was not ascertained by HPLC.   
 
 
Peptide name Sequence Organism 
derived 
Accession 
no. 
Justification 
 
GfPN1kpr 
(Kpr) 
 GPSESKPRGTSPLPAG  HERV-
K10 Gag1 
M14123 Homology to 
predicted epitope 
on Collagen II and 
also shared 
homology with 
HRES-1 p25 
GfPN2eip 
(Eip) 
PCPKEIPKESKNTEVL HERV-
K10 
Pol/Env 
M14123 Highlighted as 
superantigen 
region of HERV-
K10  
(Herve et al, 2001) 
 
PLSK VGPLESKPRGPSPLSA HERV K 
Gag 
Y18890 3 alignments with 
two from Collagen 
I and one on 
Calpastatin 
 
Negcont1 VAVADGRKLNVDGQIK Arabidopsis 
thaliana 
Gypsy/ 
Ty3 
element 
AAG51464/ 
AC069160 
Sequence of 
retroviral origin 
unrelated to 
HERVs 
 
 Table 4.2 Table showing the peptides selected as candidates for synthesis and testing against patient antiserum. 
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During the course of the assay development, the optimisation of a number of 
variable factors was taken into account.  This included optimisation of the type of 
microtitre plate, the blocking agent, time of reaction between conjugate after addition 
of substrate before stopping and both the antigen and bleed dilutions to be used.  
 
4.3.2 ELISA plate and Antigen seeding optimisation 
 
The 96-well micro-titre plate is one of the main components of an ELISA assay 
and one of the more commonly used forms of solid phase (Gonzalez-Buitrago and 
Gonzalez, 2006).  A key feature of the solid-phase ELISA is that antigen can be easily 
attached to the plate surface by passive adsorption, in a process commonly known as 
coating.  Poor binding of the peptide to the microplate may result in the low 
performance of the assay and underreporting of actual absorbances, leading to an 
increase in false-negatives. 
 
Figure 4.1 MALDI-TOF mass spectrometry analysis of the PLSK peptide, which was manually synthesised using in-house facilities 
in the Molecular Pharmacology group, University of Wolverhampton.  Of particular note is the largest peak at 1520.78 – the 
expected molecular weight of the synthesised peptide.  
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Serial dilutions of the GfPN1kpr terminal bleed ranging from 1/50, down a two-
fold dilution series to 1/3200 were tested against a single concentration of peptide (10 
µgml-1) coated on each of the four test plates.  HB2 Immunolon plates showed the 
lowest level of background binding, although binding of all plates was comparable, 
particularly at lower dilutions (Figure 4.2), i.e. 0.01 - 0.02 at 1/3200.  Results, shown in 
Figure 4.3, indicated a distinct correlation between decreasing antibody dilution and the 
level of absorbance recorded.  This trend was observed at all peptide concentrations.  
Peaks in OD values were observed at 160 µgml-1 of antigen, although levels of standard 
error were increased compared to other dilutions.  For this and economical reasons, the 
lower coating volume of 10 µgml-1 was selected and used for future assays.  
Additionally, it had been previously reported that adding higher concentrations of 
peptide to a microtiter well (up to 10 µgml-1), increased the total amount of peptide 
adsorbed (Butler et al., 1987). The reactivity of the Kpr bleed was also tested against 
the GfPN2eip peptide across the same dilution series (data not shown).  This did not 
Figure 4.2 Comparison of four separate 96-well microtitre plate types [Nunc (Sigma), Falcon (Falcon), HB2 
(Dynex) and HB4 (Immunolon)] using serial dilutions of primary antibodies (terminal bleed to GfPN1kpr).  
Error bars show Standard error of the mean (SEM).
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show the same correlation between antibody dilution and OD value, thus validating the 
specificity of the positive serum, for Kpr and demonstrating its lack of cross-reactivity 
with other peptides.  All coating steps were carried out overnight at 37 ºC.  The effect 
of temperature upon passive adsorption of antigen was also investigated thus 
confirming 37 ºC as the most optimal temperature for coating.  From this investigation 
it was concluded that HB2 plates presented the lowest background levels.  The results 
outlined above also suggested an acceptable antigen coating concentration was 10 
µgml-1. 
 
 
 
 
4.3.3 Optimisation of blocking buffers 
 
Measures were also taken to reduce the non-specific adsorption of 
contaminating proteins present in samples, after coating the bottom of wells with 
antigen.  A literature search was carried out identifying potential candidate blocking 
agents for use within the assay.  Candidate blocking agents assessed (Table 4.1) were 
tested as described previously (Section 4.2.5).  The results for the evaluation of the best 
blocking agent were shown in Figures 4.4 - 4.5.  The results in Figure 4.4 show the 
influence of blocking buffer upon final OD values when an ELISA was run in the 
absence of antigen.  This gave an overall indication of the level of non-specific binding 
Figure 4.3 Checkerboard titration results in which gradients of antigen were plotted against serum titration.  Serum 
dilutions are labelled in key.  Error bars indicate SEM.  P+ S- : Peptide, no serum control.
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of the blocking agent itself to the microtitre plate and its non-specific reactivity 
concerning the primary antibody.  After subtraction of background values 2% BSA 
showed the lowest level of non-specific binding.  Casein and Gelatin both showed high 
OD values indicating a large degree of non-specific binding was occurring.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Comparison of previously published blocking buffers omitting antigen indicating the effect of non-
specific binding due to the primary antibody.  The higher the OD value, the less blocking effect and higher 
non-specific binding is achieved.  As shown above, Gelatin and casein showed the highest OD values of those 
blocking agents tested suggesting a degree of non-specific binding.  The blocking agent exhibiting the lowest 
absorbance was 2% BSA.  As expected the highest values were observed using PBS (negative control).  These 
showed a high degree of non-specific binding occurring between the antiserum and the plate.  Error bars 
show SEM.   
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Results presented in Figure 4.5 showed a further assay carried out in the 
absence of primary serum.  This allowed the level of non-specific binding between the 
conjugate and the blocking agent to be determined.  OD values were lower in 
comparison to those shown in Figure 4.4.  Similar to the first experiment omitting 
antigen, 2% BSA gave the lowest value, although those using 1% BSA, 2% marvel and 
ovalbumin were also comparable.  2% BSA was thereby selected for inclusion within 
further investigations. 
 
4.3.4 Optimisation of reaction incubation time 
 
The optimisation of the incubation of substrate (TMB)/reaction time before 
stopping was also investigated.  The addition of a stopping agent increased the 
sensitivity of the assay with the effect of incubation time upon final absorbance was 
shown in Figure 4.6.  After 6 minutes, absorbance values increased at a slower rate than 
that observed prior to 6 minutes suggesting that this point was at the end of the linear 
phase of the reaction.  Absorbance levels still increased after 6 minutes until 10 minutes 
(data not shown); however the rate of reaction was slower than that observed 
previously.  An incubation period of 5 minutes at room temperature, in the absence of 
light was chosen for inclusion within the assay as this point was the end of the linear 
phase of the reaction before enzymatic reaction rates began to slow. 
Figure 4.5 The results of blocking buffer optimisation.  The results gave an indication of the effect of the 
omission of the primary antibody, thus allowing determination of the level of non-specific binding due to the 
conjugate.  The higher the OD values, the higher the non-specific binding to the plate.  PBS negative control 
showed the highest degree of non-specific binding as expected.  Error bars show SEM. 
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4.3.5 Antibody titres of different bleeds raised to peptides 
 
Data presented in Figures 4.7 and 4.8 shows the antibody titres of the different 
bleeds raised to Kpr and Eip peptides in rabbits.  Each bleed taken at 7-day intervals in 
Figure 4.7 (see legend) showed an increase in strength with time of exposure to the 
immunogen.  This was emphasised in the results as the terminal bleed showed the 
highest level of absorbance across all dilutions.  As expected the pre-bleed provided a 
base-line of reactivity below all other bleeds.  Bleeds raised to Eip however, showed a 
different trend (Figure 4.8).  The terminal bleed appeared to be stronger when 
undiluted, although it dipped below that of bleed 3 after a 1/200 dilution, and dropped 
below even bleed 1 at 1/1000 dilution (taken at 7 days post exposure to the 
immunogen).  The difference between bleeds was not considered significant and was 
attributed to a time delay during delivery of the individual bleeds. 
 
Figure 4.6 The effect of varying substrate incubation upon final absorbance readings.  The above graph shows 
the effect of time upon final absorbance values after TNB substrate has been added to ELISA plate wells.  
There was a positive correlation between the length of incubation and level of absorbance measured.  The rate 
of reaction is shown to alter after 6 minutes showing a change in reaction kinetics.  Error bars show standard 
error of the mean (SEM).  TMB: Trimethyl-Benzene. 
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Figure 4.7 The reactivity of pre-bleed, bleed 1, bleed 3 and the terminal bleed with peptide GfPN1kpr.  Each bleed raised 
against Kpr  in the above figure represents a single harvest taken from the animal at different time points over a month 
post immunisation.  Pre-bleed represents levels of anti-Kpr prior to immunisation with the peptide.  Bleed 1 shows levels of 
antibodies after 7 days post-immunisation.  Bleed 3 shows antibody titres after 21 days and the terminal bleed exhibits 
levels of anti-Kpr antibodies after the 1 month post immunisation period had expired.  In theory, the terminal bleed should 
show the highest antibody titres, and this is reflected in the above graph.   Error bars show SEM. 
 
Figure 4.8 The reactivity of the pre-bleed, bleed 1, bleed 3 and the terminal bleed raised to GfPN2eip.  Error bars 
show SEM. 
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4.3.6 Inhibition assay 
 
Inhibition assays were run in order to confirm the specificity of both bleeds for 
their respective peptides.  This also validated the bioinformatics work showing that the 
epitopes were able to interact with specific antibodies.  Standard curves were 
constructed for each antiserum (Figures 4.9 - 4.10) and the dilution which gave an 
absorbance of 0.5 was noted.  With both Kpr and Eip antisera, the bleeds were diluted 
to the appropriate dilution (1/1024) before being incubated with log dilutions of 
respective peptides taken from a log dilution series.   
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Figures 4.9 Standard curve generated by titrating out the GfPN1kpr terminal bleed.  Error bars show SEM  
Figures 4.10 Standard curve generated by titrating out the GfPN2eip terminal bleed.  Error bars show SEM  
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Data presented in Figures 4.11 – 4.12 suggest that antisera raised to both 
peptides were specific for their respective antigens.  Increases in absorbance correlated 
with increased dilutions of peptides used to incubate with primary antiserum before use 
in the assay.  This increase in OD values was more prominent with the Eip peptide 
showing a greater specificity between the peptide and antibody.  This was shown by a 
steeper gradient to the curve. 
 
 
 
 
Figure 4.11 The effect of incubating log dilutions of GfPN1kpr peptide with specific polyclonal antiserum.  Error bars indicate SEM. 
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In order to demonstrate that the lack of cross-reactivity between peptides was 
not limited to the two tested, a third unrelated peptide (Negcont1) was also included 
within the study.  0.5 Log10 dilutions were made up as described previously and 
incubated with both Kpr (terminal bleed) and Eip (bleed 3) at the appropriate dilution 
(as determined by the standard curves).  The reactivity of both bleeds were then 
investigated, using ELISA to assess any effects upon absorbance values (Figure 4.13).  
Both bleeds showed no overall change in trend and generally OD values were 
unaffected by incubation with different dilutions of peptide.  This emphasised the 
overall specificity of the bleeds for their respective peptides, and their lack of cross-
reactivity with other unrelated peptides.  
 
Figure 4.12 The effect of incubating log dilutions of GfPN2eip peptide with specific polyclonal antiserum.  Error 
bars indicate SEM. 
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4.4 Immunofluoresence of HERV-K expression in cultured cells 
 
In order to test antibodies in vivo, antibodies raised to peptides GfPN1kpr and 
GfPN2eip in Immunofluoresence (IF) on a number of cell lines including MCF7, T47D 
and Human synoviocytes taken from a healthy donor.  Figures 4.14 to 4.19 show 
typical images representative of staining of MCF7 and T47D cell lines.  As positive 
controls, human HLA-ABC (MHC class I) was used to confirm the IF procedure had 
worked successfully and performed as expected (Figures 4.14 and 4.17).  Negative 
controls included wells with no cells and well with cells but no primary antibody.  
Primary antibodies were used at 1/200 dilution as used with optimised ELISAs.  
Differences were apparent in the distribution of staining with Eip in MCF7 and T47Ds 
showing focal points of intense fluorescence (evident as bright spots as observed in 
figures 4.15 and 4.18).  These tended to correlate with the location of the DAPI stain 
potentially suggesting this staining may be occurring within the nucleus.  Such patterns 
were not observed with anti-GfPN1kpr, which presented a less intense but more evenly 
diffuse pattern (Figures 4.16 and 4.19).    
Figure 4.13 The effect of incubating primary serum with unrelated peptide (Negcont1) before use in novel 
optimised ELISA assay.  Error bars indicate SEM. 
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Figures 4.20 to 4.23 show images of fibroblast-like synoviocytes (healthy 
donor) after staining with both Kpr/Eip and DAPI counterstaining.  The staining of both 
HERV-K Gag and Env in these primary cells appears diffuse throughout the cytoplasm 
of the cell perhaps hinting to the localisation of the retroviral proteins in the cytoplasm 
where expected before packaging/budding.  Cells stained with anti-GfPN2eip appeared 
to exhibit a higher intensity of staining compared to that observed with GfPN1kpr.  
This difference appeared lesser in fibroblast-like synoviocytes (derived from a healthy 
donor) with Kpr showing a similar intensity to Eip.  This work validated the 
bioinformatic research carried out in Chapter 3, showing that antibodies to bind to these 
HERV epitopes within their in-vitro environment.  Additionally, this staining shows 
that HERVs are expressed as proteins to some extent within cells.  In those continuous 
cell lines tested (MCF7 and T47D) the extent to which this may occur may be due to 
the conditions the cells have been exposed to.  The fact that this is evident within 
primary cells confirms the occurrence within an in vivo setting.  ‘Substrate only’ 
negative controls were not run during immunostaining experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MCF7 cells 
 
Figure 4.14 MCF7 cells stained with positive control antibody (mouse anti-human monoclonal anti-HLA ABC), and labelled with 
rabbit anti-mouse – FITC conjugate.  Green indicates the location of HLA proteins within the cell membrane.  The blue stain 
shows DAPI stain which binds to dsDNA within the nucleus.  
 
Figure 4.15 MCF7 cells stained using rabbit anti-Eip antibodies, and a goat anti-rabbit FITC conjugate antibody.  Green staining 
shows location of HERV-K Env protein.  Blue stain shows DAPI stain which indicates the location of the nucleus. 
 
Figure 4.16 MCF7 cells after staining with rabbit anti- Kpr antibodies, with a goat anti-rabbit FITC conjugate.  Green strain 
shows the location of HERV-K Gag protein.  Blue stain at the centre of the cell shows DAPI stain bound to dsDNA within the 
nucleus. 
 
T47D cells 
 
Figure 4.17 Positive control for T47D cells using mouse anti-human HLA-ABC.  The green staining indicates the location of MHC-
I within the cells membrane.  Blue DAPI stain shows location of nucleus in which dsDNA is present. 
 
Figure 4.18 T47D cells stained with rabbit anti-GfPN2eip (Env).  These regions show as green after conjugation with a FITC 
labelled goat anti-rabbit conjugating antibody.  Blue regions after DAPI staining show location of DNA and nucleus. 
 
Figure 4.19 T47D cells showing staining with anti-GfPN1kpr (Gag), conjugated with goat anti-rabbit FITC conjugate.  Blue 
regions denote DAPI staining. 
 
 
Fibroblast-like synoviocytes (healthy donor) 
 
Figure 4.20 Fibroblast-like synoviocytes (donated by healthy individuals) using anti-GfPN2eip (Env) and labelled using goat anti-
rabbit FITC conjugating antibody.  Green regions denote expression of HERV-Env protein whereas blue staining shows location 
of location of dsDNA within the cells.  
 
Figure 4.21 Fibroblast-like synoviocytes (donated by healthy individuals) using anti-GfPN2eip (Env) and labelled using goat anti-
rabbit FITC conjugating antibody.  Green regions denote expression of HERV-Env protein whereas blue staining shows location 
of location of DNA within the cells.  
 
Figure 4.22 Fibroblast-like synoviocytes (donated by healthy individuals) using anti-GfPN1kpr (Gag) and labelled using goat anti-
rabbit FITC conjugating antibody.  Green regions denote expression of HERV-Gag protein whereas blue staining shows location 
of location of DNA within the cells.  
 
Figure 4.23 Fibroblast-like synoviocytes (donated by healthy individuals) using anti-GfPN1kpr (Gag) and labelled using 
goat anti-rabbit FITC conjugating antibody.  Green regions denote expression of HERV-Gag protein whereas blue 
staining shows location of location of dsDNA within the cells.  
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4.4.1 MCF7 cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.4.2 T47D cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.4.3 Fibroblast-like Synoviocytes derived from Healthy donor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15  Figure 4.14  Figure 4.16  
Figure 4.17  Figure 4.18  Figure 4.19  
Figure 4.21  Figure 4.20  Figure 4.23 
 
Figure 4.22  
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4.5 Testing of patient samples 
 
4.5.1 Testing of patient samples using non-biotinylated peptides 
 
Serum was extracted from the whole venous blood of RA patients (n = 48) and 
the reactivity to six peptides incorporating HERV epitopes (two biotinylated, four non-
biotinylated), assessed and compared to control groups including inflammatory non-
joint disease (IBD) (n = 20), non-inflammatory joint disease (OA) (n = 27), rheumatic 
disease (SLE) (n = 23) and healthy samples (NHD) (n =37).  
Results in Figure 4.24 show the mean levels of reactivity in patient cohorts, for 
each peptide.  All non-biotinylated peptides, across the patient groups appeared to 
exhibit a similar level of activity, although this varied somewhat between particular 
disease groups.  Perhaps surprisingly, the reactivity of the patient samples to the 
negative control peptide (Negcont1) gave comparable means to other non-biotinylated 
test peptides although this appears to be more specific for particular disease groups, i.e. 
OA.  Overall the level of reactivity to the non-biotinylated peptides was low in general 
being comparable in some cases to background reactivity, i.e. OD values of < 0.05.  As 
a result, biotinylated peptides performed significantly better than their non-biotinylated 
counterparts, showing significantly increased OD values (p < 0.0001) and possibly 
hinting that biotinylation is essential for the accurate modelling of some peptides.  
Additionally, a disease specific significant increase in RA patient reactivity was 
observed when biotinylation was used.  The improvement in orientation of the peptides 
and its consequent effect upon antibody recognition was also reflected in overall mean 
ODs per peptide (Table 4.3).   
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Peptide Sample 
(n) 
RA 
(48) 
SLE 
(23) 
OA 
(27) 
IBD 
(17) 
NHD 
(37) 
BD 0.042 0.043 0.033 0.034 0.031 Kpr 
 
SF 0.034     
BD 0.042 0.051 0.068 0.057 0.044 Eip 
 
SF 0.037     
BD 0.416 0.230 0.180 0.214 0.209 Biot - Kpr 
 
SF 0.095     
BD 0.406 0.214 0.189 0.216 0.201 Biot - Eip 
 
SF 0.097     
PLSK BD 
0.049 0.068 0.069 0.081 0.057 
Negcont1 BD 
0.026 0.072 0.107 0.025 0.078 
 
 
 
 
Using the GfPN1kpr (Kpr) peptide (Figure 4.25), it was apparent that SLE and 
RA patient sera showed the highest mean levels of reactivity (0.043, 0.042 and 0.07 
respectively).  OA patients could be classified into two groups based upon the OD 
observed.  A cluster of 11 patient samples had OD values greater than the group 
average, whereas the remaining patients exhibited OD values of less than 0.02.  The 
Figure 4.24 Mean OD values for patients in separate disease cohorts against different non-biotinylated 
peptides (Kpr, Eip, PLSK, Negcont1) and biotinylated (Biot-Kpr and Biot-Eip).  Error bars indicate SEM. 
n = RA: 48, OA: 27, NHD: 37, IBD: 17, SLE: 23. 
Table 4.3 Mean OD values for all disease cohorts against different peptides.  The mean OD values per disease 
cohort per peptide, biotinylation of peptides gave significantly increased reactivity with antibodies. n = RA: 48, 
OA: 27, NHD: 37, IBD: 17, SLE: 23. 
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group mean value of OA patient reactivity to Kpr was thus reduced due to this second 
‘lower’ cluster.  RA patients also showed considerable variation separating into two 
clusters (upper n = 10), resulting in a group mean value comparable to SLE.  These 
high responders could not be separated upon the basis of clinical details   
 
 
 
Generally patients showed a more heterogeneous response to the non-
biotinylated GfPN2eip (Eip) peptide, compared to reactivities observed with other 
peptides tested (Figure 4.26).  OA patient cohorts exhibited the highest reactivities of 
all groups tested (mean OD value of 0.06848).  Conversely NHD, SLE and RA patient 
samples exhibited the lowest levels of anti-Eip antibodies (mean OD values = 0.044, 
0.051 and 0.042 respectively).  OA patient data exhibited an increased level of 
variation, with results falling into 3 separate groupings.  These comprised of 6 samples 
showing OD values in excess of the population mean, ten samples clustering around the 
mean value and 8 samples exhibiting OD values below the disease mean.  The IBD 
patient group showed the third highest levels of reactivity to GfPN2eip, with the three 
highest OD values taken from three patients with active ulcerative colitis (patient 
details unknown).  The differences between all groups were significant using one-way 
ANOVA analysis (p = 0.0105), with only RA being significantly decreased in 
comparison to OA (p < 0.05) according to Tukey-Kramer test. 
 
Figure 4.25 OD values for patient sera from different disease groups using non-biotinylated GfPN1kpr peptide. 
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Reactivities to the PLSK peptide were most increased in OA and IBD patient 
cohorts (Figure 4.27).  In the OBD cohort the highest ODs were observed in those 
patients suffering from inactive Crohn’s disease.  In the group of OA patients tested, 
four patients in particular showed high ODs to PLSK.  Of these high responders, no 
correlations in age or sex were apparent (29F, 39M, 52M and 73F).  SLE patients 
showed a decreased reactivity to PLSK in comparison to IBD and OA however this was 
still elevated above RA and NHD.  In both cases this may hit at a role for HERV-K10 
(Kpr) as opposed to HERV-K (PLSK) in these diseases.  As with OA a small group of 
three high responding patients were evident (Figure 4.27). High responders in these 
groups and those in the SLE cohort showed no correlations in age or sex.  NHD and RA 
exhibited comparable reactivities to one another (means of 0.057 and 0.049 
respectively).  Overall, anti-PLSK responses in RA patients were significantly 
decreased in comparison to those observed in OA (p < 0.0001) and IBD patients (p < 
0.01). 
 
Figure 4.26 OD values for patient sera from different disease groups using non-biotinylated GfPN2eip 
peptide. 
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A negative control peptide ‘Negcont1’ was also used to test patient sera, in 
order to determine reactivity to random non-HERV epitopes and to eliminate bias from 
the results (Figure 4.28).  Patterns of reactivity observed with this peptide were 
intriguing as some disease groups, i.e. RA and IBD, exhibited lower OD values with 
this peptide whilst other groups such as OA, NHD and SLE, exhibited similar levels of 
reactivity than expected.  SLE and healthy cohorts both showed levels of absorbance 
and distribution of OD values, comparative to one another (mean OD values = 0.07 and 
0.073 respectively) with sample absorbance values varying more from the cohort mean 
(minimum and maximum values of both 0.02 - 0.14 and 0.01 – 0.14 respectively).   
The differences between all groups were significant according to one-way 
ANOVA analysis (p < 0.001) with Tukey-Kramer’s test showing the mean OD value 
from the OA cohort was significantly higher than other sample populations.   
 
 
 
Figure 4.27 The distribution of OD values for reactivity of patient disease cohorts using the PLSK peptide 
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4.5.2 Biotinylation of GfPN1kpr and GfPN2eip 
 
The reactivity of patient sera with biotinylated forms of the peptides Kpr and 
Eip was also explored in order to investigate different methods of antigen presentation 
(Figure 4.29 – 4.30).  Overall absorbance values were significantly increased when 
compared to those produced with non-biotinylated peptides (~0.25 compared to ~0.05 
respectively).  The effect of biotinylation compared to non-biotinylated peptides was 
highly significant (p < 0.0005) as shown by ANOVA analysis.  Of the two peptides, 
biotinylation of Kpr produced values of increased significance over Eip, despite the fact 
that Eip showed increased significance over Kpr in its non-biotinylated form.  Overall 
both peptides showed similar levels of reactivity (Figures 4.24 and Table 4.3). 
In terms of disease state, biotinylation had the greatest effect upon ODs taken 
from RA patient samples resulting in an increase in significance of the results for that 
group.   
RA patient serum presented the highest reactivity to the biotinylated Kpr 
peptide (mean OD value = 0.42) (Figure 4.29) showing the separation of RA patients 
into two clusters, i.e. those with OD values less than the cohort mean (n = 30) and 
those patients with OD values greater than the cohort mean (n = 18).    RA serum 
overall was significantly increased over all other groups by one way ANOVA analysis 
[with p values ranging from <0.05 (SLE) to < 0.001(NHD)].  SLE, similarly to non-
biotinylated Kpr, also showed a higher degree of reactivity to this peptide in 
Figure 4.28 Distribution of reactivity in patient sera using the Negcont1 peptide 
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comparison to other disease cohorts (mean OD value = 0.23).  The reactivity of OA 
patient samples showed reduced activity with the biotinylated peptides, suggesting the 
opposite of the results exhibited with the non-biotinylated antigen (mean OD value = 
0.18).   Of all disease groups tested, RA patients showed the greatest increase in 
significance and levels of reactivity to the biotinylated Kpr peptide, RA patients fell 
into two distinct subsets - those with OD values higher and those with OD values lower 
than the group mean.  High responders had an average age of 60 years old (range 40-93 
years) and comprised of 7 males and 13 females (mean = 0.89).  The 7 males were 
made up of 6 Caucasians and 1 Asian, whereas the 13 females were made up of 12 
Caucasians and 1 patient of black African origin.  The two highest responders in 
particular were 79 and 93 years old respectively.  Both were male Caucasians with 22 
and 26 years disease duration, and both exhibited high levels of RF levels (128 mg/ml). 
When healthy samples were tested using biotinylated Kpr, a cluster of four 
samples gave particularly high readings in comparison to the rest of the population, 
which showed very little variation from the mean.  Further details for these patients - 
71, 78, 79 and 81 however were not available, therefore no further conclusions could be 
drawn as to why they may present increased levels of antibodies to biotinylated Kpr.   
As shown in Table 4.3, biotinylated Eip showed a similar distribution of 
reactivities with levels of absorbance increased by almost 10-fold, compared to those 
observed using non-biotinylated forms of the same antigen (Figure 4.30).  Levels of 
absorbance were significantly higher than those of non-biotinylated peptides (p < 
0.0001 by one-way ANOVA) although with the exception of OA patient OD values, all 
other patient cohorts exhibited reduced reactivity to this peptide compared to 
biotinylated Kpr.  RA patients presented the highest levels of antibodies to the epitope 
(mean OD value = 0.4062) and this was significantly higher than all other groups [p 
values ranging from <0.05 (IBD) to <0.001 (OA) by one way ANOVA analysis].  Once 
more the prevalence in OA patients was lower in comparison to other groups and non-
biotinylated peptides (mean OD value = 0.1885). 
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Figure 4.29 OD values for patient serum from different disease groups using biotinylated GfPN1kpr 
peptide.  ** indicates levels of significance of RA over other disease cohorts.  Lines show group means. 
Figure 4.30  OD values for patient serum from different disease groups using biotinylated GfPN2eip 
peptide.  ** indicates levels of significance of RA over other disease cohorts.  Lines show group means. 
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Peptide/Disease Variance SLE OA IBD NHD 
Kpr 0.0576 NS NS NS NS 
Eip 0.0365 NS NS NS NS 
Biotinylated Kpr p <0.0001 p <0.05 p <0.001 p <0.05 p <0.01 
Biotinylated Eip p <0.0001 p <0.01 p <0.001 p <0.05 p <0.01 
PLSK* p <0.0001 NS p < 0.001 p < 0.05 NS 
Negcont1* p <0.0001 p < 0.001 p < 0.001 NS p < 0.001 
 
 
 
 
 
 
The level of significance of reactivity in RA patients compared to other disease 
cohorts is shown in Table 4.4.  Table shows the degree of significance by which the 
reactivity to each peptide of RA patients differ from reactivities observed in other 
control groups.  It is clear from this table the effect of biotinylating the peptides and the 
difference in patient samples  OA patients are shown in the analysis as that group most 
significantly different from RA patients (p < 0.001) with IBD showing the least degree 
of variance (p < 0.05).  Both PLSK and Negcont1 both show an increased level of 
variance over reactivities obtained during the analysis (Figure 4.27 and 4.28 
respectively).  However RA patients exhibited OD values significantly less than control 
groups.   
 
 
4.5.3 Inhibition studies to confirm specificity of patient bleeds for peptides 
 
After serological surveys of patient reactivity to peptides, inhibition studies 
were carried out on random RA patient sera in order to confirm the reactivity observed 
in patient samples was reflective of the reactivity to the peptides, i.e. to the HERV-K 
epitope.  Three sera were selected at random and standard curves constructed over a 
two-fold dilution series (Figure 4.31).  Figures 4.32 - 4.34 show the inhibition curves as 
bleeds after incubation with log dilutions of specific peptide (and irrelevant peptide) 
prior to application within the ELISA assay.  All three patient sera showed antibody 
responses specific for the Kpr peptide.  Incubations with log dilutions of negative 
control peptide showed no overall change in absorbance suggesting reactivity of patient 
sera is indicative of an antibody response specific for HERV-K epitopes. 
 
 
Table 4.4 Levels of significance per peptide of reactivity of RA patients, in comparison to other disease cohorts.  P < 0.05 
was considered to be significant.   
 
*PLSK and Negcont1 showed RA to be significantly decreased in comparison. 
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Figure 4.31 Standard curves for patient 8, 9 and 12.  Plots show standard curve of antibody for the Kpr peptide 
alone across 8 dilution series.  Error bars show SEM.  Blue: Patient 8; Red: Patient 9 ; Green: Patient 12. 
Figure 4.32 Inhibition curve showing degree of specificity for patient bleed GF8 for epitope  Kpr over log dilution series 
of Kpr peptide.  As peptide decreases, increased peptide specificity results in increased absorbance.  The second plot 
shows reactivity of the patient serum with a negative control peptide (Negcont1).  Overall no change in absorbance is 
observed over the log dilution series of peptide incubated with the serum.  Error bars indicate degree of SEM. 
Orange: Kpr ; Beige: Negcont1. 
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Figure 4.34 Inhibition curve showing degree of specificity for patient bleed GF12 for epitope  Kpr over log dilution series 
of Kpr peptide.  As peptide decreases, increased peptide specificity results in increased absorbance.  The second plot 
shows reactivity of the patient serum with a negative control peptide (Negcont1).  Overall no change in absorbance is 
observed over the log dilution series of peptide incubated with the serum.  Error bars indicate degree of SEM.  Red: Kpr; 
Blue: Negcont1. 
Figure 4.33 Inhibition curve showing degree of specificity for patient bleed GF9 for epitope Kpr over log dilution series of 
Kpr peptide.  As peptide concentrations increase, increased peptide specificity results in decreased absorbance.  The 
second plot shows reactivity of the patient serum with a negative control peptide (Negcont1).  Overall no change in 
absorbance is observed over the log dilution series of peptide incubated with the serum.  Error bars indicate degree of 
SEM.  Light grey: Kpr; Dark grey: Negcont1. 
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4.5.4 Levels of anti-HERV-K Gag and Env within the Synovial fluid 
& influence of rheumatoid factor 
 
4.5.4.1 Determination of HERV-K Gag & Env specific antibodies within paired 
serum and synovial fluid 
 
Paired Synovial fluid (SF) and blood samples taken from RA patients were 
tested using the novel ELISA assay, in order to identify differences in anti-HERV-K 
antibody levels within and external to the joint as increased levels within the joint may 
indicate a locally driven immune process.  Non-biotinylated Kpr and Eip both showed 
increased levels of reactivity in the SF, compared to that in the blood (mean OD values 
of 0.03 and 0.04 respectively) (Figure 4.35 & Table 4.3).  Peaks in paired samples 
correlated as observed in patients 9 and 16.  The exception to this was patient 13 who 
had elevated anti-HERV-K antibodies to both peptides in their synovial fluid, but not 
blood.  Levels of anti-Kpr and Eip showed increased variation in the SF with more 
peaks and troughs in the data, in comparison to the blood whose levels appeared more 
constant.  Absorbance values between the Blood (bld) and Synovial fluid (SF) when 
tested using non-biotinylated peptides were not significantly different from one another 
using a 2-tailed paired t-test; with Mann Whitney rank test (P values for Kpr and Eip 
were 0.3507 and 0.7278 respectively). 
 
 
 
 
 
With the non-biotinylated antigen, the synovial fluid showed an increased level 
of reactivity compared to the blood (means of 0.094 and 0.067 respectively) (Figure 
Figure 4.35 OD values from testing RA patient bld sera vs. SF for non-biotinylated Kpr and Eip. 
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4.36 and Table 4.3).  This however may be misrepresentative of the whole dataset and 
skewed by a small number of patients who showed large increased in the SF, i.e. 
patients 13, 15 and 16.  Biotinylated peptides also showed increased levels of reactivity 
to HERV peptides in the SF (Figure 4.36).  This was particularly evident with patients 
2, 4, 7, 10 and 14.  Although both biotinylated Kpr and Eip shared similar trends in 
reactivity, Eip appeared slightly increased in a small number of patients, i.e. sample 
numbers 4 and 14.  Patients 4, 10, 14 and 18 showed the highest levels in both the 
blood and synovial fluid. 
 
 
 
 
 
 
    Significance (p values) 
Presentation  Peptide  Bld Vs. SF  SF peptide 1 
 Vs. Peptide 2  
Non‐biot.  
Vs. Biot 
Kpr  0.5680  0.0553 Non‐biotinylated 
Eip  0.3328 
0.6481 
0.0878 
Kpr  0.2109   Biotinylated 
Eip  0.3543 
0.8195 
 
 
 
 
 
 
Figure 4.36 OD values from testing RA patient bld sera vs. SF for biotinylated Kpr and Eip. 
Table 4.5 Levels of significance between peptides in Bld and SF depending upon their method of presentation. 
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Using paired t-tests for analysis of paired SF and Bld samples it was concluded 
that despite reactivity in the SF being elevated to that observed in the blood (Table 4.3), 
this difference was marginal and not significant (Table 4.5).  This lack of significance 
also extended between peptides and also, surprisingly to the method of antigen 
presentation, i.e. biotinylation of the peptides.   
 
   
4.5.4.2 Quantification of RF in serum and its influence upon OD values 
 
 
RF was shown to correlate with increased reactivities to peptides in peripheral 
blood (Figure 4.37) with levels particularly elevated in patients 8, 10, 14 and 19.  
Patients 1 - 18 showed lower OD values to HERV peptides than patients 19 – 41.  
These patients also exhibited lower levels of rheumatoid factor than patients 19 – 41.  It 
could be concluded that the increased levels of HERV-K antibody responses may be 
partially masked (or contributed to) by the action of rheumatoid factor.   
 
  
 
 
 
 
Figure 4.37 Variation in RF levels and its correlation with absorbance values for all 5 peptides tested within the 
peripheral blood of RA patients.  Data on the graph shows levels of RF and correlation with reactivity with each of 
the five peptides. 
177 
 
4.5.4.3 Presence of RF in paired blood and synovial fluid samples 
 
Figure 4.38 shows levels of RF in paired blood and synovial fluid.  Sample sets 
assayed included 14 RA patients and 3 OA.  Of these, 6 RA patients exhibited 
increased levels of RF in their SF (128 mg/ml).  Of these samples 4/6 exhibited 
equivalent levels in the paired blood.  The remaining 2/6 showed the presence of lower 
levels of RF in their blood.  Three RA patients showed increased RF (albeit at lower 
levels of 16-34 mg/ml) with no detectable levels of RF in the paired SF.  The 4 
remaining RA patients lacked any detectable levels of rheumatoid factor in both blood 
and synovial fluid.  All 3 OA patients tested for RF exhibited high levels (128 mg/ml) 
in their SF, with just 1/3 showing equivalent levels within their blood.  Overall the RA 
group exhibits a heterogeneous distribution with RF seropositive and seronegative 
patients.  Additionally, it can be concluded that in the majority of patients (10/17), the 
levels of rheumatoid factor were equal to or greater within the synovial fluid than they 
were in the blood irrespective of disease.  Of the remaining 7 patients, 4 showed no 
evidence of RF when tested (patients 3, 9, 13 and 19), whereas the remaining 3 showed 
levels between 16-32 mg/ml in their peripheral blood (patients 12, 14 and 17). 
 
 
 
 
Figure 4.39 showed the levels for rheumatoid factor in paired samples of blood 
and synovial fluid.  Sample sets comprised of 14 RA patients and 3 OA patients.  Of 6 
RA patients that showed high RF levels of 128 mg/ml, 4 were also accompanied with 
high levels of RF in the blood.  The remaining 2 samples (taken from patients 2 and 8) 
Figure 4.38 Levels of RF in paired samples of blood and synovial fluid in RA and OA patient samples.  RA: 1 - 19; 
OA : 16, 20, 21.  
_     _     _ 
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showed lower levels of RF, despite the fact that at least one – patient 8 had disease 
duration of greater than 10 years.  Three RA patients showed levels of RF in blood, but 
not in the SF (patients 12, 14 and 17).  Of these patients, levels of RF were low, i.e. 16-
32 mg/ml.  These patients were male and 2 females.  They had an average age of 60.6 
years (range of 47 to 68 years).  All were white Caucasians, with erosive disease.  
Disease duration ranged from 3 - >20 years.  The remaining 4 RA patients were 
rheumatoid factor negative.  Of these 2 were of an average age of 27.5 years (range 24 
and 31 years) with the other patients of an average age of 73.5 years (range 63 and 84).  
All were female Caucasians with none with any record of erosive disease.  Of the OA 
patients tested (patients 20, 21 and 16) all showed maximum levels of RF in the SF, 
with 64 – 128 mg/ml in the paired blood.   
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4.6 Discussion 
 
4.6.1 Experimental optimisation 
 
Immunoinformatic techniques were used to predict linear epitopes of HERV-K 
and K (HML-2) Gag and Env putative proteins.  These epitopes were identified due to 
their increased antigenicity and thus potential to interact with other immune proteins, 
such as antibodies and complement.  Highlighted epitopes on HERV proteins were 
cross-referenced with those epitopes identified upon 28 autoantigens, in both RA and 
rheumatic diseases.  By identifying regions of homology between different epitopes, 
this may hint at the potential for molecular mimicry to induce disease pathogenesis 
(Oldstone, 2005). 
Those candidate epitopes with the best alignments of autoantigen sequences 
(and thus the greatest potential for molecular mimicry) were short listed and the best 
three were synthesised as short peptides (Section 4.2.2).  A novel indirect ELISA was 
developed and optimised for the detection of antibodies in patient serum samples, 
incorporating the novel HERV epitopes.  Polyclonal antisera generated to the 
commercially produced peptide antigens were tested for their strength, sensitivity and 
specificity and levels of cross reactivity between bleeds (Figure 4.7 – 4.8).  Peptide 
antisera were also investigated as they would be invaluable tools in other applications 
such as immunofluoresence.  Other variable factors such as optimal blocking agents, 
microtitre plates, antigen/antibody dilutions and time of substrate incubations were also 
investigated in order to establish the highest level of specificity, sensitivity and 
accuracy (Figure 4.2 – 4.7).  The resultant assays were robust ELISA’s which provided 
invaluable tools for the determination of levels of prevalence of anti-HERV-K(HML-2) 
antibodies in RA patients and other disease cohorts within this investigation (Figures 
4.23 – 4.30).  This assay was then used in inhibition studies, thereby validating the 
work described in Chapter 3 and demonstrating the specificity of the bleeds raised to 
the peptides.  Furthermore, this emphasised the overall specificity of the bleeds for their 
respective peptides, and the lack of cross-reactivity with other peptides (Figures 4.32 – 
4.35).   
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4.6.2 Patient samples 
 
The novel optimised HERV-K ELISA was used to survey patient sera, 
identifying different levels of reactivity to HERV-K epitopes across different disease 
groups.  Overall, biotinylated peptides showed significantly increased levels of 
reactivity with patient sera compared to non-biotinylated peptides, whose reactivites 
were homogenous albeit at a much lower level of reactivity, i.e. increased slightly 
above atypical background levels – OD values of ~0.05.   
When tested against non-biotinylated Kpr peptide, in a pattern typically 
observed in all disease groups, OA samples separated into two discrete clusters (Figure 
4.25).  Of these, the higher responding group comprised of 8 patients.  All 8 samples 
exhibited increased levels of anti-HERV-K Gag with ages ranging from 38-73 years 
with a mean of 59.1 years.  All were rheumatoid factor negative with the exception of 
one patient from New Cross who had a low RF count of 16 mg/ml, accompanied with 
erosive damage (as would be expected in OA).  Of these 8 patients, 5 were Caucasian.  
Information was not available for the ethnic origins of the remaining three patients.   
Overall there was little variation between mean reactivities of different disease 
groups, despite the heterogeneity of each group with the non-biotinylated Kpr peptide 
(Figure 4.25).  SLE and RA showed the most reactivity, however a small number of RA 
patients showed the highest OD values of all samples tested.  This may suggest a subset 
of RA patients develop antibodies to this epitope.  This may also be indicative of the 
nature of RA as an autoimmune disease with many autoantibodies specific for a large 
number of targets. 
When non-biotinylated GfPN2eip peptides were used as the coating antigen; 
NHD, SLE and RA patients’ samples exhibited the lowest levels of anti-Eip antibodies 
(means of 0.044, 0.051 and 0.042 respectively) (Figure 4.26).  The Eip peptide was 
modelled upon the superantigen region of HERV-K10 Env.  Responses in the majority 
of samples tested showed a wide distribution of reactivities across all disease groups.  
In many disease groups, the outliers were also able to influence overall group means 
causing them to appear more reactive as a group than maybe they actually are, e.g. OA 
and IBD (Figure 4.26).  OA patients fell into one of two clusters with absorbance 
values above and below the cohorts mean value.  6 high responding patients whose OD 
values were increased over the group mean (OD’s varying between 0.01 - 0.015) 
comprising of 3 male and 3 females, ages 29-73 (mean age 53.8 years).  At least 3/6 
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were Caucasian with 2/3 of those with highest values were under 40 years of age.  All 6 
exhibited high levels of RF between 64 and 128 mg/ml when tested (Figure 4.37).  The 
lower cluster (Figure 4.26) was made up of 8 patients, ranging between 38 – 82 years 
(average age of 58.5 years), 5 were female and 3 male, 7/8 were Caucasian with the 
remaining patient of Asian origin.  Rheumatoid factor was recorded in 4/8 samples, 
with patients having recorded an average disease duration of 9.75 years.  Of the three 
lowest scoring OA samples 2/3 were male, under 55 (55 & 47 years) with greater than 
10 years’ disease duration.  Reactivity to Eip in patient samples showed a higher level 
of variation than other non-biotinylated antigens tested (Figure 4.24).  Additionally, this 
was the only peptide that did not share sequence homology to an autoantigen such as 
Collagen II (Kpr) or Collagen I (PLSK) which may have been a factor contributing to 
the lower values observed.  A subset of OA patients and IBD patients however 
displayed increased reactivities to this peptide, modelled upon the HERV-K 
superantigen region.  Whether this may play a role in any of these diseases may merit 
further investigation.  
The PLSK peptide was synthesised in-house at the University of 
Wolverhampton and tested upon patient samples alongside commercially synthesised 
peptides.  This short stretch of amino acids was modelled on a similar region of the Gag 
protein to GfPN1kpr.  A 4 amino acid difference between the two, due to derivation 
from different HERV-K subfamilies, appeared to have significant influence over the 
reactivity of patient cohorts (Figure 4.18).  Overall IBD patients were the disease group 
that displayed the highest OD values with PLSK.  The two highest responding patients 
were sufferers of active Crohns disease and aged 41 and 43.  RA patients also displayed 
a degree of variation as patients followed a similar distribution as that observed in that 
observed in non-biotinylated Kpr, i.e. clustering into two discrete groups (Figure 4.27) 
although overall, RA patients exhibited marginally increased reactivities to PLSK than 
to Kpr (Table 4.3).  Of the 13 patients comprising the higher responding cluster, they 
exhibited an average age of 54 years (range 50 – 82 years), constituting 2 males and 11 
females.  Of those, 3 females and 1 male were of Asian origin with the remaining 9 of 
Caucasian descent.  Disease duration of group members showed an average of 15.9 
years (range 8-29 years) with 10/13 being RF positive.  Although there was incomplete 
data to make conclusions for all members concerning development of erosive disease, 
6/11 had records of erosive disease whilst the remaining 5 showed no records of erosive 
disease.   
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Although OD values between Kpr and PLSK were comparable, the main 
differences observed between the two peptides were in the OA and IBD control groups 
which showed increases in reactivity, (Figure 4.27).  The negative control peptide 
‘Negcont1’ was included to prevent any bias in the resulting data generated from the 
study (Section 3.3.6) and was modelled upon a retroviral element identified in 
Arabidopsis thaliana (Haupt et al., 2001).  It was identified using the same 
bioinformatics techniques used to identify Kpr, Eip and PLSK and was synthesised 
commercially at Severn Biotech, Kidderminster.  No bleed was generated to the 
Negcont1 peptide.  With the exception of OA, patients from the inflammatory disease 
cohorts, such as RA and IBD showed a more discrete clustering about their mean OD 
values, whereas those patient groups with higher means were reflected in the larger 
degree of heterogeneity within the group’s results (Figure 4.28).  Overall, both NHD 
and SLE patients showed wide variation in the antibody responses generated to the 
control epitope.  This may be partially explained by the fact that SLE is a disease whose 
patients have been frequently been documented to possess large numbers of 
autoantibodies, although such varying results in healthy patients warrant further 
investigation.  All other disease groups showed distinct patterns of reactivity with lower 
means in comparison to other peptides. OA patients were the exception to this, by 
exhibiting a significantly increased level of antibodies reactive to this peptide.  
Additionally, the apparent reactivity to Negcont1 may be an indication of patient bleed 
non-specificity as overall levels of reactivity were comparable to those observed with 
non-biotinylated HERV peptides.  It would be of interest to observe those levels of 
antibodies that bind to a biotinylated form of negative control peptide.  On the evidence 
presented here, this may suggest these act as bona fide epitopes involved in OA disease 
pathogenesis.  This however, requires further investigation as to what link exists 
between this retroviral epitope derived from a plant retroelement and OA disease 
pathology. 
The investigation also examined the impact that antigen presentation had upon 
final patient reactivities.  Kpr and Eip peptides were thus biotinylated and their 
performance compared to their non-biotinylated counterparts.  During the course of this 
investigation it became clear that levels of reactivity to biotinylated antigen differed 
significantly to that of non-biotinylated antigen, with OD values differing by almost a 
factor of ten (p < 0.0001)(Table 4.3).  Samples exhibited significantly higher levels of 
reactivity to the biotinylated peptides in comparison to their non-biotinylated 
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counterparts across all cohorts (Figure 4.24).  Such an effect was not unexpected 
however significant increases in patient responses were observed to both peptides in an 
effect that was disease specific (Figure 4.39).   
 
 
 
 
 
 
Biotinylated Eip (Figure 4.21) showed a similar pattern of reactivity with RA 
patients OD values significantly increased above those of all other disease controls.  
Once again there was an effect of clustering between the samples with one group 
accumulating below the mean, with the other present above the mean.  RA patients 
showed an increased level of reactivity to both biotinylated peptides, particularly in 
comparison to disease controls.  This was also accompanied by an increase in 
significance in biotinylated peptides.  An effect that was most evident with biotinylated 
Kpr.  Such results may hint at a potential for the epitope to play a role in RA 
immunopathogenesis.   
From the results presented here and in previously published investigations 
(Shamsuddin and Harris, 1983, Ivanov et al., 1992) it was clear that non-biotinylation 
of peptides resulted in significant modifications in the structural and conformational 
modelling of the antigens.  This low coating efficiency of peptides resulted in alteration 
of the availability of epitopes on plastic coated peptides leading to a potential masking 
of those epitopes originally deemed important.  Additionally, synthetic peptide 
Figure 4.39 Changes in significance in results upon biotinylation of Kpr peptide.  Bars represent changes in 
difference in levels of significance between non-biotinylated and biotinylated forms with patients from 
different disease cohorts.  Analysis was carried out using SPSS software and one-way ANOVA analysis, 
with bonferroni post test (Section 4.2.13).  RA shows the largest increase in significance compared to other 
disease groups due to biotinylation.  
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antigens, particularly those of an overly hydrophilic nature containing less than 20 
amino acids are notoriously difficult to immobilise upon plates for sufficiently sensitive 
assays (Fischer and Howden, 1990).  It is this process of adsorption, i.e. the 
hydrophobic interactions between the antigen and the solid phase, which are key to the 
success of an assay (Kochwa et al., 1967, Cash and McGill, 1969).  Using the so-called 
‘region or window of independence’, concentrations of antigen within this ‘window’ 
exhibited a constant relationship with protein adsorption.  It was previously reported 
that within this region, adsorbed antigen remained stably bound throughout the assay 
although this window varied with both antigen involved and other external factors such 
as adsorption temperature.  Desorption, however, was also deemed a problem and has 
been shown to affect the immunogenicity of the antigen, with one investigation 
showing that surface adsorbed ovalbumin retained only 5% of its antigenic activity 
when returned to free-solution (Dierks et al., 1986).  Additionally high concentrations 
of antigen also led to increased rates of desorption, and thus at all concentrations there 
exists a dynamic relationship between both adsorption and desorption.  Thus it seems 
likely that the convenient and popular technique of surface adsorption may also appear 
as a major source of error within the immunoassay.   
Several methodologies have been employed to solve this problem including 
coupling to larger proteins (Oshima and Atassi, 1989), using amino acids as linkers 
between the peptides and the plates (Loomans et al., 1998) and the use of multiple 
peptide systems (Tam and Zavala, 1989).  The most successful of these methods 
however has been the indirect coating of biotinylated peptides to streptavidin coated 
plates, which resulted in improved sensitivity (Ivanov et al., 1992).  For this reason 
biotinylated peptides were also included within this investigation, in conjunction with 
strepatavidin-coated plates in order to ascertain the effect of peptide presentation and 
antigen adsorption and their effects upon epitope presentation (Figure 4.22 – 4.23).  
According to evidence presented here, biotinylated peptides were more reliable models 
of in vivo epitope conformations, as potential epitopes would not be partially or wholly  
obstructed by the binding of the peptide to the solid phase (Chames et al., 2002). 
 
4.6.3 Anti-HERV-K in SF 
 
 The hypothesis behind determination of the prevalence of antibodies to HERV 
epitopes in the synovial fluid suggested that these epitopes may be driving an B cell 
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activity within the joints in RA patients (Firestein, 2003).  If levels of antigen within the 
synovial fluid were increased in comparison to those observed within the blood in the 
same patient, this may be indicative that antibodies producing B cells were present and 
being stimulated within the joint.  The result suggested that there was no significant 
difference between levels of anti-HERV antibody observed within the blood compared 
to that within the synovial fluid (Table 4.3).  When tested with the non-biotinylated 
peptides only a minority of patients showed increased levels of anti-HERV-K in the 
blood and not in their paired SF (Figure 4.35 – 4.36).  One exception to this was patient 
13 when biotinylated peptides were used (Figure 4.36) who exhibited no significant 
difference between the two.  Interestingly, when reactivity to the non-biotinylated 
peptide in the SF, was compared to its biotinylated version, the difference between the 
two was also not significant (although this was borderline in the case of Kpr) (Table 
4.5).  Biotinylation did result in a more heterogeneous response with specific patients 
showing increases in anti-HERV antibodies, e.g. patients 2, 4 and 10 (Figure 4.36).   
Despite both Kpr and Eip peptides exhibiting similar patterns of reactivity in both blood 
and SF, the absorbances shown in the synovial fluid were slightly elevated over that 
observed in the blood (Figure 4.35 – 4.36), although overall all OD values were at a 
low level.  The observed increase in levels of antibodies within the SF may be 
indicative of increased HERV activity within the joint and indicate an antigen-driven 
reaction within the synovium and synovial fluid, however as shown here those levels 
shown here were both weak in strength (Table 4.3) and not significantly increased over 
those observed in the peripheral blood (Table 4.5).  Evidence presented here does not 
support a significant increase in anti-HERV-K antibodies at the site of disease; however 
despite this marginal increases within the joint have been detected and may represent 
disease markers within patients. 
 
4.6.4 Levels of RF in serum 
 
One important potential source of non-specific binding in rheumatoid arthritis 
patients that needed to be taken into account before any conclusions could be made was 
the presence of Rheumatoid Factor, i.e. antibody specific for the Fc region of IgG. In 
order to investigate any potential skewing of reactivities by the non-specific binding of 
RF in the ELISA work, a commercial quantitative latex bead agglutination test was 
used to accurately determine levels of RF in both patient synovial fluid and blood.  
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Figure 4.30 shows the relationship between levels of rheumatoid factor present within 
patient blood for 51 RA patients tested.  Overall, the incidence of rheumatoid factor in 
the blood did appear to correlate with increased OD values in reactivities to peptides 
(Figure 4.37).   
 
4.7 Conclusions 
 
Six novel indirect ELISA assays incorporating short peptides predicted in 
Chapter 3 were developed and used to investigate the prevalence of anti-retroviral 
antibodies in RA patient serum and disease controls.   
From this data several conclusions could be drawn: 
 
1. A novel and robust assay has been developed for the detection of anti-HERV 
antibodies within patient sera.  Inhibition studies have shown this assay to be accurate 
in the determination of anti-HERV antibodies within polyclonal patient sera. 
 
2. Overall reactivities to Eip and Kpr were both increased over other non-
biotinylated and biotinylated peptides in the blood (p < 0.001).  
 
3. Antiretroviral antibodies were at marginally increased levels within the synovial 
fluid compared to that in the blood.  These increases were not significant.   
 
4. The presence of RF appeared to correlate with higher OD values in the blood in 
RA patients potentially suggesting these inflated values were potentially contributed to 
by the presence of RF.  This effect was less evident within the synovial fluid, which 
predominantly showed higher levels of RF than that observed in the blood.  RF may 
play a role in increasing OD values through non-specific binding although such a role 
would be limited due to antibody: peptide specificity shown in inhibitory studies. 
 
5. When patient sera were tested using biotinylated peptides there was a significant 
difference between the RA patients and the control populations (p < 0.001).   
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Abbreviations 
 
 
18s ribosomal RNA (18s rRNA) 
Avian myeloblastosis virus (AMV) 
Caprine arthritis encephalitis virus (CAEV) 
Coefficient of variation (CV) 
Comparative CT method (2 ΔΔ CT) 
Comparative threshold (dCT) 
Complementary deoxyribonucleic acid (cDNA) 
Deoxy-nucleotides (dNTPs) 
Deoxyribonucleic acid (DNA) 
Difference between two CT values (ΔCT) 
Epstein Barr virus negative B-lymphoma (BJAB) 
Epstein Barr virus nuclear antigen 1 (EBNA1) 
Epstein Barr virus (EBV) 
Fibroblast-like synoviocytes (SF) 
Fluorescent resonance energy transfer (FRET) 
Gene of interest (GOI) 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
Housekeeping gene (HKG) 
Human endogenous retroviruses (HERVs) 
Human endothelial kidney (HEK-293) 
Human immunodeficiency virus (HIV) 
Human leukocyte antigen (HLA) 
Human T cell leukaemia virus-1 (HTLV-1) 
Hypoxanthine phosphoribosyltransferase (HPRT) 
Late membrane protein 1 (LMP1) 
Local regional ethics committees (LRECs) 
Luria-Bertani broth (LB broth) 
Maedi visna virus (MVV) 
Magnesium ions (Mg2+) 
Messenger riboucleic acid (mRNA) 
Normal healthy donors (NHD) 
Nuclease-free water (dH20) 
Osteoarthritis (OA) 
Peripheral blood mononuclear cells (PBMCs) 
Quantitative real-time PCR (QPCR) 
Reverse transcriptase (RT) 
Reverse transcription polymerase chain reaction (RT-PCR) 
Rheumatoid arthritis (RA) 
Sjogrens syndrome (SS) 
Synovial fluid (SF) 
Systemic lupus erythematosus (SLE) 
Terrific Broth® super mix (TB) 
Threshold cycle (CT) 
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Chapter 5: 
Development and optimisation of a novel real-time PCR assay 
for the detection and quantitation of HERV-K gag mRNA in RA 
patient samples 
 
 
5.1 Introduction 
 
5.1.1 Introduction to real-time Polymerase chain reaction (PCR) 
 
Reverse transcription polymerase chain reaction (RT-PCR) remains the most sensitive 
technique for detection of mRNA targets and its application within the real-time setting 
has become the most popular method of quantifying steady state mRNA levels (Bustin 
and Nolan, 2004).  Employing Quantitative real-time PCR (QPCR) offers a novel 
aspect to this end-point assay, allowing measurement of products generated during each 
cycle of the reaction, which are directly proportional to the amount of template prior to 
the start of the PCR process.  This enables the determination of starting quantities of 
DNA or cDNA template within the sample, generated from mRNA.  The real-time 
system is based on the detection and quantitation of a fluorescent reporter (Lee et al., 
1993) and works by monitoring the fluorescence emitted during the reaction, using this 
as an indicator of amplicon production during each PCR cycle, (in real-time), as 
opposed to end point detection (Bustin and Nolan, 2004).  In comparison to 
conventional RT-PCR, QPCR offers a far superior alternative in terms of dynamic 
range of up to 107 fold (compared to 103 fold) and for these reasons it has developed 
diverse applications in a number of fields including functional genomics studies, 
molecular medicine, forensics, virology, microbiology and biotechnology 
(http://www.gene-quantification.info/). 
Quantitative RT-PCR can be carried out as either a one or two-step reaction.  In 
a one-step reaction both cDNA synthesis and PCR amplification occurs in the same 
tube in consecutive reactions.  Contrastingly, in a two-step reaction the stages take 
place in different tubes.  One-step reactions have been reported to have an increased 
sensitivity and ability to compare multiple Genes of interest (GOI) (Ginzinger, 2002), 
however sample cDNA cannot be used for any further downstream applications. 
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5.1.2 Non-specific or specific detection strategies 
 
There are two types of homogenous fluorescent reporting chemistries presently 
in use: ‘non-specific’ and ‘specific’ detection.  Template-specific chemistries require 
the design and synthesis of one or more custom-made fluorescent probes for each assay 
(Tyagi and Kramer, 1996).  Commonly, these include reporting systems employing 
Fluorescent resonance energy transfer (FRET) or similar in interactions between donor 
and quencher molecules as the basis of detection (Gendi et al., 1996, Heid et al., 1996).  
The main advantage is the additional level of specificity introduced to the assay, 
thereby eliminating the requirement for specificity & product confirmation through post 
PCR processing (Ririe et al., 1997). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Non-specific detection uses intercalating dyes such as SYBR Green (Yin et al., 
2001, Varga and James, 2006) that bind to any double-stranded DNA generated during 
the PCR reaction, emitting enhanced fluorescence (Ishiguro et al., 1995).  Although 
intrinsically non-specific in nature, these chemistries could yield quasi-template 
specific data if used in conjunction with melt curves to aid in the identification of 
specific amplification products (Ririe et al., 1997).  One recent investigation even 
Figure 5.1 Amplification plot illustrating the main nomenclature used in real-time Q-PCR experiments.  In this plot a 
solid line crosses the threshold at the PCR cycle number18, whereas the dotted line crosses at 20.  By subtracting the 
two (20-18) there is a two cycle difference between the two samples or a ΔCt of 2.  Due to the exponential nature of 
PCR, the ΔCt is converted to a linear form.  This number indicates the fold-difference between the two samples 
reflecting variation in starting template abundance. ΔRn : Increase of fluoresenct signal over threshold per run. 
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reported SYBR Green I detection being of higher precision than Taqman (and other 
‘specific’) chemistries (Livak and Schmittgen, 2001).  Non-specific assays are 
advantageous in that they could be used with previously established protocols and 
primer sets, in addition to being significantly cheaper than the specific detection 
alternatives (Bustin and Nolan, 2004).   
The Threshold cycle (CT) is a parameter most conveniently and most frequently 
quoted when reporting QPCR results.  CT values are commonly used when describing 
the data quantitatively and form the heart of the assay itself.  They are defined as the 
fractional PCR cycle number at which the fluorescent signal becomes greater than the 
minimum detection level (baseline or threshold) (Figure 5.1).   
 
5.1.3 Quantitation strategies 
 
QPCR data can be analysed differently depending upon experimental design 
and the investigative goals.  The two methods of analysis available are ‘relative 
quantitation’ and ‘absolute quantitation’ with each having profound impacts upon how 
each assay is designed and run.  ‘Relative’ is the analytic method of choice for the 
majority of published assays and involve a comparison made within a sample between 
its GOI and a control or Housekeeping gene (HKG) whose expression levels should be 
unchanged by experimental conditions (Bustin and Nolan, 2004).  Absolute 
quantification relies upon the use of a standard curve derived from known quantities of 
GOI, which is then used to calculate unknowns.  The advantage with using absolute 
quantification comes from its ability to determine the input copy number of transcripts 
of interest (Gibellini et al., 2004).  cDNA plasmids containing GOI are common 
sources of controls in such investigations in which known starting amounts of sample 
are serial diluted to construct standard curves.  This method requires fewer optimisation 
steps, although is more prone to operator error and sample variation (Bustin and Nolan, 
2004) and reported to be less sensitive (Battaglia et al., 1998).  Relative quantitation of 
gene expression can be determined using several alternative methods based upon 
comparison of reference and experimental genes. 
 
 
 
5.1.3.1  Relative standard method (relative fold change) 
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Relative standard quantitation involves one of the experimental samples (1x 
sample concentration) acting as the calibrator.  Experimental values were divided by 
the calibrator’s normalised value in order to give a value of relative expression.  As the 
calibrator is the 1x sample, all other quantities are expressed as the x-fold difference 
relative to the calibrator. 
 
5.1.3.2  Comparative threshold (dCT) 
 
Through lack of any predetermined standard, this method directly compares 
relative amount of target sequence to any of the reference values chosen.  The result is 
given as relative to the reference value, i.e. the baseline expression in resting cells, etc.  
Using this methodology the main criterion for accuracy is that in order for the CT 
comparison to hold, both target and reference amplification efficiencies should be 
equal.  This usually requires construction of a standard curve using dilutions of target 
GOI (Livak and Schmittgen, 2001). 
 
5.1.3.3  Comparative CT method (2 ΔΔ CT) 
 
This method enables the relative quantitation of template without the 
requirement for a standard curve by calculating relative to an endogenous control 
(normalizer).  Again, for maximum accuracy, both target and reference must have equal 
amplification efficiencies.  It is usual for the reference gene to have a slightly higher 
expression level to the GOI (and therefore a lower CT,) and it is the difference between 
them (ΔCT) that underpins this methodology (Livak and Schmittgen, 2001).  The 
comparative ΔΔCT method without correction for PCR efficiency was used for relative 
quantitation of the GOI against the HKG (Winer et al., 1999, Livak and Schmittgen, 
2001) thus eliminating the requirement for a standard curve for each sample. 
 
5.1.4. Normalisation strategies 
 
The identification of a valid reference for data normalisation is central to the 
type of analysis employed in relative quantitation, but also remains one of the more 
controversial problems concerning real-time analysis (Bustin and Nolan, 2004).  
Several different strategies have been applied to the normalization of the expression of 
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RNA of interest (Huggett et al., 2005).  The most appropriate strategy is to use a 
reference gene as an internal standard that is assumed to remain constant between 
experimental groups.  It now appears, however, that in most experimental situations the 
use of conventional reference genes such as Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) is inappropriate due to their variability in transcriptional 
levels (Bustin and Nolan, 2004).  Requirements for good HKG’s include those that are 
stably expressed amongst different cell types and are unaffected by experimental 
conditions (Dheda et al., 2005).  Table 5.1 shows five candidate housekeeping genes 
considered for use within the assay framework outlined within this work.  Of these, 
Hypoxanthine phosphoribosyltransferase 1 (HPRT) and Beta-Actin (ACTB) were 
selected for further use on the basis of assay suitability.  GAPDH could not be used as 
levels were altered in the presence of Fetal calf serum used in cell culture (Ke et al., 
2000).  18s ribosomal RNA (18s rRNA) could not be used due to use of oligo-dTs as 
primers for reverse transcription and the primers for Histone 3.3 (Andersson et al., 
1996) were not used further as these produced a second peak (indicating a second 
amplicon) on the melt curves.  More recently a number of kits to assess HKGs 
suitability under experimental conditions have become available commercially, e.g. 
GeNorm (Primerdesign, Southhampton, UK).   These kits assess panels of HKG under 
the experimental conditions of the investigation in hand as described previously 
(Vandesompele et al., 2002). 
For real-time analysis and quantitation, the geometric mean CT  values of two 
HKGs were combined to increase the accuracy of any resultant quantitations 
(Vandesompele et al., 2002, Bengtsson et al., 2005).  Hypoxanthine-guanine 
phosphoribothymidine (HPRT) is an enzyme associated with purine metabolism that 
functions to salvage purines from degraded DNA in order to renew their synthesis. In 
this role, it acts as a catalyst in the reaction between guanine and phosphoribosyl 
pyrophosphate (PRPP) to form GMP.  The Beta-actin has been reported to have a role 
in mRNA localisation and translation, RNA polymerase II transcription (Hu et al., 
2004) and cell motility (Kislauskis et al., 1997). 
Relative quantification determines changes in steady state mRNA levels of a 
gene across multiple samples and expresses it relative to levels of an internal control 
RNA, this reference often being a housekeeping gene (Pfaffl et al., 2002, Wittwer et 
al., 2001).  Additionally relative quantification does not require standards with known 
concentrations and can be any transcript as long as the sequence is known (Bustin, 
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2002).  Accurate quantitation is achieved by comparing GOI vs. reference gene.  In the 
majority of cases this is adequate for investigation of physiological changes. 
 
Housekeeping gene Primer sequence Expected 
product 
Size 
Reference 
Hypoxanthine 
phosphoribosyltransferase 
1 (HPRT) 
For – AAGCTTGCTGGTGAAAGG 
Rev – AAACATGATTCAAATCCCTGA 
134bp (Ramos-Nino et al., 
2003) 
 
Glyceraldehyde-3-
phosphate dehydrogenase 
(GAPDH) 
For – CCTGTTCGACAGTCAGCCG 
Rev – CGACCAAATCCGTTGACTCC 
101bp (Sonveaux et al., 
2003) 
 
Histone 3.3 For – CTCTACTGGAGGGGTGAAGAA 
Rev – TGCCTCCTGCAAAGCACCGAT 
200bp (Andersson et al., 
1996) 
 
Beta-Actin For – GGCCAACCGCGAGAAGAT 
Rev – CGTCACCGGAGTCCATCAC 
 
134bp Wang et al., 2002) 
 
 
 
 
 
 
5.1.5.  Molecular investigations of HERVs in RA 
 
As described in Chapter 1, a number of investigations have identified increased 
levels of HERV genetic material within RA samples compared to disease and healthy 
controls although, increased HERV transcriptional activity has also been reported in 
other rheumatic diseases Systemic Lupus Erythematosus (SLE) and Sjogrens Syndrome 
(SS).  The HERV-K10 gag1 gene has been identified previously to be expressed as 
encoded protein in certain cancer cell lines (Sauter et al., 1995).  A number of other 
studies have focussed upon the expression of env which in some HERVs, i.e. HERV-
W, appears to be the most intact gene (Antony et al., 2006).   
In addition to evidence drawn from parallels between human and animal 
retroviral infections such as Caprine arthritis encephalitis virus (CAEV) and Maedi 
visna virus (MVV) (Michaels et al., 1991), many early investigations focussed upon 
serological associations between retroviruses and RA.  The majority of RA patients 
were seropositive for Human immunodeficiency virus (HIV) and Human T cell 
lymphotropic virus-I (HTLV-I) reactive antibodies, despite lacking any evidence of a 
causative virus (Douvas et al., 1996, Nelson et al., 1999, Seemayer et al., 2002).  More 
recent studies have demonstrated evidence for HERVs at the site of disease, using 
Table 5.1 Details of different housekeeping genes considered for use within the investigation.  All four were tested 
three times in triplicate on Tera-1 cellular cDNA (n=3).  Their suitability was also taken into account in terms of 
variability under experimental conditions and in disease state. 
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molecular techniques with superior specificity and sensitivity such as PCR and in-situ 
hybridisation.  Nakagawa et al. (1997) showed increases in mRNA levels for HERV-L, 
ERV-9 and HERV-K in RA patients versus controls.  Increases in HERV-K10 mRNA 
in Peripheral blood mononuclear cells (PBMCs) of RA patients were reported by 
Nelson et al (1999), whose results were also confirmed in a follow-up study (Davari 
Ejtehadi et al., 2005).  Other HERV families, for example ERV3, Lambda 4-1, HRV-5 
and L1-transposons have also been implicated in RA (Takeuchi et al., 1995, Griffiths et 
al., 1999, Brand et al., 1999, Neidhart et al., 2000).  A number of studies however have 
published contradictory evidence questioning such a role for HERVs (Norval et al., 
1979, Stoye, 1999, Gaudin et al., 2000).  Additionally HERV-K (HML-2) Rec protein 
has recently been shown to be expressed in both normal and rheumatoid synovial cells 
(Ehlhardt et al., 2006). 
Interest also surrounded findings that a HERV-K10 LTR (LTR3) was reported 
within a Human leukocyte antigen (HLA) class II region (Kambhu et al., 1990).  
Almost a decade later, this was identified as a potential disease marker for RA, with its 
presence significantly increased in patients compared to healthy controls (Seidl et al., 
1999, Pascual et al., 2001, Pascual et al., 2003).  So far it has become apparent that the 
relationship between HERVs and RA is complex, and in need of clarification.  
 
5.1.6.  Comparison of Reaction efficiencies 
 
In this investigation a real time quantitative PCR assay using SYBR-green 
detection chemistries was developed to measure levels of HERV-K gag expression in 
mononuclear cells extracted from blood and synovial fluid taken from RA, OA and 
healthy patient cohorts.  ACTB and HPRT expression were used to normalise and 
calculate relative expression of gag.  The resultant assay showed greater speed and 
potential throughput, than conventional PCR whilst being more economical than 
Taqman alternatives.  The Comparative CT method was used in the assay, as described 
above, to determine relative quantitation between the GOI (HERV-K gag) and the 
HKG used (ACTB and HPRT).  The software ‘LinRegPCR’ (Ramakers et al., 2003) 
was used to determine the PCR efficiency of all reactions from the cycle fluorescence 
data generated during each reaction, thereby negating the requirement for a standard 
curve for each experimental run.  Using this methodology it was possible to eliminate 
all reactions with efficiencies outside the acceptable margin of amplification 
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efficiencies, i.e. between ‘1.7 - 2.1’ (Ramakers et al., 2003), thus ensuring only those 
samples with comparable efficiencies were used in quantitation.  The two-step QPCR 
approach was preferred, i.e. different tubes for both cDNA synthesis and PCR 
amplification as this allowed sample cDNA to be used with other downstream 
applications as opposed to the one off measurement offered by the one step assay.  This 
was also an important choice as the quantity of high quality RNA isolated from patient 
samples was a major limiting criterion.   
During this investigation a novel real time RT-qPCR assay was developed for 
the accurate quantitation of HERV-K (HML-2) gag1 mRNA in RA patient samples 
compared to healthy and disease controls.  This assay was also used to measure levels 
of HERV activity after treatment of HFLS with pro-inflammatory cytokines that have 
been reported previously to have significant influences over RA disease pathogenesis, 
including increased maturation of osteoclasts and fibroblast activation.  Additionally, 
the influence of other viral pathogens over HERV transcriptional activity was explored.  
The Herpes viruses are one group of viruses that have been associated repeatedly within 
the literature with modulation of HERV activity (Ruprecht et al., 2006).  EBV is one 
viral pathogen which has been associated within the literature with RA disease 
pathogenesis.  EBV genes EBNA1, shared sequence homology with a susceptibility 
marker for developing RA, in (HLA)-DR1 (Fawcett et al.,, 1988) whilst elevated levels 
of EBNA1 transcripts have been detected within the synovium of RA patients (Saal et 
al.,, 1999) .  Increased expression of LMP1 was also reported in the cells located at the 
apex of the villi of the synovial membrane (Takei et al., 1997).  LMP-2A was selected 
as its presence has been reported to transactivate the HERV-K18 SAg (Sutkowski et al., 
2004). 
 
5.1.7.  Aims 
 
This chapter initially set out to describe the design and experimental 
optimisation of a real-time PCR assay specific for HERV-K gag.  Once developed this 
assay was trialed by comparing the levels of HERV-K gag transcription in several 
different cell lines and by investigating the effects of hypomethylation agents upon 
HERV-K gag transcription in testicular carcinoma cells.  Application of the real-time 
assay to the investigation of a potential role of HERV-K in RA immunopathology on a 
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molecular level was carried out.  Such subsequent investigations followed three specific 
predictions. 
 
• Levels of HERV-K gag transcription would be increased in RA patient samples over 
controls. 
• Cell populations responsible for contributions to disease pathogenesis would show the 
greatest increases in HERV-K gag transcription. 
• External environmental factors, i.e. other viral pathogens or inflammatory cytokines, 
play modulatory roles in influencing HERV-K activity in RA patients. 
 
In order to follow these novel lines of investigation in clarifying the exact role 
of previously reported increases in HERV-K gag in RA patients, the highly specific and 
sensitive real-time PCR assay was used:  
 
1. To quantify levels of HERV-K gag mRNA in patient samples (relative to HKG) in 
comparison to disease controls. 
2. To identify cell populations in patient samples in which HERV-K (HML-2) gag1 
activity was increased. 
3. To explore the modulatory effect of different viral proteins upon HERV-K (HML-2) 
gag1 transcription. 
4. To explore the modulatory effects of inflammatory cytokines upon HERV-K (HML-2) 
gag1 mRNA levels. 
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5.2 Materials & Methods 
 
All reagents were obtained from (Sigma-Aldrich, Gillingham, UK) unless specified 
otherwise 
 
 
5.2.1 Collection of human blood and synovial fluid 
 
The average age for RA patients was 65 years old (n = 29) (range 40–93 years) with a 
mean duration of disease of 13.5 years (ranging between 4–46 years). Osteoarthritis 
(OA) patients had an average age of 63 years old (n = 12) (range 38-89) with a mean 
disease duration of 10.5 years (varying between 6–17 years).  Details for inflammatory 
controls were unavailable.  Venous blood was collected from were obtained from 
Normal healthy donors (NHD) comprising departmental staff and normal blood donors 
(n = 6).  The average age for healthy donors was 33 years old (range 21-40).  Patients 
with non-RA inflammatory diseases such as gout, oligoarthritis and polyarthritis (n = 
7) were also included within the analysis.  All blood samples consisted of 10mls venous 
blood and were collected in sterile preservative-free heparin and taken from patients 
with informed consent.  Blood samples were processed within 3 hours.  10 mls of 
synovial fluid (SF) were collected in empty sterile 20 ml universals with all steps 
performed under aseptic conditions.  All ethical approvals were considered by 
appropriate Local regional ethics committees (LRECs) and recruitment criteria and 
methods have been reported in detail elsewhere (Section 2.1) (Davari Ejtehadi et al., 
2005).  Fibroblast-like synoviocyte (SF) primary cells were purchased commercially 
(Cell applications, San Diego, CA) and were derived from RA, OA and healthy (NHD) 
donors.  All donors were Caucasian, 42, 66 and 58 years of age respectively.  OA and 
NHD were derived from female donors whereas the RA SFs were derived from a male. 
 
5.2.2 Sample processing 
 
Mononuclear cells were separated from 10ml whole blood using a Ficoll 
gradient.    Anti-coagulated venous blood was layered onto 7ml HISTOPAQUE-1077 
in a 20ml sterile universal.   This was then centrifuged at 400 x g for 30 min at room 
temperature.  During centrifugation, erythrocytes and granulocytes were aggregated by 
polysucrose and rapidly sedimented at the base of the tube whilst lymphocytes and 
mononuclear cells remained at the plasma-HISTOPAQUE®-1077 interface (Figure 
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2.1).  The upper layer (plasma) ending approximately ‘0.5cm’, above the central 
opaque interface (containing mononuclear cells) was aspirated and transferred to a 
sterile universal using a Pasteur pipette. Plasma was stored at -70ºC until required in 
serological investigations.  The opaque interface was also transferred to a sterile 
centrifuge tube.  These cells were resuspended in 1 ml of TRI reagent for RNA 
extraction (Chomczynski and Sacchi, 1987). Total RNA from patient samples was 
extracted as described previously by (Davari Ejtehadi et al., 2005). 
 
5.2.3 Separation of specific cell populations using paramagnetic beads 
 
For a small number of new samples, different species of lymphocytes were 
separated from one another to ascertain levels of HERV-K (HML-2) in different cell 
populations.  This was done using a series of washes with paramagnetic beads coated 
with antibody specific for CD19 (B-cells), CD4 and CD8 (T-cells).  The Ficoll interface 
containing mononuclear cells was separated into three equal aliquots.  Each aliquot was 
then mixed with dynabeads specific for the cell population being extracted i.e. B-cell 
(CD-19).  Dynabeads (25ul/ml-1 sample) were added to the interphase and incubated at 
4ºC under agitation before incubating at room temperature for 2 min with the MPC 
Dynal magnet (Dynal technologies, UK).  After separation the supernatant was 
discarded and cells/ dynabeads washed 5 times with PBS/ 0.1% BSA.  Beads and cells 
were separated from one another using commercially available Detachabead® kits 
(Dynal technologies, UK).  Cells and Detachabead® reagents were mixed and 
incubated together at room temperature for 45 min before placing upon the MPC Dynal 
magnet, for a further 5 min were decanted into a sterile centrifuge tube and washed 
three times in RPMI/1% FCS before centrifuging for 8 min at 500 x g.  Cell pellets 
were finally resuspended in appropriate volumes of RPMI/1% FCS.  These cells were 
then lysed in RLT buffer for RNA extraction using the QIAAmp kits (Qiagen, UK). 
 
5.2.4 Primer design 
 
Nucleotide reference sequences for HERV-K and HERV-K10 were extracted 
from the NCBI database (accession numbers M14123 and Y18890).  Sequences were 
copied and pasted from a standard text editor into three different primer design 
programs: Primer3 (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3.cgi) (Korwin-
Kossakowska et al., 2006); PrimerSelect (DNAstar Inc, Madison, WI) (Breslauer et al., 
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1986) and Beacon designer version 5.0 (Premier Biosoft Int., Palo Alto, CA) (Ram and 
Shanker, 2005).  Primers were designed using rules and guidelines reviewed previously 
(Dieffenbach et al., 1995).  All primers were subjected to BLAST analysis using the 
BLASTn database in order to confirm their specificity, and to prevent any cross-
reactivity from occurring (Altschul et al., 1997).  Internal hybridisation probes were 
designed for all primer sets so that later conversion to specific detection chemistries 
such as Taqman required minimal optimisation and disruption, if required. 
 
5.2.5 Two - step quantitative real-time RT-PCR 
 
cDNA template was synthesised using 1 μg of total RNA and converted into 
cDNA using  oligo(dT) and Avian Myeloblastosis Virus (AMV) RT enzyme (Promega, 
Southampton, UK).  RT cycles consisted of an initial step of 5 mins at 72°C, followed 
by addition of mastermix containing 3mM MgCl2 (Promega), 5 x Reverse transcription 
buffer [250mM Tris-HCl (pH 8.3 at 25ºC), 250mM KCl, 50mM MgCl2, 2.5mM 
spermidine and 50mM DTT], deoxy-nucleotides (200 µM), oligo (dT) (0.5 µg/µg 
RNA) and sterile nuclease-free water (dH20).  The reaction mix was incubated at 42 °C 
for 1 hour before heating to 95°C for 5 mins.  For testing in the real-time assay, cDNA 
was diluted 1:5 in dH20.  Gene specific primers for the GOI and both HKGs were 
mixed in separate 0.5ml eppendorf tubes.  These included 9 μl of sterile nuclease-free 
dH20, 0.5 μl HERV-K(HML-2) gag1 set1 primers (nM), 2.5 μl of template (diluted 1:5 
in dH20) and 12.5 μl Absolute™ QPCR SYBR green master mix (Abgene, Epsom, UK) 
(Table 5.2).  Once mixed, reagents were transferred to a 96-well plastic plate (Abgene, 
Epsom, UK) and capped with plastic strips (Abgene, Epsom, UK) before being sealed 
with plate sealers (Abgene, Epsom, UK) in order to prevent evaporation and run using 
an iCycler real-time thermocycler (Bio-Rad, Hemel Hempstead, UK) using final 
optimised cycling parameters listed in Table 5.3.  All optimisation steps and subsequent 
assay runs were performed using Absolute™ QPCR SYBR green mix (Abgene, Epsom, 
UK).  This mix had been reported previously within the literature with successful 
results (Govindarajan et al., 2003, Dittmer et al., 2006). 
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Reagent Volume (µl) Final 
concentration 
AMV Reverse Transcription  
5x reaction buffer 
5 1x 
dNTP 2.5  1 mM each dNTP 
Oligo(dT) 0.5 0.5 µg/µg RNA 
RNasin ribonuclear inhibitor 0.5 40 U 
Template RNA 1-10  1 µg 
AMV RT 0.75 30 U 
Nuclease-Free water Make up to total of 20 µl - 
Total volume 20 µl 
   
ABsolute™ QPCR SYBR 
green mix (2x) 
12.5 1x 
Forward primer 0.5 0.5 µM 
Reverse primer 0.5 0.5 µM 
cDNA Template (diluted 1:5) 2.5 < 250ng 
dH20 9 - 
Total volume 25 μl 
 
 
 
Stage  Temp (°C)  Time (mins)  No. of cycles 
Initial denaturation 94 15 1 
Denaturation 94 15s 
Annealing 55.9 30s 
Extension 72 30s 
 
40 
Melt curve analysis 
Denaturation 94 30s 1 
Start 60 30s 1 
Melting step 60 (+0.5 each cycle) 10s 80 
 
 
 
 
5.2.6 Intra and Inter-assay validation 
 
In order to assess the accuracy and reproducibility of the assay, total RNA was 
extracted from Tera-1 cells using an RNeasy RNA extraction kit (Qiagen, Crawley, 
UK).  Total RNA was eluted from spin columns in 20 µl volumes of EB buffer and 
quantified using a spectrophotometer.  Total cellular RNA was then applied to a ten-
fold serial dilution, and was used to synthesise cDNA using protocols described 
previously (Section 5.2.5).  After first strand synthesis, cDNA was diluted 1:5 in sterile 
nuclease-free dH2O and added to reagents (Table 5.2) before being amplified under 
conditions described previously (Table 5.3).  After amplification, 10 μls of reaction mix 
was run and the 120bp amplification product of gag was visualised in the presence of 
ethidium bromide in an agarose gel under long wave ultra-violet light.  Bands were 
Table 5.2 Reagent components of the real-time PCR mix making up the novel HERV-K gag real-time PCR assay. 
Table 5.3 Details of the real-time thermocycling parameters optimised for the gag1set1 primer set and both housekeeping 
genes.  S: seconds. 
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excised and purified using a MiniElute DNA purification kit (Qiagen, Crawley, UK) 
and eluted purified amplicons were then quantified using an spectrophotometer 
(Geneflow, Fradley, UK) before identity was confirmed by sequencing (Section 5.2.8).  
Intra-assay variation was assessed using five sets of triplicates per plate/run.  Inter plate 
variation was assessed with one sample at 3 specific dilutions, run in triplicate and 
repeated on five different plates.  One master mix for the RT step was made up and 
divided amongst the seven samples in order to minimise variation.  This was repeated 
three times with each sample, run in triplicate.   
 
5.2.7 Cloning of HERV-K gag amplicons into vectors for sequencing 
 
In order to both confirm specificity of the HERV-K10 gag primers, and to 
determine any disease specific variants, 12 PCR products synthesised from patient 
samples were cloned into the pGEM-T plasmid (Promega, Southampton, UK).  Initially 
PCR products were run in an agarose gel before being excised and purified using the 
QIAspin gel purification kit (Qiagen, Crawley, UK).  Purified PCR products were 
quantified in a gel against a low mass DNA ladder (Promega, Southmpton, UK), before 
being ligated into the plasmid for preparation of DNA and sequencing.  For ligating the 
amplicon into the vector two opposing ratios were set up of 3:1 and 1:3 of template to 
vector respectively.  Ligations were set up with 5 ngμl-1 and 0.5 ngμl-1 of template 
respectively before being added to the vector in ligation buffer according to 
manufacturer’s instructions.  Ligation was carried out at room temperature for 1 hour 
before ligated plasmid and inserts were transformed into 50 μl JM109 competent cells 
(Stratagene, Stockport, UK)  using the heat-shock method.  Transformed cells were 
then incubated for at least 16 hours on LB-agar with ampicillin/IPTG/X-Gal for blue-
white screening.  White colonies contained plasmids with inserts.  Negative controls 
and uncut pGEM plasmid (0.1 ngml-1) were also included for the purpose of calculating 
transformation efficiency.   
 
5.2.8 PCR product clean up and sequencing of PCR amplicons  
 
In order to confirm the identity of amplified PCR products, and so the 
specificity of the real-time PCR for HERV-K10 gag1 reverse transcribed mRNA 
amplified products were run in a 2% agarose gel.  PCR bands were cut from the gel 
under long wave UV light using a scalpel and then purified using the Minielute PCR 
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purification kit according to the kit instructions (Qiagen, Crawley, UK).  DNA 
sequencing was performed by the Sequencing service (School of Life Sciences, 
University of Dundee, Scotland) using Applied Biosystems Big-Dye version 3.1 
chemistry on an Applied Biosystems model 3730 automated capillary DNA sequencer 
(Applied Biosystems, San Diego, CA).  Sequencing was carried out using gene specific 
primers unless otherwise stated.  All DNA sequence analysis was performed using 
Lasergene software suite (version 7.1) (DNAstar, Madison, WI). 
Fluorescence data was analysed using the iCycler ‘iQ’ software (Bio-Rad, 
Hemel Hempstead, UK) and expressed as a function of the CT. and exported directly 
into Excel.  PCR reaction efficiencies were calculated using the LinRegPCR software 
(Ramakers et al., 2003) in order to ensure accurate quantification.  Validated results 
showed PCR efficiencies between ‘1.7 and 2.1’, with correlations ‘>0.999’.  Results 
outside of these margins were discarded and repeated.  Final ΔCt values were calculated 
by determining average Ct values over repeated runs and applying these normalised 
values to the relative quantitation formula.   
 
5.2.9 Restriction Digests 
 
Restriction enzymes were used to confirm the identity of sG5-EBV expression 
plasmids (Section 5.3.4.1).  Reactions were performed in 20 µl volumes using 1μg/μl of 
substrate DNA.  Reactions typically consisted of 16.3 μl sterile, deionised waster, 2 μl 
10X buffer, 0.2 μl Acetylated BSA (10μgμl), and 1 μl of template DNA (1 μg/μl) in a 
sterile 0.5 ml eppendorff.  Following gentle mixing by pipetting, 0.5 μl restriction 
enzymes – Bgl II and EcoR1 (Promega, UK) were added to the reaction mix giving a 
final volume of 20 μl.  Following further gentle mixing, the tubes were incubated at 
37°C using a thermocycler (MJ research Inc., Ramsey, US) for four hours.  After 
incubating, digested DNA was visualised using an electrophoretic agarose gel stained 
with ethidium bromide. 
 
5.2.10 5’-Aza-2’-deoxycytidine treatments 
 
Tera-1 cells were seeded at 5 x 104 cells per T75 flask and grown in RPMI 
medium (Sigma, UK) supplemented with 10% FCS and 20mM L-glutamine as 
described previously (Section 2.7).  Cells were incubated until 70% - 80% confluent at 
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37ºC in 5% CO2.  A 100 μM solution of 5’-Aza-2’-deoxycytidine was made using 
dH20, before being further diluted to 10 μM and 1 μM in supplemented media and 
added to culture flasks before being incubated for 72 hours at 37ºC in 5% CO2.  
Untreated and water only controls were also included within the experimental design to 
compensate for the effects of diluted media.  Each experiment was repeated on three 
separate occasions in order to give as accurate a result as possible.  After 48 hours, cells 
were trypsinised from the flask surface, and RNA was extracted using RNeasy 
commercial kits (Qiagen, Crawley, UK).  cDNA was synthesised as previously 
described (Section 5.2.6).  All test runs included no reverse transcriptase (RT) and no 
template negative controls. 
 
5.2.11 Viral protein studies 
 
Fibroblast-like synoviocytes (Cell applications, San Diego, CA), were 
transfected with expression plasmids containing viral proteins from different viruses 
that have been associated with RA in the literature.  Total cellular RNA was extracted 
and analysed for changes in HERV-K gag expression using quantitative RT-PCR and a 
HERV - specific retroviral microarray.  Human cell lines (both primary and continuous) 
were transfected with two pSG-5 expression plasmids containing Epstein barr nuclear 
antigen 1 (EBNA1) and Late membrane protein 1 (LMP1) genes from Epstein Barr 
virus (EBV) that had been linked previously with the etiology of RA (kindly provided 
by Dr Paul Murray, University of Birmingham).  After transfection of synoviocytes and 
controls with expression plasmids for EBV using Lipafectamine (Invitrogen, Paisley, 
UK) according to manufacturers instructions cells, were incubated at 37ºC with 5% 
CO2.  After 48 hours cells were harvested and total RNA was isolated and purified 
using RNeasy kits (Qiagen, Crawley, UK).  Total RNA was quantified and levels of 
HERV-K gag expression were determined using Quantitative RT-PCR, using iCycler 
thermocycler (BioRad, UK) and with HERV-specific microarrays. 
 
5.2.13 Transformation of viral gene expression vectors into E.coli 
 
Once their identity was confirmed, pSG5-EBNA1 and pSG5-LMP1 were both 
transformed into JM109 competent cells (Promega) using the heat-shock method 
(Sambrook J and Russell, 2000).  Once transformed into competent cells, plasmid 
stocks were grown overnight (16 – 20 hours) in Luria-Bertani broth (LB broth) and 
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bacterial cultures were prepared using QIAprep Minipreps kits (Qiagen, Crawley, UK).  
Once plasmids had been extracted from bacterial lysates, they were run in a 1% agarose 
gel in order to confirm identities.  pSG5 – LMP1 in particular gave repeatedly low 
yields of plasmids (<50 ng/μl-1) when grown for 16 – 20 hours in LB media, so media 
was changed to Terrific Broth, Modified EZmix powder.  Individual preparations of 
plasmids were then combined respectively using ethanol precipitation before being 
stored at -20ºC.  Bacterial clones containing each plasmid were picked from master 
library plates and stored at -80ºC using Protect bacterial preservers (Fischer Scientific, 
Leicestershire, UK). 
 
5.2.15 Cytokine treatments 
 
Treatments with pro-inflammatory cytokines were carried out upon human 
synoviocyte cell lines (RA, OA and healthy) and HEK-293 endothelial cells (used as 
non-synovial fibroblast control).  5 x 103 cells were seeded in vented T75 flasks before 
incubating overnight until confluent in RPMI supplemented media.  Pro-inflammatory 
cytokines – IL-1β, IL-6 and TNF-α were diluted to required concentrations using 
medium (un-supplemented).  Diluted cytokines were then incubated with cells at 5% 
C02 for 48 hours.  Cell viability was determined using Celltiter 96 AQueous one solution 
reagent (Promega, UK).  All cell viability was in excess of 70% for all treatments.  
After incubation, cells were harvested and genetic material extracted using QIAspin 
RNA extraction kits (Qiagen).  All treatments were repeated three times. 
 
5.2.17 Statistical analysis 
 
Geometric mean CT values were calculated using three repeat runs of triplicates.  
All samples were age/sex matched where possible.  Statistical analysis between 
matched samples involved paired, 2-tailed t-tests with the Mann Whitney rank sum test 
and variance between different groups was graded using the one-way ANOVA test, 
with Tukey-Kramer or Bonferroni test to compare specific groups.  Statistics and 
graphical analysis were performed using Prism 5.1 (Graphpad software, San Diego, 
CA).  Unpaired samples were compared using an unpaired, 2-tailed t-test. 
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5.3 Results 
 
5.3.1 Optimisation and Development of real-time PCR assay for 
HERV-K gag 
 
5.3.1.1 Primer design and selection of optimal primer pair:  A comparison of 3 
different programmes for primer design 
 
Table 5.2 list all primers designed and tested for the purposes of inclusion 
within the novel real-time assay for HERV-K.  The location of predicted primer sets 
and their distribution across the HERV-K sequence, using the prototype HERV-K10 as 
a model, shows a clustering towards the end of HERV-K10 gag1 and the beginning of 
gag2 genes (Figure 5.2).  In HERV-K, such regions would likely correspond to the 
central capsid sequence that forms the core shell of virus particles (Campillos et al., 
2006). Primer sets for the envelope region appeared to cluster predominantly at the 5’ 
end of the gene within the gp36 antigenic region (Sander et al., 2005).  After primer 
pairs had been synthesised, they were tested using cDNA from Tera-1 cells, known to 
harbour increased levels of HERV-K with the potential to form particles.   
The levels of Performance attained by each software application were 
comparable, with all programs predicting at least one functional primer set (Table 5.4).  
Primer 3 showed the least success with just 33.3% (1/3) primers being functional.  
Lasergene and Molecular Beacons both showed comparable levels of success (2/3 and 
4/8, respectively).  Of those primers tested, all resulted in the production of a single 
expected amplicon.  All functional primer pairs tested gave smooth melt curves and 
signal peaks, indicative of a high level of specificity, with low occurrence of 
mispriming.  In all cases, primer performance was also robust and reproducible; 
producing consistent CT values over three runs of triplicates.   
The final primer set chosen, on the basis of melt curve analysis and 
reproducibility for incorporation into the final assay, were ‘MB HERV-K10 gag1 set 1’ 
(Table 5.3).  Primers amplified a product of 120 bp from HERV-K gag, with a Tm of 
~55˚C.  BLAST analysis of the primer pair revealed no mispriming or sequence 
similarities with organisms other than HERV-K.  Additional analysis showed the 
absence of any secondary hairpin structures or dimerisation.  In order to confirm primer 
specificity amplification products were sequenced.  Figure 5.3 shows the meltcurve 
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data for a single PCR product of 120 bp from five amplifications, run in a 3% agarose 
gel (Sigma), stained and visualised under UV with Ethidium bromide (Figure 5.4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 Map of the HERV-K family prototype - HERV-K10 sequence showing locations of different primer 
sets designed for incorporation into a real-time assay.  For key see legend.  Primer pair selected for use in real-
time assay is boxed in red. 
TM : Transmembrane, EN: Envelope; RT: Reverse transcriptase; Prt: Protease ; LTR : Long terminal repeat.  
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Design 
 software 
Primer name/ Target gene Primer sequence Expected 
Prod. Size 
(bp) 
PCR 
Product 
HERV-K gag F (1773-1792) CCA CCC CCA GAA AGT CAG TA 
HERV-K gag R (1863-1877) TGG TGC CAT AGC ATT GTC TC 
104  
HERV-K10 gag1 F (1618-1637) TTA ATG GGG CCA TCA GAG TC 
HERV-K10 gag1 R (1711-1730) TGC GGT TGG  GTC TTA TTT TC 
112  
HERV-K10 gag2 F (2551-2570) ATG AAA ACG CCA ATC CTG AG 
 
 
Primer3 
HERV-K10 gag2 R (2639-2658) CGA TTC CAT CAC AGG CTT TT 
107 X 
LSRGENE HERV-K gag F (1770-1789) CGG CCA CCC CCA GAA AGT CA 
LSRGENE HERV-K gag R (1816-1838) GGT ATG GCT CTG TCC TGT GGT G 
68 X 
LSRGENE HERV-K10 gag1 F (1771-1796) GGC CAC CCC CAG AAA GTC AG 
LSRGENE HERV-K10 gag1 R (1932-1955) GAA TTG CCA TGC CTC AGT ATC TCC 
184  
LSRGENE HERV-K10 gag2 F (2952-2972) CCT CAG GCC CCA CAA CAA ACT 
 
 
Lasergene 
(PrimerSelect) 
LSRGENE HERV-K10 gag2 R (2991-3014) CTG AAA ACC CTG AGG AAC AAA 
TGG 
62 X 
MB HERV-K10 gag1 set 1 F (1623-1643) GGG GCC ATC AGA GTC TAA ACC 
MB HERV-K10 gag1 set 1 R (1720-1743) TGA TAG GCT ACT TGC GGT TGG 
120 X 
MB HERV-K10 gag1 set 2 F (1621-1642) ATG GGG CCA TCA GAG TCT AAA C 
MB HERV-K10 gag1 set 2 R (1722-1743) TGA TAG GCT ACT TGC GGT TGG 
122  
MB HERV-K10 gag2 set 1 F (1623-1643) GGG GCC ATC AGA GTC TAA ACC 
MB HERV-K10 gag2 set 1 R (1675-1699) TTG AGG TTG TAA TCT TAC GAG CAC 
76  
MB HERV-K10 gag2 set 2 F (1623-1643) GGG GCC ATC AGA GTC TAA ACC 
MB HERV-K10 gag2 set 2 R (1749-1773) GGT TGT AAT CTT ACG AGC ACC TG 
150  
MB HERV-K10 pol set 1 F (4506-4530) TGA CTG TTA TAC ATT TCT GCA AGC 
MB HERV-K10 pol set 1 R (4569-4593) TGA AAA GGA GTA GAG GTT TGG 
ATC 
87 X 
MB HERV-K10 pol set 2 F (4508-4532) ACT GTT ATA CAT TTC TGC AAG CAG 
MB HERV-K10 pol set 2 R (4593-4617) TGA AAA GGA GTA GAG GTT TGG 
ATC 
109 X 
MB HERV-K10 env set i F  (7383-7404) ATT GCT TAC TTG CAT TGA TTC AAC 
MB HERV-K10 env set i R (7484-7508) AAA ATA TGG ACG GAT GGT GAG G 
125 X 
MB HERV-K10 env set ii F (7383-7406) ATT GCT TAC TTG CAT TGA TTC AAC 
 
 
 
 
 
 
Molecular 
Beacons 
MB HERV-K10 env set ii R (7444-7468) TCA GTC AAA ATA TGGA CGG ATG G 
85 X 
 
 
 
 
 
 
 
 
 
 
Table 5.4 All candidate primer pairs that were trialled for inclusion within the real-time QPCR assay.  
Primers were then tested using the assay and those showing the most promising data were developed further.  
Primer pair highlighted in yellow indicates that chosen for incorporation into the real-time assay.  X – 
Indicates functional primer pair. 
Figure 5.3 Melt curve analysis of HERV-K10 gag1 set1 primer set designed and incorporated into a HERV-K gag specific 
real-time RT-PCR assay.  The single peak represents a single PCR product and the primer’s specificity.  The different 
coloured lines indicate reactions carried out in different wells.  In this case over a dilution series, each peak is 
progressively smaller as the starting amount of RNA becomes more diluted. 
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5.3.1.2  Assay specificity and sensitivity 
 
The sensitivity of the novel real-time quantitative PCR assay was confirmed by 
the detection of HERV-K gag mRNA at dilutions of up to 1 pg.  Assay specificity was 
confirmed by the presence of a single PCR product shown in the melt curve analysis, 
i.e. exhibiting a single large peak at between 84 - 85°C (Figure 5.3).  Additionally, the 
melt curve showed limited shouldering indicating the absence of primer dimers and 
other non-specific products.  The specificity of PCR products was further confirmed by 
a single band observed in a 3% agarose gel (Figure 5.4), which was excised, purified 
and sequenced.  Results from DNA sequence analysis (Table 5.5) showed best matches 
to HERV-K gag gene, with HERV-K 10 gag in the top 5 most homologous matches in 
each of the products sequenced thus confirming the primer specificity. 
 
 
 
 
Figure 5.4  A 2% agarose gel shows single PCR product of 120 basepairs (bp) generated using HERV 
K gag set1 primer set with  3 replicates in three samples of total RNA extracted from three different 
cell lines - Tera-1 cDNA(4, 5, 6) , HEK-293 (3) & Fibroblast-like synovial fibroblasts derived from a 
healthy donor (1).  Run 2 represent dH20 control (2).  Presence of a single band of expected size 
confirms primer specificity supporting melt-curve data.  DNA marker is the 100 bp DNA ladder 
(Promega). 
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Sample 
 
BLAST results Accession no. e value Gaps % Similarity 
1 Homo sapiens endogenous virus Human 
endogenous retrovirus K HERV-K50A 
DQ112146 2e-31 0/80 98 
1 Homo sapiens endogenous virus Human 
endogenous retrovirus K HERV-K68 
DQ112096 2e-31 0/80 98 
1 Homo sapiens endogenous retrovirus 
HERV-K103 
AF164611.1 1e-29 0/80 97 
1 Human endogenous retrovirus HERV-K10 
 
M14123 1e-29 0/80 97 
1 Homo sapiens endogenous virus Human 
endogenous retrovirus K HERV-K50D 
DQ112152.1 5e-28 0/80 96 
 
2 Human endogenous retrovirus K115 
complete genome 
AY037929.1 2e-31 0/80 98 
2 Homo sapiens human endogenous 
retrovirus HERV-K(HML-2.HOM) 
AF074086.2 1e-29 0/80 97 
2 Homo sapiens endogenous virus Human 
endogenous retrovirus K HERV-K68 
DQ112096.1 5e-33 2/90 96 
2 Human DNA sequence from clone RP11-
29H23 on chromosome 1 
AF164610.1 5e-33 2/90 96 
2 Homo sapiens endogenous retrovirus 
HERV-K102 
AF164610.1 5e-33 2/90 96 
 
3 Homo sapiens endogenous virus Human 
endogenous retrovirus K HERV-K50A 
DQ112146.1 5e-30 0/80 97 
3 Homo sapiens endogenous virus Human 
endogenous retrovirus K HERV-K68 
DQ112096.1 5e-30 0/80 97 
3 Human endogenous retrovirus K115 
complete genome 
AY037929.1 5e-30 0/80 97 
3 Homo sapiens chromosome 8, clone RP11-
1118M6, complete sequence 
AC134684.5 5e-30 0/80 97 
3 Human endogenous retrovirus HERV-K10 
 
M14123 2e-28 0/80 96 
 
 
 
 
 
 
5.3.1.3  Primer calibration curve 
 
Initial studies and attempts at optimisation included the determination of the 
reaction efficiencies of the chosen primer set – HERV-K gag1set1.  This was calculated 
using an amplification curve composed of five RNA standards of known quantity 
(Figure 5.5).  These were plotted as a standard curve and the gradient extrapolated to 
produce the primer efficiencies.  The standard curve (Figure 5.6) showed a PCR 
efficiency of 139.8 %.  This was slightly increased over the optimal value of 120%, an 
effect likely due to the presence of inhibitors and artefacts remaining from the first 
strand synthesis (Qiagen, 2006).  After this stage of optimisation all cDNA was diluted 
1:5 to limit this inhibitory effect and the ‘Linreg’ software programme was employed to 
calculate the reaction efficiency of each sample run thus eliminating the requirement 
for a standard curve to be constructed for each run (Section 5.1.4). 
Table 5.5 The top 5 matches from BLAST searches to the amplicons sequenced from three PCR products amplified from the 
Tera-1 cell line and used in experiments to determine sensitivity and specificity.  Samples 1, 2 and 3 were the PCR products 
shown in wells 4, 5 and 6 of Figure 5.4. 
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Figure 5.6 Standard curve for HERV-K gag1 set 1 primer set.  The standard curve was produced using five 
known dilutions of Tera-1 RNA starting at 1μg.  The slope of the line is then used to calculate the primer 
efficiency.  Values over 120% were liklely due to inhibitors or artefacts present from the reverse 
transcription stage (Bustin et al, 2004).
Figure 5.5 Amplification plot of RNA standards derived from Tera-1 total mRNA and used to calculate reaction 
efficiencies of the primer set HERV-K gag1 set1 as shown in Figure 5.6.  Plots were constructed using iQ 
software, Bio Rad). 
Key: 
Yellow: 100ng. Violet: 10ng. Red: 100pg. Green: 10pg. Black: 1pg. 
 
Orange line represents baseline reaction level as determined using iQ software defaults.
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5.3.1.4  Assay optimisation: Primer concentration  
 
In order to maximise the accuracy of the quantitation, primer concentrations 
were optimised using the primer chess boarding strategy, described by (Gunson et al., 
2003).  Primer concentrations varying between 50 pmol to 1.25 pmol were tested for 
optimisation purposes.  Although only small variations were observed between 
concentrations of primers tested, data shown in Table 5.5 and Figure 5.7 showed that 25 
pmol of forward and reverse primers produced the lowest CT values.  As all reactions 
were run with the underlying assumption that the initial starting quantity of template 
was constant, those exhibiting the Lowest CT values were considered as those with the 
most optimal and efficient reaction/ primer concentrations.   
 
 
 
 
 Forward primer 
Concn. 
(pmol) 
50 25 12.5 6.25 3.125 
 
50 24.9 24.4 23 26 27.1 
25 24.6 23.2 23.7 24.6 27.6 
12.5 24.8 25.2 25 24.8 27.9 
6.25 24.6 25 24.3 25.4 28.4 
 
 
Reverse 
primer 
3.125 25.6 24.5 24.3 25.6 29.4 
 
 
 
 
Figure 5.7 The effect of varying primer concentration upon CT values.  Error bars show variation over 
three runs. 
 
Table 5.5 Variation in CT with different primer concentrations using the ‘primer chess boarding’ technique (Gunson 
et al, 2003).  
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5.3.1.5  Assay optimisation: Annealing temperature  
 
Samples were tested over a range of annealing temperatures in order to 
determine the optimal conditions for the ‘gag1 set1’ primer set which produced the 
lowest CT values.  Annealing temperatures tested ranged from 55°C - 57°C at 0.2 °C 
intervals.  Annealing temperature of 55.9 °C gave the lowest CT values although it 
should be noted that there was little difference between different annealing 
temperatures tested (Figure 5.8).  An important factor was that this was a very similar 
temperature to those of the housekeeping genes (whose Tm was 56 ºC; thus both primer 
cocktails could be run simultaneously under optimal conditions). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.3.1.6  Intra and Inter-assay validation 
 
In order to assess the accuracy and reproducibility of the assay, CT values of 
different serial dilutions of Tera-1 total mRNA were compared (Table 5.6) with a ten-
fold dilution series ranging from 1 µg to 1 pg (Figure 5.9).  Average CT values for all 
intra assay dilutions varied from 14.97 (1 μg) to 29.20 (1 pg).  Standard deviation 
showed little variation between different dilutions until 10 pg, where it increased from 
~ 0.3 (1 µg) to over 2.0 (1 pg).  For all intra assay runs, Coefficient of variation (CV) 
was less than 3%, with 1 pg showing both the largest standard error and CV (0.79 and 
2.72 respectively).  Inter-assay variation observed between runs was increased slightly 
compared to inter-assay variation.  Standard deviation (SD) and CV were comparable 
across dilutions of 100ng to 100pg although markedly increased at 1pg. 
 
 
 
0 
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Figure 5.8 The effect of variation of annealing temperature on CT values for HERV-K10 gag1 set1. 
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RNA template Mean CT S.D. CV(%) 
 
Intra-assay coefficient of variation (n = 5) 
1µg 14.97  0.2887  1.9288 
100 ng 23.27  0.2887  1.2407 
10 ng 25.93  0.1528  0.5890 
1 ng 27.80  0.2646  0.9517 
100 pg 28.27  0.1155  0.4085 
10 pg 28.73  0.2082  0.7245 
1pg 29.20  0.7937  2.7182 
 
Inter-assay coefficient of variation (n = 5) 
100 ng 23.97 0.1822 0.76 
100 pg 28.45 0.2134 0.75 
1 pg 29.29 0.9578 3.27 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.6 Inter assay and intra-assay variation for HERV-K gag real-time PCR..  CT: Threshold cycle, 
S.D.: Standard deviation, CV: Coefficient of variance. 
Figure 5.9  Serial dilution series showing amplification of serially diluted RNA standards amplified using the novel 
HERV-K gag real-time PCR assay in order to determine levels of inter and intra-assay variability.  Orange line 
represents baseline as selected as default by machine. 
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5.3.1.7  Housekeeping genes 
 
Previously published primer sets for four different housekeeping genes (HKGs) 
were trialled to establish the maximum level of accuracy in quantitation of assay results 
(Table 5.1).  HKG primer pairs were tested using total RNA from two human derived 
cell lines – Tera-1 and HEK-293.  Melt curves for both HKGs showed one single peak 
in each cell type, indicating the synthesis of a single amplicon.  The PCR product of 
ACTB had a Tm of ~ 87 ºC (Figure 5.10), whereas that of HPRT showed a Tm of 82 ºC 
(Figure 5.11).  PCR products from both HKGs were run in agarose gels, with a single 
band confirming melt-curve analysis.  Amplicons were cut out, purified and sequenced 
to confirm primer specificity (Figure 5.12 and Table 5.8 for ACTB and HPRT 
respectively) 
Beta actin (ACTB) and Hypoxanthine phosphoribosyltransferase 1 (HPRT) 
were selected upon the basis of suitability to experimental conditions and primer 
performance.  In order to normalise experimental values for the GOI, the geometric 
means of both HKGs were combined and used to normalise experimental CT values, 
using the ΔCT method of relative quantitation of HERV-K gag gene expression.   
 
 
 
 
 
 
 
Figure 5.10 Melt curve showing amplification of a single PCR product of Beta-actin using housekeeping gene 
primers on HEK-293 cells.  Different traces represent replicates of same primer set/sample. 
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Figure 5.12 Alignment of sequences for amplicon sequence for Beta-actin against reference sequence 
for gene taken from NCBI (NM_001101). 16_001: Tera-1 cells; 18_015: HEK-293 cells. 
Figure 5.11 Melt curve analysis of HPRT primers used with HEK-293 cells cDNA.  The single peak indicates the 
specificity of the primers and synthesis of a single PCR product.  Different traces represent replicate wells of same 
primer set/sample. 
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Sample Accession 
 
Description 
 
Max 
score 
 
Query 
coverage 
(%) 
E 
value
 
Max 
ident
(%) 
NM_000194.1 
 
Homo sapiens hypoxanthine 
phosphoribosyltransferase 1 (Lesch-Nyhan 
syndrome) (HPRT1), mRNA 
161 51% 2e-97 97 
NT_011786.15 
 
Homo sapiens chromosome X genomic 
contig, reference assembly 
132 42 1e-28 97 
HPRT 1 
NW_927721.1 
 
Homo sapiens chromosome X genomic 
contig, alternate assembly (based on Celera 
assembly) 
132 42 1e-28 97 
 
NM_000194.1 
 
Homo sapiens hypoxanthine 
phosphoribosyltransferase 1 (Lesch-Nyhan 
syndrome) (HPRT1), mRNA 
156 51 8e-36 96 
NT_011786.15 
 
Homo sapiens chromosome X genomic 
contig, reference assembly 
128 41 2e-27 97 
HPRT 2 
NW_927721.1 
 
Homo sapiens chromosome X genomic 
contig, alternate assembly (based on Celera 
assembly) 
128 41 2e-57 97 
 
NM_000194.1 
 
Homo sapiens hypoxanthine 
phosphoribosyltransferase 1 (Lesch-Nyhan 
syndrome) (HPRT1), mRNA 
93.3 59 6e-17 86 
NT_011786.15 
 
Homo sapiens chromosome X genomic 
contig, reference assembly 
94.5 57 1e-05 90 
HPRT 3 
NW_927721.1 
 
Homo sapiens chromosome X genomic 
contig, alternate assembly (based on Celera 
assembly) 
 
94.5 57 1e-05 90 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.8 BLAST results from sequenced PCR products from HPRT1 primers shown in Table 5.1.  Sequences HPRT1 
and HPRT2 were derived from PCR products amplified from HEK-293 cells.  HPRT was derived from cDNA synthesised 
from Tera-1 RNA. 
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5.3.2 Application of real-time PCR assay specific for HERV-K 
gag  
 
 
5.3.2.1  Treatment of cells with 5 – AzacD experimental in Tera-1 cells 
 
Using the novel HERV-K gag real-time PCR, the influence of hypomethylating 
agents upon HERV transcription were investigated in Tera-1 cells.  Results showed 
increasing concentrations of hypomethylating agent resulted in increased HERV-K gag 
transcriptional activity (Figure 5.13).  HERV-K gag mRNA levels were shown to be 
increased after treatment with 10 μM of hypomethylation agent, compared to cells 
treated with lower concentrations (1 μM) and negative controls.  The 10 μM 
hypomethylation treatment was significantly increased over negative controls using one 
way ANOVA with Tukeys multiple comparison test (p < 0.001).  10 μM treatments 
were not significantly increased over 1 μM treatments (p > 0.005). 
 
 
  
 
 
 
 
 
 
Figure 5.13 Levels of HERV-K10 gag mRNA present within Tera-1 cells treated with different 
concentrations of 5-aza-2’-cytidine relative to two house keeping genes.  Error bars indicate degree of 
standard error in results (n=3). 
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5.3.2.2  Investigation into the levels of HERV-K gag RNA in cell lines 
 
The novel real-time PCR assay was used to quantify levels of HERV-K gag 
mRNA in different cell lines.  The highest levels of HERV-K mRNA relative to 
housekeeping genes were observed in the human synoviocytes taken from a donor with 
RA showing the most elevated level (2-ΔΔCT = ~11) (Figure 5.14).  Fibroblast-like 
synoviocytes (SF) derived from healthy (NHD) and OA donors showed levels 
comparable to one another (2-ΔΔCT = 3 - 4).  Levels in RA SF were significantly 
increased over OA and NHD by unpaired t-tests (NHD: p = 0.0013; OA: p = 0.0039). 
All were elevated compared with the non-synovial fibroblast control cell line – HEK-
293.  Testicular carcinoma (Tera-1) cells, EBV negative B-lymphoma (BJAB) and 
human leukemic T cell lymphoblast (Jurkat) immortalised cell lines showed levels 
approximately two-fold that of housekeeping genes (HPRT and ACTB).  Levels 
observed in human breast cancer cell line - MCF7 was reduced in comparison to both 
lymphoblastic cell lines.  In terms of negative controls, the murine fibroblasts showed a 
low 2-ΔΔCT and late CT with both gene specific and housekeeping primers.  A PCR 
product was identified by melt curve analysis for the beta-actin primer set, giving an 
indication of sequence conservation between species.   No single PCR product was 
identified by melt-curve analysis, indicating primer specificity for human specific 
endogenous retroviruses.  Human endothelial kidney (HEK-293) cells were also 
included in the analysis as human fibroblast cell line (of non-synovial origin).  They 
displayed low levels of reactivity only slightly increased over the negative controls 
(mouse fibroblast).   
  Figure 5.14 2-ΔΔCT values for HERV-K10 gag relative to overall HKG expression in different primary and continuous 
cell lines.  RA,OA and NHD are primary cells taken from patients.  MF: Mouse fibroblasts.  ** indicates the significant 
increase over both OA and healthy (SF) derived fibroblasts 
** 
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5.3.3  Use of real-time PCR with RA patient samples and 
controls 
 
5.3.3.1  Levels of HERV-K gag within mononuclear cells of patient venous 
blood in different disease cohorts 
 
Total cellular mRNA extracted from mononuclear cell populations from venous 
whole blood of RA patients and control groups were tested using the novel real-time 
PCR assay to determine levels of HERV-K gag mRNA relative to HKG (Figure 5.15) 
 
 
 
 
 
 
 
Figure 5.15 shows that several RA patients exhibited increased levels of gag 
mRNA compared to control groups.  Despite variation in 2-ΔΔCT values, overall cohort 
means were elevated in comparison to controls.  11 patients showed 2-ΔΔCT values 
elevated above the group mean.  These gave the overall distribution of HERV-K gag 
mRNA a heterogeneous appearance with 2-ΔΔCT values (between 5 and 35).  All other 
groups showed limited variation in their results.  The second most elevated group was 
that of the inflammatory disease non-RA controls.  Despite the limited size this group 
Figure 5.15 The distribution of 2-ΔΔCT values for HERV-K10 gag 2-ddCT relative to overall HKG expression in 
individual patients.  The line indicates the mean of samples. 
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of patients showed a more varied spread of values in comparison to OA and NHDs 
although the latter represented a small sample set (Figure 5.16).  Both healthy and OA 
cohorts displayed little variation in their 2-ΔΔCT results suggesting a possible baseline of 
activity for HERV-K gag in these patient groups.  Statistically, the difference between 
RA and all control groups was significant (OA, NHD and IC) (p < 0.0001, < 0.001 and 
< 0.05 respectively) (Table 5.9).  All controls were not significantly different from one 
another.  Using one-way ANOVA analysis to compare all cohorts, all groups were 
significantly different from one another (p < 0.0001).   
 
 
Disease RA OA IC 
OA < 0.0001 (***)  ? 0.05 
NHD < 0.001 (**) ? 0.05 ? 0.05 
IC < 0.05 (*) ? 0.05  
 
 
 
Table 5.9 Levels of significance of different disease cohorts compared to RA.  Analysis was 
carried out on log-transformed data, using SPSS to carry out one way ANOVA analysis with a 
Bonferroni post test to compare all columns.  
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Figure 5.16 2-ΔΔCT of HERV-K10 gag relative to overall HKG.  Graph shows disease groups RA – Rheumatoid arthritis 
(1-30); OA – Osteoarthritis (31-44); NHD - Healthy (43-49); IC - Inflammatory controls (50-54).  Error bars show SE 
for each sample.
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5.3.3.2  Age - sex matching of patient samples 
 
Twenty eight patient samples were age-sex matched into 14 pairs, from 14 RA 
and 14 OA patients.  Of those matched pairs, all showed increased gag expression in 
RA patients over their OA counterparts (Figure 5.17).  In all pairs, this excess was 
increased at least ten-fold with mean values of RA patients increased over that observed 
in OA patients (Table 5.10).  The evidence also hinted at a role for gender in HERV 
activity, as 5 of the top 6 high responders (high responders classified by 2-ΔΔCT levels in 
excess of ‘cohort mean plus 1 Standard deviation’) were female.  Additionally, female 
patients exhibited levels of HERV-K gag mRNA almost two-fold that observed in 
males (Table 5.10) and exhibited an increased heterogeneity in their distribution 
compared to their male RA counterparts. Of the 6 highest responders (Figure 5.17) 
(classified as such by exhibiting a dCT higher than the group mean plus one standard 
deviation), 5 were female RA patients (aged 51 and 77 years), and 1 male RA patient.  
The two highest dCT values were two females of 51 and 53 years of age whilst patient 
details were incomplete for three, two female were 80 and 83.  All high responders had 
disease durations in excess of 10 years, were rheumatoid factor positive and had 
histories of erosive disease.  Mean ages for both cohorts were comparatively similar 
(61.3 and 60.96 years for RA and OA patients, and 60.69 and 61.57 years for female 
and male patients respectively).  The highest levels of HERV-K gag mRNA observed 
in an OA patient were from a 38 year old female, of Caucasian descent.  The second 
and third highest responders were female and male, of 78 and 64 years of age, 
Caucasian descent.  All three OA high responders exhibited disease durations of over 
10 years. 
Overall, RA patients showed levels of HERV-K gag mRNA (relative to HKG) 
that were significantly increased over matched OA patients (p < 0.0001 using a two 
tailed, paired t-test) (Table 5.10).  This difference was significant for both genders, i.e. 
male and female (p = 0.0067 and p = 0.0009 respectively).  Female RA patients were 
also significantly increased over their male RA paired partners (p = 0.0392).  This 
effect was disease specific as in OA the difference between genders (in terms of 2-ΔΔCT) 
was not significant (p = 0.3182). 
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Figure 5.17 2-ΔΔCT values for HERV-K gag levels in OA and RA age: sex matched pairs.  Pairs 1-7 represent female: 
female matched pairs.  Pairs 8-14 represent the male matched pairs.  Error bars indicate standard experimental 
error. 
Figure 5.18 Results from the age: sex pairing of RA patients shown in the form of the two opposing 
genders. 
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RA OA Significance 
Female 
 
8.36 0.81 p = 0.0009 (***) 
Male 
 
4.21 0.49 p = 0.0067 (**) 
Significance 
 
p = 0.0362 (*) p = 0.3182 (NS) P < 0.0001 (***) 
 
 
 
 
These results were also presented as a scatter plot allowing distributions 
between both cohorts to be examined in greater detail (Figure 5.19).  Whilst all OA 
patients showed a tight clustering about their group mean, RA patients again showed an 
increasingly heterogeneous response with one cluster of six patients exhibiting levels of 
HERV-K gag mRNA below the cohort mean.  All other samples were in excess of the 
mean.  All samples with 2-ΔΔCT levels in excess of the cohort mean were female (with 
the exception of one).  This mirrored distribution observed in the general results 
(Figures 5.15 – 5.16).   
 
 
 
 
 
 
Figures 5.20 – 5.21 show the variation of 2-ΔΔCT with age.  Figure 5.20 shows 
results observed in female RA patients of Caucasian origin.  Conversely, Figure 5.21 
shows how 2-ΔΔCT levels vary with age in male RA patients of Caucasian origin.  A 
Figure 5.19 The distribution and mean values of both OA and RA age-sex matched samples. 
Table 5.10 The arithmetic means of the 2-ΔΔCT of age-sex matched pairs in RA and OA cohorts.  Statistical data 
shows the significance of the comparisons of each group using matched pairs and paired (two-way) t-tests.  NS: 
Not Significant.  Shaded box represents significance of difference between all matched RA patients vs. all 
matched OA patients. 
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potential trend in results can be observed in Figure 5.20 with levels of 2-ΔΔCT peaking 
between 40-60 years.  This then dips in the sixth decade, before increasing again after 
70 years of age.  This pattern is not observed in male RA patients who appear to exhibit 
a baseline of HERV-K gag activity that increases in the eighth decade of life (Figure 
5.21). 
 
 
 
 
 
 
 
Figure 5.20 Data showing a potential correlation between age and level of HERV-K gag activity in female 
RA patients. 
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Additionally, disease duration also appeared to contribute to increasing HERV 
activity.  Peaks in 2-ΔΔCT correlated with those patients who showed the longest disease 
duration (Figure 5.22).  No trends were observed between 2-ΔΔCT and the presence or 
concentration of Rheumatoid Factor or the development of erosive disease although 
patient details available at the time of writing were limited on these factors. 
 
 
 
 
 
 
Figure 5.21 Data showing a potential correlation between age and level of HERV-K gag activity in male RA patients.
Figure 5.22 The correlation of HERV-K gag activity in relation to disease duration in female caucasian RA patients. 
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5.3.3.3  Cloning and sequencing of HERV-K gag PCR products amplified 
from patient samples 
 
 
In order to both confirm primer specificity and to identify any disease specific 
variants in patient samples, HERV-K gag PCR amplicons from patient mRNA were 
amplified via real-time PCR, cloned into the pGEM-T plasmid (Promega, 
Southampton, UK) to be sequenced (Section 5.2.7).  Amplicons were sequenced from 4 
RA patients, 2 healthy controls and 2 OA patients were selected at random.  In three of 
the four cases, increasing the insert improved the frequency of white colonies, 
transformed by vectors with cloned insert (Table 5.11).  Problems were encountered 
during sequencing which prevented the read through of inserted products, therefore 
purified PCR products were sequenced directly using gene-specific primers.  Those 
sequences retrieved were aligned against both HERV-K gag1 and HERV-K gag 
sequences (Figure 5.23). 
  
Sample Insert : Vector White Blue 
3 : 1 445 58 1 
1 : 3 318 110 
 
3 : 1 214 76 2 
1 :3 9 23 
 
3 : 1 107 76 3 
1 : 3 10 25 
 
3 : 1 0 0 4 
1 : 3 30 49 
 
+  60 11 
 
Uncut Plasmid only  1 160 
 
Negative control 
(Media only) 
 0 0 
Transformation 
efficiency 
 
1.6 x 108 cfu/µg-1 
 
 
 
 
 
Table .5.11 The number of colonies resulting from the each ligation of four RA patient sample PCR 
products into the pGEM vector.  These were used to calculate the overall cloning efficiency for the 
transformation. 
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- . . - . . . . . . . T . . . . . . . . . . . . . . . . . . . C - . . . . . . - . . . . . . . . . . . . . A C . . A A C C . C A A . T . . C C T A T C A C G A T  22 RA1 39.seq
. . . - . . . . . . . . . . . . . . . - . . . . . . . . . . . . - . . . . - - - . . C G A . T C G G C                               85 RA1 41.seq
. . . - . . . . . . . . . . . . . . . - . . . . . . . . . . . . - . . . . . . - . . . G A . . . G G G G                              72 RA1 43.seq
- . . - . . . . . . . . . . . . . . . . . . . . . . . . . . . C - . . . . . . - . . . . . . . . . . . . . A C . . A A C C . C A A . T . . C C T A T C A A A G G  19 RA1 45.seq
- G . - . . . G . . . . . G G G A . . . . . . . . . . . . . . T A . . . . . . G . . G . . . . . G . T . . G A . . T T T A . G G G . G . . G T A G C G G A T G C  27 C1 45.seq
. . . - . . . . . . . . . . . . . . . . . . . . . . . . . . . . - . . . . . . - . . . . . . . . . . . . . A C . . A T C C . C A A . T . . C C T A T C A A T T T  31 C2 47.seq
. . . - . . . . . . . . . . . . . . . . . . . . . . . . . . . . - . . . . . . - . . . . . . . . . . . . . A C . . A A C C . C A A . T . . C C T A T C A A T G T  35 OA1 41.seq
- . . - . . . . . . . . . . . . . . . . . . . . . . . . . . . . - . . . . . . - . . . . . . . . . . . . . A C . . A A C C . C A A . T . . C C T A T C A A T T   38 OA2 43.seq
. . . - . . . . . . . . . . . . . . . - . . . . . . . . . . . . - . . . . - - - . . . G A . G                                   98 RA B BLD.seq
. . . C . . . . . . . . . . . . . . . . . . . . . . . . . . . - - . . . . - - - . . G G A . C G                                  70 RA B SF.seq
. . . C . . . . . . . . . . . . . . . . . . . . . . . . . . . C - . . . . - - - . . . G A C G                                   108 RA CD4 T BLD.seq
. . . C . . . . . . . . . . . . . . . - . . . . . . . . . . . C - . . . . - - - . . G . A . G             81 RA CD8 T BLD.seq 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.23 Alignment of sequences showing sequencing products amplified from patient samples.  Alignment was constructed 
using MEGAlign version 7 (DNAstar, Madison, Wisconsin). 
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5.3.3.4  Results for levels of HERV-K gag mRNA in different cell types 
 
 
Figures 5.24 and 5.25 show results of the investigation of levels of HERV-K 
gag in different lymphocyte populations within individual patient samples.  Cell 
populations were separated as described previously (Section 5.2.3) and levels of 
HERV-K gag mRNA measured using the novel real-time PCR.   
CD4+ T-cell populations, in both blood and synovial fluid exhibited the highest 
levels of HERV-K gag transcription.  Levels within the synovial fluid were elevated in 
comparison to those observed in the respective cell populations within the blood with 
the exception of B cells in OA patients.  Additionally, both healthy and RA patient 
lymphocyte populations showed increased levels of HERV-K gag transcription, when 
compared to 2-ΔΔCT values exhibited by the OA patient, although levels in RA patients 
were lower than those observed in healthy lymphocyte populations.  This contradicted 
previous results in PBMCs extracted from in patients samples which demonstrated 
HERV-K gag mRNA to be significantly elevated over both OA and NHDs (Section 
5.3.3.1).  In OA patient samples, both the T-cell populations showed comparable levels 
of gag activity.   
 
 
 
 
 
Figure 5.24 Comparison of levels of HERV-K gag in different cell types isolated from whole blood across 
different disease types.  Error bars indicate levels of standard error. 
231 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.25 Levels of HERV-K gag activity relative to HKG expression between cells from 
blood and synovial fluid.  Error bars indicate standard error. 
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5.3.4  Mechanisms by which HERVs may trigger or 
influence the immunopathogenesis of Rheumatoid Arthritis 
 
5.3.4.1  The role of viral proteins in influencing HERV-K10 in rheumatoid 
arthritis pathogenesis 
 
Two expression plasmids were used to investigate the influence of viral genes 
upon HERV activity.  pSG5 plasmids (Stratagene) contained the EBNA1 (pSG5-
EBNA1) and LMP1 (pSG5-LMP1) genes from the Epstein Barr virus (EBV).  
Restriction digests (Section 5.2.9) confirmed the identity of the expression plasmids as 
shown in Figures 5.26 - 5.27) 
Figure 5.26 shows the products of both single and double digests of the pSG5-
EBNA1 plasmid.  Lane 1 and 2 both show single restriction enzyme digests using Bgl 
II and EcoR1 respectively.  This had the effect of linearising the plasmid by only 
partially cutting out the insert, therefore only a single band of just over 6kb is observed 
i.e. the size of both plasmid and insert.  Lane 3 shows the products from a double digest 
using both restriction enzymes.  This completely excises the 2 kb insert from the 4.1 kb 
pSG5 plasmid. 
 
 
 
 
 
Figure 5.26 Gel confirming the identity of pSG5 – EBNA1 plasmid using a dual 
restriction digest. 
Lanes 1:  EcoR1.  2: Bgl II.  3: Dual digest (EcoR1 and  Bgl II).  4: No template.  5: No 
enzyme.  6:  dH20. 
L : DNA marker Ladder is 1Kb + DNA ladder (Promega, UK). 
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Additional controls included no template (lane 4), no enzyme (lane 5) and water 
only (lane 6).  A similar pattern as described above was observed for the restriction 
analysis of pSG5-LMP1 (Figure 5.27). 
Real-time PCR was used to determine mRNA levels in human synoviocytes, 
transfected with expression plasmids containing Epstein barr virus (EBV) genes - 
EBNA1 and LMP1 (Figure 5.28 and Table 5.12).  Cell lines tested included human 
synoviocytes derived from RA, OA and healthy donors and KMH2 (Hodgkins 
lymphoma cell line) used as an unrelated control cell line.  In addition to the treatments, 
several negative controls were included within the analysis including untreated, ‘vector 
only’ and ‘Lipofectamine only’ in order to determine the extent of their influence upon 
HERV-K transcription.  All real-time readings were repeated three times in triplicate 
and normalised with two housekeeping genes – HPRT and ACTB. 
The largest increases in HERV-K gag mRNA were observed after synoviocytes 
had been transfected with pSG5-LMP1.  Similar effects were observed in all 
synoviocytes.  A similar effect was also observed in KMH2 cells that had been 
transfected with LMP2a.   EBNA1 expression also induced increases in HERV-K gag 
mRNA relative to housekeeping genes, although the increase was not to the extent 
observed with LMP1.  Once again, effects were observed in all cell lines tested 
(synoviocytes and KMH2).   
Figure 5.27 Gel confirming the identity of pSG5 – LMP1 plasmid using a dual restriction 
digest. 
Lanes 1:  EcoR1.  2: Bgl II.  3: Dual digest (EcoR1 and  Bgl II).  4: No template.  5: No 
enzyme.  6:  dH20. 
L : DNA marker ladder shown in 1Kb +DNA ladder (Promega, UK) 
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Sample Cell line/ 
Disease  
Treatment 2-ΔΔCT SE p value  
(to Utd) 
Significance 
        
1 RA UTD 3.508 0.160 - - 
2 RA EBNA1 68.392 2.506 < 0.001 ** 
3 RA LMP1 109.926 7.712 < 0.001 ** 
4 RA pSG5 ONLY 7.666 0.210 - NS 
5 RA Lipofect. ONLY 20.727 2.322 < 0.01 * 
        
6 NHD  UTD 2.138 0.056 - - 
7 NHD EBNA1 96.244 0.334 < 0.001 ** 
8 NHD LMP1 122.880 2.924 < 0.001 ** 
9 NHD  pSG5 ONLY 17.245 0.711 - NS 
10 NHD Lipofect. ONLY 22.636 1.580 - NS 
        
11 OA UTD 0.824 0.047 - - 
12 OA EBNA1 85.031 2.178 < 0.001 ** 
13 OA LMP1 95.391 2.879 < 0.001 ** 
14 OA pSG5 ONLY 6.047 0.533 - NS 
15 OA Lipofect. ONLY 35.151 2.356 < 0.01 * 
        
16 KMH2 UTD 0.565 0.100 - - 
17 KMH2 EBNA1 68.562 1.383 < 0.001 ** 
18 KMH2 LMP1 79.809 3.074 < 0.001 ** 
19 KMH2 LMP2 100.500 5.424 < 0.001 ** 
20 KMH2 pSG5 ONLY 5.470 0.815 - NS 
 
 
 
 
 
Figure 5.28 Levels of HERV-K gag expression in response to the presence of EBV proteins EBNA1, LMP1 and 
LMP2a in fibroblast-like synoviocytes and KMH2 cells.  Expression plasmids for EBV proteins were 
transfected into cells and HERV-K gag measured.
Table 5.12 2-ddCT values for treatments of viral proteins using synoviocyte cell lines and KMH2 control cell line.  Statistical 
significance of each treatment was relative to that observed in untreated cells using a paired t-test.  NS = not significant. 
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Of the control groups, both pSG5 (no insert) and lipofectamine only controls were 
elevated above the untreated cells.  This may suggest some of the observed increases in 
HERV-K gag may have been attributable to the experimental conditions.  However 
these increases were only small compared to the increases when viral genes were 
present.  As described in Section 5.3.2.2, untreated RA synoviocytes exhibited 
significantly increased levels of HERV-K gag mRNA when compared to disease 
controls.  However, after treatment with viral genes, synoviocytes taken from healthy 
donors showed the greatest increases in HERV-K gag transcriptional activity Figure 
5.24).  All treatments showed significance over untreated and treatment controls.  The 
level of significance remained consistent for all treatments irrespective of the cell line 
investigated, i.e. p < 0.001 (Table 5.12).  For all treatments, the lipofectamine showed 
an increased significance above untreated and plasmid only controls.  This suggests that 
the actual process of transfection itself may lead to an increase in HERV-K gag.  
Despite this, treatments were of increased significance to controls suggesting these 
were representative of true effects rather than artefacts of the experimental process. 
Microarray analysis of the influence of different viral genes upon different 
members of the HERV-K superfamily was also investigated (Figure 6.2). 
 
 
5.3.4.2  Modulative properties of inflammatory cytokines 
 
After treatment with varying concentrations of inflammatory cytokines it was 
apparent that cells treated with higher concentrations of pro-inflammatory cytokines 
exhibited reduced levels of HERV-K gag transcriptional activity (Figure 5.29).  This 
was particularly evident in synoviocytes derived from diseased donors, i.e. RA and OA.  
Normal healthy synoviocytes showed the least differences between high and low 
concentrations of cytokine treatments.  The non-synovial fibroblast controls (HEK-293) 
exhibited a base level of activity far lower in comparison to those levels observed in 
synoviocytes.  Levels in HEK-293 cells also showed decreased levels of HERV-K gag 
transcription in response to being treated with higher concentrations of IL-1 Beta and 
IL-6. 
Differences in the potential for modulating HERV transcription between the 
cytokines themselves were also evident.  IL-1 β appeared to show the largest increase in 
healthy synoviocytes, however was untested in any of the other cell lines. Of those 
cytokines used in all cell lines, IL-6 appeared to show the greatest degree of modulation 
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with the 2-ΔΔCT values for 1 ngml-1 being almost five-fold higher in both RA and OA 
than the 1 ngml-1.  TNF-α treatments showed almost a two-three fold difference 
between the two concentrations.  However, 1 ngml-1 treatments showed overall peaks in 
2-ΔΔCT values for HERV-K gag mRNA (relative to HKG).  All placebo controls 
containing water were comparable to untreated negative controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.29 The effect of inflammatory cytokines upon HERV-K gag.  Cytokines at concentrations of 1 ngml-1 
had a greater influence upon gag expression compared to 10 ngml-1, that appeared to show an inhibitory 
effect.  Mouse fibroblasts showed basal levels across all treatments as expected.  This graph shows data 
normalised to ATCB and HPRT genes.  Error bars indicate degree of standard error. 
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5.5 Discussion 
 
5.5.1 Assay optimisation 
 
In this study, an accurate, novel and economical SYBR green real-time RT-PCR 
was designed to quantify expression of HERV-K gag in Rheumatoid Arthritis patients 
relative to disease controls.  Quantitative PCR was a sufficiently sensitive technique to 
detect <1pg of template (Figure 5.9) and whose specificity was confirmed by both melt 
curve analysis (Figure 5.3) and sequencing of purified amplicons (Figure 5.4 and Table 
5.5). 
The optimised assay was then used to investigate the influence of 
hypomethylation agents upon HERV activity (Section 5.3.2.1).  Findings in this 
investigation confirmed that previously reported in studies that hypomethylation of 
DNA can lead to increases in transcriptional activity (Ogasawara et al., 2003).  A 
number of in vitro cell lines were also surveyed for the presence of HERV-K gag 
(Figure 5.14).  Results of HERV-K gag expression within two of these cell lines, i.e. 
MCF7 and human fibroblast-like fibroblasts (from a healthy donor) were backed up by 
immunohistochemical staining analysis (Figure 4.16, 4.19 and 4.22 – 4.23) using 
antibodies raised to HERV gag epitopes predicted in Chapter 3.  Real-time analysis 
relative to the combined geometric means of two HKG (Section 5.3.1.7) showed 
significant increases in RA fibroblast-like synoviocytes, compared to disease and 
healthy controls (Figure 5.14).  Additionally, EBV and HTLV immortalised 
lymphoblastic cell lines – BJAB and Jurkat cell lines showed increased levels of 
HERVs compared to other cell lines tested.  Whether this has any relevance to the viral 
immortalisation of these cell lines or to any effects of long-term in-vitro culture may 
warrant further investigation.   
 
5.5.2 Patient Samples 
 
Once validated and optimised, the real-time RT-PCR was used to investigate the 
levels of HERV-K gag mRNA in RA patient samples versus disease controls (Section 
5.3.3).  From this analysis several trends became evident within the results.  The level 
of HERV-K gag expression in RA patients was significantly increased in comparison to 
that of disease controls, particularly that over OA (p < 0.0001), NHD (p < 0.001) and 
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inflammatory controls (p < 0.05) (Figure 5.15).  As inflammatory controls were also 
increased slightly, this may suggest part of an inflammatory pathway or element of the 
inflammatory environment may influence HERV-K gag expression.  This has been 
suggested previously in work by Serra et al who investigated the role of HERVs in the 
autoimmune response of MS (Serra et al., 2003) 
Gender may play a significant role in the influence of HERV activity.  This 
supports previous reports which have linked the action of sex hormones to modulation 
of HERV-K activity (Wang-Johanning et al., 2003).  Such an effect was particularly 
notable in the age-sex matching analysis of patient samples (Section 5.3.3.2).  
Statistical analysis of results (Table 5.10) showed both male and female RA patients 
were significantly increased over OA matched patients (p < 0.0001).  This was also the 
case when the gender specific analysis was completed (Female RA vs. OA: p = 0.0009; 
Male RA vs. OA: p = 0.0067) although significance of the difference in male patients 
was smaller than that observed with females.  RA females also exhibited significantly 
increased levels of HERV-K gag mRNA to their paired male counterparts (p = 0.0362).  
When OA females were compared with paired male OA patients this was not the case 
(p = 0.3182) and the effect was disease specific for RA.  This observation was disease 
specific and not observed in disease controls (p = 0.3182).  Additionally, RA, like many 
autoimmune diseases has been associated with the actions of sex hormones.  Such 
associations coupled with the fact that disease remissions are often observed during 
pregnancy (Olsen and Kovacs, 2002) and like most autoimmune diseases, patients 
appear to be predominantly female (Goronzy and Weyand, 2005) such evidence may 
contribute to a case for a role for HERVs in Rheumatoid Arthritis pathogenesis.   
The real-time data also shows an increased level of 2-ΔΔCT observed in older 
patients, although this appeared to be reduced within the sixth decade (Figure 5.20).  
Interestingly, this trend was observed only in female RA patients, and not males (Figure 
5.21).  RA is a disease that is most commonly triggered in the sixth decade of life 
(Goronzy and Weyand, 2005).  Furthermore results suggest an association between 2-
ΔΔC
T and disease duration, with increasing disease duration showing a positive 
correlation with HERV-K gag activity (Figure 5.22).  It may be that these patients who 
develop RA before the sixth decade may represent those subsets that may be 
susceptible to the disease genetically, or come into contact with environmental triggers.  
These patients in the sixth decade who show a decrease in HERV-K mRNA may 
represent a cohort that develop disease at this age, and at this point, 2-ΔΔCT remains low 
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before it increases as the disease progresses.  Unfortunately the data available at the 
time of writing is incomplete and further research is required before making further 
conclusions (Figure 5.30).  It is unlikely however those HERVs are the only factor in a 
disease such as RA and those developing the disease earlier may be due to a myriad of 
genetic and environmental variables. 
 
 
 
 
 
 
 
5.5.3 HERVs in lymphocyte subpopulations 
 
Part of the investigation also involved the analysis of HERV-K gag activity in 
individual lymphocyte cell populations extracted and purified from patient blood 
(Section 5.3.3).  From the results of this investigation it was evident that HERV 
expression was not uniform across different cell types.  This supported previous studies 
looking at HERV expression in different tissue and cell types, showing their level of 
HERV expression to be influenced by the tissues role or metabolic purpose (Seifarth, 
2005).  Results in this investigation, despite using a limited sample set, showed that 
HERV-K gag activity appeared increased in CD4+ T cells in both healthy (NHDs) and 
RA patients (Figure 5.24).  CD4+ lymphocytes form an important population of cells in 
RA pathology (Feldmann et al., 1996) which may have further implications in disease 
Figure 5.30 The correlation between age, disease duration and HERV-K gag activity in RA patients.  As 
shown in the graph levels of HERV-K mRNA decrease within the 6th decade, before it increases in 
subsequent years.  Figure 5.22 shows a correlation with HERV-K mRNA levels and disease duration.  
Red bars show disease duration and its correlation with age and HERV-K activity.   
Gaps in the line indicate where patient information is unavailable. 
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pathogenesis.  The one exception to this was in OA patients where B-cells showed a 
large increase over other cell types however due to the limited sample set further 
investigation is required before any conclusions can be made.  Despite its preliminary 
nature however, they do present an intriguing picture of HERV activity within the 
cellular microenvironment.  The vast majority of these cells are likely to be activated; 
therefore it would be useful to quantify the level of HERV-K gag in quiescent and 
activated cellular status in order to gain a clearer picture of HERV status.  
Further investigation would also identify whether the significant increase of 
HERV-K gag mRNA in B-cells of the OA patient was an artefact or contamination of 
the sample, or a true representation of HERV-K in OA patients B cells.  Furthermore 
Figure 5.24 shows levels of HERV expression to be decreased in RA patients compared 
to healthy controls, whereas the quantification of HERV-K gag levels in fibroblast-like 
synoviocytes and other PBMCs of other patients (Figure 5.14 and 5.15) to be increased 
compared to disease and healthy controls.  Clearly these results are contradictory to one 
another and require further clarification.   
Synovial fibroblasts have previously been suggested as key players in the 
process of synovitis (Huber et al., 2006) as they carry out a number of important 
functions in RA maintaining disease pathogenesis (Section 1.2.6.3).  This may suggest 
that HERVs are in fact present not in activated lymphocytes entering the joint, but in 
the fibroblast-like synoviocytes, influencing the propagation of disease pathology.  This 
not only places them at the scene of the crime, but shows their upregulation in a cell 
type, pivotal to the maintenance of disease pathology.  Further evidence supporting this 
observation was previously reported identifying increases in HERV-K expression 
within the synovial tissue (Ehlhardt et al., 2006).  This finding was also found on a 
protein level with increased levels of antibodies being detected within the synovial fluid 
in comparison to the blood (Section 4.5.4) although increases were not significant 
(Table 4.5).  Additionally our data suggested that HERV-K (HML-2) gag mRNA was 
increased in individual cell populations within the synovial fluid (Figure 4.25).  This 
has been reported previously within the literature (Ejtehadi et al., 2006) suggesting that 
HERVs may form an important part of the disease process, by acting within local cell 
populations within the joint. 
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5.5.4 Other factors influencing HERVs 
 
The heterogeneous presentation of HERV-K gag in RA patients suggests the 
lack of a straight-forward association to a disease, already renowned for its highly 
variable presentation.  It appears from this data that a number of factors in both the 
patients’ disease state, i.e. gender, age, disease duration and their genetics, e.g. MHC 
haplotype, play roles in contributing to the overall disease development.  The real-time 
PCR assay was used to determine how HERVs may be upregulated by endogenous 
factors within the joint as well as by external ones.  Two other factors explored by this 
investigation included the role of exogenous viral pathogens (Section 5.3.4.1) and the 
cytokine component of ongoing immune responses within the joint in RA (Section 
5.3.4.2).  
The presence of exogenous viruses was modulated through the transfection of 
expression plasmids containing genes cloned from EBV.  Those genes investigated 
were EBNA1, LMP1 and LMP2, with all three having been previously linked with RA 
disease pathogenesis (Takei et al., 1997, Saal et al., 1999, Blaschke et al., 2000).  All 
three viral genes were shown to have a positive effect upon HERV transcription when 
present within the expression vector within the synoviocytes (Figure 5.28).  The largest 
increases were observed compared to EBV LMP.  LMP2 was only trialled in the 
KMH2 cell lines; therefore its effects upon HERV-K gag require further verification 
(Table 5.12).  In all cell lines tested, i.e. RA, OA and healthy synoviocytes and KMH2 
cells both EBNA1 and LMP1 transfection led to significant increases in HERV-K gag 
mRNA levels (p < 0.001).  These increases were greatest in NHD derived synoviocytes 
with levels of 2ΔΔdCT    being increased almost 122 fold.  HERV-K activity was also 
increased by transfection reagent controls (lipofectamine) and to a lesser extent in 
empty vector controls, however these levels were well below those observed with viral 
gene transfection.   
Additionally, cDNA extracted from these transfected synoviocytes were tested 
using a HERV gene-chip (Seifarth et al, 2001) in order to determine activity across the 
HERV-K superfamily (Appendix ii).  From this analysis it showed the HERV-K 
(HML-2) sub-family (including HERV-K10) was not expressed to a detectable level.  
This is contradictory to the real-time data which suggests that HERV-K gag is 
significantly upregulated by the presence of the viral genes (Figure 5.28).  The most 
likely reason for this is that whilst the real-time is specific for HERV-K gag, the HERV 
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microarray is based upon pol specific primers.  For this reason it may be concluded that 
this may be the reason the two sets of results do not agree, but also that a full particle is 
not being produced.  The gag gene is showing increases in transcripts that are not being 
reflected in the env transcripts.  This data is supported by several previously published 
reports of members of the Herpes family interacting with HERVs (Sutkowski et al., 
2004, Nellaker et al., 2006, Mameli et al., 2007). 
The second part of the analysis looked at the effect of pro-inflammatory 
cytokines – IL-1β, IL-6 and TNF-α upon HERV-K (HML-2) gag1 transcription 
(Section 5.3.4.2).  Each cytokine was treated at three concentrations – untreated, 1ng/ml 
and 10ng/ml.  These concentrations were chosen in order to simulate those 
concentrations in-vivo.  Concentrations listed in Table 5.13 are those reported in the 
literature to be typical of circulatory concentrations found in RA patients (Danis et al., 
1992).  Cell lines were treated with cytokines for 48 hours before cells were trypsinised 
and RNA extracted (Section 5.2.5).  After being incubated with pro-inflammatory 
cytokines, at levels typically observed in RA patients (~1ng/ml) HML-2 gag1 was 
increased in both RA and OA derived cells.  At concentrations ten-times those observed 
in RA patients however, HML-2 gag1` transcription appeared to be reduced by over a 
half (Figure 5.29).  In fibroblast-like synoviocytes derived from a healthy donor, 
however higher concentrations appeared to result in increased transcription as expected.  
Levels of HERV-K (HML-2) gag1 mRNA were similar in all three cell lines in water 
only and untreated controls.  These levels were similar to those observed in Figure 5.14.  
Additionally, when the non-synovial fibroblast control cell line was treated, levels of 
HML-2 gag1 remained significantly lower than that observed in synoviocytes. 
   
 
Cytokine Average level in RA 
patient blood 
 
Reference 
IL-1β 1ng/ml 
IL-6 0.44ng/ml 
TNF-α 1.2ng/ml 
 
 
(Danis et al., 1992) 
 
 
 
 
Table 5.13 Typical circulating oncentrations of pro-inflammatory cytokines under investigation in RA patients. 
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5.6 Conclusions 
 
In this investigation a sensitive, specific and robust real-time PCR assay was 
developed, optimised and applied to determine levels of HERV-K gag mRNA levels 
relative to housekeeping genes.  This assay detected that HERV-K gag transcriptional 
activity was significantly increased in RA patients compared to disease and healthy 
controls.  Additionally, this real-time PCR assay was used to investigate endogenous 
factors within the microenvironment of the joint that may be capable of influencing 
HERV-K activity.  Two factors addressed by this investigation were those of 
exogenous viral pathogens and components of the immune response that play 
prominent roles in RA disease pathogenesis.  Investigations outlined here suggest that 
both of these factors present within the synovial microenvironment have the potential to 
influence HERV-K activity, whether on a transcriptional or translational level, i.e. 
independently of disease state.  Further study is however required in order to eliminate 
HERV-K activity from disease pathogenesis. 
 
A number of conclusions can be drawn from this work. 
 
1. Levels of HERV-K gag (relative to HKG) were significantly increased in RA patients, 
compared to disease controls (p < 0.0001). 
 
2. Factors such as age, gender and disease duration play important roles in influencing 
transcriptional activity of HERV-K gag.  No correlations could be determined between 
HERV-K gag 2-ΔΔCT and the occurrence of Rheumatoid factor, or erosive disease. 
 
3. In mononuclear cell populations in peripheral blood, CD4+ T cells appeared to harbour 
increased levels of HERV-K gag compared to other populations of lymphocytes.  These 
levels were found to be significantly increased in cells taken from the synovial fluid.  
The relevance of these findings requires further investigation due to the limited sample 
set available. 
 
4. The presence and expression of Herpesvirus viral proteins, such as those derived from 
Epstein Barr virus has a positive effect upon HERV-K gag transcription.  Investigations 
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showed increased levels of gag transcription compared to controls, after transfection of 
expression plasmids containing EBV genes EBNA1, LMP1 and LMP2.  This effect 
may be gene-specific for gag. 
 
5. Proinflammatory cytokines may exert a modulatory effect upon HERV transcriptional 
activity.  At the levels of cytokines present within an RA patient, HERV-K gag shows 
increased transcriptional activity.  Ten times these elevated levels show a negative 
association with HERV-K gag transcription.   
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Abbreviations 
 
 
B-Cell Epitope Prediction (BCEPRED) 
Encyclopedia of DNA Elements (ENCODE) 
Epstein - Barr virus (EBV) 
Human Endogenous Retroviruses (HERVs) 
Micro RNAs (miRNA) 
Normal Healthy Donor (NHD) 
Oral Contraceptive pill (OCP) 
Osteoarthritis (OA) 
Premature Termination Codon (PTC) 
Rheumatoid Arthritis (RA) 
RNA Interference (RNAi) 
Small interfering RNAs (siRNA) 
Sperm Adhesion Molecule-1 (SPAM1) 
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6.1 Final Discussion 
 
 
6.1.1 The Central Dogma 
 
‘Find the gene, cure the disease’, was the optimistic mantra cited by geneticists 
throughout the 1980’s and 90’s which embodied the driving force behind the genome 
cloning revolution (Salmon and Akbar, 2004).  Although this phrase embodied a period 
of paradigms reshaping the field of molecular biology, the reality was less optimistic as 
the journey from identifying a gene to proving its role and curing the resultant disease 
was generally a long and arduous one.  Over two decades ago the link between 
Rheumatoid Arthritis (RA) and retroviruses was first reported (Norval et al., 1979, Hart 
et al., 1979).  Since then this link has been the subject of numerous investigations and 
reviews (Perl, 2003, Ejtehadi et al., 2006) involving several families of Human 
Endogenous retroviruses (HERVs) in particular (Nakagawa et al., 1997).  However, no 
conclusive evidence had been identified that links HERVs to RA disease pathogenesis. 
The main purpose of this project was therefore to test the hypothesis that 
HERVs may contribute to RA disease pathogenesis.  The research also involved the 
development and optimisation of several novel molecular and serological tools and 
reagents, for use in the detection of HERV gene products in patient samples and cell 
lines.  The three approaches taken were based upon the central dogma (Figure 6.1) and 
used to determine at which level of activity HERVs may contribute towards disease 
pathology.  
The first approach assessed similarities in the primary structure of HERVs and 
identified shared regions in autoantigens, implicated in RA disease pathogenesis.  Both 
sets of sequences were mapped antigenically by an optimised and validated method of 
B-cell epitope prediction and epitopes from both sets were aligned with one another 
using bioinformatic analysis (Section 3.3.5).  From this analysis, a short list of epitopes 
was drawn up that were shared by both HERVs and autoantigens (Appendix II).  These 
suggested that HERVs may trigger the process of molecular mimicry, resulting in the 
ensuing cross-reactive autoimmune response.  
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Once candidate epitopes had been selected (Section 3.3.7), they were 
synthesised as short peptides and incorporated into an ELISA for surveying of patient 
sera (Chapter 4).  Reactivity of patient sera to the peptides gave an indication as to 
whether HERV proteins were contributing to disease, via the induction of antibodies 
that may also cross-react with self-proteins (Section 4.5).  All serological results were 
confirmed by inhibition studies using patient sera (Section 4.5.3).  Such results 
confirmed the presence of a complete gag open reading frame and HERV protein 
production, thus a potential contribution to disease on a translational level.  On a 
transcriptional level, a novel real-time RT-PCR assay was developed for the detection 
of HERV-K (HML-2) gag mRNA in both patient samples and in-vitro models (Chapter 
5).  This was used to determine levels of HERV-K mRNA in patient samples and 
disease controls (Section 5.3.3).  A novel quantitative PCR was then used to investigate 
exact mechanisms whereby HERVs were upregulated in RA.  Increased levels of 
HERV-K gag were detected upon induced expression of viral proteins in an in-vitro 
model using primary cells taken from RA patients, Osteoarthritis (OA) patients and 
Normal Healthy donors (NHD) (Section 5.3.4.1).  Transfected cells were significantly 
Figure 6.1  The central dogma of molecular biology (Watson and Crick, 1953) described the one-way direction of flow of 
genetic information in most cellular activities.  The first step is the synthesis of RNA using a DNA-dependent RNA 
polymerase (transcription).  The second step is the conversion of RNA to polypeptides / proteins (translation). 
249 
 
increased over controls (p < 0.001) showing the expression of Epstein-Barr virus (EBV) 
proteins, notably LMP1 led to increases in HERV-K gag transcription (Figure 5.28).  
Additionally pro-inflammatory cytokines were also shown to have a modulatory effect 
upon HERV-K gag transcription (Section 5.3.4.2).  These results showed that although 
pro-inflammatory cytokines were capable of modulating increases in HERV-K activity, 
at increased concentrations this appeared inhibitory, resulting in reductions in HERV-K 
gag expression (Figure 5.29).   
 
6.1.2 Bioinformatic analysis 
 
A final prediction strategy was devised which attained a maximal level of 
accuracy through the incorporation of dynamic threshold levels and secondary 
structure, i.e. the location of beta-turns (Section 3.3.3).  Using 21 experimentally 
derived epitopes as ‘gold standards’, the performance of this methodology was assessed 
and compared to that of a publicly available database – B-Cell epitope Prediction 
(BCEPRED) (Section 3.3.4).  BCEPRED is an online server that made predictions of 
B-cell epitopes using the information comprising of 1029 known B-cell epitopes.  From 
the data presented in Chapter 3, the optimal ExPASy method (incorporating input from 
beta-turns) attained a prediction accuracy of 71%.  This was compared to that of 
BCEPRED which predicted 85% of ‘gold standard’ epitopes.  Despite this increased 
overall accuracy, the BCEPRED protocol exhibited reduced sensitivity (22% to 41%) 
and specificity (17% to 25.4%) compared to the ExPASy methodology.  Thereby, 
overall the ExPASy strategy presented a more accurate method of prediction.  Despite 
this, the limitations of the sliding windows method inherently restricted the level of 
prediction accuracy.  Typically, the sliding windows procedure could attain an average 
of 60% accuracy (Claverie and Notredame, 2006).  Other limitations of this analysis 
included the limited data set of ‘gold standard’ epitopes used to assess performance, 
which would require expanding for any future analysis (Greenbaum et al., 2007).  
Additionally, the methodology was limited to the identification of continuous epitopes 
(Blythe and Flower, 2005), although many discontinuous epitopes may consist of 
stretches of several consecutive amino acids, thereby making them continuous in their 
own right (Van Regenmortel, 2006).   
B-cell epitope prediction has been notoriously difficult to predict due to the lack 
of knowledge surrounding the precise interactions between antibodies and their 
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antigens (Section 3.1.2).  Additionally, in comparison to its sister field of T-cell epitope 
prediction, B-cell epitope prediction is in urgent need of development and 
standardisation (Petrovsky and Brusic, 2006).  For the present line of investigation 
there are very few clearly set out rules or standards for both successful prediction and 
validation.  Questions should also be raised concerning the acceptable level of sequence 
homology that makes such a match significant.  Is mere sequence homology enough in 
order to generate a level of cross-reactivity capable of causing disease (Wucherpfennig, 
2001). 
Initially, bioinformatic analysis was used to determine the degree of sequence 
homology that exists between HERV derived proteins and host proteins.  Such shared 
regions located in regions most likely to be identified by antibodies (epitopes) were 
identified and short-listed before validating by serological analysis in Chapter 4.  One 
clear conclusion arising from this work was that perhaps surprisingly there was not as 
great level of homology between autoantigen and HERV epitopes or primary sequences 
as previously expected perhaps suggesting that HERVs may not be triggering RA 
through molecular mimicry (Section 3.3.5). 
The investigation of the nature of HERVs and their association with RA 
employed both serological and molecular approaches, described in Chapters 4 and 5.  
Once candidate epitopes from Chapter 3 had been identified, these were synthesised as 
short peptides and incorporated as part of an optimised ELISA to survey patient sera 
(Section 4.5).  Secondly the development and optimisation of a HERV-K gag specific 
real-time RT-PCR assay was used to detect and quantify gag mRNA.  Both approaches 
showed significant increases in HERV reactivity in RA patient samples over controls. 
Several important factors came to light during the molecular and serological 
testing of patient samples, although these trends were more prominent in the real-time 
data.  Gender appeared to play a central influence over the level of HERV activity 
within an individual (Section 5.3.3.2).  The real-time data showed females exhibited an 
almost two-fold increase on levels observed in age-matched males (Table 5.10).  More 
interesting was the fact that although female levels of HERV-K gag mRNA were 
significantly increased compared to matched males in RA (p = 0.0362), this effect was 
disease specific and the two genders were not significantly different in OA (p = 
0.3182).  It has been reported previously within the literature that low androgen levels 
act as a risk factor for RA onset (James, 1993).  This had led to suggestions that the 
Oral contraceptive pill (OCP) exerted a protective factor for development of RA, 
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although many of these reports have been found to be contradictory (Silman, 1992, 
Masi et al., 1995).  This is further supported as during pregnancy the disease goes into 
remission (Olsen and Kovacs, 2002).  These observations reaffirm the 
immunological/pro-inflammatory nature of the disease as one of a TH1 nature.  The 
reasons for the sex bias in RA and other autoimmune diseases are unclear but may 
include such factors as sex-related differences in immune responsiveness, response to 
infection, sex steroid effects, and sex-linked genetic factors (Whitacre et al., 1999).  
Additionally, increased levels of HERV-K gag in female samples may be due to the 
females having increased numbers of CD4+ lymphocytes in their peripheral blood.  
Additionally, this cell population was identified as harbouring the highest levels of 
HERV-K gag in RA patients and healthy controls (Section 5.3.3.4) although these 
findings should be considered preliminary due to small patient sample size.  Increases 
in HERV-K gag in female patients therefore may be due to an increased pro-
inflammatory environment established, due to increased levels of  estrogens (Cutolo et 
al., 1998).  Such a difference may have been identified as a result the action of a 
gender-specific ERV-derived promoter such as Sperm Adhesion molecule-1 (SPAM1) 
genes, identified in the testes of both humans and mice (Dunn and Mager, 2005). 
 
6.1.3 Transcription and Translation 
 
Intriguingly gender and disease duration showed weak if no association with 
absorbance values and serum reactivities (both markers of HERV protein synthesis) 
(Appendix i).  Age and sex matched patients exhibited no trends in their results 
suggesting that translational and transcriptional mechanisms may be influenced by 
different host factors.  It has been observed previously that differences in levels of 
antibodies in general, between the sexes are increasingly difficult to identify, thereby 
supporting findings within this work (Vranckx et al., 1986).  Real-time PCR data 
showed increases in mRNA present in RA patients (p < 0.0001) compared to disease 
controls, before translation.  In comparison the levels of immune responses to HERV 
proteins were not as significant as may be expected from the increases observed in the 
transcriptional data.  Although this may only serve as an indirect comparison between 
the two, further investigation would be required to directly quantify levels of HERV-K 
gag protein, thus enabling a direct comparison between the two.  Potentially such a 
comparison may highlight important differences in HERV activity upon both 
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translational and transcriptional levels which may also be reflected within the clinical 
histories.  The significant level of mRNA present in comparison to controls could be 
explained by several factors.  Premature termination codons (PTC) in mRNAs may be 
encountered by ribosomes, during translation, thereby preventing a complete read 
through of the open reading frame and synthesis of a functional Gag protein.  The 
process of nonsense mediated decay may also ensure the premature degradation of 
mRNAs containing PTCs or miRNAs operating at a post transcriptional stage may all 
account for such increases in mRNAs.   This would account for a decreased level of 
translated protein, in comparison to mRNA.  This would be plausible due to the well-
documented accumulation of mutations and PTCs in HERV sequences (Nelson et al., 
2003).  However, anti-HERV antibodies were still significantly increased in RA 
patients compared to controls, suggesting that translation upon some scale was 
occurring, albeit potentially to a lesser extent, thus making this unlikely. 
The increased levels of HERV mRNA observed in patients may be due to 
external or exogenous factors, affecting mRNA stability or blocking translational 
processes, thereby preventing or limiting the translational potential of HERV-K (HML-
2) gag1.  SiRNA and miRNAs pathways are two likely candidates for such host 
mechanisms that may serve such roles (Pillai et al., 2007).  miRNA in particular is 
known to repress translation at a post-initiation stage (Seggerson et al., 2002, Petersen 
et al., 2006) in addition to being a reversible process (Pillai et al., 2007).  miRNA 
mechanisms have also been previously reported to target retroviral activity within 
human cells (Lecellier et al., 2005, Smalheiser and Torvik, 2005, Smalheiser and 
Torvik, 2006, Triboulet et al., 2007).  In addition to miRNAs evolution has also led to 
the development of a number of other ancient, anti-retroviral genome defence 
mechanisms which may fulfil such a role.  These include piRNA (Aravin et al., 2007), 
APOBEC3G (Holmes et al., 2007) and paramutation/transvection (Ashe and Whitelaw, 
2007) with all three reported to suppress retroviral activity within the host genome. 
An intriguing question from this data also asks if HERVs have evolved to 
equilibrate with their host, as expected, why would HERV-K synthesise any detectable 
levels of mRNA?  Additionally, why are these levels significantly increased in RA 
patients compared to controls?  And does this mRNA play other roles within the host 
genome? 
With advances in technology and completion of several genome sequencing 
projects, (e.g. Yeast Genome Directory, 1997, C. elegans genome sequencing 
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consortium, 1998, International Human Genome Sequencing Consortium, 2004) the 
focus of investigations is now addressing the roles of those genes identified as active 
(Mansia et al., 2007, Wellcome Trust Case Control Consortium, 2007).  With attention 
turning to the transcriptome, it has become unexpectedly apparent that the genome 
displays a greater degree of plasticity than thought previously (Check, 2007).  
Preliminary data from the first wave of such projects, including that of the 
Encyclopedia of DNA Elements (ENCODE) consortium, now suggest that from 
analysis of a fraction of the genome that a larger role than previously considered is 
regulated by the transcription of vast stretches of non-protein coding DNA (Birney et 
al., 2007).  This suggests that genes are intricately regulated by a network of promoters 
provided by the so-called “junk-DNA”, made up of retroviral insertions, repeat 
elements, etc (ENCODE project consortium, 2007).  Is it plausible to suggest a 
potential role for HERVs in this capacity?  Much of the ‘junk DNA’ is composed of 
repeats, transposable elements and non-coding DNA largely from introns (Gibbs, 
2003).  It is in these sequences that retroviral integration clusters have already been 
shown to play roles in miRNA regulation (Smalheiser and Torvik, 2006, Makunin et 
al., 2007).  Additionally, recent reports from studies in mice have implicated an 
association between retroviral integrations and development of cancers through the 
alteration of miRNA profiles (He et al., 2005, Lum et al., 2007, Makunin et al., 2007).  
The existence of an entire endogenous proviral reading frame in the anti-sense 
orientation capable of producing transcripts in the Complement C4 open reading frame 
(Mack et al., 2004) suggests the potential to adopt such a role and the resulting 
implications.  This however is still a developing field and the significance of these 
findings in humans is still yet to be revealed.   
Such mRNA species may also interact directly with lymphocyte species 
resulting in their activation.  Recent studies have established the capacity for DNA and 
DNA-associated autoantigens to activate autoimmune B cells via the sequential 
engagement of BCR and Toll like receptor-9 (TLR-9) (Leadbetter et al., 2002, Viglianti 
et al., 2003).  Such interactions have also now been established in the activation of 
autoreactive B cells and RNA/RNA associated autoantigens through interactions with 
BCR and TLR-7 (Lau, 2005).  This supports the observations observed in clinical 
studies of Rituximab with amelioration of disease symptoms following elimination of 
CD-19 B cells from patients (Edwards et al., 2006).  It is therefore possible that 
autoantibody production may well reflect the presence of increased levels of HERV 
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mRNA rather than protein.  This may emphasise the importance of TLR signalling 
pathways in autoimmune disease pathogenesis (Lin and Peng, 2005). 
 
6.1.4 Heterogeneity of disease and HERV polymorphisms 
 
The literature suggests that there is significant activity of HERVs on a 
transcriptional level.  It appears that HERV expression is heterogeneous, varying 
depending upon individual host factors, i.e. ethnicity (Turner et al., 2001, Moyes et al., 
2005), cell populations (Krieg et al., 1992),  gender (Chapter 5) and tissue types 
(Seifarth et al., 2005).  This is reflected in results presented within this investigation 
(Figures 4.24 – 4.31 and Figure 5.15).  Other factors that may play a role behind this 
heterogeneous presentation may be due to host repressive mechanisms.  This includes 
the Piwi - piRNA pathway which constitutes an ancient defence mechanism targeting 
retroviral elements and transposons.  Piwis and piRNAs form a system distinct from 
RNAi and miRNA pathways, although they do share several similarities with miRNAs 
(Lau et al., 2006).  Importantly, they are substantially longer than their miRNA 
counterparts (24 to 30 nt) and poorly conserved amongst closely related species (Aravin 
et al., 2006, Girard et al., 2006).  Due to this ill conserved nature, individual 
polymorphisms may develop in individuals resulting in the variation in HERV activities 
observed in patients.  This level of heterogeneity however may not simply be a 
reflection of host factors as the provirus itself may also constitute an important variable.  
The issue of proviral polymorphism has recently become topical, with the discovery of 
several insertional polymorphic members of the HERV-K (HML-2) family – HERV-
K113 and HERV-K115 (Turner et al., 2001).  The existence of polymorphisms within 
HERV families may help to explain the occurrence of disease affecting only a small 
proportion of the population (Moyes et al., 2007).  Such polymorphisms can be either 
sequence or insertional in nature, although with one exception, disease associations 
have yet to be clearly established (Marguerat et al., 2004).  Insertional polymorphisms 
present an intriguing set of proviruses, particularly when recent studies have shown the 
potential for reinfection demonstrated by the HERV-K (HML-2) subfamily (Belshaw et 
al., 2004).  Additionally the examples of HERV-K(C4), HERV-K113 and K115 show 
the potential roles for such polymorphisms (Mack et al., 2004, Turner et al., 2001). 
Additionally although polymorphisms may pay a role in differential expression 
levels in diseased patients, expression between proviral genes within these 
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polymorphisms may also be a factor.  This is illustrated by comparison of the HERV 
microarray results using samples transfected with EBV genes in expression plasmids 
(Section 5.3.4.1).   Although the gag based real-time PCR showed significant 
differences when EBNA1 and LMP1 were transfected into synoviocytes, results from 
an env based gene chip showed little change in samples among members of the HERV-
K superfamily, most notably in HERV-K10 (Figure 6.2 – row B1).  This may be 
explained by the fact that some HERV polymorphisms may have a complete ORF for a 
single gene, rather than a whole provirus being expressed.  Additionally, this may also 
account for the decrease in significance observed in the ELISA data when the reactivity 
of Eip peptide is compared to Kpr.  Expression of single HERV proteins have been 
implicated in pathological changes previously within the literature in both germ 
tumours (Sauter et al., 1996) and in serving important functions within the host, e.g. 
HERV-W env and expression within the trophoblasts of the primate and human 
placenta (Muir et al., 2004) 
The possibility that other families of HERVs may also play a role in rheumatoid 
arthritis should also not be overlooked, although HERV-K constitutes the most 
plausible candidate.  Other HERVs previously linked to RA include ERV3, ERV9, 
HERV-L and HERV-E (CD5) (Nakagawa et al., 1997, Renaudineau et al., 2005). 
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Figure 6.2  Alignment of false colour chip sets corresponding to HERV class II transcriptional activity, observed in healthy and disease 
derived synoviocytes (RA, OA and healthy) and KMH2 cells transfected with expression plasmids containing Epstein barr virus EBNA1, 
LMP1 and LMP2a. 
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Overall polymorphic HERVs make better candidates than their ancient 
counterparts for roles in disease.  Therefore, under the right environmental conditions, 
in genetically predisposed hosts, certain HERV polymorphisms may play a role in 
disease activation.  Another factor requiring clarification was the fact that it had been 
long known that RA presents itself under the auspices of varying clinical 
manifestations, disease courses and outcomes.  This may be attributed to the possibility 
that it is in fact still an umbrella term for several separate clinical entities (Weyand et 
al., 1998).  A similar situation is observed in SLE with classic lupus, drug-induced 
lupus and subcutaneous lupus all of which are now recognised as separate disorders 
(Routsias et al., 2004, Conrad and Schlosler, 2002).  The heterogeneous nature of the 
results may indicate particular subsets of patients within a disease.  This may be 
influenced by multiple polymorphism subtypes and observed within clinical symptoms 
as a varied presentation of seroconversion, erosive disease and extra-articular 
complications (Weyand et al., 1992, Goronzy et al., 2004) and germinal centre 
development (Goronzy and Weyand, 2005). 
The second factor important in RA is the disease duration.  Once again in the 
real-time PCR results outlined in chapter 5, longer disease duration showed a positive 
correlation with HERV-K gag transcriptional activity (Figure 5.22).  This also seemed 
to be confirmed in the serological results using the ELISA. 
  Cell separation strategies were also used to show distribution of HERV activity 
in different cell types.  CD4+ T cells were identified as those with the highest levels of 
HERV-K gag activity in RA and healthy (NHD) patients.  This would appear to fit with 
the fact that T cells (notably CD4+) appear to be those most permissive for retroviral 
infection, e.g. HIV and HTLV-I.  The activation status of these cells and whether this 
increased HERV activity is due to cellular activation is unknown and requires further 
investigation.  One curious finding was that levels of HERV-K gag were shown to be 
increased in PBMCs of patient samples in RA patients’ to controls groups (Figure 
Key to Figure 6.2:  
HKG  A2: Ubiquitin (U49869), A3: GAPDH (NM_02046.1), A4: Alpha-tubulin (NM_006082), A5: 
ATCB (E01094), A6: HPRT (NM_000194).  
HML-1 A8: HML-1 (U35102), A9: HML-1 seq29 (S77579),  
HML-2 B1: HERV-K10 (M14123), B2: HERV clone M3.5 (U87592), B3: HERV-K (D1.2)(U87595), 
B4: HERV-K2.HOM (U87592), B5: HERV-K(HP1)(U87588), B6: HERV-K (P1.10)(U87594),  
HML-3 B7: HERV-K HML-3 (U35236), B8: HERV1 (S66676), B9: RT244(S77583), B10: Seq26 
(AC073115), B11: Seq34 (AL592449), B12: Seq42 (AF047595).  
HML-4  C10: HERV-K HML-4 Seq10 (AF047591), C11: HERV-K-T47D (AF020092).   
HML-5  C9: HERV-K HML-5 (U35161).   
HML-6  A10: HERV-K HML-6 (U60269), A11: Seq38 (AC010328), A12: Seq56 (AC018558).   
HML-8  C5: HERV-K (P3)(AF030047).   
HML-10  C7: Seq31 (AL162734), C8: HERV-K C4 (U07856).  
258 
 
5.15).  In Figure 5.24, which shows a breakdown of PBMCs into individual lymphocyte 
populations, the opposite is shown (although the numbers of samples are limited).  
Here, different cells within the peripheral blood were separated out using paramagnetic 
beads and levels of HERV-K gag in each population were quantified.  Results showed 
the opposite of that observed in 30 patient samples.  What else is present in PBMCs that 
could account for such a contradiction arising?  Monocytes are the other main cell type 
present within peripheral blood, which did not feature in cell separation strategies 
(Section 5.3.3.4).  Monocytes are phagocytic cells that circulate in the blood for a short 
period before maturing into macrophage.  Macrophages play important roles in RA 
disease pathogenesis.  Macrophage-like synoviocytes are activated in disease and play 
pivotal roles in synthesising large quantities of pro-inflammatory cytokines such as IL-
1, IL-6 and TNF-α in addition to upregulating MMPs, proteinases and free-radicals 
(Firestein, 2003).  Additionally, the macrophage-like synoviocytes are the most 
predominant cell type at the cartilage-pannus junction (Chung et al, 2006).  It may be 
that macrophages from blood or macrophage-like synoviocytes harbour the highest 
level of HERVs of all PBMC cell populations.  Whether this allows HERVs to play a 
role in disease pathology, or again, they play a role of bystander activation requires 
further investigation.  Levels of HERV-K gag were also shown to be significantly 
increased in cell populations isolated from the synovial fluid, e.g. Table 4.5.   This was 
supported by increased levels of anti-HERV antibodies being identified within the 
synovial fluid.  This was an important finding as it suggested HERVs were increasingly 
active at the site of disease, supporting their ‘triggering of disease’ role.  The fact that 
HERVs are upregulated at the site of disease however, may be circumstantial. 
RA patients’ lymphocytes are characterised by significantly shortened telomeres 
(Goronzy and Weyand, 2005).  This may be explained via increased levels of HERVs 
contributing to a HERV-specific immune response.  The fact that patients mount an 
antibody response to HERVs on a protein levels, and increased transcriptional activity 
may hint a chronic host response targeting HERVs from an early age.  Such a response 
may lead to the repeated clonal expansion of immune lymphocytes potentially resulting 
in the senescence of T-cells (Goronzy et al., 2006).  This repeated exposure and 
targeting by the immune system may also be reflected in the significantly shortened 
telomeres, potentially caused by a persistent viral antigen such as HERV encoded 
proteins (Pawelec et al., 2005).  This shortening of telomeres is also associated with the 
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major genetic risk factor in RA – the HLA-DRB1 allele further substantiating such a 
link (Schonland et al., 2003). 
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6.1.5 Future work 
 
Hypothesis Synopsis 
T-cell epitope mapping RA disease pathology is T cell dependent, as well as B cell 
dependent (Firestein, 2003).   
Analysis using the TEPITOPE  programme  (Hammer et al., 1997) 
may show alternative anti-HERV responses via T cell pathways 
which may play important roles in RA pathology.  This may also 
identify those antigenic regions that overlapping  with both T and 
B cell epitopes, helping to clarify what constitutes an antigenic 
region. 
Biotinylation of negative 
control peptide (Negcont1) 
How would patient sera react to the biotinylated Negcont1.  Would 
this also result in significant increases in OD values or was this 
effect specific for HERVK peptides. 
Such an investigation would validate the use of biotinylation in 
future ELISA work. 
Identification of discrete 
epitopes in peptides 
Kpr is a peptide of 28 aa’s in length.  Kpr could be synthesised as 
several shorter overlapping peptides in order to identify the 
antigenic epitope on the peptide.  Observing the effect of this upon 
patient sera reactivity may provide hints to both peptide antibody 
recognition mechansms, but also about the location of the discrete 
epitopes themselves. 
Role of HERVs in diseases other 
than Rheumatoid Arthritis 
Appendix IV shows scatter plots of data generated from chronic 
fatigue syndrome patients and their reactivity to the HERV-K 
peptides identified within this research. 
Despite a small sample size (n = 3) this data shows the potential 
for varying levels of expression within this cohort to different 
HERV-K peptides.  Further research is necessary before any 
conclusions can be drawn. 
Investigation of other HERV 
families in RA 
immunopathogenesis. 
Other HERVs of interest include HERV-L, ERV9 (Nakagawa et 
al., 1997) and HERV-E (CD5) (Renaudineau et al., 2005). 
Such investigations may include the generation of CD5+ 
rheumatoid factor producing B cell line (Burastero et al., 1990) in 
order to further investigate the effects of rheumatoid factor upon 
HERV activity. 
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The innate immune response 
and HERVs 
An investigation of interactions between HERVs and innate 
response. 
Such an investigation would identify the role of TLRs in anti-
HERV responses.  Such investigations may involve the 
transfection of retroviral RNA and proteins into cells and the use 
of real-time PCR and gene chip analysis to quantitate levels of 
approopriate TLRs 
HERV‐K K/O experiments in 
synovial tissue/ fibroblast‐like 
synoviocytes 
What would be effects on cells if HERV-K mRNA expression 
were knocked out or suppressed?   
RNA interference could be used to reduce HERV-K activity as 
described previously (Oricchio et al., 2007).  Additional 
approaches including the use of miRNAs to suppress/reduce 
HERV-K gag levels. 
Such work could be carried out in transgenic mouse models 
lacking background HERV activity (Galli et al., 2005).  Changes in 
HERV gene expression would be detected using molecular 
techniques such as genome analysis and quantitative PCR. 
Cell populations harbouring 
HERV‐K 
Which immune cells harbour the highest level of HERV-K gag 
activity? 
In order to further investigate preliminary findings described 
within this report (Section 5.3.3.4) a larger cohort of samples 
should be tested and levels of HERV-K gag quantified using real-
time PCR. 
Identification of the cell type harbouring increases in HERV-K 
may help to identify contributions to disease pathology by HERVs.  
The roles of viral proteins and 
their modulation of HERVs 
The effect of expressing transactivating proteins such as HTLV 
Tax and HIV Tat upon HERV-K gag expression would be 
explored in synoviocytes advancing work described in Section 
5.3.4.1, using real-time PCR.  
HERVs and NF‐ΚB  NF-kB is activated by pro-inflammatory cytokines IL-1β, IL-6 and 
TNF-α.  The effect of modulating NF-ΚB upon HERV-K gag 
activity could be explored. 
Investigation should be broadened to include other pro and non-
inflammatory cytokines. 
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6.2. Conclusions 
 
As the optimistic geneticists of the early 1990’s stated, ‘find the gene, cure the 
disease’ (Salmon and Akbar, 2004), at least one candidate gene is described here.   
The fact that HERV-K gag is significantly upregulated in RA patients, 
compared to disease controls suggests that it may play a role in disease pathology, even 
potentially fulfilling the elusive role of disease trigger.  Until now upregulation of 
HERV-K has only been established in RA patients compared to controls within 
peripheral blood cells (Ejtehadi et al., 2006) and at the site of disease (Ehlhardt et al., 
2006).  In recent years however, the field of molecular biology has been turned upon its 
head with gene expression now known to be far more intricately regulated than 
previously thought (Greally, 2007).  As science delves deeper into the regulatory 
workings of the genome, more repression mechanisms become apparent, with the 
majority operating by complex pathways and mechanisms (Stefani, 2007).  HERV-K 
gag is significantly upregulated in RA patients, particularly in females, on both a 
transcriptional and (although to a lesser extent) on a protein level.  This however does 
not necessarily mean it plays an active role in the disease propagation.  The results 
presented here suggest that HERVs are upregulated (on a transcriptional level) although 
whether or not this is due to other external factors within the joint microenvironment, 
such as expression of other viral pathogens, or components of the immune response 
present within the joint requires further investigation.  Evidence presented here also 
hints that the high levels of HERV-K mRNA may in fact be down-regulated or 
suppressed at the translational level by host or unknown factors.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
263 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 7: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
264 
 
References 
 
ADAMS, B. S., CHA, H. C., CLEARY, J., HAIYING, T., WANG, H., SITWALA, K. 
& MARKOVITZ, D. M. (2003) DEK binding to class II MHC Y-box sequences 
is gene- and allele-specific. Arthritis Res Ther, 5, R226-33. 
AGRAWAL, A., EASTMAN, Q. M. & SCHATZ, D. G. (1998) Transposition mediated 
by RAG1 and RAG2 and its implications for the evolution of the immune 
system. Nature, 394, 744-51. 
ALBERT, L. J. & INMAN, R. D. (1999) Molecular mimicry and autoimmunity. N Engl 
J Med, 341, 2068-74. 
ALIX, A. J. (1999) Predictive estimation of protein linear epitopes by using the 
program PEOPLE. Vaccine, 18, 311-4. 
ALTSCHUL, S. F., MADDEN, T. L., SCHAFFER, A. A., ZHANG, J., ZHANG, Z., 
MILLER, W. & LIPMAN, D. J. (1997) Gapped BLAST and PSI-BLAST: a 
new generation of protein database search programs. Nucleic Acids Res, 25, 
3389-402. 
AMFT, N., CURNOW, S. J., SCHEEL-TOELLNER, D., DEVADAS, A., OATES, J., 
CROCKER, J., HAMBURGER, J., AINSWORTH, J., MATHEWS, J., 
SALMON, M., BOWMAN, S. J. & BUCKLEY, C. D. (2001) Ectopic 
expression of the B cell-attracting chemokine BCA-1 (CXCL13) on endothelial 
cells and within lymphoid follicles contributes to the establishment of germinal 
center-like structures in Sjogren's syndrome. Arthritis Rheum, 44, 2633-41. 
ANDERSSEN, S., SJOTTEM, E., SVINENG, G. & JOHANSEN, T. (1997) 
Comparative analyses of LTRs of the ERV-H family of primate-specific 
retrovirus-like elements isolated from marmoset, African green monkey, and 
man. Virology, 234, 14-30. 
ANDERSSON, A. C., VENABLES, P. J., TONJES, R. R., SCHERER, J., ERIKSSON, 
L. & LARSSON, E. (2002) Developmental expression of HERV-R (ERV3) and 
HERV-K in human tissue. Virology, 297, 220-5. 
ANDERSSON, G., SVENSSON, A. C., SETTERBLAD, N. & RASK, L. (1998) 
Retroelements in the human MHC class II region. Trends Genet, 14, 109-14. 
ANDERSSON, M. L., MEDSTRAND, P., YIN, H. & BLOMBERG, J. (1996) 
Differential expression of human endogenous retroviral sequences similar to 
mouse mammary tumor virus in normal peripheral blood mononuclear cells. 
AIDS Res Hum Retroviruses, 12, 833-40. 
ANTONY, J. M., IZAD, M., BAR-OR, A., WARREN, K. G., VODJGANI, M., 
MALLET, F. & POWER, C. (2006) Quantitative analysis of human endogenous 
retrovirus-W env in neuroinflammatory diseases. AIDS Res Hum Retroviruses, 
22, 1253-9. 
ARAVIN, A., GAIDATZIS, D., PFEFFER, S., LAGOS-QUINTANA, M., 
LANDGRAF, P., IOVINO, N., MORRIS, P., BROWNSTEIN, M. J., 
KURAMOCHI-MIYAGAWA, S., NAKANO, T., CHIEN, M., RUSSO, J. J., 
JU, J., SHERIDAN, R., SANDER, C., ZAVOLAN, M. & TUSCHL, T. (2006) 
A novel class of small RNAs bind to MILI protein in mouse testes. Nature, 442, 
203-7. 
ARAVIN, A. A., HANNON, G. J. & BRENNECKE, J. (2007) The Piwi-piRNA 
pathway provides an adaptive defense in the transposon arms race. Science, 318, 
761-4. 
AREND, W. P., MALYAK, M., GUTHRIDGE, C. J. & GABAY, C. (1998) 
Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol, 16, 27-55. 
265 
 
ARMBRUESTER, V., SAUTER, M., KRAUTKRAEMER, E., MEESE, E., 
KLEIMAN, A., BEST, B., ROEMER, K. & MUELLER-LANTZSCH, N. 
(2002) A novel gene from the human endogenous retrovirus K expressed in 
transformed cells. Clin Cancer Res, 8, 1800-7. 
ARNETT, F. C., EDWORTHY, S. M., BLOCH, D. A., MCSHANE, D. J., FRIES, J. 
F., COOPER, N. S., HEALEY, L. A., KAPLAN, S. R., LIANG, M. H., 
LUTHRA, H. S. & ET AL. (1988) The American Rheumatism Association 
1987 revised criteria for the classification of rheumatoid arthritis. Arthritis 
Rheum, 31, 315-24. 
ARNETT, F. C., REVEILLE, J. D., MOUTSOPOULOS, H. M., GEORGESCU, L. & 
ELKON, K. B. (1996) Ribosomal P autoantibodies in systemic lupus 
erythematosus. Frequencies in different ethnic groups and clinical and 
immunogenetic associations. Arthritis Rheum, 39, 1833-9. 
ASHE, A. & WHITELAW, E. (2007) Another role for RNA: a messenger across 
generations. Trends Genet, 23, 8-10. 
AUGER, I., TOUSSIROT, E. & ROUDIER, J. (1998) HLA-DRB1 motifs and heat 
shock proteins in rheumatoid arthritis. Int Rev Immunol, 17, 263-71. 
AUPPERLE, K. R., BOYLE, D. L., HENDRIX, M., SEFTOR, E. A., ZVAIFLER, N. 
J., BARBOSA, M. AND FIRESTEIN, G. S. (1998) Regulation of synoviocyte 
proliferation, apoptosis, and invasion by the p53 tumor suppressor gene. Am J 
Pathol, 152, 1091-8. 
ARAVIND, L. & KOONIN, E. V. (1999) G-patch: a new conserved domain in 
eukaryotic RNA-processing proteins and type D retroviral polyproteins. Trends 
Biochem Sci, 24, 342-4. 
BALDI, P., BRUNAK, S., CHAUVIN, Y., ANDERSEN, C. A. & NIELSEN, H. 
(2000) Assessing the accuracy of prediction algorithms for classification: an 
overview. Bioinformatics, 16, 412-24. 
BALTIMORE, D. (1970) RNA-dependent DNA polymerase in virions of RNA tumour 
viruses. Nature, 226, 1209-11. 
BALTIMORE, D. (1975) Tumor viruses: 1974. Cold Spring Harb Symp Quant Biol, 39 
Pt 2, 1187-200. 
BANDZIULIS, R. J., SWANSON, M. S. & DREYFUSS, G. (1989) RNA-binding 
proteins as developmental regulators. Genes Dev, 3, 431-7. 
BATTAGLIA, M., PEDRAZZOLI, P., PALERMO, B., LANZA, A., BERTOLINI, F., 
GIBELLI, N., DA PRADA, G. A., ZAMBELLI, A., PEROTTI, C. & 
ROBUSTELLI DELLA CUNA, G. (1998) Epithelial tumour cell detection and 
the unsolved problems of nested RT-PCR: a new sensitive one step method 
without false positive results. Bone Marrow Transplant, 22, 693-8. 
BAUST, C., SEIFARTH, W., SCHON, U., HEHLMANN, R. & LEIB-MOSCH, C. 
(2001) Functional activity of HERV-K-T47D-related long terminal repeats. 
Virology, 283, 262-72. 
BEARDSLEY, D. J., TANG, C., CHEN, B. G., LAMBORN, C., GOMES, E. & 
SRIMATKANDADA, V. (2003) The disulfide-rich region of platelet 
glycoprotein (GP) IIIa contains hydrophilic peptide sequences that bind anti-
GPIIIa autoantibodies from patients with immune thrombocytopenic purpura 
(ITP). Biophys Chem, 105, 503-15. 
BEASLEY, B. E. & HU, W. S. (2002) cis-Acting elements important for retroviral 
RNA packaging specificity. J Virol, 76, 4950-60. 
266 
 
BELSHAW, R., PEREIRA, V., KATZOURAKIS, A., TALBOT, G., PACES, J., 
BURT, A. & TRISTEM, M. (2004) Long-term reinfection of the human 
genome by endogenous retroviruses. Proc Natl Acad Sci U S A, 101, 4894-9. 
BELSHAW, R., DAWSON, A. L., WOOLVEN-ALLEN, J., REDDING, J., BURT, A. 
& TRISTEM, M. (2005) Genomewide screening reveals high levels of 
insertional polymorphism in the human endogenous retrovirus family HERV-
K(HML2): implications for present-day activity. J Virol, 79, 12507-14. 
BENGTSSON, A., BLOMBERG, J., NIVED, O., PIPKORN, R., TOTH, L. & 
STURFELT, G. (1996) Selective antibody reactivity with peptides from human 
endogenous retroviruses and nonviral poly(amino acids) in patients with 
systemic lupus erythematosus. Arthritis Rheum, 39, 1654-63. 
BENGTSSON, M., STAHLBERG, A., RORSMAN, P. & KUBISTA, M. (2005) Gene 
expression profiling in single cells from the pancreatic islets of Langerhans 
reveals lognormal distribution of mRNA levels. Genome Res, 15, 1388-92. 
BENIT, L., DESSEN, P. & HEIDMANN, T. (2001) Identification, phylogeny, and 
evolution of retroviral elements based on their envelope genes. J Virol, 75, 
11709-19. 
BERGER, C., WEBER-BORNHAUSER, S., EGGENBERGER, J., HANES, J., 
PLUCKTHUN, A. & BOSSHARD, H. R. (1999) Antigen recognition by 
conformational selection. FEBS Lett, 450, 149-53. 
BERGLUND, P., STIGHALL, M., JIRSTROM, K., BORGQUIST, S., SJOLANDER, 
A., HEDENFALK, I. & LANDBERG, G. (2005) Cyclin E overexpression 
obstructs infiltrative behavior in breast cancer: a novel role reflected in the 
growth pattern of medullary breast cancers. Cancer Res, 65, 9727-34. 
BERMAN, H. M., BATTISTUZ, T., BHAT, T. N., BLUHM, W. F., BOURNE, P. E., 
BURKHARDT, K., FENG, Z., GILLILAND, G. L., IYPE, L., JAIN, S., 
FAGAN, P., MARVIN, J., PADILLA, D., RAVICHANDRAN, V., 
SCHNEIDER, B., THANKI, N., WEISSIG, H., WESTBROOK, J. D. & 
ZARDECKI, C. (2002) The Protein Data Bank. Acta Crystallogr D Biol 
Crystallogr, 58, 899-907. 
BERNER, B., AKCA, D., JUNG, T., MULLER, G. A. & REUSS-BORST, M. A. 
(2000) Analysis of Th1 and Th2 cytokines expressing CD4+ and CD8+ T cells 
in rheumatoid arthritis by flow cytometry. J Rheumatol, 27, 1128-35. 
BHASKARAN, R. & PONNUSWAMY, P. K. (1988) Positional Flexibilities of 
Amino-Acid Residues in Globular-Proteins. International Journal of Peptide 
and Protein Research, 32, 241-255. 
BIECHE, I., LAURENT, A., LAURENDEAU, I., DURET, L., GIOVANGRANDI, Y., 
FRENDO, J. L., OLIVI, M., FAUSSER, J. L., EVAIN-BRION, D. & VIDAUD, 
M. (2003) Placenta-specific INSL4 expression is mediated by a human 
endogenous retrovirus element. Biol Reprod, 68, 1422-9. 
BIRNEY, E., STAMATOYANNOPOULOS, J. A., DUTTA, A., GUIGO, R., 
GINGERAS, T. R., MARGULIES, E. H., WENG, Z., SNYDER, M., 
DERMITZAKIS, E. T., THURMAN, R. E., KUEHN, M. S., TAYLOR, C. M., 
NEPH, S., KOCH, C. M., ASTHANA, S., MALHOTRA, A., ADZHUBEI, I., 
GREENBAUM, J. A., ANDREWS, R. M., FLICEK, P., BOYLE, P. J., CAO, 
H., CARTER, N. P., CLELLAND, G. K., DAVIS, S., DAY, N., DHAMI, P., 
DILLON, S. C., DORSCHNER, M. O., FIEGLER, H., GIRESI, P. G., GOLDY, 
J., HAWRYLYCZ, M., HAYDOCK, A., HUMBERT, R., JAMES, K. D., 
JOHNSON, B. E., JOHNSON, E. M., FRUM, T. T., ROSENZWEIG, E. R., 
KARNANI, N., LEE, K., LEFEBVRE, G. C., NAVAS, P. A., NERI, F., 
267 
 
PARKER, S. C., SABO, P. J., SANDSTROM, R., SHAFER, A., VETRIE, D., 
WEAVER, M., WILCOX, S., YU, M., COLLINS, F. S., DEKKER, J., LIEB, J. 
D., TULLIUS, T. D., CRAWFORD, G. E., SUNYAEV, S., NOBLE, W. S., 
DUNHAM, I., DENOEUD, F., REYMOND, A., KAPRANOV, P., 
ROZOWSKY, J., ZHENG, D., CASTELO, R., FRANKISH, A., HARROW, J., 
GHOSH, S., SANDELIN, A., HOFACKER, I. L., BAERTSCH, R., KEEFE, D., 
DIKE, S., CHENG, J., HIRSCH, H. A., SEKINGER, E. A., LAGARDE, J., 
ABRIL, J. F., SHAHAB, A., FLAMM, C., FRIED, C., HACKERMULLER, J., 
HERTEL, J., LINDEMEYER, M., MISSAL, K., TANZER, A., WASHIETL, 
S., KORBEL, J., EMANUELSSON, O., PEDERSEN, J. S., HOLROYD, N., 
TAYLOR, R., SWARBRECK, D., MATTHEWS, N., DICKSON, M. C., 
THOMAS, D. J., WEIRAUCH, M. T., GILBERT, J., et al. (2007) Identification 
and analysis of functional elements in 1% of the human genome by the 
ENCODE pilot project. Nature, 447, 799-816. 
BLASCHKE, S., SCHWARZ, G., MONEKE, D., BINDER, L., MULLER, G. & 
REUSS-BORST, M. (2000) Epstein-Barr virus infection in peripheral blood 
mononuclear cells, synovial fluid cells, and synovial membranes of patients 
with rheumatoid arthritis. J Rheumatol, 27, 866-73. 
BLOND, J. L., BESEME, F., DURET, L., BOUTON, O., BEDIN, F., PERRON, H., 
MANDRAND, B. & MALLET, F. (1999) Molecular characterization and 
placental expression of HERV-W, a new human endogenous retrovirus family. J 
Virol, 73, 1175-85. 
BLOND, J. L., LAVILLETTE, D., CHEYNET, V., BOUTON, O., ORIOL, G., 
CHAPEL-FERNANDES, S., MANDRAND, B., MALLET, F. & COSSET, F. 
L. (2000) An envelope glycoprotein of the human endogenous retrovirus 
HERV-W is expressed in the human placenta and fuses cells expressing the type 
D mammalian retrovirus receptor. J Virol, 74, 3321-9. 
BLUTHNER, M., MAHLER, M., MULLER, D. B., DUNZL, H. & BAUTZ, F. A. 
(2000) Identification of an alpha-helical epitope region on the PM/Scl-100 
autoantigen with structural homology to a region on the heterochromatin 
p25beta autoantigen using immobilized overlapping synthetic peptides. J Mol 
Med, 78, 47-54. 
BLYTHE, M. J. & FLOWER, D. R. (2005) Benchmarking B cell epitope prediction: 
underperformance of existing methods. Protein Sci, 14, 246-8. 
BODMAN-SMITH, M. D., CORRIGALL, V. M., KEMENY, D. M. & PANAYI, G. S. 
(2003) BiP, a putative autoantigen in rheumatoid arthritis, stimulates IL-10-
producing CD8-positive T cells from normal individuals. Rheumatology 
(Oxford), 42, 637-44. 
BOGAN, A. A. & THORN, K. S. (1998) Anatomy of hot spots in protein interfaces. J 
Mol Biol, 280, 1-9. 
BOLLER, K., JANSSEN, O., SCHULDES, H., TONJES, R. R. & KURTH, R. (1997) 
Characterization of the antibody response specific for the human endogenous 
retrovirus HTDV/HERV-K. J Virol, 71, 4581-8. 
BONNER, T. I., O'CONNELL, C. & COHEN, M. (1982) Cloned endogenous retroviral 
sequences from human DNA. Proc Natl Acad Sci U S A, 79, 4709-13. 
BORG, A. A. (1997) Antibodies to cytokeratins in inflammatory arthropathies. Semin 
Arthritis Rheum, 27, 186-95. 
BORMAN, A. M., QUILLENT, C., CHARNEAU, P., DAGUET, C., CLAVEL, F. 
(1995) Human immunodeficiency virus type 1 Vif-mutant particles from 
268 
 
restrictive cells: role of Vif in correct particle assembly and infectivity.  J Virol, 
69, 2058-67. 
BRAND, A., GRIFFITHS, D. J., HERVE, C., MALLON, E. & VENABLES, P. J. 
(1999) Human retrovirus-5 in rheumatic disease. J Autoimmun, 13, 149-54. 
BRAND, D. D., KANG, A. H. & ROSLONIEC, E. F. (2004) The mouse model of 
collagen-induced arthritis. Methods Mol Med, 102, 295-312. 
BRANDEN C. & TOOZE., J. (1999) Introduction to Protein structure, London, 
Routledge. 
BRENDEL, V., DOHLMAN, J., BLAISDELL, B. E. & KARLIN, S. (1991) Very long 
charge runs in systemic lupus erythematosus-associated autoantigens. Proc Natl 
Acad Sci U S A, 88, 1536-40. 
BRODSKY, I., FOLEY, B., HAINES, D., JOHNSTON, J., CUDDY, K. & 
GILLESPIE, D. (1993) Expression of HERV-K proviruses in human 
leukocytes. Blood, 81, 2369-74. 
BRODY, J. R. & KERN, S. E. (2004) Sodium boric acid: a Tris-free, cooler conductive 
medium for DNA electrophoresis. Biotechniques, 36, 214-6. 
BROWNING, M. T., SCHMIDT, R. D., LEW, K. A. & RIZVI, T. A. (2001) Primate 
and feline lentivirus vector RNA packaging and propagation by heterologous 
lentivirus virions. J Virol, 75, 5129-40. 
BUCKLEY, C. D. (2003) Michael Mason prize essay 2003. Why do leucocytes 
accumulate within chronically inflamed joints? Rheumatology (Oxford), 42, 
1433-44. 
BUCKLEY, C. D., AMFT, N., BRADFIELD, P. F., PILLING, D., ROSS, E., 
ARENZANA-SEISDEDOS, F., AMARA, A., CURNOW, S. J., LORD, J. M., 
SCHEEL-TOELLNER, D. & SALMON, M. (2000) Persistent induction of the 
chemokine receptor CXCR4 by TGF-beta 1 on synovial T cells contributes to 
their accumulation within the rheumatoid synovium. J Immunol, 165, 3423-9. 
BUCKLEY, C. D., FILER, A., HAWORTH, O., PARSONAGE, G. & SALMON, M. 
(2004) Defining a role for fibroblasts in the persistence of chronic inflammatory 
joint disease. Ann Rheum Dis, 63 Suppl 2, ii92-ii95. 
BUSHMAN, F. D. (2003) Targeting survival: integration site selection by retroviruses 
and LTR-retrotransposons. Cell, 115, 135-8. 
BUSTIN, S. A. (2000) Absolute quantification of mRNA using real-time reverse 
transcription polymerase chain reaction assays. J Mol Endocrinol, 25, 169-93. 
BUSTIN, S. A. & NOLAN, T. (2004) Pitfalls of quantitative real-time reverse-
transcription polymerase chain reaction. J Biomol Tech, 15, 155-66. 
BUTLER, J. E., PETERMAN, J. H., SUTER, M. & DIERKS, S. E. (1987) The 
immunochemistry of solid-phase sandwich enzyme-linked immunosorbent 
assays. Fed Proc, 46, 2548-56. 
C. ELEGANS GENOME SEQUENCING CONSORTIUM (1998) Genome sequence of 
the nematode C. elegans: a platform for investigating biology. Science, 282, 
2012-8. 
CAMPILLOS, M., DOERKS, T., SHAH, P. K. & BORK, P. (2006) Computational 
characterization of multiple Gag-like human proteins. Trends Genet, 22, 585-9. 
CANTARERO, L. A., BUTLER, J. E. & OSBORNE, J. W. (1980) The adsorptive 
characteristics of proteins for polystyrene and their significance in solid-phase 
imunoassays. Anal Biochem, 105, 375-82. 
CANTRELL, M. A., EDERER, M. M., ERICKSON, I. K., SWIER, V. J., BAKER, R. 
J. & WICHMAN, H. A. (2005) MysTR: an endogenous retrovirus family in 
269 
 
mammals that is undergoing recent amplifications to unprecedented copy 
numbers. J Virol, 79, 14698-707. 
CARASSO, R., SANDBANK, U. & COHN, D. (1976) Electron microscopy findings in 
familial hypokalemic periodic paralysis. Harefuah, 90, 115-7. 
CASH, J. D. & MCGILL, R. C. (1969) Fibrinolytic response to moderate exercise in 
young male diabetics and non-diabetics. J Clin Pathol, 22, 32-5. 
CATRINA, A. I., ULFGREN, A. K., LINDBLAD, S., GRONDAL, L. & 
KLARESKOG, L. (2002) Low levels of apoptosis and high FLIP expression in 
early rheumatoid arthritis synovium. Ann Rheum Dis, 61, 934-6. 
CERNY, E. H., FARSHY, C. E., HUNTER, E. F. & LARSEN, S. A. (1985) 
Rheumatoid factor in syphilis. J Clin Microbiol, 22, 89-94. 
CERTO, J. L., KABDULOV, T. O., PAULSON, M. L., ANDERSON, J. A. & HU, W. 
S. (1999) The nucleocapsid domain is responsible for the ability of spleen 
necrosis virus (SNV) Gag polyprotein to package both SNV and murine 
leukemia virus RNA. J Virol, 73, 9170-7. 
CHACON, N., LOSADA, S., BERMUDEZ, H., CESARI, I. M., HOEBEKE, J. & 
NOYA, O. (2003) Immunogenicity of polymerizable synthetic peptides derived 
from a vaccine candidate against schistosomiasis: the asparaginyl endopeptidase 
(Sm32). Immunol Lett, 88, 199-210. 
CHAMES, P., HOOGENBOOM, H. R. & HENDERIKX, P. (2002) Selection of 
antibodies against biotinylated antigens. Methods Mol Biol, 178, 147-57. 
CHAN W.C. & WHITE, P. D. (Eds.) (2000) Fmoc Solid Phase Peptide Synthesis: A 
Practical Approach, New York, Oxford University Press. 
CHANG, X., YAMADA, R. & YAMAMOTO, K. (2005) Inhibition of antithrombin by 
hyaluronic acid may be involved in the pathogenesis of rheumatoid arthritis. 
Arthritis Res Ther, 7, R268-73. 
CHECK, E. (2007) Genome project turns up evolutionary surprises. Nature, 447, 760-
1. 
CHEN, H. J., CARR, K., JEROME, R. E. & EDENBERG, H. J. (2002) A retroviral 
repetitive element confers tissue-specificity to the human alcohol 
dehydrogenase 1C (ADH1C) gene. DNA Cell Biol, 21, 793-801. 
CHIU, Y. L. AND GREENE, W. C. (2008) The APOBEC3 cytidine deaminases: an 
innate defensive network opposing exogenous retroviruses and endogenous 
retroelements.  Annu Rev Immunol, 26, 317-53. 
CHOU, P. Y. & FASMAN, G. D. (1974) Conformational parameters for amino acids in 
helical, beta-sheet, and random coil regions calculated from proteins. 
Biochemistry, 13, 211-22. 
CHOY, E. H. & PANAYI, G. S. (2001) Cytokine pathways and joint inflammation in 
rheumatoid arthritis. N Engl J Med, 344, 907-16. 
CHRISTIAN, C. L. (1998) The discovery of the rheumatoid factor. II. Rose, Ragan, 
Pearce & Lipman. 1948. Clin Exp Rheumatol, 16, 345-9. 
CHUNG, E. Y., KIM, S. J. & MA, X. J. (2006) Regulation of cytokine production 
during phagocytosis of apoptotic cells. Cell Res, 16, 154-61. 
CIANCIOLO, G. J., COPELAND, T. D., OROSZLAN, S. & SNYDERMAN, R. 
(1985) Inhibition of lymphocyte proliferation by a synthetic peptide 
homologous to retroviral envelope proteins. Science, 230, 453-5. 
CLAUSEN, B. E., BRIDGES, S. L., JR., LAVELLE, J. C., FOWLER, P. G., GAY, S., 
KOOPMAN, W. J. & SCHROEDER, H. W., JR. (1998) Clonally-related 
immunoglobulin VH domains and nonrandom use of DH gene segments in 
rheumatoid arthritis synovium. Mol Med, 4, 240-57. 
270 
 
CLAVERIE, J. & NOTREDAME, C. (2006) Bioinformatics for Dummies, London, 
John Wiley & Sons. 
COFFIN J. M., HUGHES S. H & VARMUS, H. E. (Eds.) (1999) Retroviruses, 
Woodbury, Cold Spring Harbor Laboratory Press. 
COHEN, M., POWERS, M., O'CONNELL, C. & KATO, N. (1985) The nucleotide 
sequence of the env gene from the human provirus ERV3 and isolation and 
characterization of an ERV3-specific cDNA. Virology, 147, 449-58. 
COLE, G. A., HOGG, T. L. & WOODLAND, D. L. (1995) T cell recognition of the 
immunodominant Sendai virus NP324-332/Kb epitope is focused on the center 
of the peptide. J Immunol, 155, 2841-8. 
COLMEGNA, I. & GARRY, R. F. (2006) Role of endogenous retroviruses in 
autoimmune diseases. Infect Dis Clin North Am, 20, 913-29. 
CONRAD, B., WEIDMANN, E., TRUCCO, G., RUDERT, W. A., BEHBOO, R., 
RICORDI, C., RODRIQUEZ-RILO, H., FINEGOLD, D. & TRUCCO, M. 
(1994) Evidence for superantigen involvement in insulin-dependent diabetes 
mellitus aetiology. Nature, 371, 351-5. 
CONRAD, B., WEISSMAHR, R. N., BONI, J., ARCARI, R., SCHUPBACH, J. & 
MACH, B. (1997) A human endogenous retroviral superantigen as candidate 
autoimmune gene in type I diabetes. Cell, 90, 303-13. 
CONRAD, K. & SCHLOSLER, W. (2002) Autoantibodies in systemic autoimmune 
disease, Berlin, Pabst Science Publishers. 
CORDONNIER, A., CASELLA, J. F. & HEIDMANN, T. (1995) Isolation of novel 
human endogenous retrovirus-like elements with foamy virus-related pol 
sequence. J Virol, 69, 5890-7. 
CORRIGALL, V. M. & PANAYI, G. S. (2002) Autoantigens and immune pathways in 
rheumatoid arthritis. Crit Rev Immunol, 22, 281-93. 
CREIGHTON, T. E. (1992) Protein folding. Up the kinetic pathway. Nature, 356, 194-
5. 
CROWTHER J.R. (Ed.) (2000) The ELISA Guidebook, Vienna, Humana Press. 
CUFF, J. A. & BARTON, G. J. (1999) Evaluation and improvement of multiple 
sequence methods for protein secondary structure prediction. Proteins, 34, 508-
19. 
CUTOLO, M., SULLI, A., VILLAGGIO, B., SERIOLO, B. & ACCARDO, S. (1998) 
Relations between steroid hormones and cytokines in rheumatoid arthritis and 
systemic lupus erythematosus. Ann Rheum Dis, 57, 573-7. 
CUTOLO, M., VILLAGGIO, B., CRAVIOTTO, C., PIZZORNI, C., SERIOLO, B. & 
SULLI, A. (2002) Sex hormones and rheumatoid arthritis. Autoimmun Rev, 1, 
284-9. 
CYRANOWSKI, J. M., FRANK, E., WINTER, E., RUCCI, P., NOVICK, D., 
PILKONIS, P., FAGIOLINI, A., SWARTZ, H. A., HOUCK, P. & KUPFER, D. 
J. (2004) Personality pathology and outcome in recurrently depressed women 
over 2 years of maintenance interpersonal psychotherapy. Psychol Med, 34, 
659-69. 
D'ARPA, P., MACHLIN, P. S., RATRIE, H., 3RD, ROTHFIELD, N. F., 
CLEVELAND, D. W. & EARNSHAW, W. C. (1988) cDNA cloning of human 
DNA topoisomerase I: catalytic activity of a 67.7-kDa carboxyl-terminal 
fragment. Proc Natl Acad Sci U S A, 85, 2543-7. 
DANIS, V. A., FRANIC, G. M., RATHJEN, D. A., LAURENT, R. M. & BROOKS, P. 
M. (1992) Circulating cytokine levels in patients with rheumatoid arthritis: 
results of a double blind trial with sulphasalazine. Ann Rheum Dis, 51, 946-50. 
271 
 
DAVARI EJTEHADI, H., FREIMANIS, G. L., ALI, H. A., BOWMAN, S., ALAVI, 
A., AXFORD, J., PERERA, S. A., CALLAGHAN, R. & NELSON, P. N. 
(2005) The potential role of human endogenous retrovirus K10 in pathogenesis 
of rheumatoid arthritis: a preliminary study. Ann Rheum Dis. 
DAVIS, L. S., CUSH, J. J., SCHULZE-KOOPS, H. & LIPSKY, P. E. (2001) 
Rheumatoid synovial CD4+ T cells exhibit a reduced capacity to differentiate 
into IL-4-producing T-helper-2 effector cells. Arthritis Res, 3, 54-64. 
DAY, R. (2002) Adverse reactions to TNF-alpha inhibitors in rheumatoid arthritis. 
Lancet, 359, 540-1. 
DE CASTRO, J. M. & BALAGURA, S. (1976) Insulin pretreatment facilitates 
recovery after dorsal hippocampal lesions. Physiol Behav, 16, 517-20. 
DE PARSEVAL, N., ALKABBANI, H. & HEIDMANN, T. (1999) The long terminal 
repeats of the HERV-H human endogenous retrovirus contain binding sites for 
transcriptional regulation by the Myb protein. J Gen Virol, 80 ( Pt 4), 841-5. 
DEAS, J. E., LIU, L. G., THOMPSON, J. J., SANDER, D. M., SOBLE, S. S., 
GARRY, R. F. & GALLAHER, W. R. (1998) Reactivity of sera from systemic 
lupus erythematosus and Sjogren's syndrome patients with peptides derived 
from human immunodeficiency virus p24 capsid antigen. Clin Diagn Lab 
Immunol, 5, 181-5. 
DECANNIERE, K., DESMYTER, A., LAUWEREYS, M., GHAHROUDI, M. A., 
MUYLDERMANS, S. & WYNS, L. (1999) A single-domain antibody fragment 
in complex with RNase A: non-canonical loop structures and nanomolar affinity 
using two CDR loops. Structure, 7, 361-70. 
DEEN, K. C. & SWEET, R. W. (1986) Murine mammary tumor virus pol-related 
sequences in human DNA: characterization and sequence comparison with the 
complete murine mammary tumor virus pol gene. J Virol, 57, 422-32. 
DELANO, W. L., ULTSCH, M. H., DE VOS, A. M. & WELLS, J. A. (2000) 
Convergent solutions to binding at a protein-protein interface. Science, 287, 
1279-83. 
DELVES, P. J. & ROITT, I. M. (2000) The Immune System- First of Two Parts. 
DHEDA, K., HUGGETT, J. F., CHANG, J. S., KIM, L. U., BUSTIN, S. A., 
JOHNSON, M. A., ROOK, G. A. & ZUMLA, A. (2005) The implications of 
using an inappropriate reference gene for real-time reverse transcription PCR 
data normalization. Anal Biochem, 344, 141-3. 
DIEFFENBACH, C. W., T.M.J. LOWE & G.S.DVEKSLER. (1995) General concepts 
of primer design. IN C.W.DIEFFENBACH & DVEKSLER, G. S. (Eds.) PCR 
Primer: A laboratory manual. 1 ed., CSHL Press. 
DIERKS, S. E., BUTLER, J. E. & RICHERSON, H. B. (1986) Altered recognition of 
surface-adsorbed compared to antigen-bound antibodies in the ELISA. Mol 
Immunol, 23, 403-11. 
DIKE, L. E. & FARMER, S. R. (1988) Cell adhesion induces expression of growth-
associated genes in suspension-arrested fibroblasts. Proc Natl Acad Sci U S A, 
85, 6792-6. 
DINARELLO, C. A. (1996) Biologic basis for interleukin-1 in disease. Blood, 87, 
2095-147. 
DITTMER, A., VETTER, M., SCHUNKE, D., SPAN, P. N., SWEEP, F., 
THOMSSEN, C. & DITTMER, J. (2006) Parathyroid hormone-related protein 
regulates tumor-relevant genes in breast cancer cells. J Biol Chem, 281, 14563-
72. 
272 
 
DONG, Y. B., CHENG, J. Y., HUANG, R. Q., SMITH, M. D. & ZUR LOYE, H. C. 
(2003) Self-assembly of coordination polymers from AgX (X = SbF(6)(-), 
PF(6)(-), and CF(3)SO(3)(-)) and oxadiazole-containing ligands. Inorg Chem, 
42, 5699-706. 
DONNES, P. & ELOFSSON, A. (2002) Prediction of MHC class I binding peptides, 
using SVMHC. BMC Bioinformatics, 3, 25. 
DORAN, M. F., POND, G. R., CROWSON, C. S., O'FALLON, W. M. & GABRIEL, 
S. E. (2002) Trends in incidence and mortality in rheumatoid arthritis in 
Rochester, Minnesota, over a forty-year period. Arthritis Rheum, 46, 625-31. 
DORNER, T. (2006) Crossroads of B cell activation in autoimmunity: rationale of 
targeting B cells. J Rheumatol Suppl, 77, 3-11. 
DOUVAS, A., TAKEHANA, Y., EHRESMANN, G., CHERNYOVSKIY, T. & 
DAAR, E. S. (1996) Neutralization of HIV type 1 infectivity by serum 
antibodies from a subset of autoimmune patients with mixed connective tissue 
disease. AIDS Res Hum Retroviruses, 12, 1509-17. 
DUKE, O., PANAYI, G. S., JANOSSY, G. & POULTER, L. W. (1982) An 
immunohistological analysis of lymphocyte subpopulations and their 
microenvironment in the synovial membranes of patients with rheumatoid 
arthritis using monoclonal antibodies. Clin Exp Immunol, 49, 22-30. 
DUNN, C. A. & MAGER, D. L. (2005) Transcription of the human and rodent SPAM1 
/ PH-20 genes initiates within an ancient endogenous retrovirus. BMC 
Genomics, 6, 47. 
DUNN, C. A., MEDSTRAND, P. & MAGER, D. L. (2003) An endogenous retroviral 
long terminal repeat is the dominant promoter for human beta1,3-
galactosyltransferase 5 in the colon. Proc Natl Acad Sci U S A, 100, 12841-6. 
EDWARDS, J. C., CAMBRIDGE, G. & ABRAHAMS, V. M. (1999) Do self-
perpetuating B lymphocytes drive human autoimmune disease? Immunology, 
97, 188-96. 
EDWARDS, J. C., CAMBRIDGE, G. & LEANDRO, M. J. (2006) B cell depletion 
therapy in rheumatic disease. Best Pract Res Clin Rheumatol, 20, 915-28. 
EGGLETON, P., WARD, F. J., JOHNSON, S., KHAMASHTA, M. A., HUGHES, G. 
R., HAJELA, V. A., MICHALAK, M., CORBETT, E. F., STAINES, N. A. & 
REID, K. B. (2000) Fine specificity of autoantibodies to calreticulin: epitope 
mapping and characterization. Clin Exp Immunol, 120, 384-91. 
EHLHARDT, S., SEIFERT, M., SCHNEIDER, J., OJAK, A., ZANG, K. D. & 
MEHRAEIN, Y. (2006) Human endogenous retrovirus HERV-K(HML-2) Rec 
expression and transcriptional activities in normal and rheumatoid arthritis 
synovia. J Rheumatol, 33, 16-23. 
EHRENSTEIN, M. R., EVANS, J. G., SINGH, A., MOORE, S., WARNES, G., 
ISENBERG, D. A. & MAURI, C. (2004) Compromised function of regulatory 
T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp 
Med, 200, 277-85. 
EJTEHADI, H. D., FREIMANIS, G. L., ALI, H. A., BOWMAN, S., ALAVI, A., 
AXFORD, J., CALLAGHAN, R. & NELSON, P. N. (2006) The potential role 
of human endogenous retrovirus K10 in the pathogenesis of rheumatoid 
arthritis: a preliminary study. Ann Rheum Dis, 65, 612-6. 
ELKON, K., SKELLY, S., PARNASSA, A., MOLLER, W., DANHO, W., 
WEISSBACH, H. & BROT, N. (1986) Identification and chemical synthesis of 
a ribosomal protein antigenic determinant in systemic lupus erythematosus. 
Proc Natl Acad Sci U S A, 83, 7419-23. 
273 
 
EMINI, E. A., HUGHES, J. V., PERLOW, D. S. & BOGER, J. (1985) Induction of 
hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. J 
Virol, 55, 836-9. 
ENCODE PROJECT CONSORTIUM (2007) Identification and analysis of functional 
elements in 1% of the human genome by the ENCODE pilot project. Nature, 
447, 799-816. 
ENGVALL, E. & PERLMANN, P. (1972) Enzyme-linked immunosorbent assay, Elisa. 
3. Quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin 
in antigen-coated tubes. J Immunol, 109, 129-35. 
EVANS, C. F., HORWITZ, M. S., HOBBS, M. V. & OLDSTONE, M. B. (1996) Viral 
infection of transgenic mice expressing a viral protein in oligodendrocytes leads 
to chronic central nervous system autoimmune disease. J Exp Med, 184, 2371-
84. 
FARMERIE, W. G., LOEB, D. D., CASAVANT, N. C., HUTCHISON, C. A., 3RD, 
EDGELL, M. H. AND SWANSTROM, R. (1987) Expression and processing of 
the AIDS virus reverse transcriptase in Escherichia coli. Science, 236, 305-8. 
FASSBENDER, H. G. (1983) Histomorphological basis of articular cartilage 
destruction in rheumatoid arthritis. Coll Relat Res, 3, 141-55. 
FELDMANN, M., BRENNAN, F. M. & MAINI, R. N. (1996) Rheumatoid arthritis. 
Cell, 85, 307-10. 
FELSON, D. T., ANDERSON, J. J., BOERS, M., BOMBARDIER, C., FURST, D., 
GOLDSMITH, C., KATZ, L. M., LIGHTFOOT, R., JR., PAULUS, H., 
STRAND, V. & ET AL. (1995) American College of Rheumatology. 
Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum, 
38, 727-35. 
FIELDS, G. B. & NOBLE, R. L. (1990) Solid phase peptide synthesis utilizing 9-
fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res, 35, 161-214. 
FIRESTEIN, G. S. (1999) Starving the synovium: angiogenesis and inflammation in 
rheumatoid arthritis. J Clin Invest, 103, 3-4. 
FIRESTEIN, G. S. (2003) Evolving concepts of rheumatoid arthritis. Nature, 423, 356-
61. 
FIRESTEIN, G. S. & ZVAIFLER, N. J. (2002) How important are T cells in chronic 
rheumatoid synovitis?: II. T cell-independent mechanisms from beginning to 
end. Arthritis Rheum, 46, 298-308. 
FISCHER, P. M. & HOWDEN, M. E. (1990) Direct enzyme-linked immunosorbent 
assay of anti-peptide antibodies using capture of biotinylated peptides by 
immobilized avidin. J Immunoassay, 11, 311-27. 
FLEISCHER, B. (1991) Stimulation of human T cells by microbial 'superantigens'. 
Immunol Res, 10, 349-55. 
FLOWER, D. R. (2003) Towards in silico prediction of immunogenic epitopes. Trends 
Immunol, 24, 667-74. 
FLUGEL, R. M., RETHWILM, A., MAURER, B. & DARAI, G. (1987) Nucleotide 
sequence analysis of the env gene and its flanking regions of the human 
spumaretrovirus reveals two novel genes. Embo J, 6, 2077-84. 
FOURNEL, S. & MULLER, S. (2003) Synthetic peptides in the diagnosis of systemic 
autoimmune diseases. Curr Protein Pept Sci, 4, 261-74. 
FRANKLIN, G. C., CHRETIEN, S., HANSON, I. M., ROCHEFORT, H., MAY, F. E. 
& WESTLEY, B. R. (1988) Expression of human sequences related to those of 
mouse mammary tumor virus. J Virol, 62, 1203-10. 
274 
 
FRITSCH, R., ESELBOCK, D., SKRINER, K., JAHN-SCHMID, B., 
SCHEINECKER, C., BOHLE, B., TOHIDAST-AKRAD, M., HAYER, S., 
NEUMULLER, J., PINOL-ROMA, S., SMOLEN, J. S. & STEINER, G. (2002) 
Characterization of autoreactive T cells to the autoantigens heterogeneous 
nuclear ribonucleoprotein A2 (RA33) and filaggrin in patients with rheumatoid 
arthritis. J Immunol, 169, 1068-76. 
FU, W., GORELICK, R. J. & REIN, A. (1994) Characterization of human 
immunodeficiency virus type 1 dimeric RNA from wild-type and protease-
defective virions. J Virol, 68, 5013-8. 
FU, Y. X., HUANG, G., WANG, Y. & CHAPLIN, D. D. (1998) B lymphocytes induce 
the formation of follicular dendritic cell clusters in a lymphotoxin alpha-
dependent fashion. J Exp Med, 187, 1009-18. 
FUJIWARA, R., KUTSUMI, Y., HAYASHI, T., NISHIO, H., KOSHINO, Y., 
SHIMADA, Y., NAKAI, T. & MIYABO, S. (1995) Relation of 
angiographically defined coronary artery disease and plasma concentrations of 
insulin, lipid, and apolipoprotein in normolipidemic subjects with varying 
degrees of glucose tolerance. Am J Cardiol, 75, 122-6. 
GALBRAITH, D. N., KELLY, H. T., DYKE, A., REID, G., HAWORTH, C., 
BEEKMAN, J., SHEPHERD, A. & SMITH, K. T. (2000) Design and validation 
of immunological tests for the detection of Porcine endogenous retrovirus in 
biological materials. J Virol Methods, 90, 115-24. 
GALLI, U. M., SAUTER, M., LECHER, B., MAURER, S., HERBST, H., ROEMER, 
K. & MUELLER-LANTZSCH, N. (2005) Human endogenous retrovirus rec 
interferes with germ cell development in mice and may cause carcinoma in situ, 
the predecessor lesion of germ cell tumors. Oncogene, 24, 3223-8. 
GARCIA, K. C., RONCO, P. M., VERROUST, P. J., BRUNGER, A. T. & AMZEL, L. 
M. (1992) Three-dimensional structure of an angiotensin II-Fab complex at 3 A: 
hormone recognition by an anti-idiotypic antibody. Science, 257, 502-7. 
GAUDIN, P., IJAZ, S., TUKE, P. W., MARCEL, F., PARAZ, A., SEIGNEURIN, J. 
M., MANDRAND, B., PERRON, H. & GARSON, J. A. (2000) Infrequency of 
detection of particle-associated MSRV/HERV-W RNA in the synovial fluid of 
patients with rheumatoid arthritis. Rheumatology (Oxford), 39, 950-4. 
GEILER, T., KRIEGSMANN, J., KEYSZER, G. M., GAY, R. E. & GAY, S. (1994) A 
new model for rheumatoid arthritis generated by engraftment of rheumatoid 
synovial tissue and normal human cartilage into SCID mice. Arthritis Rheum, 
37, 1664-71. 
GENDI, N. S., GIBSON, K. & WORDSWORTH, B. P. (1996) Effect of HLA type and 
hypocomplementaemia on the expression of parvovirus arthritis: one year 
follow up of an outbreak. Ann Rheum Dis, 55, 63-5. 
GENOVESE, M. C., BECKER, J. C., SCHIFF, M., LUGGEN, M., SHERRER, Y., 
KREMER, J., BIRBARA, C., BOX, J., NATARAJAN, K., NUAMAH, I., LI, 
T., ARANDA, R., HAGERTY, D. T. & DOUGADOS, M. (2005) Abatacept for 
rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl 
J Med, 353, 1114-23. 
GIBBS, W. W. (2003) The unseen genome: gems among the junk. Sci Am, 289, 26-33. 
GIBELLINI, D., VITONE, F., SCHIAVONE, P., PONTI, C., LA PLACA, M. & RE, 
M. C. (2004) Quantitative detection of human immunodeficiency virus type 1 
(HIV-1) proviral DNA in peripheral blood mononuclear cells by SYBR green 
real-time PCR technique. J Clin Virol, 29, 282-9. 
275 
 
GIFFORD, R., KABAT, P., MARTIN, J., LYNCH, C. & TRISTEM, M. (2005) 
Evolution and distribution of class II-related endogenous retroviruses. J Virol, 
79, 6478-86. 
GIFFORD, R. & TRISTEM, M. (2003) The evolution, distribution and diversity of 
endogenous retroviruses. Virus Genes, 26, 291-315. 
GINZINGER, D. G. (2002) Gene quantification using real-time quantitative PCR: an 
emerging technology hits the mainstream. Exp Hematol, 30, 503-12. 
GIRARD, A., SACHIDANANDAM, R., HANNON, G. J. & CARMELL, M. A. (2006) 
A germline-specific class of small RNAs binds mammalian Piwi proteins. 
Nature, 442, 199-202. 
GOBERDHAN, D. C. & WILSON, C. (2003) PTEN: tumour suppressor, 
multifunctional growth regulator and more. Hum Mol Genet, 12 Spec No 2, 
R239-48. 
GOLDBACH-MANSKY, R., LEE, J., MCCOY, A., HOXWORTH, J., YARBORO, 
C., SMOLEN, J. S., STEINER, G., ROSEN, A., ZHANG, C., MENARD, H. A., 
ZHOU, Z. J., PALOSUO, T., VAN VENROOIJ, W. J., WILDER, R. L., 
KLIPPEL, J. H., SCHUMACHER, H. R., JR. & EL-GABALAWY, H. S. 
(2000) Rheumatoid arthritis associated autoantibodies in patients with synovitis 
of recent onset. Arthritis Res, 2, 236-43. 
GOLDBLATT, F. & ISENBERG, D. A. (2005) New therapies for rheumatoid arthritis. 
Clin Exp Immunol, 140, 195-204. 
GOLDSMITH, M. A., WARMERDAM, M. T., ATCHISON, R. E., MILLER, M. D., 
AND GREENE, W. C. (1995). Dissociation of the CD4 downregulation and 
viral infectivity enhancement functions of human immunodeficiency virus type 1 
Nef. J Virol,  69, 4112-4121. 
GONZALEZ-BUITRAGO, J. M. & GONZALEZ, C. (2006) Present and future of the 
autoimmunity laboratory. Clin Chim Acta, 365, 50-7. 
GORONZY, J. J., FUJII, H. & WEYAND, C. M. (2006) Telomeres, immune aging and 
autoimmunity. Exp Gerontol, 41, 246-51. 
GORONZY, J. J., MATTESON, E. L., FULBRIGHT, J. W., WARRINGTON, K. J., 
CHANG-MILLER, A., HUNDER, G. G., MASON, T. G., NELSON, A. M., 
VALENTE, R. M., CROWSON, C. S., ERLICH, H. A., REYNOLDS, R. L., 
SWEE, R. G., O'FALLON, W. M. & WEYAND, C. M. (2004) Prognostic 
markers of radiographic progression in early rheumatoid arthritis. Arthritis 
Rheum, 50, 43-54. 
GORONZY, J. J. & WEYAND, C. M. (2005) Rheumatoid arthritis. Immunol Rev, 204, 
55-73. 
GORONZY, J. J., ZETTL, A. & WEYAND, C. M. (1998) T cell receptor repertoire in 
rheumatoid arthritis. Int Rev Immunol, 17, 339-63. 
GOVINDARAJAN, K. R., KANGUEANE, P., TAN, T. W. & RANGANATHAN, S. 
(2003) MPID: MHC-Peptide Interaction Database for sequence-structure-
function information on peptides binding to MHC molecules. Bioinformatics, 
19, 309-10. 
GRANTHAM, R. (1974) Amino acid difference formula to help explain protein 
evolution. Science, 185, 862-4. 
GRASSI, W., DE ANGELIS, R., LAMANNA, G. & CERVINI, C. (1998) The clinical 
features of rheumatoid arthritis. Eur J Radiol, 27 Suppl 1, S18-24. 
GRAVALLESE, E. M. (2002) Bone destruction in arthritis. Ann Rheum Dis, 61 Suppl 
2, ii84-6. 
276 
 
GREALLY, J. M. (2007) Genomics: Encyclopaedia of humble DNA. Nature, 447, 782-
3. 
GREENBAUM, J. A., ANDERSEN, P. H., BLYTHE, M., BUI, H. H., CACHAU, R. 
E., CROWE, J., DAVIES, M., KOLASKAR, A. S., LUND, O., MORRISON, 
S., MUMEY, B., OFRAN, Y., PELLEQUER, J. L., PINILLA, C., 
PONOMARENKO, J. V., RAGHAVA, G. P., VAN REGENMORTEL, M. H., 
ROGGEN, E. L., SETTE, A., SCHLESSINGER, A., SOLLNER, J., ZAND, M. 
& PETERS, B. (2007) Towards a consensus on datasets and evaluation metrics 
for developing B-cell epitope prediction tools. J Mol Recognit, 20, 75-82. 
GRIESMACHER, A. & PEICHL, P. (2001) Autoantibodies associated with rheumatic 
diseases. Clin Chem Lab Med, 39, 189-208. 
GRIFFITHS, D. J., COOKE, S. P., HERVE, C., RIGBY, S. P., MALLON, E., 
HAJEER, A., LOCK, M., EMERY, V., TAYLOR, P., PANTELIDIS, P., 
BUNKER, C. B., DU BOIS, R., WEISS, R. A. & VENABLES, P. J. (1999) 
Detection of human retrovirus 5 in patients with arthritis and systemic lupus 
erythematosus. Arthritis Rheum, 42, 448-54. 
GUNSON, R., GILLESPIE, G. & W, F. C. (2003) Optimisation of PCR reactions using 
primer chessboarding. J Clin Virol, 26, 369-73. 
HAIN, N. A., STUHLMULLER, B., HAHN, G. R., KALDEN, J. R., DEUTZMANN, 
R. & BURMESTER, G. R. (1996) Biochemical characterization and 
microsequencing of a 205-kDa synovial protein stimulatory for T cells and 
reactive with rheumatoid factor containing sera. J Immunol, 157, 1773-80. 
HAMMER, J., STURNIOLO, T. & SINIGAGLIA, F. (1997) HLA class II peptide 
binding specificity and autoimmunity. Adv Immunol, 66, 67-100. 
HANAOKA, R., KASAMA, T., MURAMATSU, M., YAJIMA, N., SHIOZAWA, F., 
MIWA, Y., NEGISHI, M., IDE, H., MIYAOKA, H., UCHIDA, H. & ADACHI, 
M. (2003) A novel mechanism for the regulation of IFN-gamma inducible 
protein-10 expression in rheumatoid arthritis. Arthritis Res Ther, 5, R74-81. 
HANCOCK, W. S. & BATTERSBY, J. E. (1976) A new micro-test for the detection of 
incomplete coupling reactions in solid-phase peptide synthesis using 2,4,6-
trinitrobenzenesulphonic acid. Anal Biochem, 71, 260-4. 
HARAGUCHI, S., GOOD, R. A. & DAY, N. K. (1995) Immunosuppressive retroviral 
peptides: cAMP and cytokine patterns. Immunol Today, 16, 595-603. 
HART, H., MCCORMICK, J. N. & MARMION, B. P. (1979) Viruses and 
lymphocytes in rheumatoid arthritis. II. Examination of lymphocytes and sera 
from patients with rheumatoid arthritis for evidence of retrovirus infection. Ann 
Rheum Dis, 38, 514-25. 
HATTORI, T., TAKAHASH, K., YUTANI, Y., FUJISAWA, T., NAKANISHI, T. & 
TAKIGAWA, M. (2000) Rheumatoid arthritis-related antigen 47kDa (RA-A47) 
is a product of colligin-2 and acts as a human HSP47. J Bone Miner Metab, 18, 
328-34. 
HAUPT, W., FISCHER, T. C., WINDERL, S., FRANSZ, P. & TORRES-RUIZ, R. A. 
(2001) The centromere1 (CEN1) region of Arabidopsis thaliana: architecture 
and functional impact of chromatin. Plant J, 27, 285-96. 
HE, L., THOMSON, J. M., HEMANN, M. T., HERNANDO-MONGE, E., MU, D., 
GOODSON, S., POWERS, S., CORDON-CARDO, C., LOWE, S. W., 
HANNON, G. J. & HAMMOND, S. M. (2005) A microRNA polycistron as a 
potential human oncogene. Nature, 435, 828-33. 
HEID, C. A., STEVENS, J., LIVAK, K. J. & WILLIAMS, P. M. (1996) Real time 
quantitative PCR. Genome Res, 6, 986-94. 
277 
 
HERNANDEZ AVILA, M., LIANG, M. H., WILLETT, W. C., STAMPFER, M. J., 
COLDITZ, G. A., ROSNER, B., ROBERTS, W. N., HENNEKENS, C. H. & 
SPEIZER, F. E. (1990) Reproductive factors, smoking, and the risk for 
rheumatoid arthritis. Epidemiology, 1, 285-91. 
HERNIOU, E., MARTIN, J., MILLER, K., COOK, J., WILKINSON, M. & TRISTEM, 
M. (1998) Retroviral diversity and distribution in vertebrates. J Virol, 72, 5955-
66. 
HERVE, C. A., LUGLI, E. B., BRAND, A., GRIFFITHS, D. J. & VENABLES, P. J. 
(2002) Autoantibodies to human endogenous retrovirus-K are frequently 
detected in health and disease and react with multiple epitopes. Clin Exp 
Immunol, 128, 75-82. 
HERVE, C. A., WAIT, R. & VENABLES, P. J. (2003) Glucose-6-phosphate isomerase 
is not a specific autoantigen in rheumatoid arthritis. Rheumatology (Oxford), 42, 
986-8. 
HIDA, S., MIURA, N. N., ADACHI, Y. & OHNO, N. (2007) Cell wall beta-glucan 
derived from Candida albicans acts as a trigger for autoimmune arthritis in SKG 
mice. Biol Pharm Bull, 30, 1589-92. 
HISCOX, J. A. (2002) The nucleolus--a gateway to viral infection? Arch Virol, 147, 
1077-89. 
HOLLSTEIN, M., SIDRANSKY, D., VOGELSTEIN, B. AND HARRIS, C. C. (1991) 
p53 mutations in human cancers. Science, 253, 49-53. 
HOLMES, R. K., MALIM, M. H. & BISHOP, K. N. (2007) APOBEC-mediated viral 
restriction: not simply editing? Trends Biochem Sci, 32, 118-28. 
HOPP, T. P. (1993) Retrospective: 12 years of antigenic determinant predictions, and 
more. Pept Res, 6, 183-90. 
HOPP, T. P. (1994) Different views of protein antigenicity. Pept Res, 7, 229-31. 
HOPP, T. P. & WOODS, K. R. (1981) Prediction of protein antigenic determinants 
from amino acid sequences. Proc Natl Acad Sci U S A, 78, 3824-8. 
HORAI, R., SAIJO, S., TANIOKA, H., NAKAE, S., SUDO, K., OKAHARA, A., 
IKUSE, T., ASANO, M. & IWAKURA, Y. (2000) Development of chronic 
inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 
receptor antagonist-deficient mice. J Exp Med, 191, 313-20. 
HU, P., WU, S. & HERNANDEZ, N. (2004) A role for beta-actin in RNA polymerase 
III transcription. Genes Dev, 18, 3010-5. 
HUBER, B. T., HSU, P. N. & SUTKOWSKI, N. (1996) Virus-encoded superantigens. 
Microbiol Rev, 60, 473-82. 
HUBER, L. C., DISTLER, O., TARNER, I., GAY, R. E., GAY, S. & PAP, T. (2006) 
Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology 
(Oxford), 45, 669-75. 
HUGGETT, J., DHEDA, K., BUSTIN, S. & ZUMLA, A. (2005) Real-time RT-PCR 
normalisation; strategies and considerations. Genes Immun, 6, 279-84. 
HYRICH, K. L. & INMAN, R. D. (2001) Infectious agents in chronic rheumatic 
diseases. Curr Opin Rheumatol, 13, 300-4. 
IANNONE, F., CORRIGAL, V. M. & PANAYI, G. S. (1996) CD69 on synovial T 
cells in rheumatoid arthritis correlates with disease activity. Br J Rheumatol, 35, 
397. 
IKEUCHI, H., KUROIWA, T., HIRAMATSU, N., KANEKO, Y., HIROMURA, K., 
UEKI, K. & NOJIMA, Y. (2005) Expression of interleukin-22 in rheumatoid 
arthritis: potential role as a proinflammatory cytokine. Arthritis Rheum, 52, 
1037-46. 
278 
 
INTERNATIONAL HUMAN GENOME SEQUENCING CONSORTIUM (2004) 
Finishing the euchromatic sequence of the human genome. Nature, 431, 931-45. 
ISHIGURO, T., SAITOH, J., YAWATA, H., YAMAGISHI, H., IWASAKI, S. & 
MITOMA, Y. (1995) Homogeneous quantitative assay of hepatitis C virus RNA 
by polymerase chain reaction in the presence of a fluorescent intercalater. Anal 
Biochem, 229, 207-13. 
ISHIKAWA, H., HIRATA, S., ANDOH, Y., KUBO, H., NAKAGAWA, N., 
NISHIBAYASHI, Y. & MIZUNO, K. (1996) An immunohistochemical and 
immunoelectron microscopic study of adhesion molecules in synovial pannus 
formation in rheumatoid arthritis. Rheumatol Int, 16, 53-60. 
ITOH, Y. & REICHLIN, M. (1992) Autoantibodies to the Ro/SSA antigen are 
conformation dependent. I: Anti-60 kD antibodies are mainly directed to the 
native protein; anti-52 kD antibodies are mainly directed to the denatured 
protein. Autoimmunity, 14, 57-65. 
IVANOV, V. S., SUVOROVA, Z. K., TCHIKIN, L. D., KOZHICH, A. T. & 
IVANOV, V. T. (1992) Effective method for synthetic peptide immobilization 
that increases the sensitivity and specificity of ELISA procedures. J Immunol 
Methods, 153, 229-33. 
IVARS, F. (2007) Superantigen-induced regulatory T cells in vivo. Chem Immunol 
Allergy, 93, 137-60. 
IWAKURA, Y., SAIJO, S., KIOKA, Y., NAKAYAMA-YAMADA, J., ITAGAKI, K., 
TOSU, M., ASANO, M., KANAI, Y. & KAKIMOTO, K. (1995) Autoimmunity 
induction by human T cell leukemia virus type 1 in transgenic mice that develop 
chronic inflammatory arthropathy resembling rheumatoid arthritis in humans. J 
Immunol, 155, 1588-98. 
IWAKURA, Y., TOSU, M., YOSHIDA, E., TAKIGUCHI, M., SATO, K., KITAJIMA, 
I., NISHIOKA, K., YAMAMOTO, K., TAKEDA, T., HATANAKA, M. & ET 
AL. (1991) Induction of inflammatory arthropathy resembling rheumatoid 
arthritis in mice transgenic for HTLV-I. Science, 253, 1026-8. 
JACKS, T., POWER, M. D., MASIARZ, F. R., LUCIW, P. A., BARR, P. J. AND 
VARMUS, H. E. (1988) Characterization of ribosomal frameshifting in HIV-1 
gag-pol expression Nature, 331, 280-3. 
JAMES, J. A., GROSS, T., SCOFIELD, R. H. & HARLEY, J. B. (1995) 
Immunoglobulin epitope spreading and autoimmune disease after peptide 
immunization: Sm B/B'-derived PPPGMRPP and PPPGIRGP induce 
spliceosome autoimmunity. J Exp Med, 181, 453-61. 
JAMES, J. A. & HARLEY, J. B. (1992) Linear epitope mapping of an Sm B/B' 
polypeptide. J Immunol, 148, 2074-9. 
JAMES, J. A. & HARLEY, J. B. (1998) B-cell epitope spreading in autoimmunity. 
Immunol Rev, 164, 185-200. 
JAMES, W. H. (1993) Rheumatoid arthritis, the contraceptive pill, and androgens. Ann 
Rheum Dis, 52, 470-4. 
JANIN, J. (1979) Surface and inside volumes in globular proteins. Nature, 277, 491-2. 
JENSEN, S., GASSAMA, M. P. & HEIDMANN, T. (1999) Taming of transposable 
elements by homology-dependent gene silencing. Nat Genet, 21, 209-12. 
JONES, D. T. (1999) Protein secondary structure prediction based on position-specific 
scoring matrices. J Mol Biol, 292, 195-202. 
JONES, S. & THORNTON, J. M. (1996) Principles of protein-protein interactions. 
Proc Natl Acad Sci U S A, 93, 13-20. 
279 
 
JORDAN, I. K., ROGOZIN, I. B., GLAZKO, G. V. & KOONIN, E. V. (2003) Origin 
of a substantial fraction of human regulatory sequences from transposable 
elements. Trends Genet, 19, 68-72. 
JUNAKOVIC, N., TERRINONI, A., DI FRANCO, C., VIEIRA, C. & 
LOEVENBRUCK, C. (1998) Accumulation of transposable elements in the 
heterochromatin and on the Y chromosome of Drosophila simulans and 
Drosophila melanogaster. J Mol Evol, 46, 661-8. 
JUNGEL, A., DISTLER, J. H., KUROWSKA-STOLARSKA, M., SEEMAYER, C. A., 
SEIBL, R., FORSTER, A., MICHEL, B. A., GAY, R. E., EMMRICH, F., GAY, 
S. & DISTLER, O. (2004) Expression of interleukin-21 receptor, but not 
interleukin-21, in synovial fibroblasts and synovial macrophages of patients 
with rheumatoid arthritis. Arthritis Rheum, 50, 1468-76. 
KAMBHU, S., FALLDORF, P. & LEE, J. S. (1990) Endogenous retroviral long 
terminal repeats within the HLA-DQ locus. Proc Natl Acad Sci U S A, 87, 4927-
31. 
KAPLAN, M. (2002) Eculizumab (Alexion). Curr Opin Investig Drugs, 3, 1017-23. 
KARPLUS, P. A. & SCHULZ, G. E. (1985) Prediction of Chain Flexibility in Proteins 
- a Tool for the Selection of Peptide Antigens. Naturwissenschaften, 72, 212-
213. 
KATZOURAKIS, A., TRISTEM, M., PYBUS, O. G. & GIFFORD, R. J. (2007) 
Discovery and analysis of the first endogenous lentivirus. Proc Natl Acad Sci U 
S A, 104, 6261-5. 
KAUR, H. & RAGHAVA, G. P. (2003) A neural-network based method for prediction 
of gamma-turns in proteins from multiple sequence alignment. Protein Sci, 12, 
923-9. 
KAUR, H. & RAGHAVA, G. P. (2004) A neural network method for prediction of 
beta-turn types in proteins using evolutionary information. Bioinformatics, 20, 
2751-8. 
KE, L. D., CHEN, Z. & YUNG, W. K. (2000) A reliability test of standard-based 
quantitative PCR: exogenous vs endogenous standards. Mol Cell Probes, 14, 
127-35. 
KEFFER, J., PROBERT, L., CAZLARIS, H., GEORGOPOULOS, S., KASLARIS, E., 
KIOUSSIS, D. & KOLLIAS, G. (1991) Transgenic mice expressing human 
tumour necrosis factor: a predictive genetic model of arthritis. Embo J, 10, 
4025-31. 
KEYSTONE, E. (2002) Treatments no longer in development for rheumatoid arthritis. 
Ann Rheum Dis, 61 Suppl 2, ii43-5. 
KIM, H. J. & BEREK, C. (2000) B cells in rheumatoid arthritis. Arthritis Res, 2, 126-
31. 
KINOMOTO, M., KANNO, T., SHIMURA, M., ISHIZAKA, Y., KOJIMA, A., 
KURATA, T., SATA, T. & TOKUNAGA, K. (2007) All APOBEC3 family 
proteins differentially inhibit LINE-1 retrotransposition. Nucleic Acids Res, 35, 
2955-64. 
KISLAUSKIS, E. H., ZHU, X. & SINGER, R. H. (1997) beta-Actin messenger RNA 
localization and protein synthesis augment cell motility. J Cell Biol, 136, 1263-
70. 
KJELLMAN, C., SJOGREN, H. O. & WIDEGREN, B. (1995) The Y chromosome: a 
graveyard for endogenous retroviruses. Gene, 161, 163-70. 
KJELLMAN, C., SJOGREN, H. O. & WIDEGREN, B. (1999) HERV-F, a new group 
of human endogenous retrovirus sequences. J Gen Virol, 80 ( Pt 9), 2383-92. 
280 
 
KLAVINSKIS, L. S., WHITTON, J. L. & OLDSTONE, M. B. (1989) Molecularly 
engineered vaccine which expresses an immunodominant T-cell epitope induces 
cytotoxic T lymphocytes that confer protection from lethal virus infection. J 
Virol, 63, 4311-6. 
KLIMIUK, P. A., YANG, H., GORONZY, J. J. & WEYAND, C. M. (1999) Production 
of cytokines and metalloproteinases in rheumatoid synovitis is T cell dependent. 
Clin Immunol, 90, 65-78. 
KLIPPEL K. H. & DIEPPE, P. A. (Eds.) (1997) Rheumatology, St. Louis ; London : 
Mosby, Mosby. 
KNOSSL, M., LOWER, R. & LOWER, J. (1999) Expression of the human endogenous 
retrovirus HTDV/HERV-K is enhanced by cellular transcription factor YY1. J 
Virol, 73, 1254-61. 
KOCHWA, S., BROWNELL, M., ROSENFIELD, R. E. & WASSERMAN, L. R. 
(1967) Adsorption of proteins by polystyrene particles. I. Molecular unfolding 
and acquired immunogenicity of IgG. J Immunol, 99, 981-6. 
KOHSAKA, H., YAMAMOTO, K., FUJII, H., MIURA, H., MIYASAKA, N., 
NISHIOKA, K. & MIYAMOTO, T. (1990) Fine epitope mapping of the human 
SS-B/La protein. Identification of a distinct autoepitope homologous to a viral 
gag polyprotein. J Clin Invest, 85, 1566-74. 
KOLASKAR, A. S. & TONGAONKAR, P. C. (1990) A semi-empirical method for 
prediction of antigenic determinants on protein antigens. FEBS Lett, 276, 172-4. 
KORTHAUER, U., GRAF, D., MAGES, H. W., BRIERE, F., PADAYACHEE, M., 
MALCOLM, S., UGAZIO, A. G., NOTARANGELO, L. D., LEVINSKY, R. J. 
& KROCZEK, R. A. (1993) Defective expression of T-cell CD40 ligand causes 
X-linked immunodeficiency with hyper-IgM. Nature, 361, 539-41. 
KOSHLAND, D. E. (1958) Application of a Theory of Enzyme Specificity to Protein 
Synthesis. Proc Natl Acad Sci U S A, 44, 98-104. 
KOUSKOFF, V., KORGANOW, A. S., DUCHATELLE, V., DEGOTT, C., BENOIST, 
C. & MATHIS, D. (1996) Organ-specific disease provoked by systemic 
autoimmunity. Cell, 87, 811-22. 
KRANE, D. E. & RAYMER., M. L. (2002) Fundamental Concepts of Bioinformatics  
 New York, Benjamin Cummings. 
KREMER, J. M., WESTHOVENS, R., LEON, M., DI GIORGIO, E., ALTEN, R., 
STEINFELD, S., RUSSELL, A., DOUGADOS, M., EMERY, P., NUAMAH, I. 
F., WILLIAMS, G. R., BECKER, J. C., HAGERTY, D. T. & MORELAND, L. 
W. (2003) Treatment of rheumatoid arthritis by selective inhibition of T-cell 
activation with fusion protein CTLA4Ig. N Engl J Med, 349, 1907-15. 
KRIEG, A. M., GOURLEY, M. F., KLINMAN, D. M., PERL, A. & STEINBERG, A. 
D. (1992) Heterogeneous expression and coordinate regulation of endogenous 
retroviral sequences in human peripheral blood mononuclear cells. AIDS Res 
Hum Retroviruses, 8, 1991-8. 
KROESEN, S., WIDMER, A. F., TYNDALL, A. & HASLER, P. (2003) Serious 
bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha 
therapy. Rheumatology (Oxford), 42, 617-21. 
KROOT, E. J., DE JONG, B. A., VAN LEEUWEN, M. A., SWINKELS, H., VAN 
DEN HOOGEN, F. H., VAN'T HOF, M., VAN DE PUTTE, L. B., VAN 
RIJSWIJK, M. H., VAN VENROOIJ, W. J. & VAN RIEL, P. L. (2000) The 
prognostic value of anti-cyclic citrullinated peptide antibody in patients with 
recent-onset rheumatoid arthritis. Arthritis Rheum, 43, 1831-5. 
281 
 
KULSKI, J. K., GAUDIERI, S., INOKO, H. & DAWKINS, R. L. (1999) Comparison 
between two human endogenous retrovirus (HERV)-rich regions within the 
major histocompatibility complex. J Mol Evol, 48, 675-83. 
KUWANA, M., KABURAKI, J., MIMORI, T., TOJO, T. & HOMMA, M. (1993) 
Autoantigenic epitopes on DNA topoisomerase I. Clinical and immunogenetic 
associations in systemic sclerosis. Arthritis Rheum, 36, 1406-13. 
LA MANTIA, G., MAGLIONE, D., PENGUE, G., DI CRISTOFANO, A., SIMEONE, 
A., LANFRANCONE, L. & LANIA, L. (1991) Identification and 
characterization of novel human endogenous retroviral sequences prefentially 
expressed in undifferentiated embryonal carcinoma cells. Nucleic Acids Res, 19, 
1513-20. 
LA MANTIA, G., MAJELLO, B., DI CRISTOFANO, A., STRAZZULLO, M., 
MINCHIOTTI, G. & LANIA, L. (1992) Identification of regulatory elements 
within the minimal promoter region of the human endogenous ERV9 
proviruses: accurate transcription initiation is controlled by an Inr-like element. 
Nucleic Acids Res, 20, 4129-36. 
LANDER, E. S., LINTON, L. M., BIRREN, B., NUSBAUM, C., ZODY, M. C., 
BALDWIN, J., DEVON, K., DEWAR, K., DOYLE, M., FITZHUGH, W., 
FUNKE, R., GAGE, D., HARRIS, K., HEAFORD, A., HOWLAND, J., KANN, 
L., LEHOCZKY, J., LEVINE, R., MCEWAN, P., MCKERNAN, K., 
MELDRIM, J., MESIROV, J. P., MIRANDA, C., MORRIS, W., NAYLOR, J., 
RAYMOND, C., ROSETTI, M., SANTOS, R., SHERIDAN, A., SOUGNEZ, 
C., STANGE-THOMANN, N., STOJANOVIC, N., SUBRAMANIAN, A., 
WYMAN, D., ROGERS, J., SULSTON, J., AINSCOUGH, R., BECK, S., 
BENTLEY, D., BURTON, J., CLEE, C., CARTER, N., COULSON, A., 
DEADMAN, R., DELOUKAS, P., DUNHAM, A., DUNHAM, I., DURBIN, R., 
FRENCH, L., GRAFHAM, D., GREGORY, S., HUBBARD, T., HUMPHRAY, 
S., HUNT, A., JONES, M., LLOYD, C., MCMURRAY, A., MATTHEWS, L., 
MERCER, S., MILNE, S., MULLIKIN, J. C., MUNGALL, A., PLUMB, R., 
ROSS, M., SHOWNKEEN, R., SIMS, S., WATERSTON, R. H., WILSON, R. 
K., HILLIER, L. W., MCPHERSON, J. D., MARRA, M. A., MARDIS, E. R., 
FULTON, L. A., CHINWALLA, A. T., PEPIN, K. H., GISH, W. R., CHISSOE, 
S. L., WENDL, M. C., DELEHAUNTY, K. D., MINER, T. L., 
DELEHAUNTY, A., KRAMER, J. B., COOK, L. L., FULTON, R. S., 
JOHNSON, D. L., MINX, P. J., CLIFTON, S. W., HAWKINS, T., 
BRANSCOMB, E., PREDKI, P., RICHARDSON, P., WENNING, S., 
SLEZAK, T., DOGGETT, N., CHENG, J. F., OLSEN, A., LUCAS, S., ELKIN, 
C., UBERBACHER, E., FRAZIER, M., et al. (2001) Initial sequencing and 
analysis of the human genome. Nature, 409, 860-921. 
LANDRY, J. R., ROUHI, A., MEDSTRAND, P. & MAGER, D. L. (2002) The Opitz 
syndrome gene Mid1 is transcribed from a human endogenous retroviral 
promoter. Mol Biol Evol, 19, 1934-42. 
LARSSON, E. & ANDERSSON, G. (1998) Beneficial role of human endogenous 
retroviruses: facts and hypotheses. Scand J Immunol, 48, 329-38. 
LAU, C. M., BROUGHTON, C., TABOR, A. S., AKIRA, S., FLAVELL, R. A., 
MAMULA, M. J., CHRISTENSEN, S. R., SHLOMCHIK, M. J., VIGLIANTI, 
G. A., RIFKIN, I. R. & MARSHAK-ROTHSTEIN, A. (2005) RNA-associated 
autoantigens activate B cells by combined B cell antigen receptor/Toll-like 
receptor 7 engagement. J Exp Med, 202, 1171-7. 
282 
 
LAU, N. C., SETO, A. G., KIM, J., KURAMOCHI-MIYAGAWA, S., NAKANO, T., 
BARTEL, D. P. & KINGSTON, R. E. (2006) Characterization of the piRNA 
complex from rat testes. Science, 313, 363-7. 
LEADBETTER, E. A., RIFKIN, I. R., HOHLBAUM, A. M., BEAUDETTE, B. C., 
SHLOMCHIK, M. J. & MARSHAK-ROTHSTEIN, A. (2002) Chromatin-IgG 
complexes activate B cells by dual engagement of IgM and Toll-like receptors. 
Nature, 416, 603-7. 
LEANDRO, M. J., EDWARDS, J. C. & CAMBRIDGE, G. (2002) Clinical outcome in 
22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann 
Rheum Dis, 61, 883-8. 
LECELLIER, C. H., DUNOYER, P., ARAR, K., LEHMANN-CHE, J., EYQUEM, S., 
HIMBER, C., SAIB, A. & VOINNET, O. (2005) A cellular microRNA 
mediates antiviral defense in human cells. Science, 308, 557-60. 
LEE, B. & RICHARDS, F. M. (1971) The interpretation of protein structures: 
estimation of static accessibility. J Mol Biol, 55, 379-400. 
LEE, D. M., FRIEND, D. S., GURISH, M. F., BENOIST, C., MATHIS, D. & 
BRENNER, M. B. (2002) Mast cells: a cellular link between autoantibodies and 
inflammatory arthritis. Science, 297, 1689-92. 
LEE, L. G., CONNELL, C. R. & BLOCH, W. (1993) Allelic discrimination by nick-
translation PCR with fluorogenic probes. Nucleic Acids Res, 21, 3761-6. 
LEE, W. J., KWUN, H. J. & JANG, K. L. (2003) Analysis of transcriptional regulatory 
sequences in the human endogenous retrovirus W long terminal repeat. J Gen 
Virol, 84, 2229-35. 
LEFKOWITH, J. B., KIEHL, M., RUBENSTEIN, J., DIVALERIO, R., BERNSTEIN, 
K., KAHL, L., RUBIN, R. L. & GOURLEY, M. (1996) Heterogeneity and 
clinical significance of glomerular-binding antibodies in systemic lupus 
erythematosus. J Clin Invest, 98, 1373-80. 
LEHMANN, P. V., FORSTHUBER, T., MILLER, A. & SERCARZ, E. E. (1992) 
Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. 
Nature, 358, 155-7. 
LEVELY, M. E., BANNOW, C. A., SMITH, C. W. & NICHOLAS, J. A. (1991) 
Immunodominant T-cell epitope on the F protein of respiratory syncytial virus 
recognized by human lymphocytes. J Virol, 65, 3789-96. 
LEVITT, M. (1976) A simplified representation of protein conformations for rapid 
simulation of protein folding. J Mol Biol, 104, 59-107. 
LEWIS, S. M. & WU, G. E. (1997) The origins of V(D)J recombination. Cell, 88, 159-
62. 
LIAO, D., PAVELITZ, T., KIDD, J. R., KIDD, K. K. & WEINER, A. M. (1997) 
Concerted evolution of the tandemly repeated genes encoding human U2 
snRNA (the RNU2 locus) involves rapid intrachromosomal homogenization and 
rare interchromosomal gene conversion. Embo J, 16, 588-98. 
LIN, L. & PENG, S. L. (2005) Interleukin-18 receptor signaling is not required for 
autoantibody production and end-organ disease in murine lupus. Arthritis 
Rheum, 52, 984-6. 
LINDESKOG, M., MAGER, D. L. & BLOMBERG, J. (1999) Isolation of a human 
endogenous retroviral HERV-H element with an open env reading frame. 
Virology, 258, 441-50. 
LINDESKOG, M., MEDSTRAND, P., CUNNINGHAM, A. A. & BLOMBERG, J. 
(1998) Coamplification and dispersion of adjacent human endogenous retroviral 
283 
 
HERV-H and HERV-E elements; presence of spliced hybrid transcripts in 
normal leukocytes. Virology, 244, 219-29. 
LIPSKY, P. E. (2001) Systemic lupus erythematosus: an autoimmune disease of B cell 
hyperactivity. Nat Immunol, 2, 764-6. 
LIU, A. Y. & ABRAHAM, B. A. (1991) Subtractive cloning of a hybrid human 
endogenous retrovirus and calbindin gene in the prostate cell line PC3. Cancer 
Res, 51, 4107-10. 
LIVAK, K. J. & SCHMITTGEN, T. D. (2001) Analysis of relative gene expression 
data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. 
Methods, 25, 402-8. 
LO CONTE, L., CHOTHIA, C. & JANIN, J. (1999) The atomic structure of protein-
protein recognition sites. J Mol Biol, 285, 2177-98. 
LOOMANS, E. E., GRIBNAU, T. C., BLOEMERS, H. P. & SCHIELEN, W. J. (1998) 
Adsorption studies of tritium-labeled peptides on polystyrene surfaces. J 
Immunol Methods, 221, 131-9. 
LUM, A. M., WANG, B. B., LI, L., CHANNA, N., BARTHA, G. & WABL, M. (2007) 
Retroviral activation of the mir-106a microRNA cistron in T lymphoma. 
Retrovirology, 4, 5. 
LUO, K., WANG, T., BINDONG, L., CHUNJUAN, T., ZUOXIANG, X., KAPPES, J. 
AND YU, X. F. (2007) Cytidine deaminases APOBEC3G and APOBEC3F 
interact with human immunodeficiency virus type 1 integrase and inhibit 
proviral DNA formation.  J Virol, 81, 7238-7248.   
MACDONALD, K. P., NISHIOKA, Y., LIPSKY, P. E. & THOMAS, R. (1997) 
Functional CD40 ligand is expressed by T cells in rheumatoid arthritis. J Clin 
Invest, 100, 2404-14. 
MACK, M., BENDER, K. & SCHNEIDER, P. M. (2004) Detection of retroviral 
antisense transcripts and promoter activity of the HERV-K(C4) insertion in the 
MHC class III region. Immunogenetics, 56, 321-32. 
MADANI, N. AND KABAT, D. (1998) An endogenous inhibitor of human 
immunodeficiency virus in human lymphocytes is overcome by the viral Vif 
protein. J Virol, 72, 10251-5. 
MAHLER, M., MIERAU, R. & BLUTHNER, M. (2000) Fine-specificity of the anti-
CENP-A B-cell autoimmune response. J Mol Med, 78, 460-7. 
MAKUNIN, I. V., PHEASANT, M., SIMONS, C. & MATTICK, J. S. (2007) 
Orthologous MicroRNA Genes Are Located in Cancer-Associated Genomic 
Regions in Human and Mouse. PLoS ONE, 2, e1133. 
MALE, D., BROSTOFF J. & I ROITT (2006) Immunology, London, Mosby. 
MALIM, M. H., TILEY, L. S., MCCARN, D. F., RUSCHE, J. R., HAUBER, J. AND 
CULLEN, B. R. (1990) HIV-1 structural gene expression requires binding of the 
Rev trans-activator to its RNA target sequence. Cell, 60, 675-83. 
MALONEY, D. G., GRILLO-LOPEZ, A. J., WHITE, C. A., BODKIN, D., 
SCHILDER, R. J., NEIDHART, J. A., JANAKIRAMAN, N., FOON, K. A., 
LILES, T. M., DALLAIRE, B. K., WEY, K., ROYSTON, I., DAVIS, T. & 
LEVY, R. (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody 
therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood, 
90, 2188-95. 
MAMELI, G., ASTONE, V., ARRU, G., MARCONI, S., LOVATO, L., SERRA, C., 
SOTGIU, S., BONETTI, B. & DOLEI, A. (2007) Brains and peripheral blood 
mononuclear cells of multiple sclerosis (MS) patients hyperexpress MS-
284 
 
associated retrovirus/HERV-W endogenous retrovirus, but not Human 
herpesvirus 6. J Gen Virol, 88, 264-74. 
MANGASARIAN, A., AND TRONO, D. (1997). The multifaceted role of HIV Nef. 
Res Virol, 148, 30-33. 
 
MANGENEY, M., DE PARSEVAL, N., THOMAS, G. & HEIDMANN, T. (2001) The 
full-length envelope of an HERV-H human endogenous retrovirus has 
immunosuppressive properties. J Gen Virol, 82, 2515-8. 
MANIATIS, T., GOODBOURN, S. & FISCHER, J. A. (1987) Regulation of inducible 
and tissue-specific gene expression. Science, 236, 1237-45. 
MANSIA, G., DE BACKER, G., DOMINICZAK, A., CIFKOVA, R., FAGARD, R., 
GERMANO, G., GRASSI, G., HEAGERTY, A. M., KJELDSEN, S. E., 
LAURENT, S., NARKIEWICZ, K., RUILOPE, L., RYNKIEWICZ, A., 
SCHMIEDER, R. E., STRUIJKER BOUDIER, H. A. & ZANCHETTI, A. 
(2007) 2007 ESH-ESC Guidelines for the management of arterial hypertension: 
the task force for the management of arterial hypertension of the European 
Society of Hypertension (ESH) and of the European Society of Cardiology 
(ESC). Blood Press, 16, 135-232. 
MARE, L. & TRINCHERA, M. (2007) Comparative analysis of retroviral and native 
promoters driving expression of beta1,3-galactosyltransferase beta3Gal-T5 in 
human and mouse tissues. J Biol Chem, 282, 49-57. 
MARGUERAT, S., WANG, W. Y., TODD, J. A. & CONRAD, B. (2004) Association 
of human endogenous retrovirus K-18 polymorphisms with type 1 diabetes. 
Diabetes, 53, 852-4. 
MARTIN, A. C., CHEETHAM, J. C. & REES, A. R. (1989) Modeling antibody 
hypervariable loops: a combined algorithm. Proc Natl Acad Sci U S A, 86, 
9268-72. 
MARTIN, M. A., BRYAN, T., RASHEED, S. & KHAN, A. S. (1981) Identification 
and cloning of endogenous retroviral sequences present in human DNA. Proc 
Natl Acad Sci U S A, 78, 4892-6. 
MARTIN, T. & PASQUALI, J. L. (1992) CD5 negative IGM rheumatoid factor B cells 
in B-chronic lymphocytic leukemia and benign mixed cryoglobulinemia. Leuk 
Lymphoma, 7, 55-62. 
MASI, A. T., FEIGENBAUM, S. L. & CHATTERTON, R. T. (1995) Hormonal and 
pregnancy relationships to rheumatoid arthritis: convergent effects with 
immunologic and microvascular systems. Semin Arthritis Rheum, 25, 1-27. 
MASUKO-HONGO, K., KATO, T. & NISHIOKA, K. (2003) Virus-associated 
arthritis. Best Pract Res Clin Rheumatol, 17, 309-18. 
MAYER, J., EHLHARDT, S., SEIFERT, M., SAUTER, M., MULLER-LANTZSCH, 
N., MEHRAEIN, Y., ZANG, K. D. & MEESE, E. (2004) Human endogenous 
retrovirus HERV-K(HML-2) proviruses with Rec protein coding capacity and 
transcriptional activity. Virology, 322, 190-8. 
MAZZUCCHELLI, L., BLASER, A., KAPPELER, A., SCHARLI, P., LAISSUE, J. 
A., BAGGIOLINI, M. & UGUCCIONI, M. (1999) BCA-1 is highly expressed 
in Helicobacter pylori-induced mucosa-associated lymphoid tissue and gastric 
lymphoma. J Clin Invest, 104, R49-54. 
MCCLAIN, M. T., RAMSLAND, P. A., KAUFMAN, K. M. & JAMES, J. A. (2002) 
Anti-sm autoantibodies in systemic lupus target highly basic surface structures 
of complexed spliceosomal autoantigens. J Immunol, 168, 2054-62. 
285 
 
MCGUFFIN, L. J., BRYSON, K. & JONES, D. T. (2000) The PSIPRED protein 
structure prediction server. Bioinformatics, 16, 404-5. 
MCNEILAGE, L. J., MACMILLAN, E. M. & WHITTINGHAM, S. F. (1990) 
Mapping of epitopes on the La(SS-B) autoantigen of primary Sjogren's 
syndrome: identification of a cross-reactive epitope. J Immunol, 145, 3829-35. 
MEDSTRAND, P. & BLOMBERG, J. (1993) Characterization of novel reverse 
transcriptase encoding human endogenous retroviral sequences similar to type A 
and type B retroviruses: differential transcription in normal human tissues. J 
Virol, 67, 6778-87. 
MEDSTRAND, P., LINDESKOG, M. & BLOMBERG, J. (1992) Expression of human 
endogenous retroviral sequences in peripheral blood mononuclear cells of 
healthy individuals. J Gen Virol, 73 ( Pt 9), 2463-6. 
MEDSTRAND, P. & MAGER, D. L. (1998) Human-specific integrations of the 
HERV-K endogenous retrovirus family. J Virol, 72, 9782-7. 
MEDSTRAND, P., VAN DE LAGEMAAT, L. N. & MAGER, D. L. (2002) 
Retroelement distributions in the human genome: variations associated with age 
and proximity to genes. Genome Res, 12, 1483-95. 
MEESE, E., GOTTERT, E., ZANG, K. D., SAUTER, M., SCHOMMER, S. & 
MUELLER-LANTZSCH, N. (1996) Human endogenous retroviral element k10 
(HERV-K10): chromosomal localization by somatic hybrid mapping and 
fluorescence in situ hybridization. Cytogenet Cell Genet, 72, 40-2. 
MEISLER, M. H. & TING, C. N. (1993) The remarkable evolutionary history of the 
human amylase genes. Crit Rev Oral Biol Med, 4, 503-9. 
MENARD, H. A., LAPOINTE, E., ROCHDI, M. D. & ZHOU, Z. J. (2000) Insights 
into rheumatoid arthritis derived from the Sa immune system. Arthritis Res, 2, 
429-32. 
MEYLAN, F., DE SMEDT, M., LECLERCQ, G., PLUM, J., LEUPIN, O., 
MARGUERAT, S. & CONRAD, B. (2005) Negative thymocyte selection to 
HERV-K18 superantigens in humans. Blood, 105, 4377-82. 
MI, S., LEE, X., LI, X., VELDMAN, G. M., FINNERTY, H., RACIE, L., LAVALLIE, 
E., TANG, X. Y., EDOUARD, P., HOWES, S., KEITH, J. C., JR. & MCCOY, 
J. M. (2000) Syncytin is a captive retroviral envelope protein involved in human 
placental morphogenesis. Nature, 403, 785-9. 
MICHAELS, F. H., BANKS, K. L. & REITZ, M. S., JR. (1991) Lessons from caprine 
and ovine retrovirus infections. Rheum Dis Clin North Am, 17, 5-23. 
MIKECZ, K., BRENNAN, F. R., KIM, J. H. & GLANT, T. T. (1995) Anti-CD44 
treatment abrogates tissue oedema and leukocyte infiltration in murine arthritis. 
Nat Med, 1, 558-63. 
MIKSZTA, J. A., JANG, Y. S. & KIM, B. S. (1997) Role of a C-terminal residue of an 
immunodominant epitope in T cell activation and repertoire diversity. J 
Immunol, 158, 127-35. 
MILICH, D. R., MCLACHLAN, A., THORNTON, G. B. & HUGHES, J. L. (1987) 
Antibody production to the nucleocapsid and envelope of the hepatitis B virus 
primed by a single synthetic T cell site. Nature, 329, 547-9. 
MILLS, R. E., BENNETT, E. A., ISKOW, R. C. & DEVINE, S. E. (2007) Which 
transposable elements are active in the human genome? Trends Genet, 23, 183-
91. 
MIMORI, T. & TANAKA, M. (2002) [Novel autoantibodies and their target antigens 
in rheumatoid arthritis]. Nippon Rinsho, 60, 2263-8. 
286 
 
MINOTA, S., KOYASU, S., YAHARA, I. & WINFIELD, J. (1988) Autoantibodies to 
the heat-shock protein hsp90 in systemic lupus erythematosus. J Clin Invest, 81, 
106-9. 
MITCHELL, R. S., BEITZEL, B. F., SCHRODER, A. R., SHINN, P., CHEN, H., 
BERRY, C. C., ECKER, J. R. & BUSHMAN, F. D. (2004) Retroviral DNA 
integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS 
Biol, 2, E234. 
MOHAN, N., EDWARDS, E. T., CUPPS, T. R., OLIVERIO, P. J., SANDBERG, G., 
CRAYTON, H., RICHERT, J. R. & SIEGEL, J. N. (2001) Demyelination 
occurring during anti-tumor necrosis factor alpha therapy for inflammatory 
arthritides. Arthritis Rheum, 44, 2862-9. 
MOUDGIL, K. D., CHANG, T. T., ERADAT, H., CHEN, A. M., GUPTA, R. S., 
BRAHN, E. & SERCARZ, E. E. (1997) Diversification of T cell responses to 
carboxy-terminal determinants within the 65-kD heat-shock protein is involved 
in regulation of autoimmune arthritis. J Exp Med, 185, 1307-16. 
MOUDGIL, K. D. (1998) Diversification of response to hsp65 during the course of 
autoimmune arthritis is regulatory rather than pathogenic. Immunol Rev, 164, 
175-84. 
MOULT J., HUBBARD T., FIDELIS K. & ZEMLA., A. (2000) Critical Assessment of 
Techniques for Protein Structure Prediction (CASP4). Fourth Community Wide 
Experiment on the Critical Assessment of Techniques for Protein Structure 
Prediction. Asilomar Conference Center  
MOYES, D., GRIFFITHS, D. J. & VENABLES, P. J. (2007) Insertional 
polymorphisms: a new lease of life for endogenous retroviruses in human 
disease. Trends Genet, 23, 326-33. 
MOYES, D. L., MARTIN, A., SAWCER, S., TEMPERTON, N., WORTHINGTON, 
J., GRIFFITHS, D. J. & VENABLES, P. J. (2005) The distribution of the 
endogenous retroviruses HERV-K113 and HERV-K115 in health and disease. 
Genomics, 86, 337-41. 
MU, J., KANZAKI, T., SI, X., TOMIMATSU, T., FUKUDA, H., SHIOJI, M., 
MURATA, Y., SUGIMOTO, Y. & ICHIKAWA, A. (2003) Apoptosis and 
related proteins in placenta of intrauterine fetal death in prostaglandin f 
receptor-deficient mice. Biol Reprod, 68, 1968-74. 
MUIR, A., LEVER, A. & MOFFETT, A. (2004) Expression and functions of human 
endogenous retroviruses in the placenta: an update. Placenta, 25 Suppl A, S16-
25. 
MULLER-LADNER, U., KRIEGSMANN, J., FRANKLIN, B. N., MATSUMOTO, S., 
GEILER, T., GAY, R. E. & GAY, S. (1996) Synovial fibroblasts of patients 
with rheumatoid arthritis attach to and invade normal human cartilage when 
engrafted into SCID mice. Am J Pathol, 149, 1607-15. 
MULLER-LADNER, U., PAP, T., GAY, R. E. & GAY, S. (2003) Gene transfer as a 
future therapy for rheumatoid arthritis. Expert Opin Biol Ther, 3, 587-98. 
MULLER, Y. A., CHEN, Y., CHRISTINGER, H. W., LI, B., CUNNINGHAM, B. C., 
LOWMAN, H. B. & DE VOS, A. M. (1998) VEGF and the Fab fragment of a 
humanized neutralizing antibody: crystal structure of the complex at 2.4 A 
resolution and mutational analysis of the interface. Structure, 6, 1153-67. 
MURO, Y., IWAI, T. & OHASHI, M. (1996) A charged segment mainly composed of 
basic amino acids forms an autoepitope of CENP-A. Clin Immunol 
Immunopathol, 78, 86-9. 
287 
 
MURPHY, E. L., WANG, B., SACHER, R. A., FRIDEY, J., SMITH, J. W., NASS, C. 
C., NEWMAN, B., OWNBY, H. E., GARRATTY, G., HUTCHING, S. T. & 
SCHREIBER, G. B. (2004) Respiratory and urinary tract infections, arthritis, 
and asthma associated with HTLV-I and HTLV-II infection. Emerg Infect Dis, 
10, 109-16. 
NAKAGAWA, K., BRUSIC, V., MCCOLL, G. & HARRISON, L. C. (1997) Direct 
evidence for the expression of multiple endogenous retroviruses in the synovial 
compartment in rheumatoid arthritis. Arthritis Rheum, 40, 627-38. 
NAKAJIMA, T., AONO, H., HASUNUMA, T., YAMAMOTO, K., MARUYAMA, I., 
NOSAKA, T., HATANAKA, M. & NISHIOKA, K. (1993) Overgrowth of 
human synovial cells driven by the human T cell leukemia virus type I tax gene. 
J Clin Invest, 92, 186-93. 
NAKANE, P. K. & PIERCE, G. B., JR. (1966) Enzyme-labeled antibodies: preparation 
and application for the localization of antigens. J Histochem Cytochem, 14, 929-
31. 
NAKANO, K., OKADA, Y., SAITO, K. & TANAKA, Y. (2004) Induction of RANKL 
expression and osteoclast maturation by the binding of fibroblast growth factor 
2 to heparan sulfate proteoglycan on rheumatoid synovial fibroblasts. Arthritis 
Rheum, 50, 2450-8. 
NAKELCHIK, M. & MANGINO, J. E. (2002) Reactivation of histoplasmosis after 
treatment with infliximab. Am J Med, 112, 78. 
NATVIG, J. B. & TONDER, O. (1998) The discovery of the rheumatoid factor. I. Erik 
Waaler. 1940. Clin Exp Rheumatol, 16, 340-4. 
NEIDHART, M., RETHAGE, J., KUCHEN, S., KUNZLER, P., CROWL, R. M., 
BILLINGHAM, M. E., GAY, R. E. & GAY, S. (2000) Retrotransposable L1 
elements expressed in rheumatoid arthritis synovial tissue: association with 
genomic DNA hypomethylation and influence on gene expression. Arthritis 
Rheum, 43, 2634-47. 
NELLAKER, C., YAO, Y., JONES-BRANDO, L., MALLET, F., YOLKEN, R. H. & 
KARLSSON, H. (2006) Transactivation of elements in the human endogenous 
retrovirus W family by viral infection. Retrovirology, 3, 44. 
NELSON, P. N., BOWMAN, S. J., HAY, F. C., LANCHBURY, J. S., PANAYI, G. S. 
& LEVER, A. M. (1995) Absence of exogenous retroviruses in Felty's 
syndrome. Br J Rheumatol, 34, 185-7. 
NELSON, P. N., CARNEGIE, P. R., MARTIN, J., DAVARI EJTEHADI, H., 
HOOLEY, P., RODEN, D., ROWLAND-JONES, S., WARREN, P., ASTLEY, 
J. & MURRAY, P. G. (2003) Demystified. Human endogenous retroviruses. 
Mol Pathol, 56, 11-8. 
NELSON, P. N., GOODALL, M. & JEFFERIS, R. (1994) Characterisation of putative 
monoclonal anti-G3m(u) and anti-G3m(g) reagents and their antigenic 
determinants. Immunol Invest, 23, 39-45. 
NELSON, P. N., HOOLEY, P., RODEN, D., DAVARI EJTEHADI, H., RYLANCE, 
P., WARREN, P., MARTIN, J. & MURRAY, P. G. (2004) Human endogenous 
retroviruses: transposable elements with potential? Clin Exp Immunol, 138, 1-9. 
NELSON, P. N., LEVER, A. M., SMITH, S., PITMAN, R., MURRAY, P., PERERA, 
S. A., WESTWOOD, O. M., HAY, F. C., EJTEHADI, H. D. & BOOTH, J. C. 
(1999) Molecular investigations implicate human endogenous retroviruses as 
mediators of anti-retroviral antibodies in autoimmune rheumatic disease. 
Immunol Invest, 28, 277-89. 
288 
 
NEMETHY, G. & SCHERAGA, H. A. (1980) Stereochemical requirements for the 
existence of hydrogen bonds in beta-bends. Biochem Biophys Res Commun, 95, 
320-7. 
NEWMAN, W. (1982) Selective blockade of human natural killer cells by a 
monoclonal antibody. Proc Natl Acad Sci U S A, 79, 3858-62. 
NISHIMOTO, N. & KISHIMOTO, T. (2004) Inhibition of IL-6 for the treatment of 
inflammatory diseases. Curr Opin Pharmacol, 4, 386-91. 
NISHIMOTO, N. & KISHIMOTO, T. (2006) Interleukin 6: from bench to bedside. Nat 
Clin Pract Rheumatol, 2, 619-26. 
NORVAL, M., HART, H. & MARMION, B. P. (1979) Viruses and lymphocytes in 
rheumatoid arthritis. I. Studies on cultured rheumatoid lymphocytes. Ann Rheum 
Dis, 38, 507-13. 
OGASAWARA, H., OKADA, M., KANEKO, H., HISHIKAWA, T., SEKIGAWA, I. 
& HASHIMOTO, H. (2003) Possible role of DNA hypomethylation in the 
induction of SLE: relationship to the transcription of human endogenous 
retroviruses. Clin Exp Rheumatol, 21, 733-8. 
OKULICZ, W. C. & ACE, C. I. (2003) Temporal regulation of gene expression during 
the expected window of receptivity in the rhesus monkey endometrium. Biol 
Reprod, 69, 1593-9. 
OLDSTONE, M. B. (2005) Molecular mimicry, microbial infection, and autoimmune 
disease: evolution of the concept. Curr Top Microbiol Immunol, 296, 1-17. 
OLSEN, N. J., BROOKS, R. H., CUSH, J. J., LIPSKY, P. E., ST CLAIR, E. W., 
MATTESON, E. L., GOLD, K. N., CANNON, G. W., JACKSON, C. G., 
MCCUNE, W. J., FOX, D. A., NELSON, B., LORENZ, T. & STRAND, V. 
(1996) A double-blind, placebo-controlled study of anti-CD5 immunoconjugate 
in patients with rheumatoid arthritis. The Xoma RA Investigator Group. 
Arthritis Rheum, 39, 1102-8. 
OLSEN, N. J. & KOVACS, W. J. (2002) Hormones, pregnancy, and rheumatoid 
arthritis. J Gend Specif Med, 5, 28-37. 
ONO, M., YASUNAGA, T., MIYATA, T. & USHIKUBO, H. (1986) Nucleotide 
sequence of human endogenous retrovirus genome related to the mouse 
mammary tumor virus genome. J Virol, 60, 589-98. 
OOKA, S., MATSUI, T., NISHIOKA, K. & KATO, T. (2003) Autoantibodies to low-
density-lipoprotein-receptor-related protein 2 (LRP2) in systemic autoimmune 
diseases. Arthritis Res Ther, 5, R174-80. 
ORICCHIO, E., SCIAMANNA, I., BERALDI, R., TOLSTONOG, G. V., 
SCHUMANN, G. G. & SPADAFORA, C. (2007) Distinct roles for LINE-1 and 
HERV-K retroelements in cell proliferation, differentiation and tumor 
progression. Oncogene, 26, 4226-33. 
ORTENDAHL, M., HOLMES, T., SCHETTLER, J. D. & FRIES, J. F. (2002) The 
methotrexate therapeutic response in rheumatoid arthritis. J Rheumatol, 29, 
2084-91. 
OSHIMA, M. & ATASSI, M. Z. (1989) Comparison of peptide-coating conditions in 
solid phase plate assays for detection of anti-peptide antibodies. Immunol Invest, 
18, 841-51. 
PADYUKOV, L., SILVA, C., STOLT, P., ALFREDSSON, L. & KLARESKOG, L. 
(2004) A gene-environment interaction between smoking and shared epitope 
genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. 
Arthritis Rheum, 50, 3085-92. 
289 
 
PALIARD, X., WEST, S. G., LAFFERTY, J. A., CLEMENTS, J. R., KAPPLER, J. 
W., MARRACK, P. & KOTZIN, B. L. (1991) Evidence for the effects of a 
superantigen in rheumatoid arthritis. Science, 253, 325-9. 
PALMARINI, M., MURA, M. & SPENCER, T. E. (2004) Endogenous betaretroviruses 
of sheep: teaching new lessons in retroviral interference and adaptation. J Gen 
Virol, 85, 1-13. 
PALMER K. T. & COOPER, C. (2006) Work-Related Disorders of the Upper Limb. 
Reports on the Rheumatic Diseases, 5, 1-7. 
PAP, T., FRANZ, J. K., HUMMEL, K. M., JEISY, E., GAY, R. & GAY, S. (2000a) 
Activation of synovial fibroblasts in rheumatoid arthritis: lack of Expression of 
the tumour suppressor PTEN at sites of invasive growth and destruction. 
Arthritis Res, 2, 59-64. 
PAP, T., MULLER-LADNER, U., GAY, R. E. & GAY, S. (2000b) Fibroblast biology. 
Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis 
Res, 2, 361-7. 
PAP, T., AUPPERLE, K. R., GAY, S., FIRESTEIN, G. S. AND GAY, R. E. (2001) 
Invasiveness of synovial fibroblasts is regulated by p53 in the SCID mouse in 
vivo model of cartilage invasion. Arthritis Rheum, 44, 676-81. 
PARKER, J. M., GUO, D. & HODGES, R. S. (1986) New hydrophilicity scale derived 
from high-performance liquid chromatography peptide retention data: 
correlation of predicted surface residues with antigenicity and X-ray-derived 
accessible sites. Biochemistry, 25, 5425-32. 
PAROLINI, S., BOTTINO, C., FALCO, M., AUGUGLIARO, R., GILIANI, S., 
FRANCESCHINI, R., OCHS, H. D., WOLF, H., BONNEFOY, J. Y., 
BIASSONI, R., MORETTA, L., NOTARANGELO, L. D. & MORETTA, A. 
(2000) X-linked lymphoproliferative disease. 2B4 molecules displaying 
inhibitory rather than activating function are responsible for the inability of 
natural killer cells to kill Epstein-Barr virus-infected cells. J Exp Med, 192, 337-
46. 
PARSONAGE, G., FALCIANI, F., BURMAN, A., FILER, A., ROSS, E., BOFILL, 
M., MARTIN, S., SALMON, M. & BUCKLEY, C. D. (2003) Global gene 
expression profiles in fibroblasts from synovial, skin and lymphoid tissue 
reveals distinct cytokine and chemokine expression patterns. Thromb Haemost, 
90, 688-97. 
PASCUAL, M., KOELEMAN, B. P., EERLIGH, P., ROEP, B. O. & MARTIN, J. 
(2003) Distribution of HERV-LTR elements in HLA-DQB1 alleles: comments 
on the article by Bieda et al. Diabetologia, 46, 869-70; author reply 870-1. 
PASCUAL, M., MARTIN, J., NIETO, A., GIPHART, M. J., VAN DER SLIK, A. R., 
DE VRIES, R. R. & ZANELLI, E. (2001) Distribution of HERV-LTR elements 
in the 5'-flanking region of HLA-DQB1 and association with autoimmunity. 
Immunogenetics, 53, 114-8. 
PASPARAKIS, M., ALEXOPOULOU, L., EPISKOPOU, V. & KOLLIAS, G. (1996) 
Immune and inflammatory responses in TNF alpha-deficient mice: a critical 
requirement for TNF alpha in the formation of primary B cell follicles, follicular 
dendritic cell networks and germinal centers, and in the maturation of the 
humoral immune response. J Exp Med, 184, 1397-411. 
PATTISON, D. J., SILMAN, A. J., GOODSON, N. J., LUNT, M., BUNN, D., 
LUBEN, R., WELCH, A., BINGHAM, S., KHAW, K. T., DAY, N. & 
SYMMONS, D. P. (2004a) Vitamin C and the risk of developing inflammatory 
polyarthritis: prospective nested case-control study. Ann Rheum Dis, 63, 843-7. 
290 
 
PATTISON, D. J., SYMMONS, D. P., LUNT, M., WELCH, A., LUBEN, R., 
BINGHAM, S. A., KHAW, K. T., DAY, N. E. & SILMAN, A. J. (2004b) 
Dietary risk factors for the development of inflammatory polyarthritis: evidence 
for a role of high level of red meat consumption. Arthritis Rheum, 50, 3804-12. 
PAVLICEK, A., PACES, J., ELLEDER, D. & HEJNAR, J. (2002) Processed 
pseudogenes of human endogenous retroviruses generated by LINEs: their 
integration, stability, and distribution. Genome Res, 12, 391-9. 
PAWELEC, G., AKBAR, A., CARUSO, C., SOLANA, R., GRUBECK-
LOEBENSTEIN, B. & WIKBY, A. (2005) Human immunosenescence: is it 
infectious? Immunol Rev, 205, 257-68. 
PEELING, R. W., WANG, S. P., GRAYSTON, J. T., BLASI, F., BOMAN, J., CLAD, 
A., FREIDANK, H., GAYDOS, C. A., GNARPE, J., HAGIWARA, T., JONES, 
R. B., ORFILA, J., PERSSON, K., PUOLAKKAINEN, M., SAIKKU, P. & 
SCHACHTER, J. (2000) Chlamydia pneumoniae serology: interlaboratory 
variation in microimmunofluorescence assay results. J Infect Dis, 181 Suppl 3, 
S426-9. 
PELLEQUER, J. L. & WESTHOF, E. (1993) PREDITOP: a program for antigenicity 
prediction. J Mol Graph, 11, 204-10, 191-2. 
PELTON, B. K., NORTH, M., PALMER, R. G., HYLTON, W., SMITH-
BURCHNELL, C., SINCLAIR, A. L., MALKOVSKY, M., DALGLEISH, A. 
G. & DENMAN, A. M. (1988) A search for retrovirus infection in systemic 
lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis, 47, 206-9. 
PERL, A. (2001) Endogenous retroviruses in pathogenesis of autoimmunity. J 
Rheumatol, 28, 461-4. 
PERL, A. (2003) Role of endogenous retroviruses in autoimmune diseases. Rheum Dis 
Clin North Am, 29, 123-43, vii. 
PERRON, H., JOUVIN-MARCHE, E., MICHEL, M., OUNANIAN-PARAZ, A., 
CAMELO, S., DUMON, A., JOLIVET-REYNAUD, C., MARCEL, F., 
SOUILLET, Y., BOREL, E., GEBUHRER, L., SANTORO, L., MARCEL, S., 
SEIGNEURIN, J. M., MARCHE, P. N. & LAFON, M. (2001) Multiple 
sclerosis retrovirus particles and recombinant envelope trigger an abnormal 
immune response in vitro, by inducing polyclonal Vbeta16 T-lymphocyte 
activation. Virology, 287, 321-32. 
PETERHANS, E., ZANONI, R. & BERTONI, G. (1999) How to succeed as a virus: 
strategies for dealing with the immune system. Vet Immunol Immunopathol, 72, 
111-7. 
PETERSEN, C. P., BORDELEAU, M. E., PELLETIER, J. & SHARP, P. A. (2006) 
Short RNAs repress translation after initiation in mammalian cells. Mol Cell, 21, 
533-42. 
PETROPOULUS, C. (1997) Retroviral taxonomy, protein structures, sequences and 
genetic maps. IN COFFIN, J. M., HUGHES, S. H., AND VARMUS, H. E., 
(Ed.) Retroviruses. New York, Cold Spring Harbour Laboratory press. 
PETROVSKY, N. & BRUSIC, V. (2006) Bioinformatics for study of autoimmunity. 
Autoimmunity, 39, 635-43. 
PFAFFL, M. W., GEORGIEVA, T. M., GEORGIEV, I. P., ONTSOUKA, E., 
HAGELEIT, M. & BLUM, J. W. (2002) Real-time RT-PCR quantification of 
insulin-like growth factor (IGF)-1, IGF-1 receptor, IGF-2, IGF-2 receptor, 
insulin receptor, growth hormone receptor, IGF-binding proteins 1, 2 and 3 in 
the bovine species. Domest Anim Endocrinol, 22, 91-102. 
291 
 
PIERER, M., RETHAGE, J., SEIBL, R., LAUENER, R., BRENTANO, F., WAGNER, 
U., HANTZSCHEL, H., MICHEL, B. A., GAY, R. E., GAY, S. & KYBURZ, 
D. (2004) Chemokine secretion of rheumatoid arthritis synovial fibroblasts 
stimulated by Toll-like receptor 2 ligands. J Immunol, 172, 1256-65. 
PILLAI, R. S., BHATTACHARYYA, S. N. & FILIPOWICZ, W. (2007) Repression of 
protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol, 17, 
118-26. 
PILLINGER, M. H. & ABRAMSON, S. B. (1995) The neutrophil in rheumatoid 
arthritis. Rheum Dis Clin North Am, 21, 691-714. 
POGUE, G. P., HOFMANN, J., DUNCAN, R., BEST, J. M., ETHERINGTON, J., 
SONTHEIMER, R. D. & NAKHASI, H. L. (1996) Autoantigens interact with 
cis-acting elements of rubella virus RNA. J Virol, 70, 6269-77. 
POLGAR, A., FALUS, A., KOO, E., UJFALUSSY, I., SESZTAK, M., SZUTS, I., 
KONRAD, K., HODINKA, L., BENE, E., MESZAROS, G., ORTUTAY, Z., 
FARKAS, E., PAKSY, A. & BUZAS, E. I. (2003) Elevated levels of synovial 
fluid antibodies reactive with the small proteoglycans biglycan and decorin in 
patients with rheumatoid arthritis or other joint diseases. Rheumatology 
(Oxford), 42, 522-7. 
PONFERRADA, V. G., MAUCK, B. S. & WOOLEY, D. P. (2003) The envelope 
glycoprotein of human endogenous retrovirus HERV-W induces cellular 
resistance to spleen necrosis virus. Arch Virol, 148, 659-75. 
PONNUSWAMY, P. K., PRABHAKARAN, M. & MANAVALAN, P. (1980) 
Hydrophobic packing and spatial arrangement of amino acid residues in 
globular proteins. Biochim Biophys Acta, 623, 301-16. 
POSTEPSKI, J., OPOKA-WINIARSKA, V., KOZIOL-MONTEWKA, M., 
KOROBOWICZ, A. & TUSZKIEWICZ-MISZTAL, E. (2003) Role of 
mycoplasma pneumoniae infection in aetiopathogenesis of juvenile idiopatic 
arthritis. Med Wieku Rozwoj, 7, 271-7. 
POWELL, A. M. & BLACK, M. M. (2001) Epitope spreading: protection from 
pathogens, but propagation of autoimmunity? Clin Exp Dermatol, 26, 427-33. 
PROCACCIA, S., GASPARINI, A., COLUCCI, A., LANZANOVA, D., BIANCHI, 
M., FORCELLINI, P., VILLA, P., BLASIO, R. & ZANUSSI, C. (1987) ELISA 
determined IgM, IgG and IgA rheumatoid factors in rheumatoid arthritis and in 
other connective tissue diseases. Clin Exp Rheumatol, 5, 335-42. 
QIAGEN (2006) Critical Factors for Successful Real-Time PCR Nanogene. 
RAHMAN, A. & HIEPE, F. (2002) Anti-DNA antibodies--overview of assays and 
clinical correlations. Lupus, 11, 770-3. 
RAM, S. & SHANKER, R. (2005) Computing TaqMan probes for multiplex PCR 
detection of E. coli O157 serotypes in water. In Silico Biol, 5, 499-504. 
RAMAKERS, C., RUIJTER, J. M., DEPREZ, R. H. & MOORMAN, A. F. (2003) 
Assumption-free analysis of quantitative real-time polymerase chain reaction 
(PCR) data. Neurosci Lett, 339, 62-6. 
RAMAN, C. (2002) CD5, an important regulator of lymphocyte selection and immune 
tolerance. Immunol Res, 26, 255-63. 
RAMOS-NINO, M. E., SCAPOLI, L., MARTINELLI, M., LAND, S. & MOSSMAN, 
B. T. (2003) Microarray analysis and RNA silencing link fra-1 to cd44 and c-
met expression in mesothelioma. Cancer Res, 63, 3539-45. 
RANDEN, I., BROWN, D., THOMPSON, K. M., HUGHES-JONES, N., PASCUAL, 
V., VICTOR, K., CAPRA, J. D., FORRE, O. & NATVIG, J. B. (1992) Clonally 
292 
 
related IgM rheumatoid factors undergo affinity maturation in the rheumatoid 
synovial tissue. J Immunol, 148, 3296-301. 
RANTAPAA-DAHLQVIST, S., DE JONG, B. A., BERGLIN, E., HALLMANS, G., 
WADELL, G., STENLUND, H., SUNDIN, U. & VAN VENROOIJ, W. J. 
(2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor 
predict the development of rheumatoid arthritis. Arthritis Rheum, 48, 2741-9. 
RAU, R., HERBORN, G., MENNINGER, H. & BLECHSCHMIDT, J. (1997) 
Comparison of intramuscular methotrexate and gold sodium thiomalate in the 
treatment of early erosive rheumatoid arthritis: 12 month data of a double-blind 
parallel study of 174 patients. Br J Rheumatol, 36, 345-52. 
REES, A. R., STAUNTON, D., WEBSTER, D. M., SEARLE, S. J., HENRY, A. H. & 
PEDERSEN, J. T. (1994) Antibody design: beyond the natural limits. Trends 
Biotechnol, 12, 199-206. 
REFF, M. E., CARNER, K., CHAMBERS, K. S., CHINN, P. C., LEONARD, J. E., 
RAAB, R., NEWMAN, R. A., HANNA, N. & ANDERSON, D. R. (1994) 
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody 
to CD20. Blood, 83, 435-45. 
RENAUDINEAU, Y., VALLET, S., LE DANTEC, C., HILLION, S., SARAUX, A. & 
YOUINOU, P. (2005) Characterization of the human CD5 endogenous 
retrovirus-E in B lymphocytes. Genes Immun, 6, 663-71. 
REPASKE, R., STEELE, P. E., O'NEILL, R. R., RABSON, A. B. & MARTIN, M. A. 
(1985) Nucleotide sequence of a full-length human endogenous retroviral 
segment. J Virol, 54, 764-72. 
REUS, K., MAYER, J., SAUTER, M., ZISCHLER, H., MULLER-LANTZSCH, N. & 
MEESE, E. (2001) HERV-K(OLD): ancestor sequences of the human 
endogenous retrovirus family HERV-K(HML-2). J Virol, 75, 8917-26. 
REVIRON, D., PERDRIGER, A., TOUSSIROT, E., WENDLING, D., 
BALANDRAUD, N., GUIS, S., SEMANA, G., TIBERGHIEN, P., MERCIER, 
P. & ROUDIER, J. (2001) Influence of shared epitope-negative HLA-DRB1 
alleles on genetic susceptibility to rheumatoid arthritis. Arthritis Rheum, 44, 
535-40. 
RINI, J. M., SCHULZE-GAHMEN, U. & WILSON, I. A. (1992) Structural evidence 
for induced fit as a mechanism for antibody-antigen recognition. Science, 255, 
959-65. 
RIRIE, K. M., RASMUSSEN, R. P. & WITTWER, C. T. (1997) Product differentiation 
by analysis of DNA melting curves during the polymerase chain reaction. Anal 
Biochem, 245, 154-60. 
RIZOU, C., IOANNIDIS, J. P., PANOU-POMONIS, E., SAKARELLOS-
DAITSIOTIS, M., SAKARELLOS, C., MOUTSOPOULOS, H. M. & 
VLACHOYIANNOPOULOS, P. G. (2000) B-Cell epitope mapping of DNA 
topoisomerase I defines epitopes strongly associated with pulmonary fibrosis in 
systemic sclerosis. Am J Respir Cell Mol Biol, 22, 344-51. 
ROBERTS, C. R., HERRMANN, M., AICHER, W. K., MULLERLADNER, U., 
MATSUMOTO, S., GAY, R. E., KALDEN, J. R. & GAY, S. (1995) Sequences 
Derived from Pcr Amplification of Virus-Like Particles (Vlp) Present in 
Synovial-Fluid of Patients with Rheumatoid Arthritis(Ra). Arthritis and 
Rheumatism, 38, 388-388. 
RONAGHY, A., PRAKKEN, B. J., TAKABAYASHI, K., FIRESTEIN, G. S., 
BOYLE, D., ZVAILFLER, N. J., ROORD, S. T., ALBANI, S., CARSON, D. 
293 
 
A. & RAZ, E. (2002) Immunostimulatory DNA sequences influence the course 
of adjuvant arthritis. J Immunol, 168, 51-6. 
ROSE, G. D., GIERASCH, L. M. & SMITH, J. A. (1985) Turns in peptides and 
proteins. Adv Protein Chem, 37, 1-109. 
ROUTSIAS, J. G., TZIOUFAS, A. G. & MOUTSOPOULOS, H. M. (2004) The 
clinical value of intracellular autoantigens B-cell epitopes in systemic rheumatic 
diseases. Clin Chim Acta, 340, 1-25. 
ROUTSIAS, J. G., TZIOUFAS, A. G., SAKARELLOS-DAITSIOTIS, M., 
SAKARELLOS, C. & MOUTSOPOULOS, H. M. (1996) Epitope mapping of 
the Ro/SSA60KD autoantigen reveals disease-specific antibody-binding 
profiles. Eur J Clin Invest, 26, 514-21. 
ROY-BURMAN, P. (1995) Endogenous env elements: partners in generation of 
pathogenic feline leukemia viruses. Virus Genes, 11, 147-61. 
RUBIN, H. (1965) Genetic Control of Cellular Susceptibility to Pseudotypes of Rous 
Sarcoma Virus. Virology, 26, 270-6. 
RUPRECHT, K., OBOJES, K., WENGEL, V., GRONEN, F., KIM, K. S., PERRON, 
H., SCHNEIDER-SCHAULIES, J. AND RIECKMANN, P. (2006) Regulation 
of human endogenous retrovirus W protein expression by herpes simplex virus 
type 1: implications for multiple sclerosis. J Neurovirol, 12, 65-71. 
RYAN, F. P. (2004) Human endogenous retroviruses in health and disease: a symbiotic 
perspective. J R Soc Med, 97, 560-5. 
SAAG, K. G., CRISWELL, L. A., SEMS, K. M., NETTLEMAN, M. D. & KOLLURI, 
S. (1996) Low-dose corticosteroids in rheumatoid arthritis. A meta-analysis of 
their moderate-term effectiveness. Arthritis Rheum, 39, 1818-25. 
SAAL, J. G., KRIMMEL, M., STEIDLE, M., GERNETH, F., WAGNER, S., FRITZ, 
P., KOCH, S., ZACHER, J., SELL, S., EINSELE, H. & MULLER, C. A. (1999) 
Synovial Epstein-Barr virus infection increases the risk of rheumatoid arthritis 
in individuals with the shared HLA-DR4 epitope. Arthritis Rheum, 42, 1485-96. 
SAHA, S. & RAGHAVA, G. P. S. (2004) BcePred: Prediction of continuous B-cell 
epitopes in antigenic sequences using physico-chemical properties. Artificial 
Immune Systems, Proceedings. 
SALAFFI, F., FERRACCIOLI, G., PERONI, M., CAROTTI, M., BARTOLI, E. & 
CERVINI, C. (1994) Progression of erosion and joint space narrowing scores in 
rheumatoid arthritis assessed by nonlinear models. J Rheumatol, 21, 1626-30. 
SALGHETTI, S., MARIANI, R., AND SKOWRONSKI, J. (1995). Human 
immunodeficiency virus type 1 Nef and p56lck protein-tyrosine kinase interact 
with a common element in CD4 cytoplasmic tail. Proc Natl Acad Sci U S A 92, 
349-353. 
SALMON, M. & AKBAR, A. N. (2004) Telomere erosion: a new link between HLA 
DR4 and rheumatoid arthritis? Trends Immunol, 25, 339-41. 
SALMON, M., SCHEEL-TOELLNER, D., HUISSOON, A. P., PILLING, D., 
SHAMSADEEN, N., HYDE, H., D'ANGEAC, A. D., BACON, P. A., EMERY, 
P. & AKBAR, A. N. (1997) Inhibition of T cell apoptosis in the rheumatoid 
synovium. J Clin Invest, 99, 439-46. 
SALMONS, B. & GUNZBURG, W. H. (1987) Current perspectives in the biology of 
mouse mammary tumour virus. Virus Res, 8, 81-102. 
SALTARELLI, M., QUERAT, G., KONINGS, D. A., VIGNE, R. & CLEMENTS, J. E. 
(1990) Nucleotide sequence and transcriptional analysis of molecular clones of 
CAEV which generate infectious virus. Virology, 179, 347-64. 
294 
 
SALZER, U., CHAPEL, H. M., WEBSTER, A. D., PAN-HAMMARSTROM, Q., 
SCHMITT-GRAEFF, A., SCHLESIER, M., PETER, H. H., ROCKSTROH, J. 
K., SCHNEIDER, P., SCHAFFER, A. A., HAMMARSTROM, L. & 
GRIMBACHER, B. (2005) Mutations in TNFRSF13B encoding TACI are 
associated with common variable immunodeficiency in humans. Nat Genet, 37, 
820-8. 
SAMBROOK J & RUSSELL, D. (2000) Molecular Cloning: A Laboratory Manual, 
Cold Spring Harbor Laboratory Press. 
SANDER, D. M., SZABO, S., GALLAHER, W. R., DEAS, J. E., THOMPSON, J. J., 
CAO, Y., LUO-ZHANG, H., LIU, L. G., COLMEGNA, I., KOEHLER, J., 
ESPINOZA, L. R., ALEXANDER, S. S., HART, D. J., TOM, D. M., FERMIN, 
C. D., JASPAN, J. J., KULAKOSKY, P. C., TENENBAUM, S. A., WILSON, 
R. B. & GARRY, R. F. (2005) Involvement of human intracisternal A-type 
retroviral particles in autoimmunity. Microsc Res Tech, 68, 222-34. 
SAUTER, M., SCHOMMER, S., KREMMER, E., REMBERGER, K., DOLKEN, G., 
LEMM, I., BUCK, M., BEST, B., NEUMANN-HAEFELIN, D. & MUELLER-
LANTZSCH, N. (1995) Human endogenous retrovirus K10: expression of Gag 
protein and detection of antibodies in patients with seminomas. J Virol, 69, 414-
21. 
SCHETT, G., HAYER, S., ZWERINA, J., REDLICH, K. & SMOLEN, J. S. (2005) 
Mechanisms of Disease: the link between RANKL and arthritic bone disease. 
Nat Clin Pract Rheumatol, 1, 47-54. 
SCHMITT, J. & PAPISCH, W. (2002) Recombinant autoantigens. Autoimmun Rev, 1, 
79-88. 
SCHON, U., SEIFARTH, W., BAUST, C., HOHENADL, C., ERFLE, V. & LEIB-
MOSCH, C. (2001) Cell type-specific expression and promoter activity of 
human endogenous retroviral long terminal repeats. Virology, 279, 280-91. 
SCHONLAND, S. O., LOPEZ, C., WIDMANN, T., ZIMMER, J., BRYL, E., 
GORONZY, J. J. & WEYAND, C. M. (2003) Premature telomeric loss in 
rheumatoid arthritis is genetically determined and involves both myeloid and 
lymphoid cell lineages. Proc Natl Acad Sci U S A, 100, 13471-6. 
SCHUELER-FURMAN, O., ELBER, R. & MARGALIT, H. (1998) Knowledge-based 
structure prediction of MHC class I bound peptides: a study of 23 complexes. 
Fold Des, 3, 549-64. 
SCOFIELD, R. H. (2004) Autoantibodies as predictors of disease. Lancet, 363, 1544-6. 
SCOFIELD, R. H. & HARLEY, J. B. (1991) Autoantigenicity of Ro/SSA antigen is 
related to a nucleocapsid protein of vesicular stomatitis virus. Proc Natl Acad 
Sci U S A, 88, 3343-7. 
SEEMAYER, C. A., KOLB, S. A., NEIDHART, M., OHSHIMA, S., GAY, R. E., 
MICHEL, B. A., GAY, S., BONI, J. & SCHUPBACH, J. (2002) Absence of 
inducible retroviruses from synovial fibroblasts and synovial fluid cells of 
patients with rheumatoid arthritis. Arthritis Rheum, 46, 2811-3. 
SEEMAYER, C. A., KUCHEN, S., NEIDHART, M., KUENZLER, P., RIHOSKOVA, 
V., NEUMANN, E., PRUSCHY, M., AICHER, W. K., MULLER-LADNER, 
U., GAY, R. E., MICHEL, B. A., FIRESTEIN, G. S. & GAY, S. (2003) p53 in 
rheumatoid arthritis synovial fibroblasts at sites of invasion. Ann Rheum Dis, 62, 
1139-44. 
SEGGERSON, K., TANG, L. & MOSS, E. G. (2002) Two genetic circuits repress the 
Caenorhabditis elegans heterochronic gene lin-28 after translation initiation. 
Dev Biol, 243, 215-25. 
295 
 
SEIDL, C., DONNER, H., PETERSHOFEN, E., USADEL, K. H., SEIFRIED, E., 
KALTWASSER, J. P. & BADENHOOP, K. (1999) An endogenous retroviral 
long terminal repeat at the HLA-DQB1 gene locus confers susceptibility to 
rheumatoid arthritis. Hum Immunol, 60, 63-8. 
SEIFARTH, W., BAUST, C., MURR, A., SKLADNY, H., KRIEG-SCHNEIDER, F., 
BLUSCH, J., WERNER, T., HEHLMANN, R. & LEIB-MOSCH, C. (1998) 
Proviral structure, chromosomal location, and expression of HERV-K-T47D, a 
novel human endogenous retrovirus derived from T47D particles. J Virol, 72, 
8384-91. 
SEIFARTH, W., FRANK, O., ZEILFELDER, U., SPIESS, B., GREENWOOD, A. D., 
HEHLMANN, R. & LEIB-MOSCH, C. (2005) Comprehensive analysis of 
human endogenous retrovirus transcriptional activity in human tissues with a 
retrovirus-specific microarray. J Virol, 79, 341-52. 
SEKINE, T., MASUKO-HONGO, K., MATSUI, T., ASAHARA, H., TAKIGAWA, 
M., NISHIOKA, K. & KATO, T. (2001) Recognition of YKL-39, a human 
cartilage related protein, as a target antigen in patients with rheumatoid arthritis. 
Ann Rheum Dis, 60, 49-54. 
SERRA, C., MAMELI, G., ARRU, G., SOTGIU, S., ROSATI, G. & DOLEI, A. (2003) 
In vitro modulation of the multiple sclerosis (MS)-associated retrovirus by 
cytokines: implications for MS pathogenesis. J Neurovirol, 9, 637-43. 
SHAHINIAN, A., PFEFFER, K., LEE, K. P., KUNDIG, T. M., KISHIHARA, K., 
WAKEHAM, A., KAWAI, K., OHASHI, P. S., THOMPSON, C. B. & MAK, 
T. W. (1993) Differential T cell costimulatory requirements in CD28-deficient 
mice. Science, 261, 609-12. 
SHAMSUDDIN, A. M. & HARRIS, C. C. (1983) Improved enzyme immunoassays 
using biotin-avidin-enzyme complex. Arch Pathol Lab Med, 107, 514-7. 
SHEEHY, A. M., GADDIS, N. C., CHOI, J. D. & MALIM, M. H. (2002) Isolation of a 
human gene that inhibits HIV-1 infection and is suppressed by the viral Vif 
protein. Nature, 418, 646-50. 
SHEN, G. Q., SHOENFELD, Y. & PETER, J. B. (1998) Anti-DNA, antihistone, and 
antinucleosome antibodies in systemic lupus erythematosus and drug-induced 
lupus. Clin Rev Allergy Immunol, 16, 321-34. 
SHLOMCHIK, M., NEMAZEE, D., VAN SNICK, J. & WEIGERT, M. (1987a) 
Variable region sequences of murine IgM anti-IgG monoclonal autoantibodies 
(rheumatoid factors). II. Comparison of hybridomas derived by 
lipopolysaccharide stimulation and secondary protein immunization. J Exp Med, 
165, 970-87. 
SHLOMCHIK, M. J., MARSHAK-ROTHSTEIN, A., WOLFOWICZ, C. B., 
ROTHSTEIN, T. L. & WEIGERT, M. G. (1987b) The role of clonal selection 
and somatic mutation in autoimmunity. Nature, 328, 805-11. 
SHRAKE, A. & RUPLEY, J. A. (1973) Environment and exposure to solvent of 
protein atoms. Lysozyme and insulin. J Mol Biol, 79, 351-71. 
SICAT, J., SUTKOWSKI, N. & HUBER, B. T. (2005) Expression of human 
endogenous retrovirus HERV-K18 superantigen is elevated in juvenile 
rheumatoid arthritis. J Rheumatol, 32, 1821-31. 
SILMAN, A. J. (1992) Pregnancy and scleroderma. Am J Reprod Immunol, 28, 238-40. 
SIMON, J. H., GADDIS, N. C., FOUCHIER, R. A. AND MALIM, M. H. (1998) 
Evidence for a newly discovered cellular anti-HIV-1 phenotype.  Nat Med, 4, 
1397-400. 
296 
 
SIMON, M., GIRBAL, E., SEBBAG, M., GOMES-DAUDRIX, V., VINCENT, C., 
SALAMA, G. & SERRE, G. (1993) The cytokeratin filament-aggregating 
protein filaggrin is the target of the so-called "antikeratin antibodies," 
autoantibodies specific for rheumatoid arthritis. J Clin Invest, 92, 1387-93. 
SJOTTEM, E., ANDERSSEN, S. & JOHANSEN, T. (1996) The promoter activity of 
long terminal repeats of the HERV-H family of human retrovirus-like elements 
is critically dependent on Sp1 family proteins interacting with a GC/GT box 
located immediately 3' to the TATA box. J Virol, 70, 188-98. 
SMALHEISER, N. R. & TORVIK, V. I. (2005) Mammalian microRNAs derived from 
genomic repeats. Trends Genet, 21, 322-6. 
SMALHEISER, N. R. & TORVIK, V. I. (2006) Alu elements within human mRNAs 
are probable microRNA targets. Trends Genet, 22, 532-6. 
SMETS, F. & SOKAL, E. M. (2002) Lymphoproliferation in children after liver 
transplantation. J Pediatr Gastroenterol Nutr, 34, 499-505. 
SMITH, J. M. & HAIGH, J. (1974) The hitch-hiking effect of a favourable gene. Genet 
Res, 23, 23-35. 
SMITH, K. A., NELSON, P. N., WARREN, P., ASTLEY, S. J., MURRAY, P. G. & 
GREENMAN, J. (2004) Demystified...recombinant antibodies. J Clin Pathol, 
57, 912-7. 
SMOLEN, J. S. & STEINER, G. (2003) Therapeutic strategies for rheumatoid arthritis. 
Nat Rev Drug Discov, 2, 473-88. 
SONVEAUX, P., BROUET, A., HAVAUX, X., GREGOIRE, V., DESSY, C., 
BALLIGAND, J. L. & FERON, O. (2003) Irradiation-induced angiogenesis 
through the up-regulation of the nitric oxide pathway: implications for tumor 
radiotherapy. Cancer Res, 63, 1012-9. 
SPECTOR, T. D. & HOCHBERG, M. C. (1990) The protective effect of the oral 
contraceptive pill on rheumatoid arthritis: an overview of the analytic 
epidemiological studies using meta-analysis. J Clin Epidemiol, 43, 1221-30. 
SPENCER, T. E., JOHNSON, G. A., BAZER, F. W., BURGHARDT, R. C. & 
PALMARINI, M. (2007) Pregnancy recognition and conceptus implantation in 
domestic ruminants: roles of progesterone, interferons and endogenous 
retroviruses. Reprod Fertil Dev, 19, 65-78. 
STANFIELD, R. L., FIESER, T. M., LERNER, R. A. & WILSON, I. A. (1990) Crystal 
structures of an antibody to a peptide and its complex with peptide antigen at 
2.8 A. Science, 248, 712-9. 
STAUFFER, Y., THEILER, G., SPERISEN, P., LEBEDEV, Y. & JONGENEEL, C. V. 
(2004) Digital expression profiles of human endogenous retroviral families in 
normal and cancerous tissues. Cancer Immun, 4, 2. 
STEENBAKKERS, P. G., BAETEN, D., ROVERS, E., VEYS, E. M., RIJNDERS, A. 
W., MEIJERINK, J., DE KEYSER, F. & BOOTS, A. M. (2003) Localization of 
MHC class II/human cartilage glycoprotein-39 complexes in synovia of 
rheumatoid arthritis patients using complex-specific monoclonal antibodies. J 
Immunol, 170, 5719-27. 
STEFANI, G. (2007) Roles of microRNAs and their targets in cancer. Expert Opin Biol 
Ther, 7, 1833-40. 
STEIGMANN, F., DOURDOUREKAS, D., SHOBASSAY, N., VITTAL, S. B., 
SZANTO, P. B., AINIS, H., KHIN, U. & TELISCHI, M. (1974) Humoral 
response in patients with liver disease. Am J Gastroenterol, 61, 349-55. 
STOLT, P., BENGTSSON, C., NORDMARK, B., LINDBLAD, S., LUNDBERG, I., 
KLARESKOG, L. & ALFREDSSON, L. (2003) Quantification of the influence 
297 
 
of cigarette smoking on rheumatoid arthritis: results from a population based 
case-control study, using incident cases. Ann Rheum Dis, 62, 835-41. 
STOYE, J. P. (1999) The pathogenic potential of endogenous retroviruses: a sceptical 
view. Trends Microbiol, 7, 430; author reply 431-2. 
STOYE, J. P. (2002) An intracellular block to primate lentivirus replication. Proc Natl 
Acad Sci U S A, 99, 11549-51. 
STRANSKY, G., VERNON, J., AICHER, W. K., MORELAND, L. W., GAY, R. E. & 
GAY, S. (1993) Virus-like particles in synovial fluids from patients with 
rheumatoid arthritis. Br J Rheumatol, 32, 1044-8. 
STREMLAU, M., OWENS, C. M., PERRON, M. J., KIESSLING, M., AUTISSIER, P. 
& SODROSKI, J. (2004) The cytoplasmic body component TRIM5alpha 
restricts HIV-1 infection in Old World monkeys. Nature, 427, 848-53. 
STREMLAU, M., PERRON, M., LEE, M., LI, Y., SONG, B., JAVANBAKHT, H., 
DIAZ-GRIFFERO, F., ANDERSON, D. J., SUNDQUIST, W. I. & 
SODROSKI, J. (2006) Specific recognition and accelerated uncoating of 
retroviral capsids by the TRIM5alpha restriction factor. Proc Natl Acad Sci U S 
A, 103, 5514-9. 
STRYNADKA, N. C., REDMOND, M. J., PARKER, J. M., SCRABA, D. G. & 
HODGES, R. S. (1988) Use of synthetic peptides to map the antigenic 
determinants of glycoprotein D of herpes simplex virus. J Virol, 62, 3474-83. 
SUN, Y., ZENG, X. R., WENGER, L., FIRESTEIN, G. S. AND CHEUNG, H. S. 
(2004) P53 down-regulates matrix metalloproteinase-1 by targeting the 
communications between AP-1 and the basal transcription complex. J Cell 
Biochem, 92, 258-69. 
SUNDBERG, E. J., LI, Y. & MARIUZZA, R. A. (2002) So many ways of getting in 
the way: diversity in the molecular architecture of superantigen-dependent T-
cell signaling complexes. Curr Opin Immunol, 14, 36-44. 
SUNDBERG, E. J. & MARIUZZA, R. A. (2002) Molecular recognition in antibody-
antigen complexes. Adv Protein Chem, 61, 119-60. 
SUTKOWSKI, N., CHEN, G., CALDERON, G. & HUBER, B. T. (2004) Epstein-Barr 
virus latent membrane protein LMP-2A is sufficient for transactivation of the 
human endogenous retrovirus HERV-K18 superantigen. J Virol, 78, 7852-60. 
SUTKOWSKI, N., CONRAD, B., THORLEY-LAWSON, D. A. & HUBER, B. T. 
(2001) Epstein-Barr virus transactivates the human endogenous retrovirus 
HERV-K18 that encodes a superantigen. Immunity, 15, 579-89. 
SUZUKI, A., YAMADA, R., CHANG, X., TOKUHIRO, S., SAWADA, T., SUZUKI, 
M., NAGASAKI, M., NAKAYAMA-HAMADA, M., KAWAIDA, R., ONO, 
M., OHTSUKI, M., FURUKAWA, H., YOSHINO, S., YUKIOKA, M., 
TOHMA, S., MATSUBARA, T., WAKITANI, S., TESHIMA, R., NISHIOKA, 
Y., SEKINE, A., IIDA, A., TAKAHASHI, A., TSUNODA, T., NAKAMURA, 
Y. & YAMAMOTO, K. (2003) Functional haplotypes of PADI4, encoding 
citrullinating enzyme peptidylarginine deiminase 4, are associated with 
rheumatoid arthritis. Nat Genet, 34, 395-402. 
SUZUKI, M., TETSUKA, T., YOSHIDA, S., WATANABE, N., KOBAYASHI, M., 
MATSUI, N. & OKAMOTO, T. (2000) The role of p38 mitogen-activated 
protein kinase in IL-6 and IL-8 production from the TNF-alpha- or IL-1beta-
stimulated rheumatoid synovial fibroblasts. FEBS Lett, 465, 23-7. 
SVENSSON, A. C. & ANDERSSON, G. (1997) Presence of retroelements reveal the 
evolutionary history of the human DR haplotypes. Hereditas, 127, 113-24. 
298 
 
SWEENEY, S. E. & FIRESTEIN, G. S. (2004) Rheumatoid arthritis: regulation of 
synovial inflammation. Int J Biochem Cell Biol, 36, 372-8. 
SZEKANECZ, Z. & KOCH, A. E. (2000) Cell-cell interactions in synovitis. 
Endothelial cells and immune cell migration. Arthritis Res, 2, 368-73. 
SZEKANECZ, Z. & KOCH, A. E. (2001) Chemokines and angiogenesis. Curr Opin 
Rheumatol, 13, 202-8. 
TAKAYANAGI, H., IIZUKA, H., JUJI, T., NAKAGAWA, T., YAMAMOTO, A., 
MIYAZAKI, T., KOSHIHARA, Y., ODA, H., NAKAMURA, K. & TANAKA, 
S. (2000) Involvement of receptor activator of nuclear factor kappaB 
ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes 
in rheumatoid arthritis. Arthritis Rheum, 43, 259-69. 
TAKEI, M., MITAMURA, K., FUJIWARA, S., HORIE, T., RYU, J., OSAKA, S., 
YOSHINO, S. & SAWADA, S. (1997) Detection of Epstein-Barr virus-encoded 
small RNA 1 and latent membrane protein 1 in synovial lining cells from 
rheumatoid arthritis patients. Int Immunol, 9, 739-43. 
TAKEMURA, S., KLIMIUK, P. A., BRAUN, A., GORONZY, J. J. & WEYAND, C. 
M. (2001) T cell activation in rheumatoid synovium is B cell dependent. J 
Immunol, 167, 4710-8. 
TAKEUCHI, K., KATSUMATA, K., IKEDA, H., MINAMI, M., WAKISAKA, A. & 
YOSHIKI, T. (1995) Expression of endogenous retroviruses, ERV3 and lambda 
4-1, in synovial tissues from patients with rheumatoid arthritis. Clin Exp 
Immunol, 99, 338-44. 
TALAL, N., GARRY, R. F., SCHUR, P. H., ALEXANDER, S., DAUPHINEE, M. J., 
LIVAS, I. H., BALLESTER, A., TAKEI, M. & DANG, H. (1990) A conserved 
idiotype and antibodies to retroviral proteins in systemic lupus erythematosus. J 
Clin Invest, 85, 1866-71. 
TAM, J. P. & ZAVALA, F. (1989) Multiple antigen peptide. A novel approach to 
increase detection sensitivity of synthetic peptides in solid-phase 
immunoassays. J Immunol Methods, 124, 53-61. 
TAN, E. M. (1989) Do autoantibodies inhibit function of their cognate antigens in 
vivo? Arthritis Rheum, 32, 924-5. 
TANI, Y., TIWANA, H., HUKUDA, S., NISHIOKA, J., FIELDER, M., WILSON, C., 
BANSAL, S. & EBRINGER, A. (1997) Antibodies to Klebsiella, Proteus, and 
HLA-B27 peptides in Japanese patients with ankylosing spondylitis and 
rheumatoid arthritis. J Rheumatol, 24, 109-14. 
TARLINTON, R. E., MEERS, J. & YOUNG, P. R. (2006) Retroviral invasion of the 
koala genome. Nature, 442, 79-81. 
TARUSCIO, D. & MANTOVANI, A. (1998) Human endogenous retroviral sequences: 
possible roles in reproductive physiopathology. Biol Reprod, 59, 713-24. 
TARUSCIO, D. & MANUELIDIS, L. (1991) Integration site preferences of 
endogenous retroviruses. Chromosoma, 101, 141-56. 
TASSABEHJI, M., STRACHAN, T., ANDERSON, M., CAMPBELL, R. D., 
COLLIER, S. & LAKO, M. (1994) Identification of a novel family of human 
endogenous retroviruses and characterization of one family member, HERV-
K(C4), located in the complement C4 gene cluster. Nucleic Acids Res, 22, 5211-
7. 
TEMIN, H. M. & MIZUTANI, S. (1970) RNA-dependent DNA polymerase in virions 
of Rous sarcoma virus. Nature, 226, 1211-3. 
TER STEEGE, J., VIANEN, M., VAN BILSEN, J., BIJLSMA, J., LAFEBER, F. & 
WAUBEN, M. (2003) Identification of self-epitopes recognized by T cells in 
299 
 
rheumatoid arthritis demonstrates matrix metalloproteinases as a novel T cell 
target. J Rheumatol, 30, 1147-56. 
TERATO, K., HARPER, D. S., GRIFFITHS, M. M., HASTY, D. L., YE, X. J., 
CREMER, M. A. & SEYER, J. M. (1995) Collagen-induced arthritis in mice: 
synergistic effect of E. coli lipopolysaccharide bypasses epitope specificity in 
the induction of arthritis with monoclonal antibodies to type II collagen. 
Autoimmunity, 22, 137-47. 
TIAN, J., ATKINSON, M. A., CLARE-SALZLER, M., HERSCHENFELD, A., 
FORSTHUBER, T., LEHMANN, P. V. AND KAUFMAN, D. L. (1996) Nasal 
administration of glutamate decarboxylase (GAD65) peptides induces Th2 
responses and prevents murine insulin-dependent diabetes. J Exp Med, 183, 
1561-7. 
TING, C. N., ROSENBERG, M. P., SNOW, C. M., SAMUELSON, L. C. & 
MEISLER, M. H. (1992) Endogenous retroviral sequences are required for 
tissue-specific expression of a human salivary amylase gene. Genes Dev, 6, 
1457-65. 
TISCH, R., YANG, X. D., SINGER, S. M., LIBLAU, R. S., FUGGER, L. AND 
MCDEVITT, H. O. (1993) Immune response to glutamic acid decarboxylase 
correlates with insulitis in non-obese diabetic mice. Nature, 366, 72-5. 
TORMO, J., BLAAS, D., PARRY, N. R., ROWLANDS, D., STUART, D. & FITA, I. 
(1994) Crystal structure of a human rhinovirus neutralizing antibody complexed 
with a peptide derived from viral capsid protein VP2. Embo J, 13, 2247-56. 
TOWERS, G. J. (2007) The control of viral infection by tripartite motif proteins and 
cyclophilin A. Retrovirology, 4, 40. 
TRABANDT, A., GAY, R. E., FASSBENDER, H. G. & GAY, S. (1991) Cathepsin B 
in synovial cells at the site of joint destruction in rheumatoid arthritis. Arthritis 
Rheum, 34, 1444-51. 
TRIBOULET, R., MARI, B., LIN, Y. L., CHABLE-BESSIA, C., BENNASSER, Y., 
LEBRIGAND, K., CARDINAUD, B., MAURIN, T., BARBRY, P., BAILLAT, 
V., REYNES, J., CORBEAU, P., JEANG, K. T. & BENKIRANE, M. (2007) 
Suppression of microRNA-silencing pathway by HIV-1 during virus replication. 
Science, 315, 1579-82. 
TRISTEM, M. (2000) Identification and characterization of novel human endogenous 
retrovirus families by phylogenetic screening of the human genome mapping 
project database. J Virol, 74, 3715-30. 
TURNER, B. G. AND SUMMERS, M. F. (1999) Structural biology of HIV. J Mol Biol, 
285, 1-32. 
TURNER, G., BARBULESCU, M., SU, M., JENSEN-SEAMAN, M. I., KIDD, K. K. 
& LENZ, J. (2001) Insertional polymorphisms of full-length endogenous 
retroviruses in humans. Curr Biol, 11, 1531-5. 
TYAGI, S. & KRAMER, F. R. (1996) Molecular beacons: probes that fluoresce upon 
hybridization. Nat Biotechnol, 14, 303-8. 
TZIOUFAS, A. G., TZORTZAKIS, N. G., PANOU-POMONIS, E., BOKI, K. A., 
SAKARELLOS-DAITSIOTIS, M., SAKARELLOS, C. & MOUTSOPOULOS, 
H. M. (2000) The clinical relevance of antibodies to ribosomal-P common 
epitope in two targeted systemic lupus erythematosus populations: a large 
cohort of consecutive patients and patients with active central nervous system 
disease. Ann Rheum Dis, 59, 99-104. 
TZIOUFAS, A. G., WASSMUTH, R., DAFNI, U. G., GUIALIS, A., HAGA, H. J., 
ISENBERG, D. A., JONSSON, R., KALDEN, J. R., KIENER, H., 
300 
 
SAKARELLOS, C., SMOLEN, J. S., SUTCLIFFE, N., VITALI, C., 
YIANNAKI, E. & MOUTSOPOULOS, H. M. (2002) Clinical, immunological, 
and immunogenetic aspects of autoantibody production against Ro/SSA, 
La/SSB and their linear epitopes in primary Sjogren's syndrome (pSS): a 
European multicentre study. Ann Rheum Dis, 61, 398-404. 
UEMATSU, S. & AKIRA, S. (2006) Toll-like receptors and innate immunity. J Mol 
Med, 84, 712-25. 
UEMATSU, Y., WEGE, H., STRAUS, A., OTT, M., BANNWARTH, W., 
LANCHBURY, J., PANAYI, G. & STEINMETZ, M. (1991) The T-cell-
receptor repertoire in the synovial fluid of a patient with rheumatoid arthritis is 
polyclonal. Proc Natl Acad Sci U S A, 88, 8534-8. 
URNOVITZ, H. B. & MURPHY, W. H. (1996) Human endogenous retroviruses: 
nature, occurrence, and clinical implications in human disease. Clin Microbiol 
Rev, 9, 72-99. 
VAN BOEKEL, M. A., VOSSENAAR, E. R., VAN DEN HOOGEN, F. H. & VAN 
VENROOIJ, W. J. (2002) Autoantibody systems in rheumatoid arthritis: 
specificity, sensitivity and diagnostic value. Arthritis Res, 4, 87-93. 
VAN DE LAGEMAAT, L. N., MEDSTRAND, P. & MAGER, D. L. (2006) Multiple 
effects govern endogenous retrovirus survival patterns in human gene introns. 
Genome Biol, 7, R86. 
VAN DER GRAAFF, W. L., PRINS, A. P., NIERS, T. M., DIJKMANS, B. A. & VAN 
LIER, R. A. (1999) Quantitation of interferon gamma- and interleukin-4-
producing T cells in synovial fluid and peripheral blood of arthritis patients. 
Rheumatology (Oxford), 38, 214-20. 
VAN DER HEIJDE, D. M. (1995) Joint erosions and patients with early rheumatoid 
arthritis. Br J Rheumatol, 34 Suppl 2, 74-8. 
VAN GENT, D. C., MIZUUCHI, K. & GELLERT, M. (1996) Similarities between 
initiation of V(D)J recombination and retroviral integration. Science, 271, 1592-
4. 
VAN REGENMORTEL, M. H. (2006) Immunoinformatics may lead to a reappraisal of 
the nature of B cell epitopes and of the feasibility of synthetic peptide vaccines. 
J Mol Recognit, 19, 183-7. 
VAN WEEMEN, B. K. & SCHUURS, A. H. (1971) Immunoassay using antigen-
enzyme conjugates. FEBS Lett, 15, 232-236. 
VANDESOMPELE, J., DE PRETER, K., PATTYN, F., POPPE, B., VAN ROY, N., 
DE PAEPE, A. & SPELEMAN, F. (2002) Accurate normalization of real-time 
quantitative RT-PCR data by geometric averaging of multiple internal control 
genes. Genome Biol, 3, RESEARCH0034. 
VARGA, A. & JAMES, D. (2006) Real-time RT-PCR and SYBR Green I melting 
curve analysis for the identification of Plum pox virus strains C, EA, and W: 
effect of amplicon size, melt rate, and dye translocation. J Virol Methods, 132, 
146-53. 
VAUGHAN, J. H., FOX, R. I., ABRESCH, R. J., TSOUKAS, C. D., CURD, J. G. & 
CARSON, D. A. (1984) Thoracic duct drainage in rheumatoid arthritis. Clin 
Exp Immunol, 58, 645-53. 
VENKATACHALAM, C. M. (1968) Stereochemical criteria for polypeptides and 
proteins. VI. Non-bonded energy of polyglycine and poly-L-alanine in the 
crystalline beta-form. Biochim Biophys Acta, 168, 411-6. 
VERHOEF, C. M., VAN ROON, J. A., VIANEN, M. E., BRUIJNZEEL-KOOMEN, C. 
A., LAFEBER, F. P. & BIJLSMA, J. W. (1998) Mutual antagonism of 
301 
 
rheumatoid arthritis and hay fever; a role for type 1/type 2 T cell balance. Ann 
Rheum Dis, 57, 275-80. 
VIGLIANTI, G. A., LAU, C. M., HANLEY, T. M., MIKO, B. A., SHLOMCHIK, M. 
J. & MARSHAK-ROTHSTEIN, A. (2003) Activation of autoreactive B cells by 
CpG dsDNA. Immunity, 19, 837-47. 
VIHINEN, M., TORKKILA, E. & RIIKONEN, P. (1994) Accuracy of protein 
flexibility predictions. Proteins, 19, 141-9. 
VILLARREAL, L. P. (1997) On viruses, sex, and motherhood. J Virol, 71, 859-65. 
VILLESEN, P., AAGAARD, L., WIUF, C. & PEDERSEN, F. S. (2004) Identification 
of endogenous retroviral reading frames in the human genome. Retrovirology, 1, 
32. 
VINEN, C. S. & OLIVEIRA, D. B. (2003) Acute glomerulonephritis. Postgrad Med J, 
79, 206-13; quiz 212-3. 
VINOGRADOVA, T., VOLIK, S., LEBEDEV, Y., SHEVCHENKO, Y., 
LAVRENTYEVA, I., KHIL, P., GRZESCHIK, K. H., ASHWORTH, L. K. & 
SVERDLOV, E. (1997) Positioning of 72 potentially full size LTRs of human 
endogenous retroviruses HERV-K on the human chromosome 19 map. 
Occurrences of the LTRs in human gene sites. Gene, 199, 255-64. 
VOIGT, L. F., KOEPSELL, T. D., NELSON, J. L., DUGOWSON, C. E. & DALING, 
J. R. (1994) Smoking, obesity, alcohol consumption, and the risk of rheumatoid 
arthritis. Epidemiology, 5, 525-32. 
VOLLER, A., BIDWELL, D., HULDT, G. & ENGVALL, E. (1974) A microplate 
method of enzyme-linked immunosorbent assay and its application to malaria. 
Bull World Health Organ, 51, 209-11. 
VRANCKX, R., MUYLLE, L., COLE, J., MOLDENHASER, R. & PEETERMANS, 
M. E. (1986) HBV vaccinations in medical and paramedical staff: the impact of 
age on immunization results. Vox Sang, 50, 220-2. 
WANG-JOHANNING, F., FROST, A. R., JIAN, B., EPP, L., LU, D. W. & 
JOHANNING, G. L. (2003) Quantitation of HERV-K env gene expression and 
splicing in human breast cancer. Oncogene, 22, 1528-35. 
WANG, C. L., WU, Y. T., LEE, C. J., LIU, H. C., HUANG, L. T. & YANG, K. D. 
(2002a) Decreased nitric oxide production after intravenous immunoglobulin 
treatment in patients with Kawasaki disease. J Pediatr, 141, 560-5. 
WANG, J., LIU, X., LI, F. & YAO, L. (2002b) Rheumatoid arthritis is auto-
immunoreaction to collagen II in cartilage happened in synovial tissue. Med 
Hypotheses, 59, 411-5. 
WATSON, J. D. & CRICK, F. H. (1953) Molecular structure of nucleic acids; a 
structure for deoxyribose nucleic acid. Nature, 171, 737-8. 
WEIDHAAS, J. B., ANGELICHIO, E. L., FENNER, S. & COFFIN, J. M. (2000) 
Relationship between retroviral DNA integration and gene expression. J Virol, 
74, 8382-9. 
WEISS, R. A. (2006) The discovery of endogenous retroviruses. Retrovirology, 3, 67. 
WEISS, R. A., FRIIS, R. R., KATZ, E. & VOGT, P. K. (1971) Induction of avian 
tumor viruses in normal cells by physical and chemical carcinogens. Virology, 
46, 920-38. 
WELLCOME TRUST CASE CONTROL CONSORTIUM (2007) Genome-wide 
association study of 14,000 cases of seven common diseases and 3,000 shared 
controls. Nature, 447, 661-78. 
302 
 
WELLING, G. W., WEIJER, W. J., VAN DER ZEE, R. & WELLING-WESTER, S. 
(1985) Prediction of sequential antigenic regions in proteins. FEBS Lett, 188, 
215-8. 
WESTHOF, E., ALTSCHUH, D., MORAS, D., BLOOMER, A. C., MONDRAGON, 
A., KLUG, A. & VAN REGENMORTEL, M. H. (1984) Correlation between 
segmental mobility and the location of antigenic determinants in proteins. 
Nature, 311, 123-6. 
WESTWOOD, O. M., NELSON, P. N. & HAY, F. C. (2006) Rheumatoid factors: 
what's new? Rheumatology (Oxford), 45, 379-85. 
WEYAND, C. M. (2000) New insights into the pathogenesis of rheumatoid arthritis. 
Rheumatology (Oxford), 39 Suppl 1, 3-8. 
WEYAND, C. M., HICOK, K. C., CONN, D. L. & GORONZY, J. J. (1992) The 
influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann 
Intern Med, 117, 801-6. 
WEYAND, C. M., KLIMIUK, P. A. & GORONZY, J. J. (1998) Heterogeneity of 
rheumatoid arthritis: from phenotypes to genotypes. Springer Semin 
Immunopathol, 20, 5-22. 
WHITACRE, C. C., REINGOLD, S. C. & O'LOONEY, P. A. (1999) A gender gap in 
autoimmunity. Science, 283, 1277-8. 
WHITTON, J. L., TISHON, A., LEWICKI, H., GEBHARD, J., COOK, T., 
SALVATO, M., JOLY, E. & OLDSTONE, M. B. (1989) Molecular analyses of 
a five-amino-acid cytotoxic T-lymphocyte (CTL) epitope: an immunodominant 
region which induces nonreciprocal CTL cross-reactivity. J Virol, 63, 4303-10. 
WILDER, R. L. & ELENKOV, I. J. (1999) Hormonal regulation of tumor necrosis 
factor-alpha, interleukin-12 and interleukin-10 production by activated 
macrophages. A disease-modifying mechanism in rheumatoid arthritis and 
systemic lupus erythematosus? Ann N Y Acad Sci, 876, 14-31. 
WILLIAMS, D. G., SHARPE, N. G., WALLACE, G. & LATCHMAN, D. S. (1990) A 
repeated proline-rich sequence in Sm B/B' and N is a dominant epitope 
recognized by human and murine autoantibodies. J Autoimmun, 3, 715-25. 
WILLS, J. W. & CRAVEN, R. C. (1991) Form, function, and use of retroviral gag 
proteins. Aids, 5, 639-54. 
WINCHESTER, R. J. & GREGERSEN, P. K. (1988) The molecular basis of 
susceptibility to rheumatoid arthritis: the conformational equivalence 
hypothesis. Springer Semin Immunopathol, 10, 119-39. 
WINER, J., JUNG, C. K., SHACKEL, I. & WILLIAMS, P. M. (1999) Development 
and validation of real-time quantitative reverse transcriptase-polymerase chain 
reaction for monitoring gene expression in cardiac myocytes in vitro. Anal 
Biochem, 270, 41-9. 
WITTWER, C. T., HERRMANN, M. G., GUNDRY, C. N. & ELENITOBA-
JOHNSON, K. S. (2001) Real-time multiplex PCR assays. Methods, 25, 430-42. 
WOOLEY, P. H., LUTHRA, H. S., SINGH, S. K., HUSE, A. R., STUART, J. M. & 
DAVID, C. S. (1984) Passive transfer of arthritis to mice by injection of human 
anti-type II collagen antibody. Mayo Clin Proc, 59, 737-43. 
WRIGHT, D. A. & VOYTAS, D. F. (2002) Athila4 of Arabidopsis and Calypso of 
soybean define a lineage of endogenous plant retroviruses. Genome Res, 12, 
122-31. 
WUCHERPFENNIG, K. W. (2001) Structural basis of molecular mimicry. J 
Autoimmun, 16, 293-302. 
303 
 
XIONG, Y. & EICKBUSH, T. H. (1990) Origin and evolution of retroelements based 
upon their reverse transcriptase sequences. Embo J, 9, 3353-62. 
YANG, L., HAKODA, M., IWABUCHI, K., TAKEDA, T., KOIKE, T., KAMATANI, 
N. & TAKADA, K. (2004) Rheumatoid factors induce signaling from B cells, 
leading to Epstein-Barr virus and B-cell activation. J Virol, 78, 9918-23. 
YEAST GENOME DIRECTORY (1997) The yeast genome directory. Nature, 387, 5. 
YIANNAKI, E. E., TZIOUFAS, A. G., BACHMANN, M., HANTOUMI, J., 
TSIKARIS, V., SAKARELLOS-DAITSIOTIS, M., SAKARELLOS, C. & 
MOUTSOPOULOS, H. M. (1998) The value of synthetic linear epitope 
analogues of La/SSB for the detection of autoantibodies to La/SSB; specificity, 
sensitivity and comparison of methods. Clin Exp Immunol, 112, 152-8. 
YIN, J. L., SHACKEL, N. A., ZEKRY, A., MCGUINNESS, P. H., RICHARDS, C., 
PUTTEN, K. V., MCCAUGHAN, G. W., ERIS, J. M. & BISHOP, G. A. (2001) 
Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) for 
measurement of cytokine and growth factor mRNA expression with fluorogenic 
probes or SYBR Green I. Immunol Cell Biol, 79, 213-21. 
YODER, J. A., WALSH, C. P. & BESTOR, T. H. (1997) Cytosine methylation and the 
ecology of intragenomic parasites. Trends Genet, 13, 335-40. 
YU, M., JOHNSON, J. M. & TUOHY, V. K. (1996) A predictable sequential 
determinant spreading cascade invariably accompanies progression of 
experimental autoimmune encephalomyelitis: a basis for peptide-specific 
therapy after onset of clinical disease. J Exp Med, 183, 1777-88. 
YU, X., YU, Y., LIU, B., LOU, K., KONG, W., MAO, P. AND YU, X. F. (2003) 
Induction of APOBEC3G ubiquitination and degraded by an HIV-1-Cul5-SCF 
complex.  Science, 302, 1056-60.  
ZANDMAN-GODDARD, G. & SHOENFELD, Y. (2002) HIV and autoimmunity. 
Autoimmun Rev, 1, 329-37. 
ZARE, F., BOKAREWA, M., NENONEN, N., BERGSTROM, T., ALEXOPOULOU, 
L., FLAVELL, R. A. & TARKOWSKI, A. (2004) Arthritogenic properties of 
double-stranded (viral) RNA. J Immunol, 172, 5656-63. 
ZHOU, Z. & MENARD, H. A. (2002) Autoantigenic posttranslational modifications of 
proteins: does it apply to rheumatoid arthritis? Curr Opin Rheumatol, 14, 250-3. 
ZIEGLER, B., GAY, R. E., HUANG, G. Q., FASSBENDER, H. G. & GAY, S. (1989) 
Immunohistochemical localization of HTLV-I p19- and p24-related antigens in 
synovial joints of patients with rheumatoid arthritis. Am J Pathol, 135, 1-5. 
ZOU, J., ZHANG, Y., THIEL, A., RUDWALEIT, M., SHI, S. L., RADBRUCH, A., 
POOLE, R., BRAUN, J. & SIEPER, J. (2003) Predominant cellular immune 
response to the cartilage autoantigenic G1 aggrecan in ankylosing spondylitis 
and rheumatoid arthritis. Rheumatology (Oxford), 42, 846-55. 
ZSIROS, J., JEBBINK, M. F., LUKASHOV, V. V., VOUTE, P. A. & BERKHOUT, B. 
(1999) Biased nucleotide composition of the genome of HERV-K related 
endogenous retroviruses and its evolutionary implications. J Mol Evol, 48, 102-
11. 
ZUURBIER, C. J. & HUIJING, P. A. (1993) Changes in geometry of actively 
shortening unipennate rat gastrocnemius muscle. J Morphol, 218, 167-80. 
ZVAIFLER, N. J. (1973) The immunopathology of joint inflammation in rheumatoid 
arthritis. Adv Immunol, 16, 265-336. 
ZWERINA, J., HAYER, S., TOHIDAST-AKRAD, M., BERGMEISTER, H., 
REDLICH, K., FEIGE, U., DUNSTAN, C., KOLLIAS, G., STEINER, G., 
SMOLEN, J. & SCHETT, G. (2004) Single and combined inhibition of tumor 
304 
 
necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-
induced arthritis: effects on synovial inflammation, bone erosion, and cartilage 
destruction. Arthritis Rheum, 50, 277-90. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
305 
 
 
 
 
 
 
 
 
 
 
 
Appendix I: 
HERV/Autoantigen Epitope maps 
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HERV Epitope maps 
 
 
 
 
 
 
Figure APP1.1.  Epitope map for HERV-K (Y168890) 
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Figure APP1.2.  Epitope map for HERV-E (4-1) (M10976) 
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Figure APP1.3.  Epitope map for ERV3 (M12140) 
309 
 
Autoantigen epitope maps 
 
 
 
Figure APP1.4.  Epitope map for Ro/SSA 60 (NP_004591)
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Figure APP1.5.  Epitope map for Ro/SSA 52 (NP_003132) 
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 Figure APP1.6.  Epitope map for Ku80 (NP_066964)
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Figure APP1.7.  Epitope map for La/SSB (NP_003133) 
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Appendix II:  
Full ELISA results for all diseases 
tested - CFS. 
 
 
 
314 
 
RA SL
E OA IB
D
CF
S
NH
D
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
0.16
0.18
Disease state
A
45
0
 
 
 
 
 
 
 
 
 
Figure APP2.1 OD values for patient sera from different disease groups using non-biotinylated GfPN1kpr peptide. 
Figure APP2.2 OD values for patient sera from different disease groups using non-biotinylated GfPN2eip peptide.
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Figure APP2.3 The distribution of OD values for reactivity of patient disease cohorts using the PLSK 
peptide 
Figure APP2.4 Distribution of reactivity in patient sera using the Negcont1 peptide 
* 
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Figure APP2.5 OD values for patient serum from different disease groups using biotinylated GfPN1kpr 
peptide.  ** indicates levels of significance of RA over other disease cohorts.  Lines show group means. 
Figure APP2.6  OD values for patient serum from different disease groups using biotinylated GfPN2eip 
peptide.  ** indicates levels of significance of RA over other disease cohorts.  Lines show group means. 
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Appendix III: 
Cell culture reagents and conditions 
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Cell culture reagents 
Growth media and conditions  
 
Equipment 
 
Hanks’ Buffered salt solution (Sigma, H6648)     
1xTrypsin-EDTA solution (Sigma, T4415)      
FCS (PAA, A14-144)         
DMSO – Dimethyl sulphoxide (Sigma, D8418)     
500ml filter system (0.2mm nylon) (Corning) 
T25/T75/T175 Tissue culture flasks (Sarstedt) 
10ml/25ml pipettes (Sarstedt) 
1000μl pipette tips (Starstedt) 
Sterile aspirator tips (Starstedt) 
20ml Centrifuge tubes 
Cryovials (Nalgene) 
 
 
Methodology 
To one bottle of RPMI 1640 (Tera-1/GH/BJAB/Jurkat/B95.8) add: 
• Fetal bovine serum (10%) 
• L-Glutamine (0.3g/l) 
• Either: Penicillin (50000IU/l) or Streptomycin (50mg/l) 
 
To one bottle of MEM (HEK-293) add: 
• Fetal bovine serum (10%) 
• 1M HEPES 
• 0.1mM non-essential amino acids 
 
To one bottle of MEM (MCF7) add: 
• Fetal bovine serum (10%) 
• 1.5g/l sodium bicarbonate 
• 0.1mM non essential amino acids 
• 1mM sodium pyruvate 
 
To one bottle of human synoviocyte basal medium (HFLS) add: 
• One bottle of human fibroblast growth supplement (Cell applications, San 
Diego). 
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1. Pour all of the above ingredients into the upper unit of a 500ml filter system, 
and apply vacuum pressure.   
2. Label bottle with cell line used for, media and additives/supplements, name and 
date.   
 
Feeding and maintenance of cell lines (subculture): Tera-1/GH/BJAB 
Feeding 
1. Incubate medium in water bath at 37˚C. 
2. Aspirate off/ take off the contents of the flask – 7ml for T25/28ml for T175. 
3. Incubate flask at 37˚C under appropriate conditions. 
Passaging 
1. Aspirate flask and wash twice with 2ml Hanks’ buffered salt solution. 
2. Add 2ml Trypsin-EDTA to each and incubate for ~3 minutes (or until cells 
detach from the flask surface). 
3. Add 15ml of media into 2xT75 flasks (30ml of T175 flasks). 
4. Resuspend trypsinised cells in 8ml of media to inhibit Trypsin and add 2.5ml of 
media/ trypsinised cells to each flask (assuming 1 in 4 split between equal sized 
flasks).  For higher seedings add more cell suspension, etc. 
Nb.  If transferring to different sized flasks 
T75 ⇒ T175 – Double 
T175 ⇒ T75 – Halve 
5. Label flasks and incubate at 37˚C. 
 
Feeding and maintenance of cell lines (subculture): B95.8 
Feeding 
1. Aspirate and discard 5 ml spent media from flask taking care not to take up 
suspended cells if possible. 
2. Replace spent medium with fresh supplemented media. 
Passaging 
3. Aspirate cells off into a 50ml universal flask.   
4. Wash flask twice with 2ml Hanks’ buffered salt solution. 
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5. Add 2ml 0.5M Trypsin-EDTA to the flask and incubate for ~3 minutes at 37˚C, 
5% CO2 until cells detach from the flask surface.  Detached cells are diluted in 
fresh medium and added to universal containing cells. 
6. Detached and suspended cells are centrifuged at 1000 rpm for 5 minutes to 
pellet cells. 
7. Pelleted cells are resuspended in fresh medium before reseeding into sterile 
flasks. 
 
Maintenance of cell lines: Fibroblasts/ HFLS 
 
1. Aspirate flask and wash twice with 2ml Hanks’ buffered salt solution. 
2. Add 2ml Trypsin-EDTA to each flask and incubate for a minimum of 3 minutes 
(or until cells detach from the flask surface). 
3. Add 15ml of media into 2xT75 flasks (30ml of T175 flasks). 
4. Resuspend trypsinised cells in 5ml of neutralising solution to inhibit Trypsin 
and add 2.5ml of neutralised cells to each flask (assuming 1 in 4 split between 
equal sized flasks).  For higher seedings add more cell suspension, etc. 
5. Take 5ml of the media and cells and transfer to new flask. 
6. To the 5ml in the new flask add 15ml media. 
7. Label and incubate new flasks at 37˚C, 5% CO2. 
 
Freezing down of cells: All cell lines 
 
1. Pour the old cell culture media into a beaker of virkon. 
2. Add 5ml of medium into each flask. 
3. Scrape the cells in the flask using a cell scraper.   
4. Pour the cells & media into universal 25ml tubes, and label each tube 
accordingly.   
5. Spin down cells at 1500xg for 5 minutes. 
6. Some of the medium supernatant should be eluted off the cell pellet, leaving 
about 0.5ml (for larger pellets, leave more media supernatant). 
7. The cell pellet should be resuspended in the media supernatant. 
8. Make up ‘freezing mix’ using FCS and DMSO.   
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The two reagents should be present at a 9:1 ratio respectively. 
 
9. 0.5ml of freezing mix should be added to the resuspended cell pellet, and this 
should be transferred to the relevantly labelled cryovials.   
10. The freezing media should be added slowly to the resuspended cells. 
11. The end concentration of the mixture should be: 
7 :3 :1 
Medium : FCS: DMSO 
 
12. The cryovials are then transferred to the fridge (+4˚C) for 30 minutes, -20˚C 
overnight and then onto liquid nitrogen after a days storage. 
 
Resuscitation of cell lines from frozen 
 
1. Add 6ml of supplemented media to a T25 flask, and warm at 37˚C in an 
incubator. 
2. Retrieve the cryovial from liquid nitrogen storage and transfer to a small vessel 
containing water for 1 minute (do not submerge cryovial). 
3. Using a pipette, transfer the thawed cells to a T25 flask and incubate at 37˚C 
under appropriate conditions until cells adhere (4-24 hours).  Label flask with 
contents, passage number, name and date. 
4. Aspirate media from the flask and replace with 8ml fresh media, before 
incubating. 
5. Once cells approach confluency, transfer contents to T75 flask as follows. 
6. Aspirate off contents, and wash twice in 2ml of HBSS. 
7. Aspirate flask and add 1 ml of Trypsin-EDTA before incubating for ~3 minutes, 
or until cells detach. 
8. Add 10ml of medium to T75 flask. 
9. Add 4 ml of media to T25 flask to inhibit trypsin and add 5ml of contents to 
T75 flask. 
10. Label flask and incubate at 37˚C until cells require feeding and subculturing. 
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